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About the  
Arizona Tuberculosis Program Manual 
Purpose 
This manual is designed to present the key steps and crucial information needed to 
perform tuberculosis (TB) control tasks in states in which TB occurs with a low 
incidence—defined by the Centers for Disease Control and Prevention (CDC) as less 
than 3.5 cases/100,000 population/year.1 Where additional or more detailed information 
is available, hyperlinks to CDC guidelines and other resources are provided. Arizona has 
a rate of 4.7 cases/100,000 population/year thus The Arizona Tuberculosis Program 
Manual adapted this manual to meet the needs of the case rate for Arizona.  
The Arizona Tuberculosis Program Manual is based on a template created by an 
advisory group convened during CDC Task Order #6. The advisory group developed the 
template’s format and created its content by reviewing other TB control manuals, current 
CDC guidelines, and needs in the four low-incidence states of Idaho, Montana, Utah, 
and Wyoming.  
Audience 
The audience for this manual includes city/county/regional public health nurses, 
outreach workers, physicians, and public health officers; Indian Health Services (IHS) 
staff; physician consultants; private sector physicians; infection control nurses in 
hospitals and other facilities; disease intervention specialists; state epidemiologists; and 
state TB program staff.  
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How to Use This Manual 
Portable Document Format  
This manual is available electronically as a portable document format (PDF) file. To view 
the PDF file, you will need the free Adobe Reader, available at 
http://www.adobe.com/products/acrobat/readstep2.html . 
Hyperlinks 
When viewing this manual online with an Internet connection, you can go directly to 
underlined Web addresses by clicking on them. 
Cross-References 
When viewing this manual electronically, you can go directly to other 
sections or topics in the manual by clicking on text next to this icon: 
 
Forms 
 
Required and recommended forms are available in the forms section  
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Bookmarks 
In PDF files, you can use bookmarks to go quickly to a section or topic. If the bookmarks 
are not visible on the left, click the Bookmarks icon or tab on the left of the window.   
To view sections and topics in the bookmarks list:  
 Click + to see a more detailed list. 
 Click – to hide the more detailed list. 
To go to a section or topic in the bookmarks list, point to its name and left-click.  
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Printing 
To access the print dialog box, click the File drop-down menu, click Print, and then make 
your selections in the Print dialog box.  
  
Some printers have older 
printer drivers that cause 
spaces to appear in the middle 
of words.  To avoid this 
problem, click File/Print, click 
the Advanced button, check 
Print as Image, and then click 
OK. If you need further 
assistance with printing, call the 
ADHS TB Control Section at 
602-364-4750 if you have any 
problems. 
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Icons 
Throughout the manual, these icons quickly cue you about important information and 
other resources:  
 
This warns about high-consequence information you must understand 
when performing the task. 
This signals when you should call to report or to consult on the task. 
This highlights special considerations for pediatric patients. 
This suggests another relevant area in the manual or another resource that 
you may want to review. 
This alerts you that a form is available for the task. 
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L  Introduction  1 . 7  
Revised 12/4/07 
Abbreviations  
Refer to the list below for abbreviations used in the manual. 
 
ACET   Advisory Council for the Elimination of Tuberculosis 
ACH   air changes per hour 
AFB   acid-fast bacilli 
AIDS   acquired immunodeficiency syndrome 
AII   airborne infection isolation  
ALT   alanine aminotransferase 
ARPE   Aggregate Report for Program Evaluation 
ART   antiretroviral therapy 
AST    aspartate aminotransferase 
ATS   American Thoracic Society 
BAMT   blood assay for Mycobacterium tuberculosis 
BCG   Bacille Calmette-Guérin 
CDC   Centers for Disease Control and Prevention 
CT   computed tomography 
CXR   chest radiograph 
DNA   deoxyribonucleic acid 
DOT   directly observed therapy 
DTBE   Division of Tuberculosis Elimination 
DTH   delayed-type hypersensitivity 
ED   emergency department 
EMB   ethambutol 
EMS   emergency medical service 
ESRD   end-stage renal disease 
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FDA   U.S. Food and Drug Administration 
HAART  highly active antiretroviral therapy 
HCW   healthcare worker 
HEPA   high-efficiency particulate air 
HIPAA   Health Insurance Portability and Accountability Act 
HIV   human immunodeficiency virus 
IDSA   Infectious Diseases Society of America 
IGRA   interferon gamma release assay 
INH   isoniazid 
LTBI   latent tuberculosis infection 
M. tuberculosis Mycobacterium tuberculosis 
MDR-TB  multidrug-resistant tuberculosis 
MIRU   mycobacterial interspersed repetitive units 
MOTT   mycobacterium other than tuberculosis 
NAA   nucleic acid amplification 
NIOSH   National Institute for Occupational Safety and Health 
NNRTI   nonnucleoside reverse transcriptase inhibitors 
NTCA   National Tuberculosis Controllers Association 
NTNC   National Tuberculosis Nurse Coalition 
NTM   nontuberculous mycobacteria 
OSHA   Occupational Safety and Health Administration 
PAPR   powered air-purifying respirator 
PCR    polymerase chain reaction 
PI   protease inhibitor 
PPD   purified protein derivative 
PZA   pyrazinamide 
QA   quality assurance 
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QFT   QuantiFERON®-TB test 
QFT-G   QuantiFERON®-TB Gold test 
RFB   rifabutin 
RFLP   restriction fragment length polymorphism  
RIF   rifampin 
RNA   ribonucleic acid 
RPT   rifapentine 
RVCT   Report of Verified Case of Tuberculosis 
RZ   rifampin and pyrazinamide 
TB   tuberculosis 
TIMS   Tuberculosis Information Management System  
TNF-α   tumor necrosis factor-alpha 
TST   tuberculin skin test 
TU   tuberculin units 
USCIS   U.S. Citizenship and Immigration Services 
UVGI   ultraviolet germicidal irradiation 
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Purpose of Tuberculosis Control  
Tuberculosis (TB) is caused by a bacterial organism named Mycobacterium 
tuberculosis. (These organisms are sometimes called tubercle bacilli.) Mycobacteria can 
cause a variety of diseases. Some mycobacteria are called tuberculous mycobacteria 
because they cause TB or diseases similar to TB. These mycobacteria are M. 
tuberculosis, M. bovis, and M. africanum. Other mycobacteria are called nontuberculous 
mycobacteria (NTM) because they do not cause TB. One common type of 
nontuberculous mycobacteria is M. avium complex. Tuberculous mycobacteria readily 
spread from person to person; nontuberculous mycobacteria do not usually spread from 
person to person. 
The goal of TB control in the United States is to reduce TB morbidity and mortality by  
 preventing transmission of M. tuberculosis from persons with contagious forms of the 
disease to uninfected persons, and  
 preventing progression from latent TB infection (LTBI) to active TB disease among 
persons who have contracted M. tuberculosis infection.2 
 
For information on the transmission of M. tuberculosis and on how LTBI 
progresses to TB disease, see the Centers for Disease Control and 
Prevention’s (CDC’s) online course Interactive Core Curriculum on 
Tuberculosis (2004) at 
http://www.cdc.gov/tb/webcourses/corecurr/index.htm . 
The four fundamental strategies to reduce TB morbidity and mortality are 
1. early and accurate detection, diagnosis, and reporting of TB cases, leading to 
initiation and completion of treatment;  
2. identification of contacts of patients with infectious TB and treatment of those at risk 
with an effective drug regimen; 
3. identification of other persons with latent TB infection at risk for progression to TB 
disease, and treatment of those persons with an effective drug regimen; and 
4. identification of settings in which a high risk exists for transmission of M. tuberculosis 
and application of effective infection control measures.3 
 
For more information on these strategies and the thinking behind them, 
see “Controlling Tuberculosis in the United States: Recommendations from 
the American Thoracic Society, CDC, and the Infectious Diseases Society 
of America” (MMWR 2005;54[No. RR-12]) at 
http://www.cdc.gov/MMWR/PDF/rr/rr5412.pdf . 
 
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L  Introduction  1 . 1 1  
Revised 12/4/07 
Arizona Laws and Rules  
on Tuberculosis Control  
Arizona laws and rules on tuberculosis (TB) are available by 
clicking on the following locations: 
 
Arizona Laws/Rules Regarding Tuberculosis Control 
Arizona Revised Statutes.  Title 36:  Public Health and 
Safety; Chapter 6:  Public Health Control; Title 6:  
Tuberculosis Control.  (ARS§36-711 through §36-738)  
ARS§36-711.  Definitions.   
ARS§36-712. Administration by the department.   
ARS§36-714.  Tuberculosis control officer.   
ARS§36-715.  Costs; removals; proceedings.   
ARS§36-716.  Payment of assistance.   
ARS§36-717.  Responsibility for care or treatment by 
counties.   
ARS§36-718.  Contracting for care of afflicted persons.   
ARS§36-721.  Rules.   
ARS§36-723.  Investigation of tuberculosis cases.   
ARS§36-724.  Voluntary control measures.   
ARS§36-725.  Orders to cooperate; emergency custody.    
ARS§36-726.  Petition for court ordered examination, 
monitoring, treatment, isolation or quarantine.   
ARS§36-727. Hearings; procedure; confidentiality.   
ARS§36-728. Judicial action.   
ARS§36-729. Amended orders for intervention and 
transport of afflicted persons.   
ARS§36-730.  Appointment of guardian or conservator.   
ARS§36-731.  Confinement; selection; jails; prohibition.   
ARS§36-732.  Early release from court ordered treatment.   
ARS§36-733.  Choice of physician and mode of treatment.   
ARS§36-734.  Treatment; exemption.   
ARS§36-735.  Notification of rights.   
ARS§36-736.  Administrative procedures act; judicial review 
of administrative procedures; exemption; appeals.  
ARS§36-737.  Violation; classification.   
ARS§36-738.  Qualified immunity.   
 
Arizon Administrative Code.  Title 9. Chapter 6.  
Department of Health Services Communicable Diseases 
and Infestations.   
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Contact the Arizona Department of Health Services TB Program at 602-
364-4750 for assistance with interpreting laws and rules regarding TB 
control. 
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Objectives and Standards 
Quality of Care 
For tuberculosis (TB) programs, quality of care is measured by means of objectives and 
standards.   Such objectives and standards are used as yardsticks to direct the program 
and measure its success.  
Objectives reflect outcomes or results and program desires. Programs require 
objectives to define expected outcomes and results for case management activities.  
Standards are an accepted set of conditions or behaviors that define what is expected 
and acceptable regarding job duties, performance, and provision of services. The TB 
control program works to achieve objectives through a series of standards.  
 
In Arizona, TB program objectives and standards are established from the following: 
State Laws and Regulations 
See the above laws and regulations 
TB Program Agreements, Plans, and Protocols 
 Contracts between Arizona, TB Control and the local health agencies 
 Centers for Disease Control and Prevention (CDC) Cooperative Agreement 
National TB Guidelines 
The national organizations or TB guidelines that help to establish the TB program’s 
goals, objectives, and standards of performance include: 
 
 American Thoracic Society (ATS) 
 Infectious Diseases Society of America (IDSA) 
 CDC  Division of Tuberculosis Elimination (DTBE) guidelines  
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National Program Objectives  
Below are national TB program objectives. The CDC program objectives are current as 
of December 2006.4   
 
TABLE 1: PROGRAM OBJECTIVES AND PERFORMANCE TARGETS 
 
Indicator 
National Tuberculosis Program Objectives  
 
1 Percent 
completion of 
treatment 
Increase timely completion of treatment  
National Objective: At least 93% of patients with newly diagnosed tuberculosis (TB), 
for whom therapy for 12 months or less is indicated, will complete treatment within 
12 months by 2015.  
2 TB case rate Decline in TB rates 
 
a. National Objective: The average yearly decline in TB rates in U.S. born will 
be >11%. 
b. National Objective: The average yearly decline in TB rates in foreign born 
will be >4%. 
c. National Objective: The TB rate in U.S. born will be <0.7 cases/100,000 by 
2015.  
d. National Objective: The TB rate in foreign born will be <14 cases/100,000 by 
2015.  
e. National Objective: The TB rate in U.S.-born black non-Hispanics will be 
<1.3 cases/100,000 by 2015.  
f. National Objective: The TB rate in children <5 years of age will be 
<0.4/100,000 by 2015.  
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Indicator 
National Tuberculosis Program Objectives  
 
3 Thorough 
contact 
investigations 
Improve contact identification, evaluation, and treatment 
 
a. National Objective: All sputum-AFB-smear-positive TB cases will have at 
least one contact listed by 2015.  
b. National Objective: At least 93% of contacts to sputum-AFB-smear-positive 
TB cases will be evaluated for infection and disease by 2015.   
c. National Objective: At least 88% of infected contacts will start treatment by 
2015.  
d. National Objective: At least 79% of contacts who start treatment will 
complete treatment.  
4 Timely 
laboratory 
reporting 
Ensure timely laboratory reporting 
a. National Objective: State public health labs will report 100% of results of 
culture identification of M. tuberculosis complex to submitter and state TB 
program within 21 days of receipt of specimen by 2015.  
b. National Objective: Increase the percentage of TB patients with initial 
positive cultures who also are tested for and receive drug susceptibility 
results to 100% by 2015.  
Source: National TB Indicators Project. Initial Indicators and Performance Targets. Atlanta, GA: CDC Division of 
Tuberculosis Elimination; November 1, 2006. [Cleared by CDC but unpublished as of December 2006.] 
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In addition to the national program objectives listed above, the CDC has two goals (listed 
below) that do not have national program objectives established at this time. Specific 
objectives relating to these two goals will be established in the future. In the meantime, 
states should review the following two goals and establish objectives that are specific, 
measurable, and time phased, if applicable. National Goal 2 is listed for reference; it 
does not apply to low-incidence areas. 
 
1. National Goal: Increase the percentage of immigrants and refugees designated as 
Class A, B1, or B2 who are appropriately evaluated and treated. Refer to the 
following Web link, pages 2-6, for classification descriptions: 
http://www.cdc.gov/ncidod/dq/pdf/ds-forms-instructions.pdf. 
 
 
2. National Goal: For jurisdictions with greater than 50 reported cases of TB occurring 
annually in U.S.-born African Americans, decrease the case rate. 
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Standards 
Program standards are what the stakeholders of the TB program would consider to be 
"reasonable expectations" for the program. For TB, standards have been established by 
nationally accepted authorities, such as ATS, IDSA and CDC, and generally recognized 
TB control experts, such as the National Tuberculosis Nurse Coalition (NTNC) and 
National Tuberculosis Controllers Association (NTCA). Many state programs, and some 
local TB control programs, have established their own standards and objectives for case 
management. As of late 2007, the NTNC currently is revising its Tuberculosis Nursing 
manual, which will contain the most current program, structural, and patient care 
standards that the NTNC recommends. Check for updates at http://www.ntca-tb.org. 
 The standards of care for the medical treatment and control of TB are published jointly 
by the American Thoracic Society (ATS), the Infectious Diseases Society of America 
(IDSA), and the CDC. These standards should be available for reference by each TB 
staff member. The standards are included in the following guidelines: 
 ATS, CDC, IDSA. “Controlling Tuberculosis in the United States: Recommendations 
from the American Thoracic Society, CDC, and the Infectious Diseases Society of 
America” (MMWR 2005;54[No. RR-12]). Available at: 
http://www.cdc.gov/mmwr/PDF/rr/rr5412.pdf . 
 ATS, CDC, IDSA. “Diagnostic Standards and Classification of Tuberculosis in Adults 
and Children” (Am J Respir Crit Care Med 2000;161[4 Pt 1]). Available at:  
http://www.cdc.gov/tb/pubs/PDF/1376.pdf . 
 ATS, CDC, IDSA. “Treatment of Tuberculosis” (MMWR 2003;52[No. RR-11]). 
Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
 CDC, NTCA. “Guidelines for the Investigation of Contacts of Persons with Infectious 
Tuberculosis: Recommendations from the National Tuberculosis Controllers 
Association and CDC” (MMWR 2005;54 [No. RR-15]). Available at:  
http://www.cdc.gov/mmwr/pdf/rr/rr5415.pdf . 
 CDC. “Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in 
Health-care Settings, 2005” (MMWR 2005;54[No. RR-17]). Available at: 
http://www.cdc.gov/mmwr/pdf/rr/rr5417.pdf . 
 CDC. “Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection” 
(MMWR 2000;49[No. RR-6]). Available at:  
http://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf . 
For additional guidelines, see the Division of Tuberculosis Elimination’s “TB Guidelines” 
Web page (Division of Tuberculosis Elimination Web site; accessed November 25, 
2006). Available at:  
http://www.cdc.gov/nchstp/tb/pubs/mmwrhtml/Maj_guide/List_categories.htm . 
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Roles, Responsibilities, and Contact Information 
 
The TB Control Section (TBCS) has the overall responsibility for surveillance, 
containment, management and assessment of TB activities in the state. Specific duties 
include the formulation and distribution of guidelines for TB control and prevention in 
Arizona, utilizing established recommendations from the CDC and ATS. The 
responsibilities of TBCS include: 
a) Providing epidemiological, technical, medical, nursing, and programmatic 
consultative services regarding TB prevention and control to public and private 
health care providers, including local and Native American public health 
departments, public and private physicians and nurses, and public and private 
health care facilities, 
b) Providing training upon request or identified need for individuals and groups with 
responsibility for diagnosing/evaluation and treating persons with Tb disease and 
LTBI,  
c) Providing technical assistance as necessary, 
d) Providing notification to the local health departments of any information received 
by the Refugee Health Program,  
e) Providing reports as necessary to the CDC, 
f) Working with Arizona State Laboratory to ensure quality TB laboratory services 
are provided in the state, 
g) Ensuring that reporting regulations are met and assists local health departments 
in enforcing commitment laws when necessary, 
h) Verification and accurate count of all new and recurrent cases of TB disease and 
known LTBI in children < six (6) years of age within the state, 
i) Maintaining a registry for all known persons with LTBI who have been placed on 
preventive treatment, including contacts to persons with infectious TB disease,  
j) Aggregating non-patient specific information and transmitting this information to 
CDC for inclusion in national statistics on the incidences of TB, as well as data 
on the utilization of recommended control and prevention measures, 
k) Maintaining a registry of TB cases with drug resistant organisms, and provides 
drug resistance incidence data and technical advice regarding appropriate 
treatment regimens to health care providers throughout the state, 
l) Providing case management consultation to local and district health departments 
and other health care providers,  
m) Developing and distributing epidemiological data on the incidence and location of 
TB disease in Arizona, 
n) Providing/assisting local health departments’ TB programs with program 
evaluations, chart audits,   
o) Initiating, developing, approving and monitoring contracts with local and district 
health departments to provide TB services. 
p) Providing on-site evaluations of TB control programs in each local health 
department, and 
q) Evaluating the TB control program and providing that information to CDC 
semiannually. 
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Roles and Responsibilities of the Local Health 
Departments 
 
The basic role of the Local Tuberculosis Control Programs is to assure the provision of 
comprehensive TB prevention and control services to persons with known or suspected 
TB disease or latent TB infection, with as little disruption in their daily lives as possible. 
Each program is expected to ensure their practices are current based on the CDC 
guidelines. Local TB clinics have a major responsibility to prevent unnecessary 
hospitalization by performing, when possible, necessary screening and diagnostic 
testing along with providing appropriate treatment on an outpatient basis. The local 
health departments’ responsibilities include: 
 
a) Physician evaluation, including medical history; 
b) Tuberculin skin test (Mantoux only) administration, reading and interpretation; 
c) Chest x-rays (on-site or at a reasonable convenient location for the patient);  
d) Chest x-rays reading and interpretation by a radiologist;  
e) Collection of sputum specimens – natural and/or induced (on-site or at a 
reasonable convenient location for the patient); 
f) Ensuring that persons on therapeutic or preventive regimens take their 
medication to completions, including directly observed therapy (DOT); 
g) Monitoring persons on therapeutic or preventive regimens;  
h) Contact identification, notification, and examination, with appropriate follow-up; 
i) Consultation to other health care providers regarding TB control and prevention 
methods; 
j) TB educational services for patients and their families, other health care 
providers, and the general public, as requested or required; and 
k) Referral to appropriate agencies for assistance with identified problems/needs. 
 
TB Nurses/Coordinators in the Local Health Department 
 
The TB nurse/coordinators at the local health department have a major responsibility for 
a successful TB control program. They are the prime link in effective TB prevention and 
control for all persons in the community, whether hospitalized or on an outpatient basis. 
The responsibilities include:  
a) Instructing the patient on the importance of continuous and uninterrupted drug 
therapy and precautions to take to prevent the transmission of infection 
b) Case management to ensure the patient successfully completes anti-TB 
chemotherapy and treatment of LTBI. 
c) Monitoring of the patient’s clinical status and obtaining liver function studies 
monthly 
d) Ensuring compliance with treatment 
e) Collecting specimens as necessary 
f) Ensuring other testing is completed as necessary 
g) Referring patient to other appropriate agencies as necessary 
h) Working with the physician to maintain standards of care for each patient 
i) Contacting any health care provider (i.e. outpatient departments, infirmaries of 
state and local correctional and mental health institutions, federal facilities, and 
private physicians) to monitor the current status of the TB patient 
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j) Maintaining surveillance for TB within the community, an 
k) Serving as a liaison between local health care providers and facilities and the 
TBCS. 
 
Specific responsibilities include: 
a) Initial patient visit – within 3 working days after receiving the report of a newly 
diagnosed or suspected case of TB. This visit is often the key to eventual 
successful completion of adequate treatment for the patient. 
b) Assessment of the patient (See Case Management Section)  
c) Development of the Nursing Care Plan (See Case Management Section) 
d) Observation for infectiousness, i.e. coughing, general hygiene (if patient covers 
their cough, disposes of tissues, and collection of specimens without 
contamination, 
e) Current and prior medical history, i.e., contacts with other TB cases or a previous 
history of TB of LTBI, length of illness, other chronic conditions, current 
medications (including over the counter and herbal), HIV status (or risk factors if 
not known), 
f) Coping skills i.e., reaction of the patient and family regarding present condition. 
Identification of barriers to care in order to develop a plan of care, 
g) Assessment of the patient’s environment i.e. home, school work to determine 
shared environments with others. Also note the climate, central heating and air 
conditions, confined spaces, air movement within a home, office, classroom, etc., 
all may be factors to be taken into consideration, 
h) Contact identification, ensuring all contacts are examined and appropriately 
managed. Identification of contacts to a smear positive TB case/suspect is a high 
priority activity and should begin within 3 working days of notification; 
i) Initial contact evaluation, examination of close contacts of current infectious 
cases of pulmonary or laryngeal TB is the most productive method of case 
finding and initial evaluations should be completed within 10 working days of the 
initial report of the TB case/suspect. Tuberculin skin tests (TSTs) to household 
contacts and other close contact within one week of notification of the case. 
Standing orders may be used. If the TB suspect later prove to have disease 
caused by a mycobacterium other than tuberculosis (MOTT), the contacts with 
documented TSTs, > 10 mm should be re-evaluated and determination made 
regarding preventive treatment. If the TST is > 10 mm, it is appropriate to 
continue preventive treatment of LTBI to completion if the TB clinician, the 
primary health care provider and the patient agree. 
j) Patient and family education, focusing on achieving an understanding of:  
•  The disease process 
• The reason for chemotherapy for the patient and preventive treatment for 
contacts 
• The importance of continuous and uninterrupted therapy 
• The importance of maintaining regular medical supervision 
• The signs and symptoms of potential side effects of the prescribed 
medications and what course of action to follow should these occur 
• Transmission of TB and methods of prevention 
• The importance of covering the nose and mouth with tissue every time when 
coughing or sneezing whether alone or with others, and proper disposal of 
tissue 
• The probable duration of the infectious period 
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• The need for adequate ventilation 
• The fact that dishes, linens, and other fomites require no special precaution  
• The potential benefit of sleeping apart from the rest of the family during the 
infectious period 
• The reason for contact identification and examination. 
k) Medication orders for anti-tuberculosis chemotherapy from the primary health 
care provider and/or the TB clinician for the local health department. Directly 
observed therapy (DOT) is the standard of care. Rarely, there may be times 
when self administered therapy (SAT) is an acceptable option. For patients who 
are on SAT, only a one (1) month supply of medication may be given to the 
patient at any time. Monitoring for potential side effects of the medication is 
provided at each does for patients on DOT, and at least monthly for patients on 
SAT. If any prescription calls for a dose or method of administration which is 
different from what the CDC and or the ATS recommends the TB 
nurse/coordinator should consult with TBCS, the TB clinician for the local health 
department and/or the local health officer. 
l) Specimen collection containers should be provided along with mailing tubes and 
instructions to the patient for collecting routine laboratory specimens and referral 
to a local health care provider for sputum induction may be necessary. 
m) Contact follow-up is the responsibility of the TB nurse/coordinator when a TB 
case or suspect is identified in any long term care facility, including state or 
federal correctional institutions. Usually the institution is responsible to test 
contacts residing or employed within the institution and the local health 
department to test contacts outside the facility. The TB nurse/coordinator assures 
that the contact investigation has begun, assists in the investigation if requested, 
administers TSTs to contacts identified outside the institution but within that 
county and notifies TBCS of contacts requiring examination but residing in other 
jurisdictions. Contacts are to be evaluated and managed according to current 
recommendations as noted in this manual. Contacts on preventive therapy for 
LTBI must be followed and monitored at least monthly. Results of the contact 
investigation are sent to TBCS using the approved ADHS TB Prevention Registry 
form (see forms section), no later than four (4) months after the report of the 
index case.   
n) Documenting records and reports in the patient’s folder including components of 
the home, hospital, or clinic visits, contact examination results and follow-up 
treatment regimen, collection of specimens, smear and culture results, chest x-
ray reports, other laboratory reports, assessment of compliance, and any other 
information pertinent to the appropriate case management of the patient in a 
timely manner and forwarded to TBCS. Examples of some of the forms include, 
Report of Verified Case of Tuberculosis (RVCT), RVCT Follow-up 1 & 2 forms 
and the ADHS TB Prevention Registry form (See the Forms Section). 
o) Isolation assistance should be requested from the local deputy TB control office 
and/or the local health office and enforced, when necessary. 
p) Quarantine enforcement should be used only in consultation with the local deputy 
TB control office and/or the local health officer and must by in compliance with 
the Arizona statues and/or rules to protect the health of the public. TBCS will 
assist the local TB nurse/coordinator with this responsibility as necessary and 
when requested (See page 1.10 on Arizona TB laws/rules) 
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Local Health Departments’ Tuberculosis Program  
 
Apache County Health Department  
PO Box 1952, Springerville, AZ 85938 
(928) 333-2475 
 
Cochise County Health Department 
1415 W. Melody Lane, Bldg A, Bisbee, AZ 85603 
(520) 432-9464 
 
Coconino County Health Department 
2625 N. King Street, Flagstaff, AZ 86004 
(928) 522-7108 
 
Gila County Health Department 
1400 E. Ash, Globe, AZ 85501 
(928) 402-8848 
 
Graham County Health Department  
826 W. Main, Safford, AZ 85546 
(928) 428-0110 
 
Greenlee County Health Department 
PO Box 936, Clifton, AZ 85533 
(928) 865-2601 
 
La Paz County Health Department 
1112 Joshua St. #204, Parker, AZ 85344 
(928) 669-1100 
 
Maricopa County Health Department 
1645 E. Roosevelt, Phoenix AZ 85006 
(602) 506-6643 or (602) 506-6661 
 
Mohave County Health Department 
PO Box 7000, Kingman AZ 86401 
(928) 753-0714, ext. 4281 
 
Navajo County Health Department 
117 E. Buffalo, PO Box 639, Holbrook, AZ 86025 
(928) 535-6050 
 
Navajo Nation TB Program 
Gallup Indian Medical Center 
(505) 722-1589 
Public Health Nursing Department #39 
PO Box 1337, Gallup NM 87301 
 
Pima County Health Department 
150 W. Congress, Tucson, AZ 85701 
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(520) 740-8613 
 
Pinal County Health Department  
188 S. Main St. Coolidge, AZ 85228 
(520) 866-7362 
 
Santa Cruz County Health Department 
91 E. La Castellana Dr. Nogales, AZ 85621 
(520) 375-5046 
 
Tohono O’odham Health Department 
PO Box 815, Sells, AZ  85634 
(520) 383-6200  
 
Yavapai County Health Department 
930 Division St. Prescott, AZ 86301 
(928) 771-3134 
 
Yuma County Health Department  
2200 W. 28th St. Yuma, AZ 85364 
 (928) 317-4585 
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Health Care Providers 
 
Health care providers, including general hospital, outpatient departments, infirmaries of 
state and local correctional and mental institutions, federal facilities, as well as local 
health departments and private providers in the community, carry out the roles of 
evaluation, diagnosing, prescribing, and monitoring the medical care of those persons 
with TB disease or LTBI.  
 
Health care providers and operators of homeless shelters in Arizona who know of a 
person who has or is suspected of having tuberculosis, are required by Arizona Revised 
Statues (ARS 36-723D, Section X.1) to notify the state TB control officer or the local 
health officer, and to cooperate in any investigation conducted as a result of the 
notification. Notification shall include, if known, the name, address and physical location 
of the person who has or is suspected of having TB. If the person reporting is a licensed 
physician, the report shall also include the condition of the person and the status of the 
disease. 
 
According to Arizona Administrative Code (AAC R9-6-202A), a physician or an 
administrator of a health care facility or any authorized representative, shall report within 
twenty-four (24) hours to the local health agency by telephone or other equally 
expeditious means, any suspected or confirmed TB disease in any person, as well as any 
LTBI in a child less than six (6) years of age. 
 
The reporting of each person with known or suspected new or recurrent TB disease and 
each child less than six (6) years of age with LTBI allows the resources of the local 
health department and TBCS to become available to assist the provider in the appropriate 
management of the patient. Epidemiological services are available to identify and 
examine source cases and contacts. The local health department may have chest x-ray 
availability on site, or will have arrangements made with other nearby health care 
facilities to provide x-ray services, including reading and interpretation. Some local 
health department may have laboratory services and local medical consultation. All local 
health departments have a Deputy TB Control Officer to assist the provider in the 
treatment and follow-up of each TB patient. All local health departments are also able to 
link the health care provider with all services provided by ADHS. 
 
Close cooperation between health care providers and the local health department is 
imperative for the optimal outcome for the patient, contacts, and the community as a 
whole.  Physicians and other providers described above are required to cooperate with the 
local health department when a report is requested on the follow-up care being given to a 
patient (ARS 36-723D).   Periodic updates are required to monitor the patient’s 
bacteriological, radiological, and chemotherapy status, or status of treatment for LTBI.  
Physicians and other health care providers are required to promptly report to the local 
health department if the patient ceases to or refuses to comply with medical 
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recommendations for voluntary examination, isolation, monitoring, quarantine or 
treatment for active TB (ARS 36-723E). 
 
Any treating, screening or attending health care provider, clinical laboratory, or an 
operator of a homeless shelter, who knowingly fails or refuses to perform a duty or legal 
responsibility regarding known or suspected tuberculosis disease is guilty of a class 3 
misdemeanor (ARS 36-737A).   
 
Any person who knowingly obstructs, impairs or hinders an investigation into known or 
suspected tuberculosis disease is guilty of a class 3 misdemeanor (ARS 36-737D). 
 
Any person who knowingly makes a false report of tuberculosis to the tuberculosis 
control officer or the local health officer is guilty of a class 3 misdemeanor (ARS 36-
737E). 
  
 
Clinical Laboratories 
 
A clinical laboratory director, or authorized representative, in accordance with Arizona 
Administrative Code (AAC R9-6-202D), shall submit to the Arizona Department of Health 
Services a weekly written or electronic report of positive laboratory findings for 
Mycobacterium tuberculosis and its drug sensitivity patterns.  AAC R9-6-202E requires 
that the written or electronic laboratory report shall include the patient’s name, address 
and telephone number (if available), date of birth, reference number, specimen type, date 
of collection, type of test, test results, and the ordering physician’s name and telephone 
number.  This required report includes the findings of any test that is suggestive of 
tuberculosis, most specifically positive smears for acid-fast bacilli (AFB) as well as 
positive cultures for Mycobacterium tuberculosis.  
 
In addition, in order to provide epidemiological data and information regarding TB in 
Arizona including drug-resistance patterns, all clinical laboratories are strongly 
encouraged to provide an isolate of all cultures positive for Mycobacterium tuberculosis 
to the Arizona State Laboratory, 250 N. 17th Ave., Phoenix, Arizona, 85007, telephone 
(602) 542-1188. 
 
The following is from “Guidelines for Preventing the Transmission of Mycobacterium 
tuberculosis in Health Care Settings Facilities, 2005/1994” published in Morbidity and 
Mortality Weekly Report, Vol. 5 434, No. RR 1713, December 30, 2005.   
 
“Prompt laboratory results are crucial to the proper treatment of the TB patient and to 
early initiation of infection control measures.  To ensure timely results, laboratories 
performing mycobacteriologic tests should be proficient at both the laboratory and 
administrative aspects of specimen processing.  Laboratories should use the most rapid 
methods available (e.g., fluorescent microscopy for AFB smears; radiometric culture 
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methods for isolation of mycobacteria, nucleic acid probes, or high-pressure liquid 
chromatography (HPLC) for species identification; and radiometric methods for drug 
susceptibility testing).  As other more rapid or sensitive tests become available, practical, 
and affordable, such tests should be incorporated promptly into the mycobacteriology 
laboratory.   Laboratories that rarely receive specimens for mycobacteriologic analysis 
should refer the specimens to a laboratory that more frequently performs these tests.” 
Arizona State Laboratory 
 
The Arizona State Laboratory processes sputum and other specimens for tuberculosis 
diagnostic and monitoring purposes as submitted by local health departments, private 
health care providers, health care facilities, and other laboratories at no charge to the 
patient, health care provider or facility, laboratory, or local health department.  The 
results of acid-fast bacilli (AFB) smears, direct identification of mycobacteria from 
clinical specimens (rapid method), mycobacterial cultures, anti-tuberculosis drug 
sensitivity studies, and mycobacterial organism identification are included in the services 
provided. The laboratory serves as the tuberculosis reference laboratory for the entire 
state.  
 
Specimen containers and mailing tubes may be obtained at no charge to patients or local 
health departments by calling (800) 542-3156, extension 1195, or (602) 542-1188.  
Governmental and Voluntary Agencies 
 
The Centers for Disease Control and Prevention (CDC) and the American Thoracic 
Society (ATS), formerly the medical Section of the American Lung Association (ALA), 
provide official recommendations and guidelines for the control of tuberculosis, 
including standards of care for persons with known or suspected tuberculosis infection or 
disease, diagnostic methods, effective and appropriate anti-tuberculosis drug regimens, 
laboratory standards, contact identification, examination and follow-up, and methods for 
the prevention of transmission of tuberculosis within health care facilities and long-term 
care institutions.  Both agencies also provide education, consultation and technical 
assistance as necessary to the Arizona Department of Health Services, Tuberculosis 
Control Section (TBCS), as well as public and private health care providers throughout 
the state upon request. 
 
The CDC also provides a portion of the funds for the prevention and control of 
tuberculosis in Arizona.  These funds are provided by an ongoing cooperative agreement 
between TBCS and the CDC, as well as special grants.   
 
Cooperative agreement funds provide for salaries and travel funds for some TBCS staff, 
and supplemental contracted tuberculosis control services for the major tuberculosis 
incidence areas of the state, including three Mexican border areas, as well as 
mycobacterial laboratory services.   
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The State of Arizona provides General Revenue funds for contracts for tuberculosis 
services in local health departments, salaries for some TBCS staff, and laboratory 
services at the Arizona State Laboratory. 
 
The American Lung Association of Arizona, through contracts with TBCS, provides 
continuing education offerings, and leadership in the Arizona TB-Free Coalition. 
 
Resources and References 
Resources 
 CDC. “Framework for Program Evaluation in Public Health” (MMWR 1999;48[No. 
RR-11]). Available at: ftp://ftp.cdc.gov/pub/Publications/mmwr/rr/rr4811.pdf . 
 Division of Tuberculosis Elimination. A Guide to Developing a TB Program 
Evaluation Plan (Division of Tuberculosis Elimination Web site; accessed November 
1, 2006). Available at: http://www.cdc.gov/tb/Program_Evaluation/default.htm . 
 Division of Tuberculosis Elimination. Understanding the TB Cohort Review Process: 
Instruction Guide (Division of Tuberculosis Elimination Web site; accessed 
November 1, 2006). Available at: http://www.cdc.gov/tb/pubs/cohort/default.htm   
 New Jersey Medical School National Tuberculosis Center. Planning & Implementing 
the TB Case Management Conference: A Unique Opportunity for Networking, Peer 
Support and Ongoing Training (Newark, NJ; 2004). Available at: 
http://www.umdnj.edu/globaltb/products/planning&implementing.htm .  
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Introduction 
Purpose 
Use this section to 
 Understand the importance of surveillance in tuberculosis (TB) control and 
prevention 
 Report suspected and confirmed TB cases 
 Ensure you are using the required data collection form 
 Understand how the computerized TB registry works, and 
 Understand how genotyping can assist TB control efforts. 
 
Surveillance—the ongoing systematic collection, analysis, interpretation, and 
dissemination of data about a health-related event—is a critical component of successful 
TB control, providing essential information needed to  
1. Determine TB patterns and trends of the disease 
2. Identify sentinel events, such as potential outbreaks, recent transmission, multidrug 
resistance, and deaths 
3. Identify high-risk populations and settings 
4. Establish priorities for control and prevention activities, and 
5. Strategically plan use of limited resources.1 
Surveillance data are also essential for quality-assurance purposes, program evaluation, 
and measurement of progress toward TB elimination.  
State and local TB control programs should have the capability to monitor trends in TB 
disease and latent TB infection (LTBI) in populations at high risk, in order to detect new 
patterns of disease and possible outbreaks. Populations at high risk should be identified 
and targeted for active surveillance and prevention, including targeted testing and 
treatment of LTBI. The following populations have been demonstrated to be at risk for 
TB exposure, progression from exposure to disease, or both:  
• Children,  
• Foreign-born persons,  
• Human immunodeficiency virus (HIV)-infected persons,  
• Homeless persons, and  
• Detainees and prisoners.  
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Surveillance and surveys from throughout the United States indicate that certain 
epidemiologic patterns of TB are consistently observed among these populations, 
suggesting that the recommended control measures are generalizable. State and local 
surveillance data should be analyzed to determine additional high-risk population 
groups.  
In addition to providing the epidemiologic profile of TB in a given jurisdiction, state and 
local surveillance are essential to national TB surveillance.2 Data for the national TB 
surveillance system are reported by state health departments in accordance with 
standard TB case definition and case-report formats. The Report of Verified Case of 
Tuberculosis (RVCT) forms are designed to collect information on cases of TB. The 
Centers for Disease Control and Prevention’s (CDC’s) national TB surveillance system 
publishes epidemiologic analyses of reported TB cases in the United States.3 
Reporting of new cases is essential for surveillance purposes.4 
Surveillance in TB Control Activities 
Case detection: Case reporting to the jurisdictional public health agency is done for 
surveillance purposes and for facilitating a treatment plan and case management 
services.5 
For more information on case reporting, see the “Reporting Tuberculosis” 
topic in this section. 
Outbreak detection: Surveillance data should be routinely reviewed to determine if 
there is an increase in the expected number of TB cases, one of the criteria for 
determining if an outbreak is occurring. For an increase in the expected number of TB 
cases to be identified, the local epidemiology of TB should be understood. Detection of a 
TB outbreak in an area in which prevalence is low might depend on a combination of 
factors, including recognition of sentinel events, routine genotype cluster analysis of 
surveillance data, and analysis of Mycobacterium tuberculosis drug-resistance and 
genotyping patterns.6 Genotyping data should routinely be reviewed because genotype 
clusters also may indicate an outbreak. Prompt identification of potential outbreaks and 
rapid responses are necessary to limit further TB transmission. When an outbreak is 
identified, short-term investigation activities should follow the same principles as those 
for the epidemiologic part of the contact investigation (i.e., defining the infectious period, 
settings, risk groups, mode of transmission, contact identification, and follow-up). 
However, long-term activities require continued active surveillance.  
For more information on outbreak investigations, see the “Outbreak 
Investigation” topic in the Contact Investigation section. 
Contact investigation: Collecting, analyzing, interpreting, and disseminating data on 
contacts and contact investigations are necessary for prioritizing the highest-risk 
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contacts, resulting in focused use of resources, in accordance with national guidelines. 
Although surveillance of individual contacts to TB cases is not conducted in the United 
States, the CDC collects aggregate data from state and local TB programs through the 
Aggregate Report for Program Evaluation (ARPE). Routine collection and review of this 
data can provide the basis for evaluation of contact investigations for TB control 
programs.7 
For more information on surveillance in contact investigations, see the 
Contact Investigation section.  
 
Targeted testing: Review and interpretation of surveillance data inform targeted testing 
policies and strategies. Targeted testing is intended to identify persons other than TB 
contacts who have an increased risk for acquiring TB and to offer such persons 
diagnostic testing for M. tuberculosis infection and treatment, if indicated, to prevent 
subsequent progression to TB disease. Targeted testing and treatment of LTBI is best 
accomplished through cost-effective programs aimed at patients and populations 
identified on the basis of local surveillance data as being at increased risk for TB.8  
For more information on surveillance and targeted testing, see the 
Targeted Testing section.  
 
Treatment of LTBI: Surveillance of persons with LTBI does not routinely occur in the 
United States. However, the CDC is developing a national surveillance system to record 
adverse events leading to the hospitalization or death of a person under treatment for 
LTBI. Healthcare providers are encouraged to report such events to the CDC's Division 
of Tuberculosis Elimination by calling 1-404-639-8401. Surveillance of these events will 
provide data to evaluate the safety of treatment regimens recommended in current 
guidelines.9  
 
For more information on surveillance and targeted testing, see the 
Targeted Testing section. For more information on updated LTBI treatment 
recommendations, see the CDC’s “Update: Adverse Event Data and 
Revised American Thoracic Society/CDC Recommendations Against the 
Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis 
Infection—United States, 2003” (MMWR 2003;52[31];735–739) at 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm . 
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Policy  
Data collection and reporting on TB should be done in accordance with Arizona laws and 
regulations. Reporting and recordkeeping requirements are covered in this section. 
For roles and responsibilities, refer to the “Roles, Responsibilities, and 
Contact Information” topic in the Introduction.  
For more information on confidentiality and the Health Insurance Portability 
and Accountability Act (HIPAA), see the Confidentiality section.  
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L  Surveillance 2 . 5  
Revised 12/04/07 
Laws and Rules 
Arizona laws and rules on tuberculosis (TB) are located 
by clicking the appropriate section below: 
 
Arizona Laws/Rules Regarding Tuberculosis Control 
Arizona Revised Statutes.  Title 36:  Public Health and 
Safety; Chapter 6:  Public Health Control; Title 6:  
Tuberculosis Control.  (ARS§36-711 through §36-738)  
ARS§36-711.  Definitions.   
ARS§36-712. Administration by the department.   
ARS§36-714.  Tuberculosis control officer.   
ARS§36-715.  Costs; removals; proceedings.   
ARS§36-716.  Payment of assistance.   
ARS§36-717.  Responsibility for care or treatment by 
counties.   
ARS§36-718.  Contracting for care of afflicted persons.   
ARS§36-721.  Rules.   
ARS§36-723.  Investigation of tuberculosis cases.   
ARS§36-724.  Voluntary control measures.   
ARS§36-725.  Orders to cooperate; emergency custody.    
ARS§36-726.  Petition for court ordered examination, 
monitoring, treatment, isolation or quarantine.   
ARS§36-727. Hearings; procedure; confidentiality.   
ARS§36-728. Judicial action.   
ARS§36-729. Amended orders for intervention and 
transport of afflicted persons.   
ARS§36-730.  Appointment of guardian or conservator.   
ARS§36-731.  Confinement; selection; jails; prohibition.   
ARS§36-732.  Early release from court ordered treatment.   
ARS§36-733.  Choice of physician and mode of treatment.   
ARS§36-734.  Treatment; exemption.   
ARS§36-735.  Notification of rights.   
ARS§36-736.  Administrative procedures act; judicial review 
of administrative procedures; exemption; appeals.  
ARS§36-737.  Violation; classification.   
ARS§36-738.  Qualified immunity.   
 
Arizon Administrative Code.  Title 9. Chapter 6.  
Department of Health Services Communicable Diseases 
and Infestations 
Contact the Arizona TB Program at 602-364-4750 for assistance with 
interpreting state laws and rules regarding TB control. 
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Reporting Tuberculosis  
Detecting and reporting suspected cases of tuberculosis (TB) is the key step in stopping 
transmission of Mycobacterium tuberculosis because it leads to prompt initiation of 
effective multiple-drug treatment, which rapidly reduces infectiousness. The Centers for 
Disease Control and Prevention (CDC) reports that delays in reporting cases of 
pulmonary TB are one of the major challenges to successful control of TB.10 As one of 
the strategies to achieve the goal of reduction of TB morbidity and mortality, the CDC 
recommends immediate reporting of a suspected or confirmed case of TB to the 
jurisdictional health agency.11 Also, by Arizona law and regulation, a case of TB disease 
in the United States must be reported to the local public health agency.  
When reporting TB, keep the following definitions in mind: 
 Case: An episode of TB disease in a person meeting the laboratory or clinical criteria 
for TB, as defined in the document “Case Definitions for Infectious Conditions Under 
Public Health Surveillance.”12 These criteria are listed below in Table 1.13 
 Suspect: A person for whom there is a high index of suspicion for active TB (e.g., a 
known contact to an active TB case or a person with signs or symptoms consistent 
with TB) who is currently under evaluation for TB disease.14 
 Confirmed: A case that meets the clinical case definition or is laboratory confirmed, 
as described below in Table 1.15 
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Table 1: CASE DEFINITIONS16 
Clinical Case Definition Laboratory Criteria for Diagnosis 
A case that meets all of the following criteria: 
 A positive tuberculin skin test  
 Other signs and symptoms compatible with 
tuberculosis (e.g., an abnormal, unstable [i.e., 
worsening or improving] chest radiograph, or clinical 
evidence of current disease) 
 Treatment with 2 or more antituberculosis 
medications 
 Completed diagnostic evaluation 
A case is laboratory confirmed when it meets one of 
the following criteria: 
 Isolation of Mycobacterium tuberculosis from a 
clinical specimen* 
 Demonstration of M. tuberculosis from a clinical 
specimen by nucleic acid amplification (NAA) test†  
 Demonstration of acid-fast bacilli (AFB) in a clinical 
specimen when a culture has not been or cannot be 
obtained 
 
* Use of rapid identification techniques for M. tuberculosis (e.g., deoxyribonucleic acid [DNA] probes and mycolic acids high-
pressure liquid chromatography performed on a culture from a clinical specimen) is acceptable under this criterion. 
† NAA tests must be accompanied by culture for mycobacteria species. However, for surveillance purposes, the CDC will accept 
results obtained from NAA tests approved by the Food and Drug Administration and used according to the approved product 
labeling on the package insert.  
Source: Adapted from: CDC. Case definitions for infectious conditions under public health surveillance. MMWR 
1997;46(No. RR-10):40–41. 
 
Suspect pulmonary TB and initiate a diagnostic investigation when the historic features, 
signs, symptoms, and radiographic findings of TB are evident among adults. TB should 
be suspected in any patient who has a persistent cough for over two to three weeks, or 
other indicative signs and symptoms.17 
For more information on suspected pulmonary TB, see the Diagnosis of 
Tuberculosis Disease section. 
Mandatory and timely case reporting from community sources (e.g., providers, 
laboratories, hospitals, and pharmacies) should be enforced and evaluated regularly. 
Reporting enables the TB control program to take action at local, state, and national 
levels and to understand the magnitude and distribution of the TB problem.18 
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Prompt reporting (prior to culture confirmation) allows the state and local public health 
agency to do the following quickly: 
 Verify diagnosis 
 Assign a case manager and coordinate treatment 
 Determine if an outbreak is occurring 
 Control the spread of TB19  
Failure to report cases threatens public health because it may result in the adverse 
outcome of a patient’s treatment or delayed contact investigation of an infectious case.20 
Reporting gives physicians access to resources provided by the local public health 
agency. Private physicians are encouraged to work collaboratively with their local public 
health agency in the management of their TB cases and contacts. All providers who 
undertake evaluation and treatment of patients with TB must recognize that, not only are 
they delivering care to an individual, they are assuming an important public health 
function that entails a high level of responsibility to the community, as well as to the 
individual patient. The following public health services may be available to assist 
physicians with managing their TB cases: 
 
 Epidemiologic investigation, including identification and examination of contacts 
 Chest radiographic services 
 Antituberculosis medications 
 Local public health agency laboratory services and consultation: The actual 
M. tuberculosis isolate should be sent to the state laboratory so that genotyping can 
be performed when needed. 21 
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State Laws and Regulations 
Arizona Laws/Rules Regarding Tuberculosis Control 
Arizona Revised Statutes.  Title 36:  Public Health and Safety; Chapter 6:  
Public Health Control; Title 6:  Tuberculosis Control.  (ARS§36-711 
through §36-738)  
ARS§36-711.  Definitions.   
ARS§36-712. Administration by the department.   
ARS§36-714.  Tuberculosis control officer.   
ARS§36-715.  Costs; removals; proceedings.   
ARS§36-716.  Payment of assistance.   
ARS§36-717.  Responsibility for care or treatment by counties.   
ARS§36-718.  Contracting for care of afflicted persons.   
ARS§36-721.  Rules.   
ARS§36-723.  Investigation of tuberculosis cases.   
ARS§36-724.  Voluntary control measures.   
ARS§36-725.  Orders to cooperate; emergency custody.    
ARS§36-726.  Petition for court ordered examination, monitoring, 
treatment, isolation or quarantine.   
ARS§36-727. Hearings; procedure; confidentiality.   
ARS§36-728. Judicial action.   
ARS§36-729. Amended orders for intervention and transport of afflicted 
persons.   
ARS§36-730.  Appointment of guardian or conservator.   
ARS§36-731.  Confinement; selection; jails; prohibition.   
ARS§36-732.  Early release from court ordered treatment.   
ARS§36-733.  Choice of physician and mode of treatment.   
ARS§36-734.  Treatment; exemption.   
ARS§36-735.  Notification of rights.   
ARS§36-736.  Administrative procedures act; judicial review of 
administrative procedures; exemption; appeals.  
ARS§36-737.  Violation; classification.   
ARS§36-738.  Qualified immunity.   
 
Arizona Administrative Code.  Title 9. Chapter 6.  Department of 
Health Services Communicable Diseases and Infestations.   
 
For more information on confidentiality and the Health Insurance Portability 
and Accountability Act (HIPAA), see the Confidentiality section.  
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Reporting Suspected or Confirmed Cases of 
Tuberculosis to the Local Public Health Agency 
Healthcare providers and laboratories should report suspected or confirmed cases of TB 
using the information in Table 2.  
Table 2: WHEN TO REPORT TUBERCULOSIS 
What Condition/ 
Test Result 
 
Who Reports  
 
When to Report 
 
How to Report 
Confirmed or 
suspected cases of 
tuberculosis (TB) 
disease 
Confirmation by 
laboratory tests is not 
required. 
This includes 
pulmonary and 
extrapulmonary 
cases. 
 
 Physicians 
 Other healthcare 
providers 
 Hospitals 
 Other similar private or 
public institutions 
 Anyone providing 
treatment to the 
confirmed or suspected 
case 
Note: The attending 
physician or other 
healthcare provider must 
report even if the 
laboratory is also 
reporting the test results. 
Within one working (1) day  
 
 
Telephone 
Contact the local health 
department 
 
 
 
Sputum smears 
positive for acid-
fast bacilli (AFB)  
 
Cultures growing 
AFB or cultures 
that are 
demonstrated 
positive for 
Mycobacterium 
tuberculosis 
complex* 
 
Nucleic acid 
amplification 
tests/DNA probes 
positive for M. 
tuberculosis 
complex 
All laboratories that 
perform TB testing  
In-state laboratories that 
send specimens for out-
of-state testing 
Note: The laboratory 
must report even if the 
attending physician or 
other healthcare provider 
is also reporting. 
 
Within one day 
 
 
 
*  Note: Preliminary report of cultures growing AFB without confirmation of M. tuberculosis complex; final report of cultures that are 
demonstrated to be positive for M. tuberculosis complex. 
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L  Surveillance 2 . 1 1  
Revised 12/04/07 
 The local health departments are to use the Report of Verified Case of 
Tuberculosis (RVCT) to report confirmed cases of TB to the state. 
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Healthcare Providers 
  
Healthcare providers should report the following information on confirmed or suspected 
cases of TB. 
 
Reporting Healthcare Provider  
 Name 
 Address 
 Phone number 
 Date of report 
 
Patient Information  
 Name 
 Address 
 Phone numbers 
 Marital status 
 Employment information 
 Hospital admission information (name 
of hospital if applicable, date of 
admission) 
 Type of isolation arrangements (if 
applicable, home, hospital, other) 
 
Demographic and Social Information 
 Date of birth 
 Sex 
 Race/ethnic origin 
 Country of birth/date of arrival in the 
U.S. 
 Drug and alcohol use 
 Homeless within past year? 
 Diagnosed in a correctional facility or 
long-term care facility? 
 
Medical Information 
 Reason for test 
 Symptoms/onset 
 Disease site 
 Comorbid health conditions  
 Human immunodeficiency virus (HIV) 
testing information 
 Results of QuantiFERON®-TB Gold 
(QFT-G) or tuberculin skin test (TST) 
(TST in mm) and date of test 
 Chest radiograph results and dates (if 
applicable) 
 Bacteriology results, date(s), and 
name of laboratory performing test(s) 
 Drug therapy (medications used, 
dates given, mode of treatment) 
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Laboratories 
Laboratories should complete a Report of a Positive Laboratory Finding for Mycobacteria 
and submit to the Arizona Department of Health, TB Control Section with the following 
information on test results. All appropriate data fields need to be completed. If you need 
additional reporting forms contact the Arizona Department of Health, TB Control Section 
at 602-364-4750. 
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Required Reports from Local Public Health Agencies to 
to the Arizona Tuberculosis Program 
Local public health agencies are required to complete and submit the reports listed in 
Table 3 to the TB Control Program at the Arizona Department of Health Services: 
 
Table 3: REQUIRED REPORTS 
 
ADHS Prevention Registry Form 
Report of Verified Case of Tuberculosis (RVCT) 
RVCT Initial Drug Susceptibility Report 
RVCT Case Completion Report 
RVCT Addendum Form 
Report of a positive laboratory finding for mycobacteria 
 
 
 
The ADHS registry form is available in the Forms Sections. To obtain the 
other forms for the above required reports, contact ADHS at 602-364-4750. 
The Report of Verified Case of Tuberculosis (RVCT) forms are designed to collect 
information on cases of TB. Data obtained from RVCT forms are entered into the 
Tuberculosis Information Management System (TIMS) by the Arizona Department of 
Health Services, TB Control Program and then transferred electronically to the CDC. 
While a case of TB is required to be reported to the CDC only if active disease is verified 
and the case is to be part of the annual morbidity count, the CDC encourages the use of 
the RVCT forms and TIMS for the collection of data on suspected cases of TB. 
Verification of suspect cases can be accomplished through period updates of the 
records in TIMS.22  
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Data Collection  
Forms 
It is recommended that the following standardized forms (or similar forms developed by 
local public health agencies) be completed and placed in the patient’s chart if and when 
the related activities are performed.  
 
Table 4: RECOMMENDED FORMS FOR A TUBERCULOSIS PATIENT’S CHART 
Chart of a Patient on Treatment for Tuberculosis Disease 
Tuberculosis (TB) Disease Treatment/Case 
Management 
 
Patient Education 
 
Confidentiality and Medical Records  
 
Contact Investigation 
 
B Notifications 
 
Transfer Notifications 
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The following forms (or similar forms developed by local public health agencies) should 
be completed and placed in files for LTBI treatment and contact investigations.  
Table 5: RECOMMENDED FORMS FOR A LATENT TUBERCULOSIS INFECTION 
PATIENT’S CHART AND FOR A CONTACT INVESTIGATION FILE 
Chart of a Patient on Treatment for Latent Tuberculosis Infection 
Latent Tuberculosis Infection (LTBI) Treatment 
Contact Investigation Form 
Transfer Notifications 
 
 
 
 
To download forms for the above required reports, go to the Forms Section 
Computerized Tuberculosis Registry 
To carry out mandatory community public health responsibilities, the state TB control 
program maintains a computerized record system (case registry) with up-to-date 
information on all current clinically active and suspected TB cases in the community.23 
The TB case registry should ensure that laboratory data, including all initial diagnostic 
tests, are promptly reported, if applicable, to the healthcare provider and local and state 
TB control programs. Follow-up tests, including data on sputum culture conversion and 
drug susceptibility testing of clinical isolates, should also be promptly reported so any 
needed modifications in management can be made. Aggregate program data should be 
analyzed, interpreted, and made available to the healthcare community and to 
community groups and organizations with specific interests in public health. Providing 
this information supports education and advocacy and facilitates their collaboration in the 
planning process. 
To ensure appropriate follow-up of all TB patients and persons suspected of having TB, 
the following registry information is updated by the Arizona Department of Health 
Services on a continuing basis:24 
 Acid-fast bacilli smear results 
 Culture results  
 Drug susceptibility results 
 Clinical status 
 Chest radiograph results 
 Doses of medications being administered 
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 Document Retention 
 
State Laws and Regulations 
http://www.azleg.gov/FormatDocument.asp?inDoc=/ars/12/02297.htm&Title=12&DocType=ARS
http://www.lib.az.us/records/pdf/State_RD.pdf 
 
The Arizona TB Program will maintain all state TB public health records for five (5) 
years.  
Radiographs are not stored by the state. Radiographs are held by the principle 
healthcare provider or radiology office where the radiographs were obtained. 
Case management health information and other TB records should be maintained at the 
local public health agency according to current applicable record retention rules and 
regulations. 
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Genotyping 
Genotyping is a useful tool for studying the pathogenesis, epidemiology, and 
transmission of Mycobacterium tuberculosis. M. tuberculosis genotyping refers to 
laboratory procedures developed to identify M. tuberculosis isolates that are identical in 
specific parts of the genome (of similar strain types).  
The addition of genotype information to the pool of information generated by surveillance 
data and data collected through epidemiologic investigation allow confirmation of 
suspected transmission. A potential outbreak should be suspected whenever there is 
more than one case of TB whose isolate has the same genotype (genotype cluster). 
Further investigation that includes review of surveillance data, chart review, and 
reinterview of TB cases may refute or confirm the epidemiologic connection between 
more than one TB case. In some instances, a genotype cluster reflects a false-positive 
culture that may be a result of laboratory cross-contamination. Routine review of 
genotyping data, along with epidemiologic, clinical, and laboratory data, may identify 
patients who are wrongly classified as TB patients and should be further investigated.  
The Arizona Department of Health Services, TB Control Program reviews all genotype 
results for clusters and contacts the appropriate local health agency or others as 
necessary. 
 
For more information on genotyping, see the National Tuberculosis 
Controllers Association/Centers for Disease Control and Prevention 
Advisory Group on Tuberculosis Genotyping’s Guide to the Application of 
Genotyping to Tuberculosis Prevention and Control (2004) at 
http://www.cdc.gov/tb/genotyping/manual.htm . 
 
All positive M. tuberculosis cultures should be sent to your state public 
health laboratory for referral to the appropriate national genotyping 
laboratory.  
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Dissemination and Evaluation 
Dissemination  
Tuberculosis (TB) surveillance data should be disseminated periodically to healthcare 
providers, health agencies, and the public through multiple channels including health 
alerts, reports, summaries, and presentations.  
Evaluation 
The purpose of evaluating public health surveillance systems is to ensure that problems 
of public health importance are being monitored efficiently and effectively. TB 
surveillance systems should be evaluated periodically, and the evaluation should include 
recommendations for improving quality, efficiency, and usefulness. Evaluation of a public 
health surveillance system focuses on how well the system operates to meet its purpose 
and objectives.  
 
For more information see the CDC’s “Updated Guidelines for Evaluating 
Public Health Surveillance Systems” (MMWR 2001;50[No RR-13]) at  
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5013a1.htm . 
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Introduction 
Purpose 
Use this section to understand and follow national and the Arizona Department of Health 
Services guidelines to conduct targeted testing to screen for latent tuberculosis infection 
(LTBI). 
In the 2005 guideline “Controlling Tuberculosis in the United States: Recommendations 
from the American Thoracic Society, CDC, and the Infectious Diseases Society of 
America,” one of the recommended strategies to achieve the goal of reduction of 
tuberculosis (TB) morbidity and mortality is the identification of persons with LTBI at risk 
for progression to TB disease, and treatment of those persons with an effective drug 
regimen.1 
For information on treatment, refer to the Treatment of Tuberculosis 
Disease and Treatment of Latent Tuberculosis Infection sections.  
 
 
Reducing LTBI in high-risk populations is an important strategy to control TB. With an 
estimated 9.5–14.7 million persons with LTBI in the United States, continued progress 
toward eliminating TB in the United States and reducing TB among foreign-born persons 
requires effective strategies to meet this challenge.2 Targeted testing for LTBI is a 
strategic component of TB control that identifies persons at high risk for developing TB 
who would benefit by treatment of LTBI, if detected. Persons with increased risk for 
developing TB include those who have had recent infection with Mycobacterium 
tuberculosis and those who have clinical conditions that are associated with an 
increased risk for progression of LTBI to active TB.3  
Policy  
 
In Arizona: 
 Persons who show or report signs and symptoms of TB should be evaluated for TB 
disease as described in the “Diagnosis of Tuberculosis Disease” topic in this section 
and reported as suspected cases of TB as described in the “Reporting Tuberculosis” 
topic in the Surveillance section.  
 Contacts should be evaluated as described in the Contact Investigation section. 
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 Targeted testing for LTBI should be conducted only among persons in groups with 
identified risk factors for LTBI and/or progression to TB disease.  
 For a list of groups at high risk, refer to Table 1: Persons at High Risk for 
Tuberculosis Infection and Progression to Tuberculosis Disease.  
 
For roles and responsibilities, refer to the “Roles, Responsibilities, and 
Contact Information” topic in the Introduction. 
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State Laws and Regulations 
Arizona Laws/Rules Regarding Tuberculosis Control 
Arizona Revised Statutes.  Title 36:  Public Health and Safety; Chapter 6:  
Public Health Control; Title 6:  Tuberculosis Control.  (ARS§36-711 
through §36-738)  
ARS§36-711.  Definitions.   
ARS§36-712. Administration by the department.   
ARS§36-714.  Tuberculosis control officer.   
ARS§36-715.  Costs; removals; proceedings.   
ARS§36-716.  Payment of assistance.   
ARS§36-717.  Responsibility for care or treatment by counties.   
ARS§36-718.  Contracting for care of afflicted persons.   
ARS§36-721.  Rules.   
ARS§36-723.  Investigation of tuberculosis cases.   
ARS§36-724.  Voluntary control measures.   
ARS§36-725.  Orders to cooperate; emergency custody.    
ARS§36-726.  Petition for court ordered examination, monitoring, 
treatment, isolation or quarantine.   
ARS§36-727. Hearings; procedure; confidentiality.   
ARS§36-728. Judicial action.   
ARS§36-729. Amended orders for intervention and transport of afflicted 
persons.   
ARS§36-730.  Appointment of guardian or conservator.   
ARS§36-731.  Confinement; selection; jails; prohibition.   
ARS§36-732.  Early release from court ordered treatment.   
ARS§36-733.  Choice of physician and mode of treatment.   
ARS§36-734.  Treatment; exemption.   
ARS§36-735.  Notification of rights.   
ARS§36-736.  Administrative procedures act; judicial review of 
administrative procedures; exemption; appeals.  
ARS§36-737.  Violation; classification.   
ARS§36-738.  Qualified immunity.   
 
Arizona Administrative Code.  Title 9. Chapter 6.  Department of 
Health Services Communicable Diseases and Infestations.   
.   
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Tuberculosis Classification System  
The system for classifying tuberculosis (TB) is based on how the infection and disease 
develop in the body. Use this classification system to help track the status of TB in your 
patients and to allow comparison with other reporting areas.  
 
Table 1: TUBERCULOSIS CLASSIFICATION SYSTEM4  
Class Type Description 
0  No tuberculosis (TB) exposure 
 Not infected 
 No history of exposure 
 Negative reaction to the tuberculin skin test (TST) or 
interferon gamma release assay (IGRA)  
1  TB exposure 
 No evidence of infection 
 History of exposure 
 Negative reaction to the TST or IGRA 
2  TB infection 
 No disease 
 Positive reaction to the TST or IGRA 
 Negative bacteriologic studies (if done) 
 No clinical, bacteriologic, or radiographic evidence of TB 
disease 
3  TB disease 
 Clinically active 
 Mycobacterium tuberculosis complex cultured (if this has 
been done) 
 Clinical, bacteriologic, or radiographic evidence of 
current disease 
4  TB disease 
 Not clinically active 
 History of episode(s) of TB 
 Or 
 Abnormal but stable radiographic findings 
 Positive reaction to the TST or IGRA 
 Negative bacteriologic studies (if done) 
 And 
 No clinical or radiographic evidence of current disease 
5  TB suspect  Diagnosis pending  
Source: Adapted from: CDC. Classification system. In: Chapter 2: transmission and pathogenesis. Core Curriculum on 
Tuberculosis (2000) [Division of Tuberculosis Elimination Web site]. Updated November 2001. Available at: 
http://www.cdc.gov/tb/pubs/corecurr/default.htm . Accessed July 3, 2006. 
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High-Risk Groups  
Certain factors identify persons at high risk for tuberculosis (TB) infection and/or for 
progression to TB disease. Persons in the high-risk groups listed in Table 1: Persons at 
High Risk for Tuberculosis Infection and Progression to Tuberculosis Disease are 
candidates for tuberculin skin testing in Arizona.  
Persons with risk factors from both columns may be at much higher risk than those with 
risk factors in only one column. For example, an individual born in a high-TB-prevalence 
country with HIV infection is at much higher risk of having active TB than a US-born 
individual with HIV infection.  
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TABLE 2: Persons at high risk for Tuberculosis Infection and Progression to Tuberculosis 
Disease5 
For Tuberculosis Infection For Progression to Tuberculosis Disease6  
 High-priority contacts such as housemates or 
coworkers or contacts of persons who have smear-
positive pulmonary or laryngeal TB  
 Infants, children, and adolescents exposed to adults 
in high-risk categories 
 Recent immigrants (<5 years) from countries with 
high incidence of TB (Asian, African, Latin American, 
and Eastern European countries have TB rates 5–30 
times higher than U.S. rates, and an increasing 
percentage of TB cases here are occurring among 
immigrants from those countries)  
 Recent immigrants from Mexico 
 Migrant workers 
 Persons who have recently spent over 3 months in 
high-incidence countries (such as missionaries from 
the Church of Jesus Christ of Latter-Day Saints) 
 Native Americans 
 Persons with high rates of TB transmission:  
• Homeless persons 
• Injection drug users 
• Persons with human immunodeficiency virus 
(HIV) infection  
• Persons living or working in institutions with 
individuals at risk for TB such as:  
 Hospitals, especially staff in nursing, 
emergency departments, and laboratories  
 Long-term care facilities  
 Homeless shelters 
 Residences for acquired immunodeficiency 
syndrome (AIDS) patients 
 Correctional facilities 
 Persons with HIV infection 
 Infants and children aged <5 years 
 Persons infected with Mycobacterium tuberculosis 
within the previous 2 years 
 Persons with a history of untreated or inadequately 
treated TB disease 
 Persons with radiographic findings consistent with 
previous TB disease 
 Persons who use alcohol or illegal drugs (such as 
injection drugs or crack cocaine)  
 Persons with any of the following clinical conditions 
or other immunocompromising conditions: 
• Silicosis 
• Diabetes mellitus 
• End-state renal disease (ESRD)/chronic renal 
failure, hemodialysis  
• Some hematologic disorders (e.g., leukemias and 
lymphomas) 
• Other malignancies (e.g., carcinoma of head, 
neck, or lung) 
• Body weight ≥10% below idea body weight  
• Prolonged corticosteroid use 
• Use of other immunosuppressive treatments (e.g., 
prednisone or tumor necrosis factor-alpha [TNF- 
α] antagonists) 
• Organ transplantation  
• Gastrectomy 
• Chronic malabsorption syndromes 
• Jejunoileal bypass 
 
Source: Adapted from: CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care 
settings, 2005. MMWR 2005;54(No. RR-17):4–5; CDC. Targeted tuberculin testing and treatment of latent tuberculosis 
infection. MMWR 2000;49(No. RR-6):7–9.  
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When to Conduct Targeted Testing 
Targeted testing programs should be conducted only among groups at high risk, and 
testing should be discouraged for groups at low risk.7 High-risk groups include persons 
with increased risk for developing tuberculosis (TB) and those who have clinical 
conditions that are associated with an increased risk for progress of latent TB infection 
(LTBI) to TB disease.  
Factors that identify persons at high risk of LTBI infection and/or 
progressing to TB disease are listed in Table 1: Persons at High Risk for 
Tuberculosis Infection and Progression to Tuberculosis Disease. 
Evaluate high-risk patients for LTBI as specified in the Diagnosis of Latent 
Tuberculosis Infection section.  
Offer treatment of LTBI to infected persons, irrespective of age, who are 
considered to be at high risk for developing active TB.8 See the Treatment 
of Latent Tuberculosis Infection section. 
 
Approaches to Increasing Targeted Testing  
and Treatment of Latent Tuberculosis Infection 
The Centers for Disease Control and Prevention (CDC) describes two approaches to 
increasing targeted testing and treatment of LTBI. To plan and implement programs for 
targeted testing and treatment of LTBI, follow the recommended approaches outlined 
below.9 
One approach is to promote clinic-based testing of persons who are under a clinician’s 
care for a medical condition (e.g., human immunodeficiency virus [HIV] infection or 
diabetes mellitus) that also confers a risk for acquiring TB. This approach depends on a 
person’s risk profile for TB.10  
The other approach is to establish specific programs that target a subpopulation of 
persons who have a high prevalence of LTBI or who are at high risk for acquiring TB 
disease if they have LTBI, or both. This approach requires identifying the subpopulations 
or areas with high TB risk through epidemiologic analysis and profiling.11   
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 For information on the system for prioritizing persons for targeted testing, refer 
to “Controlling Tuberculosis in the United States: Recommendations from the 
American Thoracic Society, CDC, and the Infectious Diseases Society of 
America” (MMWR 2005;54[No. RR-12]:40–42) at 
http://www.cdc.gov/mmwr/PDF/rr/rr5412.pdf . 
For assistance in planning targeted testing, contact the Arizona Department of 
Health Services TB Program at 602-364-4750. 
 
Screening for Latent Tuberculosis Infection in Facilities 
Screening for LTBI should be conducted based upon each facility’s risk for transmission 
of Mycobacterium tuberculosis (i.e., low risk, medium risk, or potential for ongoing 
transmission),12 as determined in its TB risk assessment (both initial baseline 
assessment and periodic reassessments).  
 
Risk assessment protocols and elements are outlined in the CDC’s 
“Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in 
Health-care Settings, 2005” (MMWR 2005;54[No. RR-17]) at 
http://www.cdc.gov/mmwr/pdf/rr/rr5417.pdf . 
 
In Arizona facilities such as hospitals should follow the Occupational Safety 
and Health Administration (OSHA) located at the following web-site: 
http://www.osha.gov/SLTC/tuberculosis/standards.html 
 
Screening determines if a person should be evaluated for LTBI or TB disease by asking 
questions to gather information about whether the person 
 Has signs or symptoms of TB disease;  
 Belongs to a group at high risk for LTBI or (if infected) for progression to TB disease; 
or 
 Has a prior positive tuberculin skin test (TST). 
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Introduction 
Purpose 
Use this section to: 
 Follow up on B1 and B2 notifications and 
 Evaluate and treat immigrants with B1 and B2 notifications. 
B notifications are sent by the Centers for Disease Control and Prevention (CDC) to the 
Arizona Department of Health Services Tuberculosis (TB) Program as follow-up to the 
screening mandated by US immigration law. The CDC and the Advisory Council for the 
Elimination of Tuberculosis (ACET) recommend screening high-risk populations for TB, 
including recent arrivals from areas of the world with a high prevalence of TB. Therefore, 
screening of foreign-born persons is a public health priority.1 On the basis of its very 
high success rate of detecting TB cases, domestic follow-up evaluation of immigrants 
and refugees with Class B1 and B2 TB notification status should be given highest priority
by all TB control programs.
 
B 
 
e 
obtained.  
2 Legal immigrants and refugees with Class B1 and B2 T
notification status are also a high-priority subpopulation for screening for latent TB 
infection (LTBI).3  
The purpose of mandated screening is to deny entry to persons who have either 
communicable diseases of public health import or physical or mental disorders 
associated with harmful behavior, abuse drugs or are addicted to drugs, or are likely to 
become wards of the state.4  
Not all foreign-born persons who enter the United States go through the same official 
channels or through the screening process.5 For a summary of which groups of foreign-
born persons are screened, refer to Table 1: Numbers of Foreign-Born Persons Who 
Entered the United States, by Immigration Category, 2002. 
Persons entering in the nonimmigrant category do not require pre-entry screening, but 
as a condition of entry, persons migrating as immigrants, refugees, and asylees are 
required to be screened outside the United States for diseases of public health 
significance, including TB.6,7 Applicants for immigration who plan to relocate 
permanently to the United States are required to have a medical evaluation prior to 
entering the country. Visa applicants 15 years or older must have a chest radiograph
performed overseas as part of that medical evaluation. If the chest radiograph is 
suggestive of pulmonary TB disease, sputa for acid-fast bacilli (AFB) smears must b
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Table 1: NUMBERS OF FOREIGN-BORN PERSONS WHO ENTERED THE UNITED 
STATES, BY IMMIGRATION CATEGORY, 20028,9 
Category Number  Percentage 
of Total 
Screening 
Required? 
Immigrants are defined by the Office of Immigration 
Statistics (OIS) as persons legally admitted to the United 
States as permanent residents.   
384,000 
 
1.38% 
 
Yes 
Refugees and asylees, as defined by OIS, are persons 
admitted to the United States because they are unable 
or unwilling to return to their country of nationality due to 
persecution or a well-founded fear of persecution. 
Refugees apply for admission at an overseas facility and 
enter the United States only after their application is 
granted; asylees apply for admission when already in 
the United States or at a point of entry. 
132,000 
 
0.46% 
 
Yes 
Nonimmigrants are aliens granted temporary entry to 
the United States for a specific purpose (most common 
visa classifications for nonimmigrants are visitors for 
pleasure, visitors for business, temporary workers, and 
students). 
27,907,000 
 
98.18% 
 
No 
The foreign-born population, as defined by the 
Census Bureau, refers to all residents of the United 
States who were not US citizens at birth, regardless of 
their current legal or citizenship status.  
28,423,000 100% See above 
Unauthorized immigrants (also referred to as illegal or undocumented immigrants) are foreign citizens illegally 
residing in the United States. They include both those who entered without inspection and those who violated the 
terms of a temporary admission without having gained either permanent resident status or temporary protection 
from removal.10  
Sources: Congress of the United States, Congressional Budget Office. A Description of the Immigrant Population. 
Washington, DC: Congressional Budget Office; November 2004; and ATS, CDC, IDSA. Controlling tuberculosis in the 
United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of 
America. MMWR 2005;54(No. RR-12):46. 
Applicants who are identified as having abnormalities in their chest radiographs 
consistent with TB are classified according to the criteria in Table 2: Classification of 
Immigrants and Refugees in the B Notification Program. An applicant whose chest 
radiograph is compatible with active TB but whose sputum AFB smear results are 
negative is classified as having Class B1 status and may enter the United States. If the 
chest radiograph is compatible with inactive TB, no sputum specimens are required, and 
the applicant enters the country with Class B2 status.11 If abnormalities are present in a 
chest radiograph and if sputum AFB smears are positive, the applicant must receive a 
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Class A waiver before entry into the United States. Very few persons with A waivers 
enter the United States, so A waivers are not covered in these guidelines. 
The Class B notification system follows up on medical screenings of persons with B1 
and B2 classifications after their arrival in the United States.12,13 Immigrants with a Class 
A waiver or with Class B1 or B2 status are identified at ports of entry to the United States 
by the US Citizenship and Immigration Services (USCIS) on entry to the United States 
and reported to CDC’s Division of Global Migration and Quarantine (DGMQ). The 
DGMQ notifies state and local health departments of refugees and immigrants with TB 
classifications who are moving to their jurisdiction and need follow-up evaluations. 
Persons with a Class A waiver are required to report to the jurisdictional public health 
agency for evaluation or risk deportation. For persons with Class B1 and B2 status, 
however, the stipulated evaluation visits to the health agency are voluntary.14 
Table 2: CLASSIFICATION OF IMMIGRANTS AND REFUGEES IN  
THE B NOTIFICATION PROGRAM15 
Immigrant/ 
Refugee 
Classification 
Overseas Chest 
Radiograph 
Overseas 
Sputum Acid-
Fast Bacilli 
Smears 
Restrictions 
A Waiver* Abnormal, 
suggestive of 
active tuberculosis 
(TB) disease 
Positive May not enter the United States 
unless started on antituberculosis 
therapy and sputum smears are 
negative and apply for a waiver signed 
by the local health department in their 
intended US destination (A Waiver) 
or 
 Complete TB therapy overseas 
B1 Abnormal, 
suggestive of 
active TB disease 
Negative Instructed to voluntarily report to the 
local health department in the United 
States for further medical evaluation 
within 30 days of arrival  
B2 Abnormal, 
suggestive of 
inactive TB 
disease 
Negative Same as above 
* Very few persons with A waivers enter the United States, so they are excluded from these guidelines. 
Source: California Department of Health Services (CDHS)/California Tuberculosis Controllers Association (CTCA). 
Guidelines for the follow-up and assessment of persons with Class B1/B2 tuberculosis. CDHS/CTCA Joint Guidelines 
[CTCA Web site]. September 1999:1. Available at: http://www.ctca.org/guidelines/IIA7bnotification.pdf .  Accessed 
November 1, 2006. 
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Policy  
Newly arrived refugees and immigrants with Class B1/B2 TB will receive thorough and 
timely TB evaluations and appropriate treatment to ensure prompt detection of TB 
disease and prevention of future cases.16 
For roles and responsibilities, refer to the “Roles, Responsibilities, and 
Contact Information” topic in the Introduction. 
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State Laws and Regulations 
Arizona Laws/Rules Regarding Tuberculosis Control 
Arizona Revised Statutes.  Title 36:  Public Health and Safety; Chapter 6:  
Public Health Control; Title 6:  Tuberculosis Control.  (ARS§36-711 
through §36-738)  
ARS§36-711.  Definitions.   
ARS§36-712. Administration by the department.   
ARS§36-714.  Tuberculosis control officer.   
ARS§36-715.  Costs; removals; proceedings.   
ARS§36-716.  Payment of assistance.   
ARS§36-717.  Responsibility for care or treatment by counties.   
ARS§36-718.  Contracting for care of afflicted persons.   
ARS§36-721.  Rules.   
ARS§36-723.  Investigation of tuberculosis cases.   
ARS§36-724.  Voluntary control measures.   
ARS§36-725.  Orders to cooperate; emergency custody.    
ARS§36-726.  Petition for court ordered examination, monitoring, 
treatment, isolation or quarantine.   
ARS§36-727. Hearings; procedure; confidentiality.   
ARS§36-728. Judicial action.   
ARS§36-729. Amended orders for intervention and transport of afflicted 
persons.   
ARS§36-730.  Appointment of guardian or conservator.   
ARS§36-731.  Confinement; selection; jails; prohibition.   
ARS§36-732.  Early release from court ordered treatment.   
ARS§36-733.  Choice of physician and mode of treatment.   
ARS§36-734.  Treatment; exemption.   
ARS§36-735.  Notification of rights.   
ARS§36-736.  Administrative procedures act; judicial review of 
administrative procedures; exemption; appeals.  
ARS§36-737.  Violation; classification.   
ARS§36-738.  Qualified immunity.   
 
Arizona Administrative Code.  Title 9. Chapter 6.  Department of 
Health Services Communicable Diseases and Infestations.   
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Follow-up of B1 and B2  
Tuberculosis Arrivals  
Division of Global Migration and Quarantine Forms 
The Centers for Disease Control and Prevention (CDC) Division of Global Migration and 
Quarantine (DGMQ) generates the following Class B notification forms:  
 CDC 75.17: “Notice of Arrival of Alien with Tuberculosis” 
 DS-2053: “Medical Examination for Immigrant or Refugee Application” 
 DS-3024: “Chest X-Ray and Classification Worksheet”  
The DGMQ sends the notifications to the state TB program. The DGMQ also sends a 
letter to any immigrant or refugee with a tuberculosis (TB) condition, indicating that a 
follow-up is needed in the United States.17 
The Class B notification forms are then faxed and mailed to the appropriate local health 
departments. 
Data Entry 
Enter all immigrants’ names and addresses in the logbook or registry at the state TB 
program. 
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L  B Notifications 4.7 
Revised 12/04/07 
Patient Follow-up 
 
The immigration paperwork may make it appear that a patient has had a 
complete evaluation for TB disease. However, the overseas evaluation is 
designed only to detect abnormal radiographs and determine 
infectiousness at the time of travel and does not rule out disease. 
Remember that all B1 and B2 arrivals need a new diagnostic evaluation for 
active disease, including a tuberculin skin test and new chest radiograph. 
Even if active TB disease is ruled out, most B1 and B2 arrivals are priority 
candidates for treatment of latent TB infection. 
Follow-up on each B1 and B2 arrival is described below. 
1. Check to see if the immigrant has already visited the health department or a private 
provider.  
2. If not, then make a telephone call to the home of the immigrant’s sponsor or relative 
within five business days after receiving the notification. Arrange for the immigrant to 
come in during clinic hours at the health department and/or arrange for the patient to 
see a private provider. Whenever possible, communications should be made in the 
immigrant’s first language. 
3. If the immigrant does not visit the health department or a private provider within 10 
business days (two weeks) of the telephone call, send a letter to the home of the 
immigrant’s sponsor or relative. Whenever possible, communications should be 
made in the immigrant’s first language. 
4. If the immigrant does not visit the health department or a private provider within 10 
business days (two weeks) of the letter, make a visit to the home of the immigrant’s 
sponsor or relative. Take a representative who speaks the immigrant’s first language 
if at all possible (if needed). 
5. Every effort should be made to locate B1 or B2 arrivals as these immigrants are 
considered high risk for TB disease. Call the Arizona Department of Health Services 
TB Program for consultation when an immigrant is not located. 
6. Complete Class B follow-up within one month.   
7. Complete and return the B notification form CDC 75.17 to the Arizona Department of 
Health Services TB Program.18 This form is essential for the Arizona Department of 
Health Services TB Program to conduct statewide surveillance and follow-up on all 
B1 and B2 arrivals and report results to the CDC. 
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Evaluation of B1 and B2  
Tuberculosis Arrivals  
Evaluation Activities 
B1 arrivals had negative sputum acid-fast bacilli results overseas and have overseas 
chest radiographs that are abnormal and suggestive of active TB disease 
B2 arrivals had negative sputum acid-fast bacilli results overseas and have overseas 
chest radiographs that are abnormal and suggestive of inactive TB disease. 
Refer to Table 3 to determine which evaluation tasks should be done for B1 and B2 
arrivals. 
Table 3: EVALUATION ACTIVITIES FOR B1 AND B2 ARRIVALS19 
Evaluation Activities B1 
Active TB 
B2 
Inactive TB 
Determine tuberculin skin test (TST) status. If documentation is not 
available, administer a TST. A reaction of ≥5 mm is considered significant for 
persons with an abnormal chest radiograph.  
Yes Yes 
Review the chest radiograph. Even if patients have their overseas chest 
radiographs available for comparison, a new chest radiograph generally 
should be taken.  
Yes Yes 
Review tuberculosis (TB) treatment history with the patient. Treatment 
history may be on the visa medical examination report, form DS-2053: 
Medical Examination for Immigrant or Refugee Application. In some cases, 
patients have received treatment not documented on the DS-2053. 
Regardless of chest radiograph result, collect sputum specimens if the patient 
is symptomatic. 
Yes Yes 
Collect sputum for testing. Sputum specimens should be collected 8 to 24 
hours apart, with at least one being an early morning specimen. Collect 
sputum for testing, at the provider’s discretion, based on the evaluation. 
Remember that a chest radiograph does not rule out TB disease with 
certainty. Regardless of chest radiograph result, collect sputum specimens if 
the patient is symptomatic. 
Yes If symptoms 
present 
Sources: Francis J. Curry National Tuberculosis Center. Recommended TB clinic procedures for Class B1 TB arrivals and 
recommended TB clinic procedures for Class B2 TB arrivals. In: Text: step-by-step guide. B Notification Assessment 
and Follow-up Toolbox [Francis J. Curry National Tuberculosis Center Web site]. San Francisco, CA; January 2004. 
Available at: http://www.nationaltbcenter.edu/products/product_details.cfm?productID=WPT-06%20A . Accessed 
November 1, 2006. 
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Treatment 
Prescribe medications as appropriate. Do not start patients on single-drug therapy for 
latent TB infection (LTBI) until tuberculosis (TB) disease is ruled out. B1/B2 immigrants 
with positive tuberculin skin tests and for whom active TB has been ruled out are priority 
candidates for treatment of LTBI because of the increased probability of recent infection 
and subsequent progression to active TB disease. Patients with fibrotic lesions on a 
chest radiograph suggestive of old, healed TB are candidates for treatment of LTBI, 
regardless of age.  
 
The overseas diagnosis of clinically active TB disease is based on the 
abnormal chest radiograph. Reevaluation in the United States may show 
the patient to actually have old, healed TB. According to current 
CDC/American Thoracic Society (ATS) recommendations, old, healed TB 
can be treated with four months of isoniazid and rifampin using a combined 
pill, Rifamate (if available) or with nine months of isoniazid.20
For more information on treatment, see the Treatment of Latent 
Tuberculosis Infection and Treatment of Tuberculosis Disease sections. 
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Resources and References 
Resources 
 California Department of Health Services (CDHS)/California Tuberculosis Controllers 
Association (CTCA). “Guidelines for the Follow-up and Assessment of Persons with 
Class B1/B2 Tuberculosis” (CDHS/CTCA Joint Guidelines; September 1999). 
Available at: http://www.ctca.org/guidelines/IIA7bnotification.pdf . 
 Centers for Disease Control and Prevention (CDC) Division of Global Migration and 
Quarantine (DGMQ). “Medical Examinations of Aliens (Refugees and Immigrants)” 
(CDC Web site; accessed September 25, 2006). Available at: 
http://www.cdc.gov/ncidod/dq/health.htm  
 Francis J. Curry National Tuberculosis Center. B-Notification Assessment and 
Follow-up Toolbox (Francis J. Curry National Tuberculosis Center Web site; January 
2004). Available at: 
http://www.nationaltbcenter.edu/products/product_details.cfm?productID=WPT-
06%20A . 
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Introduction 
Purpose 
Use this section to understand and follow national and Arizona guidelines to 
 Classify patients with tuberculosis (TB) disease and latent TB infection (LTBI); 
 Detect suspected cases of TB; 
 Know when to report suspected or confirmed cases of TB; and 
 Diagnose TB disease. 
 
It is important to understand when a person should be evaluated further for TB disease. 
Not recognizing TB symptoms promptly will lead to delays in treating a TB case—and to 
more infection, TB disease, and contacts to evaluate.  
In the 2005 guideline, “Controlling Tuberculosis in the United States: Recommendations 
from the American Thoracic Society, Centers for Disease Control and Prevention, and 
the Infectious Diseases Society of America,” one of the recommended strategies to 
achieve the goal of reduction of TB morbidity and mortality is early and accurate 
detection, diagnosis, and reporting of TB cases, leading to initiation and completion of 
treatment.1 
 
Contacts are mentioned within this section, but their evaluation and follow-
up and contact investigation are covered in more depth in the Contact 
Investigation section. For information on treatment, refer to the Treatment 
of Tuberculosis Disease section. 
Improvement in the detection of TB cases is essential to progress toward elimination of 
TB in the United States.2 Case detection includes the processes that lead to the 
presentation, evaluation, receipt of diagnosis, and reporting of persons with active TB.3 
Detecting and reporting suspected cases of TB are key steps in stopping transmission of 
Mycobacterium tuberculosis because it leads to prompt initiation of effective multiple-
drug treatment, which rapidly reduces infectiousness.4  
TB is commonly diagnosed when a person seeks medical attention for symptoms 
caused by the disease or a concomitant medical condition. Thus, healthcare providers, 
particularly those providing primary healthcare to populations at high risk, are key 
contributors to TB case detection.5 The majority of pulmonary TB cases continue to be 
diagnosed at an advanced stage. Earlier diagnosis would result in less individual 
morbidity and death, greater success in treatment, less transmission to contacts, and 
fewer outbreaks of TB.6 
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A diagnosis of TB disease is usually based on positive cultures for M. tuberculosis. 
However, TB may also be diagnosed on the basis of clinical signs and symptoms in the 
absence of a positive culture. Positive cultures for M. tuberculosis confirm the diagnosis 
of TB; however, TB may also be diagnosed on the basis of clinical signs and symptoms 
in the absence of a positive culture.  
Policy  
In Arizona: 
 Persons who show or report signs and symptoms of TB should be evaluated for TB 
disease as described in the “Diagnosis of Tuberculosis Disease” topic in this section 
and reported as suspected cases of TB as described in the “Reporting Tuberculosis” 
topic in the Surveillance section.  
 Contacts should be evaluated as described in the Contact Investigation section. 
 
For roles and responsibilities, refer to the “Roles, Responsibilities, and 
Contact Information” topic in the Introduction.  
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State Laws and Regulations 
Arizona Laws/Rules Regarding Tuberculosis Control 
Arizona Revised Statutes.  Title 36:  Public Health and Safety; Chapter 6:  
Public Health Control; Title 6:  Tuberculosis Control.  (ARS§36-711 
through §36-738)  
ARS§36-711.  Definitions.   
ARS§36-712. Administration by the department.   
ARS§36-714.  Tuberculosis control officer.   
ARS§36-715.  Costs; removals; proceedings.   
ARS§36-716.  Payment of assistance.   
ARS§36-717.  Responsibility for care or treatment by counties.   
ARS§36-718.  Contracting for care of afflicted persons.   
ARS§36-721.  Rules.   
ARS§36-723.  Investigation of tuberculosis cases.   
ARS§36-724.  Voluntary control measures.   
ARS§36-725.  Orders to cooperate; emergency custody.    
ARS§36-726.  Petition for court ordered examination, monitoring, 
treatment, isolation or quarantine.   
ARS§36-727. Hearings; procedure; confidentiality.   
ARS§36-728. Judicial action.   
ARS§36-729. Amended orders for intervention and transport of afflicted 
persons.   
ARS§36-730.  Appointment of guardian or conservator.   
ARS§36-731.  Confinement; selection; jails; prohibition.   
ARS§36-732.  Early release from court ordered treatment.   
ARS§36-733.  Choice of physician and mode of treatment.   
ARS§36-734.  Treatment; exemption.   
ARS§36-735.  Notification of rights.   
ARS§36-736.  Administrative procedures act; judicial review of 
administrative procedures; exemption; appeals.  
ARS§36-737.  Violation; classification.   
ARS§36-738.  Qualified immunity.   
 
Arizona Administrative Code.  Title 9. Chapter 6.  Department of 
Health Services Communicable Diseases and Infestations.   
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Tuberculosis Classification System  
The system for classifying tuberculosis (TB) is based on how the infection and disease 
develop in the body. Use this classification system to help track the status of TB in your 
patients and to allow comparison with other reporting areas.  
 
Table 1: TUBERCULOSIS CLASSIFICATION SYSTEM7  
Class Type Description 
0  No tuberculosis (TB) exposure 
 Not infected 
 No history of exposure 
 Negative reaction to the tuberculin skin test (TST) or 
interferon gamma release assay (IGRA)  
1  TB exposure 
 No evidence of infection 
 History of exposure 
 Negative reaction to the TST or IGRA 
2  TB infection 
 No disease 
 Positive reaction to the TST or IGRA 
 Negative bacteriologic studies (if done) 
 No clinical, bacteriologic, or radiographic evidence of TB 
disease 
3  TB disease 
 Clinically active 
 Mycobacterium tuberculosis complex cultured (if this has 
been done) 
 Clinical, bacteriologic, or radiographic evidence of 
current disease 
4  TB disease 
 Not clinically active 
 History of episode(s) of TB 
 Or 
 Abnormal but stable radiographic findings 
 Positive reaction to the TST or IGRA 
 Negative bacteriologic studies (if done) 
 And 
 No clinical or radiographic evidence of current disease 
5  TB suspect  Diagnosis pending  
Source: Adapted from: CDC. Classification system. In: Chapter 2: transmission and pathogenesis. Core Curriculum on 
Tuberculosis (2000) [Division of Tuberculosis Elimination Web site]. Updated November 2001. Available at: 
http://www.cdc.gov/tb/pubs/corecurr/default.htm . Accessed July 3, 2006. 
 
 
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L  Diagnosis of Tuberculosis Disease 5 . 5  
R e v i s e d  1 2 / 0 4 / 0 7  
High-Risk Groups  
Certain factors identify persons at high risk for tuberculosis (TB) infection and/or for 
progression to TB disease. Persons in the high-risk groups listed in Table 2: Persons at 
High Risk for Tuberculosis Infection and Progression to Tuberculosis Disease are 
candidates for tuberculin skin testing in Arizona. 
Persons with risk factors from both columns may be at much higher risk than those with 
risk factors in only one column. For example, an individual born in a high-TB-prevalence 
country with HIV infection is at much higher risk of having active TB than a US-born 
individual with HIV infection.  
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TABLE 2: Persons at high risk for Tuberculosis Infection and Progression to 
Tuberculosis Disease8 
For Tuberculosis Infection For Progression to Tuberculosis Disease9  
 High-priority contacts such as housemates or 
coworkers or contacts of persons who have smear-
positive pulmonary or laryngeal TB  
 Infants, children, and adolescents exposed to adults 
in high-risk categories 
 Recent immigrants (<5 years) from countries with 
high incidence of TB (Asian, African, Latin American, 
and Eastern European countries have TB rates 5–30 
times higher than U.S. rates, and an increasing 
percentage of TB cases here are occurring among 
immigrants from those countries)  
 Recent immigrants from Mexico 
 Migrant workers 
 Persons who have recently spent over 3 months in 
high-incidence countries (such as missionaries from 
the Church of Jesus Christ of Latter-Day Saints) 
 Native Americans 
 Persons with high rates of TB transmission:  
• Homeless persons 
• Injection drug users 
• Persons with human immunodeficiency virus 
(HIV) infection  
• Persons living or working in institutions with 
individuals at risk for TB such as:  
 Hospitals, especially staff in nursing, 
emergency departments, and laboratories  
 Long-term care facilities  
 Homeless shelters 
 Residences for acquired immunodeficiency 
syndrome (AIDS) patients 
 Correctional facilities 
 Persons with HIV infection 
 Infants and children aged <5 years 
 Persons infected with Mycobacterium tuberculosis 
within the previous 2 years 
 Persons with a history of untreated or inadequately 
treated TB disease 
 Persons with radiographic findings consistent with 
previous TB disease 
 Persons who use alcohol or illegal drugs (such as 
injection drugs or crack cocaine)  
 Persons with any of the following clinical conditions 
or other immunocompromising conditions: 
• Silicosis 
• Diabetes mellitus 
• End-state renal disease (ESRD)/chronic renal 
failure, hemodialysis  
• Some hematologic disorders (e.g., leukemias and 
lymphomas) 
• Other malignancies (e.g., carcinoma of head, 
neck, or lung) 
• Body weight ≥10% below idea body weight  
• Prolonged corticosteroid use 
• Use of other immunosuppressive treatments (e.g., 
prednisone or tumor necrosis factor-alpha [TNF- 
α] antagonists) 
• Organ transplantation  
• Gastrectomy 
• Chronic malabsorption syndromes 
• Jejunoileal bypass 
 
Source: Adapted from: CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care 
settings, 2005. MMWR 2005;54(No. RR-17):4–5; CDC. Targeted tuberculin testing and treatment of latent tuberculosis 
infection. MMWR 2000;49(No. RR-6):7–9.  
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Case Finding 
Identifying Suspected Tuberculosis Cases 
The majority of tuberculosis (TB) cases are detected during the medical evaluation of 
symptomatic illnesses. Persons experiencing symptoms ultimately attributable to TB 
usually seek care not at a public health TB clinic but rather from other medical 
practitioners in other healthcare settings.10 Professionals in the primary healthcare 
sector, including hospital and emergency department clinicians, should be trained to 
recognize patients with symptoms consistent with TB.11 
Be alert for cases of TB among persons who have not sought medical care during 
evaluation of contacts of patients with pulmonary TB and of other persons with newly 
diagnosed infection with Mycobacterium tuberculosis. Perform screening for TB also 
during evaluation of immigrants and refugees with Class B1 or Class B2 TB notification 
status, during evaluations of persons involved in TB outbreaks, and occasionally in 
working with populations with a known high incidence of TB. Also, screen for TB disease 
when the risk for TB in the population is high and when the consequences of an 
undiagnosed case of TB are severe, such as in jails, prisons, and other correctional 
facilities.12 
Suspect pulmonary TB and initiate a diagnostic investigation when the historic features, 
signs, symptoms, and radiographic findings listed in Table 3 occur among adults. The 
clinical presentation of TB varies considerably as a result of the extent of the disease 
and the patient’s response. TB should be suspected in any patient who has a persistent 
cough for more than two to three weeks, or other compatible signs and symptoms.13  
Note that these symptoms should suggest a diagnosis of TB but are not required. TB 
should still be considered a diagnosis in asymptomatic patients who have risk factors for 
TB and chest radiographs compatible with TB. 
 
 
All persons who have a chronic cough for more than two to three weeks14 
should be evaluated and be asked to use a mask or tissue to cover their 
mouth. Hemoptysis, or coughing up blood, is a serious symptom, and 
patients who cough up blood should be evaluated as soon as possible. Be 
sure to have these patients use a mask and tissues. 
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Table 3: WHEN TO SUSPECT PULMONARY TUBERCULOSIS IN ADULTS15 
Historic Features  Exposure to a person with infectious tuberculosis (TB) 
 Positive test result for Mycobacterium tuberculosis infection 
 Presence of risk factors, such as immigration from a high-prevalence area, human 
immunodeficiency virus (HIV) infection, homelessness, or previous incarceration*  
 Diagnosis of community-acquired pneumonia that has not improved after 7 days of 
treatment†,16 
Signs and 
Symptoms Typical 
of TB 
 Prolonged coughing (≥2–3 weeks) with or without production of sputum that might be 
bloody (hemoptysis)§,17 
 Chest pain18 
 Chills19 
 Fever 
 Night sweats 
 Loss of appetite20 
 Weight loss 
 Weakness or easy fatigability21 
 Malaise (a feeling of general discomfort or illness)22 
Chest Radiograph: 
Immunocompetent 
patients 
 Classic findings of TB are upper-lobe opacities, frequently with evidence of 
contraction fibrosis and cavitation¶ 
Chest Radiograph: 
Patients with 
advanced HIV 
infection 
 Lower-lobe and multilobar opacities, hilar adenopathy, or interstitial opacities might 
indicate TB 
*  See Table 2: Persons at High Risk for Tuberculosis Infection and Progression to Tuberculosis Disease. 
†  Patients treated with levofloxacin or moxifloxacin may have a clinical response when TB is the cause of the pneumonia. 
§  Do not wait until sputum is bloody to consider a productive cough a symptom of TB. Sputum produced by coughing does 
not need to be bloody to be a symptom of TB.  
¶  These features are not specific for TB, and, for every person in whom pulmonary TB is diagnosed, an estimated 10–100 
persons are suspected on the basis of clinical criteria and must be evaluated. 
Source: Adapted from: ATS, CDC, IDSA. Controlling tuberculosis in the United States: recommendations from the 
American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR 2005;54(No. RR-12):33. 
Extrapulmonary Tuberculosis  
If a patient has a positive tuberculin skin test or interferon gamma release assay (IGRA), 
consider signs and symptoms of extrapulmonary TB.  
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Follow-up on Suspected Cases of Tuberculosis 
When a suspected case of TB is identified, the following should be done: 
 
When a suspected case of pulmonary TB is identified, refer to Table 4: 
Guidelines for the Evaluation of Pulmonary Tuberculosis in Adults in 
Five Clinical Scenarios in the “Diagnosis of Tuberculosis Disease” topic 
in this section. This table presents guidelines for the initial steps of TB 
case detection in five clinical scenarios encountered by providers of 
primary health care, including those serving in medical emergency 
departments.23
To formally report a suspected case of TB, see the “Reporting 
Tuberculosis” topic in the Surveillance section.  
 
The patient should be masked and immediately excluded from the 
workplace or placed in airborne infection isolation (AII) until confirmed 
noninfectious. For more information, see the “Isolation” topic in the 
Infection Control section of this manual.  
 
Laboratories should report positive smears or positives cultures, and 
primary healthcare providers should report suspected or confirmed cases 
of TB to the health department, as specified in the “Reporting 
Tuberculosis” topic in the Surveillance section. Prompt reporting allows the 
health department to organize treatment and case management services 
and to initiate a contact investigation as quickly as possible.24  
 
Within 48 hours of suspect identification, administer a tuberculin skin test 
(TST) or perform an interferon gamma release assay (IGRA) and/or 
provide a chest radiograph. Evaluate the patient for TB disease as 
specified in the “Diagnosis of Tuberculosis Disease” topic in this section.  
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Diagnosis of Tuberculosis Disease 
Consideration of tuberculosis (TB) disease as a possible diagnosis is the first step that 
must be taken before further evaluation, diagnosis, and management can occur. The 
diagnosis of TB disease is often overlooked because of the failure to consider it among 
possible diagnoses. While a definitive diagnosis may involve the addition of laboratory 
and radiographic findings, a high degree of suspicion can be based on epidemiology, 
medical history, and physical examination. In considering TB disease, it is also important 
to consider factors that may affect the typical presentation of TB, such as the patient’s 
age, nutritional status, and coexisting diseases. 
An individual who is suspected of having TB disease requires a complete medical 
evaluation, including the following: 
 Medical history, including exposure, symptoms, previous treatment for TB, and risk 
factors 
 Human immunodeficiency virus (HIV) screening 
 Physical examination 
 Tuberculin skin test or interferon gamma release assay 
 Chest radiography 
 Bacteriologic examination  
When a suspected case of pulmonary TB is identified, refer to Table 4 for guidelines for 
the initial steps of TB case detection in five clinical scenarios encountered by providers 
of primary healthcare, including those serving in medical emergency departments.25 
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Table 4: GUIDELINES FOR THE EVALUATION OF PULMONARY TUBERCULOSIS IN 
ADULTS IN FIVE CLINICAL SCENARIOS26 
 
Patient and Setting 
 
Recommended Evaluation 
Any patient with a cough of ≥2–3 weeks’ duration Chest radiograph: If suggestive of tuberculosis (TB)*, 
collect 3 sputum specimens for acid-fast bacilli (AFB) 
smear microscopy, culture, and nucleic acid 
amplification (NAA), if available27  
Any patient at high risk for TB with an unexplained 
illness, including respiratory symptoms of ≥2–3 weeks’ 
duration† 
Chest radiograph: If suggestive of TB, collect 3 sputum 
specimens for AFB smear microscopy, culture, and 
NAA, if available 
Any patient with human immunodeficiency virus (HIV) 
infection and unexplained cough or fever 
Chest radiograph, and collect 3 sputum specimens for 
AFB smear microscopy, culture, and NAA, if available 
Any patient at high risk for TB with a diagnosis of 
community-acquired pneumonia who has not improved 
after 7 days of treatment† 
Chest radiograph, and collect 3 sputum specimens for 
AFB smear microscopy, culture, and NAA, if available 
Any patient at high risk for TB with incidental findings 
on chest radiograph suggestive of TB even if 
symptoms are minimal or absent†§ 
Review of previous chest radiographs, if available, 3 
sputum specimens for AFB smear microscopy, culture, 
and NAA, if available 
* Opacities with or without cavitation in the upper lobes or the superior segments of the lower lobes.28  
†  See Table 2: Persons at High Risk for Tuberculosis Infection and Progression to Tuberculosis Disease. 
§  Chest radiograph performed for any reason, including targeted testing for latent TB infection and screening for TB disease. 
Source: Adapted from: ATS, CDC, IDSA. Controlling tuberculosis in the United States: recommendations from the 
American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR 2005;54(No. RR-12):33. 
Medical History 
The clinician should interview patients to document their medical histories. A written 
record of a patient’s medical history should include the following:  
 Exposure to infectious TB 
 Symptoms of TB disease (as listed in Table 3: When to Suspect Pulmonary 
Tuberculosis in Adults, Table 4: Guidelines for the Evaluation of Pulmonary 
Tuberculosis in Adults in Five Clinical Scenarios, and Table 5: Symptoms of 
Tuberculosis Disease) 
 Previous TB infection or disease 
 Risk factors (as listed in Table 2: Persons at High Risk for Tuberculosis Infection 
and Progression to Tuberculosis Disease) 
 Recent medical encounters (e.g., going to the emergency department for 
pneumonia) 
 Previous antibiotic therapy 
 
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L  Diagnosis of Tuberculosis Disease 5 . 1 2  
R e v i s e d  1 2 / 0 4 / 0 7  
1. Exposure to Infectious TB:  
Ask patients if they have spent time with someone with infectious TB.   
Question patients about whether they know of any contact in the recent or distant past 
with persons diagnosed with pulmonary or laryngeal TB. It is important to note that 
patients often refer to latent TB infection (LTBI) as TB disease. Be aware that most 
persons become infected with Mycobacterium tuberculosis without knowing they were 
exposed. Clinicians should also consider demographic factors that may increase a 
patient’s risk for exposure to TB disease and drug-resistant TB, such as country of 
origin, age, ethnic or racial group, occupation, and residence in congregate settings 
(such as a jail, homeless shelter, or refugee camp).  
2. Symptoms of TB Disease:  
Ask patients about their symptoms. 
Although TB disease does not always produce symptoms, most patients with TB disease 
have one or more symptoms that led them to seek medical care. When symptoms are 
present, they usually have developed gradually and been present for weeks or even 
months. Occasionally, however, TB is discovered during a medical examination for an 
unrelated condition, such as ruling out a cancer diagnosis (e.g., through a chest 
radiograph given to patients before surgery).  
The symptoms in Table 5 below may be caused by other diseases, but they should 
prompt the clinician to suspect TB disease. For historic features and chest radiograph 
results that should raise suspicion of pulmonary TB disease, refer to Table 3: When to 
Suspect Pulmonary Tuberculosis in Adults. 
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L  Diagnosis of Tuberculosis Disease 5 . 1 3  
R e v i s e d  1 2 / 0 4 / 0 7  
Table 5: SYMPTOMS OF TUBERCULOSIS DISEASE29 
Pulmonary General: Pulmonary and 
Extrapulmonary 
Extrapulmonary 
 Coughing 
 Coughing up sputum or blood 
 Pain in the chest when 
breathing or coughing 
 Chills30 
 Fever 
 Night sweats 
 Loss of appetite31 
 Weight loss 
 Weakness or easy fatigability32 
 Malaise (a feeling of general 
discomfort or illness)33 
The symptoms depend on part of 
body affected by tuberculosis (TB) 
disease:  
 TB of the spine may cause pain 
in the back. 
 TB of the kidney may cause 
blood in the urine. 
 Meningeal TB may cause 
headaches or psychiatric 
symptoms. 
 Lymphatic TB may cause 
swollen and tender lymph 
nodes, often at the base of the 
neck. 
Source: Adapted from: ATS, CDC, IDSA. Controlling tuberculosis in the United States: recommendations from the 
American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR 2005;54(No. RR-12):33. 
 
3. Previous Latent TB Infection or TB Disease:  
Ask patients whether they have ever been diagnosed with or treated for TB 
infection or disease. 
 
 Patients who have had TB disease before should be asked when they had the 
disease and how the disease was treated. Ask how many pills were taken per day (to 
determine what treatment regimen was used and whether they received injections). If 
the regimen prescribed was inadequate or if the patient did not follow the 
recommended treatment, TB may recur, and it may be resistant to one or more of the 
drugs used.  
 Patients known to have a positive skin test reaction probably have TB infection. 
If they were infected within the past two years, they are at high risk for TB disease if 
certain immunosuppressive conditions exist or if immunosuppressive therapies are 
being taken. (See Table 2: Persons at High Risk for Tuberculosis Infection and 
Progression to Tuberculosis Disease.)34 For persons previously skin tested, an 
increase in induration of 10 mm within a two-year period is classified as a conversion 
to positive.  
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4. Risk Factors for Developing TB Disease:  
Determine whether patients have any conditions or behaviors that are risk 
factors for developing TB disease.  
For a list of behaviors and conditions that appear to increase the risk that TB infection 
will progress to disease, see Table 2: Persons at High Risk for Tuberculosis 
Infection and Progression to Tuberculosis Disease. 
Human Immunodeficiency Virus Screening 
Voluntary counseling and testing for human immunodeficiency virus (HIV) is 
recommended for all patients with TB. HIV counseling and testing has also been 
recommended for contacts of persons with TB.35  
The Centers for Disease Control and Prevention (CDC) recommends the following: 
 Routine HIV screening for all patients ages 13–64 seeking health care for any 
reason, without regard to any patient’s known risks for HIV infection 
 Annual HIV screening of patients known to be at high risk36 
Physical Examination  
A physical examination is an essential part of the evaluation of any patient. It cannot be 
used to confirm or rule out TB, but it can provide valuable information about the patient’s 
overall condition; other factors, such as human immunodeficiency virus (HIV) infection, 
which may affect how TB is manifested; and the presence of extrapulmonary TB.37 
Tuberculin Skin Test  
and Interferon Gamma Release Assays  
Use the Mantoux TST or an interferon gamma release assay (IGRA) to test for M. 
tuberculosis infection. Note that for patients with a previous documented positive TST 
reaction, a TST is not necessary. However, an IGRA can be done if there is suspicion 
that the TST result was a false positive.   
Blood assay for Mycobacterium tuberculosis (BAMT) is a general term referring to 
recently developed in vitro diagnostic tests that assess for the presence of infection with 
M. tuberculosis. This term includes, but is not limited to IGRAs. The IGRA currently 
approved by the Food and Drug Administration (FDA) and available on the market is 
QuantiFERON®-TB Gold (QFT-G), which can be used in all circumstances in which the 
TST is used. QFT-G usually can be used in place of the TST.38 Other cytokine-based 
immunoassays are under development and may also become useful in the diagnosis of 
M. tuberculosis infection. Future FDA-licensed products, in combination with Centers for 
Disease Control and Prevention (CDC)-issued recommendations, may provide additional 
diagnostic alternatives.39 
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The advantages of IGRA, compared with the TST, are that results can be obtained after 
a single patient visit, and that, because it is a blood test performed in a qualified 
laboratory, the variability associated with skin test reading can be eliminated.40 In 
addition, the QFT-G test appears to be less affected by past Bacille of Calmette-Guérin 
(BCG) vaccination than the TST and may eliminate the unnecessary treatment of 
patients with BCG-related false-positive results.41 However, the QFT-G test has practical 
limitations that include the need to draw blood and to ensure its receipt in a qualified 
laboratory in time for testing. For QFT-G tests, the blood must be incubated with the test 
antigens less than12 hours after collection, while the lymphocytes are viable.42 Refer to 
www.quantiferon.com for available test sites. Refer to the Celestis web-site 
http://cellestis.com/ for additional information regarding a.new QuantiFERON®-TB Gold 
In-Tube (IT) test that has recently been approved by the FDA. 
For both the TST and IGRA, additional tests, such as chest radiography and 
bacteriologic examination, are required to confirm TB disease.43  
Persons with a positive QFT-G result or a positive TST result, regardless of symptoms 
and signs, should be evaluated for TB disease before LTBI is diagnosed. At minimum, a 
chest radiograph should be examined for abnormalities consistent with TB disease.44 
A negative TST does not rule out TB disease45—as many as 20% of patients with TB 
disease have a negative TST reaction.46 A negative TST result or a negative QFT-G 
result should not be used alone to exclude M. tuberculosis infection in persons with 
symptoms or signs suggestive of TB disease. Medical evaluation of such persons should 
include a history and physical examination, chest radiograph, bacteriologic studies, 
serology for human immunodeficiency virus (HIV), and, when indicated, other tests or 
studies.47 
 
 
For more information on the Mantoux TST, see the Diagnosis of Latent 
Tuberculosis Infection section. For more information on IGRAs and the 
QuantiFERON®-TB Gold (QFT-G) Test, see the CDC’s “Guidelines for Using 
the QuantiFERON®-TB Gold Test for Detecting Mycobacterium tuberculosis 
Infection, United States” (MMWR 2005;54[No. RR-15]) at 
http://www.cdc.gov/mmwr/pdf/rr/rr5415.pdf . 
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Chest Radiography 
A posterior-anterior radiograph of the chest is the standard view used for the detection 
and description of chest abnormalities in adults. In some instances, other views (e.g., 
lateral, lordotic) or additional studies (e.g., computed tomography [CT] scans) may be 
necessary.  
Children younger than 5 years of age should receive posterior-anterior and 
lateral radiographs.48 
Certain abnormalities on chest radiographs are suggestive, but are not diagnostic, of TB. 
In pulmonary TB, radiographic abnormalities are often seen in the apical and posterior 
segments of the upper lobe or in the superior segments of the lower lobe. However, 
lesions may appear anywhere in the lungs and may differ in size, shape, density, and 
presence or absence of cavitation, especially in HIV-infected and other 
immunosuppressed persons. 
In HIV-infected persons, pulmonary TB may present atypically on the chest radiograph. 
For example, TB may cause opacities without cavities in any lung zone, or it may cause 
mediastinal or hilar lymphadenopathy with or without accompanying opacities and/or 
cavities. In HIV-infected persons, almost any abnormality on a chest radiograph may 
indicate TB. In fact, the radiograph of an HIV-infected person with TB disease may even 
appear entirely normal.49  
 
For more information on chest radiography, see the Francis J. Curry National 
Tuberculosis Center’s Radiographic Manifestations of Tuberculosis: A Primer 
for Clinicians (2006) at 
http://www.nationaltbcenter.edu/products/product_details.cfm?productID=EDP-
04 . 
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Bacteriologic Examination 
Refer to Table 6 below to determine the types of specimens needed to assist in the 
diagnosis of TB. 
Table 6: SPECIMENS FOR DIAGNOSING TUBERCULOSIS DISEASE 
Suspected Diagnosis Specimen Needed 
Pulmonary or laryngeal 
tuberculosis (TB)  
Sputum (phlegm from deep in the lungs) samples for smear and culture 
examination. 
 
If a diagnosis of pulmonary TB cannot be established from sputum smear, 
other procedures may be necessary, including nucleic acid amplification 
(NAA), bronchoscopy, and gastric aspiration in children. 
Extrapulmonary TB Depending on the anatomical site, other clinical specimens are necessary, 
such as: 
 Urine 
 Cerebrospinal fluid 
 Pleural fluid 
 Pus or other aspirated fluid 
 Biopsy specimens 
 Blood (heparinized) 
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Refer to Table 7 below for information on the bacteriology tests used to diagnose TB. 
Table 7: BACTERIOLOGY TESTS USED IN DIAGNOSING TUBERCULOSIS DISEASE50 
Test Description Laboratory Turnaround Times 
Acid-Fast Bacilli 
(AFB) Smear 
 Provides the physician with a preliminary 
confirmation of the diagnosis. It usually is the 
first bacteriologic evidence of the presence of 
mycobacteria in a clinical specimen.   
 If positive, gives a semiquantitative estimate 
of the number of bacilli being excreted (which 
is of vital clinical and epidemiologic 
importance in assessing the patient’s 
infectiousness). 
 On-site test: within 24 hours from 
specimen collection.  
 Off-site test: within 24 hours from 
laboratory receipt of specimen (time 
from specimen collection to 
laboratory receipt should be 24 
hours or less).51 
Nucleic Acid 
Amplification 
(NAA) Assay52
 A test done on sputum specimens for the 
direct and rapid identification of the 
Mycobacterium tuberculosis complex. 
 Allows for the amplification of specific target 
sequences of nucleic acids that will be 
detected by a nucleic acid probe.  
 Does not replace the need for routine AFB 
smear and culture.53 
 Within 48 hours from specimen 
collection54,55 
Culture  Usually necessary for species identification of 
all clinical specimens suspected of containing 
mycobacteria.  
 Is required for drug susceptibility testing and 
genotyping. 
 Mycobacterial growth detection: 
within 14 days from specimen 
collection 
 Identification of mycobacteria:  
within 21 days from specimen  
collection 56,57 
Drug 
Susceptibility 
Testing 
 For first-line drugs: Is performed on initial 
isolates of all patients to identify an effective 
antituberculosis regimen.  
 For both first-line and second-line drugs: Is 
repeated on interim isolates when a patient 
remains culture-positive after 3 months of 
treatment.58,59 
 First-line drugs: within 30 days from 
specimen collection  
 Second-line drugs: within 4 weeks 
from date of request 
Sources: ATS, CDC, IDSA. Controlling tuberculosis in the United States: recommendations from the American Thoracic 
Society, CDC, and the Infectious Diseases Society of America. MMWR 2005;54(No. RR-12):19; and Tenover, R., et al. 
The resurgence of tuberculosis: is your laboratory ready? Journal of Clinical Microbiology 1993:767–770. 
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Laboratories should report positive smears or positives cultures, and primary healthcare 
providers should report suspected or confirmed cases of TB to the health department, as 
specified in the “Reporting Tuberculosis” topic in the Surveillance section. Prompt 
reporting allows the health department to organize treatment and case management 
services and to initiate a contact investigation as quickly as possible.60 
For information on reporting, see the “Reporting Tuberculosis” topic in the 
Surveillance section. 
For a list of all of the laboratory services available and information on 
specimen collection and shipment, see the Laboratory Services section.  
 
For laboratory services available in Arizona contact the state lab at (602) 542-
1188.   
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Resources and References 
Resources  
 ATS, CDC, IDSA. “Diagnostic Standards and Classification of Tuberculosis in Adults 
and Children” (Am J Respir Crit Care Med 2000;161[4 Pt 1]). Available at:  
http://www.cdc.gov/tb/pubs/PDF/1376.pdf .  
 CDC. Self-Study Modules on Tuberculosis (Division of Tuberculosis Elimination Web 
site; 1999). Available at:  http://www.phppo.cdc.gov/phtn/tbmodules/Default.htm . 
 CDC. Core Curriculum on Tuberculosis (2000) (Division of Tuberculosis Elimination 
Web site; updated November 2001). Available at: 
http://www.cdc.gov/tb/pubs/corecurr/default.htm . 
 Tenover, R., et al. “The Resurgence of Tuberculosis: Is Your Laboratory Ready?” 
(Journal of Clinical Microbiology 1993:767–770). 
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Introduction 
Purpose 
The overall goals for treatment of tuberculosis (TB) are to cure the patient and to 
minimize the transmission of Mycobacterium tuberculosis to others. Successful 
treatment of TB has benefits both for the individual patient and the community in which 
the patient resides.  
Use this section to understand and follow national and Arizona guidelines to 
 follow basic treatment principles for TB disease; 
 select appropriate treatment regimens, dosages, and duration; 
 monitor patients for side effects and adverse reactions; 
 assess patients’ response to treatment; 
 determine completion of therapy; 
 determine the need for post-treatment evaluation; 
 provide treatment in special situations, such as when a patient has drug-resistant TB 
or TB–human immunodeficiency virus (HIV) coinfection; and 
 hospitalize and coordinate hospital discharges of patients with infectious TB.  
In the 2005 “Controlling Tuberculosis in the United States: Recommendations from the 
American Thoracic Society, Centers for Disease Control and Prevention, and the 
Infectious Diseases Society of America,” one of the recommended strategies to achieve 
the goal of reduction of TB morbidity and mortality is the early and accurate detection, 
diagnosis, and reporting of TB cases, leading to initiation and completion of treatment.1 
Policy 
Patients with TB disease in Arizona or who move to Arizona with reported TB disease 
should receive and complete treatment in accordance with the national guidelines set 
forth in this manual and in accordance with the following Arizona laws and regulations. 
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State Laws and Regulations 
Arizona Laws/Rules Regarding Tuberculosis Control 
Arizona Revised Statutes.  Title 36:  Public Health and Safety; Chapter 6:  
Public Health Control; Title 6:  Tuberculosis Control.  (ARS§36-711 
through §36-738)  
ARS§36-711.  Definitions.   
ARS§36-712. Administration by the department.   
ARS§36-714.  Tuberculosis control officer.   
ARS§36-715.  Costs; removals; proceedings.   
ARS§36-716.  Payment of assistance.   
ARS§36-717.  Responsibility for care or treatment by counties.   
ARS§36-718.  Contracting for care of afflicted persons.   
ARS§36-721.  Rules.   
ARS§36-723.  Investigation of tuberculosis cases.   
ARS§36-724.  Voluntary control measures.   
ARS§36-725.  Orders to cooperate; emergency custody.    
ARS§36-726.  Petition for court ordered examination, monitoring, 
treatment, isolation or quarantine.   
ARS§36-727. Hearings; procedure; confidentiality.   
ARS§36-728. Judicial action.   
ARS§36-729. Amended orders for intervention and transport of afflicted 
persons.   
ARS§36-730.  Appointment of guardian or conservator.   
ARS§36-731.  Confinement; selection; jails; prohibition.   
ARS§36-732.  Early release from court ordered treatment.   
ARS§36-733.  Choice of physician and mode of treatment.   
ARS§36-734.  Treatment; exemption.   
ARS§36-735.  Notification of rights.   
ARS§36-736.  Administrative procedures act; judicial review of 
administrative procedures; exemption; appeals.  
ARS§36-737.  Violation; classification.   
ARS§36-738.  Qualified immunity.   
 
Arizona Administrative Code.  Title 9. Chapter 6.  Department of 
Health Services Communicable Diseases and Infestations.   
 
Forms 
 
Required and recommended forms are available in the forms section. 
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For roles and responsibilities, refer to the chapter on “Roles, Responsibilities, 
and Contact Information,”  
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Basic Treatment Principles 
Follow the basic treatment principles for tuberculosis (TB) disease, as outlined below in 
Table 1. 
Table 1: BASIC TREATMENT PRINCIPLES FOR TUBERCULOSIS DISEASE 
Phase Principles  
At Start of 
Treatment 
Patient-centered care and directly observed therapy (DOT). An adherence plan should 
tailor treatment and supervision to each patient by considering his or her clinical and social 
circumstances (patient-centered care), as well as emphasizing DOT. 
 Cultural competence. It is imperative to become culturally competent and guide other 
healthcare providers toward culturally competent healthcare. A culturally competent system 
acknowledges cultural differences regarding healthcare and incorporates them into all levels 
of the healthcare delivery system, from policy to provider to patient. 
 
 
Human immunodeficiency virus (HIV) testing. HIV testing should be offered to all patients 
with TB disease. 
 Medical supervision. Patients with confirmed or suspected tuberculosis (TB) disease must 
be under the supervision of a medical provider. 
 Prompt start. Start patients with confirmed or suspected TB disease promptly on 
appropriate treatment. It is not necessary to wait for laboratory confirmation. 
Regimen 
During 
Treatment  
Multiple drugs. Treatment regimens must contain multiple drugs to which the organism is 
susceptible. The administration of a single drug or the addition of a single drug to a failing 
regimen can lead to the development of resistance. 
 Single doses. TB medications should be administered together as a single dose rather than 
in divided doses. A single dose leads to higher, and potentially more effective, peak serum 
concentrations, and facilitates DOT. Although ingesting the medications with food will delay 
or moderately decrease the absorption of the medications, the effects are of little clinical 
significance. 
 Pyridoxine to prevent neuropathy. Pyridoxine (Vitamin B-6, 25 mg) is recommended for 
some individuals receiving isoniazid (INH) as part of their treatment regimen to prevent 
peripheral neuropathy. It should be used in persons at risk for neuropathy (women who are 
pregnant or breastfeeding or persons with nutritional deficiency, diabetes, HIV infection, 
renal failure, or alcoholism). 
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Phase Principles  
Persistent 
Positive 
Cultures 
Evaluation when positive cultures persist. Monitor for culture conversion and promptly 
evaluate patients with persistently positive cultures after 3 months of therapy to identify the 
cause. Treatment failure is defined as continued or recurrent positive cultures after 4 months 
of treatment. 
At Completion 
of Treatment 
Completion in terms of the number of doses. The criteria for treatment completion are 
based upon the total number of doses taken and not solely on the duration of therapy. 
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Treatment Regimens and Dosages 
Use this information to: 
 Identify the appropriate regimen; 
 Determine the appropriate dosage for each drug; and 
 Determine the duration of treatment. 
The information in this topic was provided using guidelines for treating tuberculosis (TB) 
that have been developed by the American Thoracic Society (ATS), Centers for Disease 
Control and Prevention (CDC), and Infectious Diseases Society of America (IDSA).  
 
See the “Treatment in Special Situations” topic in this section for 
information on treatment when there is drug-resistant TB, human 
immunodeficiency virus (HIV) infection, liver disease, or renal disease; 
when the patient is taking tumor necrosis factor-alpha (TNF-α) antagonists; 
where there is culture-negative TB or extrapulmonary TB; when the patient 
is pregnant or breastfeeding; or when the patient is considered to be of 
pediatric age. 
As you use this section, remember the abbreviations for first-line drugs, which are listed 
below. 
Table 2: ABBREVIATIONS FOR FIRST-LINE DRUGS 
 Ethambutol: EMB 
 Isoniazid: INH 
 Pyrazinamide: PZA 
 Rifabutin: RFB  
 Rifampin: RIF 
 Rifapentine: RPT 
Regimens  
Identify the appropriate regimen for the patient. There are four basic regimens 
recommended for treating adults with TB caused by organisms that are known or 
presumed to be susceptible to isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and 
ethambutol (EMB). Children, depending on the circumstances, may not receive EMB in 
the initial phase of a six-month regimen, but the regimens are otherwise identical. Per 
the 2003 Red Book, American Academy of Pediatrics, page 653 “When drug resistance 
is suspected, …initial therapy should include a fourth drug, either ethambutol or an 
aminoglycoside, until drug susceptibility results are available. If an isolate from the 
pediatric case under treatment is not available, drug susceptibilities can be inferred by 
the drug susceptibility pattern of rates of single and multiple drug resistance can be 
helpful. Data may not be available for foreign-born children or in circumstances of 
foreign travel. If this information is not available, a 4-drug initial regimen is 
recommended.” 
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For consultation regarding the treatment of TB, contact the Arizona 
Department of Health Services TB Control at 602-364-4750. Additional 
information can be obtained by contacting the Heartland National TB 
Center at 800-839-5864. 
 
 
The recommended regimens, and the number of doses specified by each regimen, are 
described on the next page in Table 3.   
Directly observed therapy (DOT) is the preferred initial management strategy for all 
regimens and should be used whenever feasible. All patients being given drugs less 
than seven days per week (five, three, or two days per week) must receive DOT. 
Each regimen has an initial phase of two months, followed by a choice of several options 
for a continuation phase of either four or seven months. In Table 3: Drug Regimens for 
Culture-Positive Pulmonary Tuberculosis Caused by Drug-Susceptible 
Organisms, the initial phase is denoted by a number (1, 2, 3, or 4), and the options for 
the continuation phase are denoted by the respective number and a letter designation 
(a, b, or c). 
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Table 3: DRUG REGIMENS FOR CULTURE-POSITIVE PULMONARY TUBERCULOSIS CAUSED BY DRUG-SUSCEPTIBLE 
ORGANISMS2 
Initial Phase Continuation Phase Rating* 
(evidence)† 
 
Regimen 
 
Drugs 
Interval and doses‡ 
(minimal duration) 
 
Regimen 
 
Drugs 
Interval and doses‡ § 
(minimal duration) 
 
Range of total doses 
(minimal duration)  
HIV– 
 
HIV+ 
1 INH 
RIF 
PZA 
EMB 
Seven days/week for 56 doses 
(8 wk) or 5 d/wk for 40 doses 
(8 wk)¶  
 
1a INH 
RIF 
Seven days/week for 126 
doses (18 wk) or 5 d/wk for 90 
doses (18 wk)¶ 
182–130 (26 wk) A (I) A (II)  
   1b INH 
RIF 
Twice weekly for 36 doses (18 
wk) 
92–76 (26 wk) A (I) A (II)# 
   1c** INH 
RPT 
Once weekly for 18 doses (18 
wk) 
74–58 (26 wk) B (I) E (I) 
2 INH 
RIF 
PZA 
EMB 
Seven days/week for 14 doses 
(2 wk), then twice weekly for 
12 doses (6 wk) or 5 d/wk for 
10 doses (2 wk),¶ then twice 
weekly for 12 doses (6 wk) 
2a INH 
RIF 
Twice weekly for 36 doses (18 
wk) 
62–58 (26 wk) A (II) B (II)# 
   2b** INH 
RPT 
Once weekly for 18 doses (18 
wk) 
44–40 (26 wk) B (I) E (I) 
3 INH 
RIF 
PZA 
EMB 
Three times weekly for 24 
doses (8 wk) 
3a INH 
RIF 
Three times weekly for 54 
doses (18 wk) 
78 (26 wk) B (I) B (II) 
4 INH 
RIF 
EMB 
Seven days/week for 56 doses 
(8 wk) or 5 d/wk for 40 doses 
(8 wk)¶ 
4a INH 
RIF 
Seven days/week for 217 
doses (31 wk) or 5 d/wk for 
155 doses (31 wk)¶ 
273–195 (39 wk) C (I) C (II) 
   4b INH 
RIF 
Twice weekly for 62 doses (31 
wk) 
118–102 (39 wk) C (I) C (II) 
 
Definitions of abbreviations: DOT = directly observed therapy; EMB = ethambutol; INH = isoniazid; HIV = human immunodeficiency virus; PZA = pyrazinamide; RIF = rifampin; RPT = rifapentine.  
* Definitions of evidence ratings: A = preferred; B = acceptable alternative; C = offer when A and B cannot be given; D = should generally not be offered; E = should never be given. 
† Definition of evidence ratings: I = randomized clinical trial; II = data from clinical trials that were not randomized or were conducted in other populations; III = expert opinion. 
‡ When DOT is used, drugs may be given 5 days/week and the necessary number of doses adjusted accordingly. Although there are no studies that compare 5 with 7 daily doses, extensive experience 
indicates this would be an effective practice. 
§ Patients with cavitation on initial chest radiograph and positive cultures at completion of 2 months of therapy should receive a 7-month (31 week; either 217 doses [daily] or 62 doses [twice weekly]) 
continuation phase. 
¶ Five-day-a-week administration is always given by DOT. Rating for 5 day/week regimens is rated AIII. 
# Not recommended for HIV-infected patients with CD4+ cell counts <100 cells/microliter.  
** Options 1c and 2b should be used only in HIV-negative patients who have negative sputum smears at the time of completion of 2 months of therapy and who do not have cavitation on initial chest 
radiograph. For patients started on this regimen and found to have a positive culture from the 2-month specimen, treatment should be extended an extra 3 months. 
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 Pyrazinamide (PZA) 
 Ethambutol (EMB) 
 Rifapentine (RPT) 
 Rifabutin (RFB) 
 Rifampin (RIF) 
 Isoniazid (INH) 
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Dosages 
The following drugs are available in the State of Arizona for treating TB disease. These 
drugs are provided free of charge upon approval of the TB Program. 
Once the appropriate regimen has been identified, refer to the following tables for 
instructions on dosages for each drug. First-line antituberculosis medications should be 
administered together; split dosing should be avoided.  
For information regarding second-line drugs, contact the local health 
department. 
 
For consultation regarding the treatment of TB, contact the Arizona 
Department of Health Services at 602-364-4750. 
Table 4: DOSES*OF FIRST-LINE ANTITUBERCULOSIS DRUGS FOR ADULTS AND CHILDREN† 3  
   Doses  
Drug Preparation Adults/children Daily 1x/wk 2x/wk 3x/wk 
Adults (max.) 5 mg/kg (300 mg) 15 mg/kg (900 mg) 15 mg/kg (900 mg) 15 mg/kg (900 mg) INH Tablets (50 mg, 100 
mg, 300 mg); elixir (50 
mg/5 ml); aqueous 
solution (100 mg/ml) for  
intramuscular injection¶ 
Children (max.) 10–15 mg/kg (300 mg) __ 20–30 mg/kg (900 mg) __ 
Adults‡ (max.) 10 mg/kg (600 mg) __ 10 mg/kg (600 mg) 10 mg/kg (600 mg) RIF Capsule (150 mg, 300 
mg); powder may be 
suspended for oral 
administration; aqueous 
solution for intravenous 
injection 
Children (max.) 10–20 mg/kg (600 mg) __ 10–20 mg/kg (600 mg) __ 
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   Doses  
Drug Preparation Adults/children Daily 1x/wk 2x/wk 3x/wk 
Adults‡ (max.) 5 mg/kg (300 mg) __ 5 mg/kg (300 mg) 5 mg/kg (300 mg) RFB Capsule (150 mg) 
Children Appropriate dosing for 
children is unknown 
Appropriate dosing for 
children is unknown 
Appropriate dosing for 
children is unknown 
Appropriate dosing for 
children is unknown 
Adults __ 10 mg/kg (continuation 
phase) (600 mg) 
__ __ RPT Tablet (150 mg, film 
coated) 
Children This drug is not 
approved for use in 
children 
This drug is not 
approved for use in 
children 
This drug is not 
approved for use in 
children 
This drug is not 
approved for use in 
children 
Adults See Table 5 __ See Table 5 See Table 5 PZA Tablet (500 mg, scored) 
Children (max.) 15–30 mg/kg (2.0 g) __ 50 mg/kg (2.0 g) __ 
Adults See Table 6 __ See Table 6 See Table 6 EMB Tablet (100 mg, 400 
mg) 
Children§ (max.) 15–20 mg/kg daily (1.0 
g) 
__ 50 mg/kg (2.5 g) __ 
   Definitions of abbreviations: EMB = ethambutol; FDA = Food and Drug Administration; INH = isoniazid; PZA = pyrazinamide; RFB = rifabutin; RIF = rifampin; RPT = rifapentine.  
*  Dose per weight is based on ideal body weight. Children weighing more than 40 kg should be dosed as adults. 
†  For the purposes of this document, adult dosing begins at the age of 15 years. 
¶  INH is used, but not FDA-approved, for intravenous administration. For intravenous use of INH, please consult with the Arizona Department of Health Services, TB Control Section at 602-364-
4750. 
‡  Dose may need to be adjusted when there is concomitant use of protease inhibitors or nonnucleoside reverse transcriptase inhibitors. 
§  The drug can likely be used safely in older children but should be used with caution in children less than 5 years of age, in whom visual acuity cannot be monitored. In younger children, EMB 
at the dose of 15 mg/kg per day can be used if there is suspected or proven resistance to INH or RIF. 
Source: ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):4. 
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Table 5: SUGGESTED PYRAZINAMIDE DOSES, USING WHOLE TABLETS,  
FOR ADULTS WEIGHING 40 TO 90 KILOGRAMS4 
Weight (kg)*  
Interval 
40–55 kg 56–75 kg 76–90 kg 
Daily, mg (mg/kg) 1,000 (18.2–25.0) 1,500 (20.0–26.8) 2,000 † (22.2–26.3) 
Thrice weekly, mg 
(mg/kg) 
1,500 (27.3–37.5) 2,500 (33.3–44.6) 3,000 †  (33.3–39.5) 
Twice weekly, mg (mg/kg) 2,000 (36.4–50.0) 3,000 (40.0–53.6) 4,000 †  (44.4–52.6) 
* Based on estimated lean body weight. 
† Maximum dose regardless of weight. 
Source: ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):5.   
 
Table 6: SUGGESTED ETHAMBUTOL DOSES, USING WHOLE TABLETS,  
FOR ADULTS WEIGHING 40 TO 90 KILOGRAMS5 
Weight (kg)*  
Interval 
40–55 kg 56–75 kg 76–90 kg 
Daily, mg (mg/kg) 800 (14.5–20.0) 1,200 (16.0–21.4) 1,600 † (17.8–21.1) 
Thrice weekly, mg 
(mg/kg) 
1,200 (21.8–30.0) 2,000 (26.7–35.7) 2,400 † (26.7–31.6) 
Twice weekly, mg (mg/kg) 2,000 (36.4–50.0) 2,800 (37.3–50.0) 4,000 † (44.4–52.6) 
* Based on estimated lean body weight. 
† Maximum dose regardless of weight. 
Source: ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):5.   
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Duration of Treatment 
Use the treatment algorithm in Figure 1: Treatment Algorithm for Tuberculosis to 
determine the duration of treatment. The four recommended regimens for treating 
patients with TB caused by drug-susceptible organisms have a duration of six to nine 
months. Each regimen has an initial phase of two months, followed by a continuation 
phase of either four or seven months.  
Figure 1 gives directions for treating patients with pulmonary and extrapulmonary TB. 
The standard duration of treatment for pulmonary TB should be six months unless both 
cavitation is present and the patient is still culture positive after two months, in which 
case nine months is recommended. Note that there are three exceptions to the standard 
six-month duration of treatment.  
1. For tuberculous meningitis, the optimal length of therapy has not been established, 
although some experts recommend 9 to 12 months.6  
2. Treatment for bone or joint TB may need to extend to nine months.7  
3. In HIV-negative, culture-negative patients, treatment for four months may be 
adequate if there is clinical or radiographic improvement and no other etiology 
identified.8 However, HIV-infected patients with culture-negative pulmonary TB 
should be treated for a minimum of six months.9 
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Figure 1. TREATMENT ALGORITHM FOR TUBERCULOSIS10 
 
Definition of abbreviations: AFB = acid-fast bacilli; CXR = chest radiograph; EMB = ethambutol; HIV = human immunodeficiency 
virus; INH = isoniazid; PZA = pyrazinamide; RIF = rifampin; RPT = rifapentine. 
* EMB may be discontinued when results of drug susceptibility testing indicate no drug resistance. 
† PZA may be discontinued after it has been taken for 2 months (56 doses). 
‡ RPT should not be used in HIV-infected patients with TB or in patients with extrapulmonary TB. 
§ Therapy should be extended to 9 months if 2-month culture is positive. 
¶ At 2 months, review drug susceptibility and culture results, if applicable, and review these results regularly throughout treatment 
if the patient is drug resistant.  
Source: ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):6.  
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Side Effects and Adverse Reactions 
The patient should be monitored by a registered nurse and/or clinician or case manager 
at least weekly for signs and symptoms of adverse reactions until treatment is 
completed. If a patient is symptomatic, the provider should be consulted and the patient 
monitored more frequently. Chemistries and complete blood count (CBC), aspartate 
aminotransferase (AST)/alanine aminotransferase (ALT), or other tests based on 
specific drugs should be done periodically. See Clinical Care Pathway and  Table 8: 
Monitoring and Interventions for Side Effects and Adverse Reactions in this 
section. 
As is true with all medications, combination chemotherapy for tuberculosis is associated 
with a predictable incidence of adverse effects, some mild, some serious.11  
Adverse effects are fairly common and often manageable. Although it is important to be 
attuned to the potential for adverse effects, it is at least equally important that first-line 
drugs not be stopped without adequate justification.12 However, adverse reactions can 
be severe, and thus, it is important to recognize adverse reactions that indicate when a 
drug should not be used. Mild adverse effects can generally be managed with 
symptomatic therapy; whereas with more severe effects, the offending drug or drugs 
must be discontinued.13 In addition, proper management of more serious adverse 
reactions often requires expert consultation.14 
Monitor patients for side effects and adverse reactions following the basic monitoring 
steps listed below. 
Basic Monitoring Steps  
 
1. All healthcare workers providing treatment for TB disease should be familiar with the 
American Thoracic Society (ATS)/Centers for Disease Control and Prevention (CDC) 
guidelines.  
a. All jurisdictions should follow the national monitoring guidelines identified in the 
current guidelines for treatment of TB, “Treatment of Tuberculosis” (MMWR 
2003;52[No. RR-11]) at http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf  . 
b. It is also important to check for guideline updates posted on the CDC’s Division 
of Tuberculosis Elimination home page at http://www.cdc.gov/tb/default.htm and 
the list of guidelines by date at 
http://www.cdc.gov/tb/pubs/mmwr/Maj_guide/List_date.htm .  
2. While on treatment, all patients should be evaluated in person, at baseline (before 
starting treatment) and then at least monthly for side effects and adverse reactions.  
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3. The common side effects of and adverse reactions to drugs used to treat for TB 
disease are listed in Table 7: Reporting Reactions to Antituberculosis 
Medications. Educate patients to stop the medicine and promptly report any of the 
symptoms or signs listed in Table 7 or any unexplained illness to the prescribing 
clinic immediately. 
a. If a patient reports a potentially serious adverse reaction, call the patient’s 
provider immediately and alert the state TB program by calling 602-364-4750. 
b. If a patient reports a potentially less severe side effect, call the patient’s provider 
immediately and monitor the patient.  
4. If you suspect that an antituberculosis drug may be causing a particular side effect or 
adverse reaction: 
a. Refer to Table 8: Monitoring and Interventions for Side Effects and Adverse 
Reactions.  
b. Consult with the state TB program by calling 602-364-4750. 
5. If you suspect that an antituberculosis drug may be interacting with other 
medications that the patient is taking, refer to pages 45–47 in the “Treatment of 
Tuberculosis” (MMWR 2003;52[No. RR-11]) at 
http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
6. Document the following patient information: 
a. Review of symptoms, side effects, and adverse reactions (and any labs that were 
drawn)  
b. Education given 
c. Refill provided 
d. Description of any problems encountered and action taken for that visit 
e. Next appointment 
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Reporting Reactions  
The table below is intended for use by a healthcare worker who performs case 
management services. The healthcare worker should instruct the patient to report to the 
provider the side effects and adverse reactions listed in Table 7.  
If a patient reports to a healthcare worker a potentially serious adverse reaction, the 
healthcare worker should call the patient’s provider immediately and alert the state TB 
program by calling 602-364-4750. 
If a patient reports to a healthcare worker a potentially less severe side effect, the 
healthcare worker should call the patient’s provider immediately and monitor the patient.  
Table 7: REPORTING REACTIONS TO ANTITUBERCULOSIS MEDICATIONS15 
Potentially Serious  
Adverse Reactions* 
Less Severe  
Signs and Symptoms* 
Immediately report the following signs and symptoms 
or other abnormalities or unexpected events to the 
patient’s provider. These signs and symptoms 
suggest side effects, including hepatotoxicity: 
 Jaundice  
 Dark urine 
 Vomiting 
 Abdominal pain  
 Fever  
 Visual changes  
 Marked clinical rash 
In consultation with the provider, instruct the patient 
to stop TB medications until evaluated by the 
provider.  
Report the following signs and symptoms to the 
patient’s provider within 24 hours:  
 Anorexia 
 Nausea 
 Malaise 
 Peripheral neuropathy: tingling or burning sensation 
in hands or feet 
 Rashes  
 
 
* These lists are not all-inclusive. Second-line drugs are not included. For a complete list, refer to the current guidelines for 
treatment of TB, “Treatment of Tuberculosis” (MMWR 2003;52[No. RR-11]), at 
http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
Source: California Department of Health Services (CDHS)/California Tuberculosis Controllers Association (CTCA). TB 
case management—core components. CDHS/CTCA Joint Guidelines [CTCA Web site]. May 11, 1998:9. Available at: 
http://www.ctca.org/guidelines/index.html . Accessed July 11, 2006. 
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Monitoring for Side Effects and Adverse Reactions  
by Antituberculosis Drug  
Refer to Table 8: Monitoring and Interventions for Side Effects and Adverse 
Reactions to  
 identify the side effects and adverse reactions associated with particular 
antituberculosis drugs 
 determine how to monitor for side effects and adverse reactions 
Table 8 is based upon national guidelines. 
Table 8: MONITORING AND INTERVENTIONS FOR SIDE EFFECTS AND ADVERSE REACTIONS16,17,18  
Anti-
tuberculosis 
Drug 
Side Effects/ 
Adverse Reactions 
Monitoring Comments 
Isoniazid (INH)  Rash 
 Hepatic enzyme elevation 
 Hepatitis 
 Peripheral neuropathy 
 Mild central nervous system 
effects 
 
Clinical monitoring monthly 
 
Liver function tests (aspartate aminotransferase  
[AST], alanine aminotransferase [ALT], and serum 
bilirubin) at baseline in selected cases ((human 
immunodeficiency virus [HIV] infection, history of 
liver disease, alcoholism, and pregnancy)  
 
Repeat measurements if 
 Baseline results are abnormal 
 Patient is pregnant, in the immediate postpartum 
period, or at high risk for adverse reactions 
 Patient has symptoms of adverse reactions  
 
Hepatitis risk increases with age and alcohol 
consumption. 
 
Pyridoxine (vitamin B6, 10–25 mg/d) might prevent 
peripheral neurophathy and central nervous system 
effects. 
 
Serum concentrations of phenytoin, disulfiram 
(Antabuse), and carbamazepine may be increased in 
persons taking INH. Measure serum concentrations of 
phenytoin and carbamazepine in patients receiving INH 
(with or without rifampin), and adjust the dose if 
necessary. 
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Anti- Side Effects/ Monitoring Comments 
tuberculosis Adverse Reactions 
Drug 
Rifampin (RIF)  Rash 
 Gastrointestinal upset  
 Hepatitis 
 Fever 
 Bleeding problems 
 Thrombocytopenia 
 Renal failure 
 Flu-like symptoms 
 Orange-colored body fluids 
(secretions, urine, tears) 
 
Complete blood count, platelets, and liver function 
tests (aspartate aminotransferase  [AST], alanine 
aminotransferase [ALT], and serum bilirubin) at 
baseline in selected cases (human 
immunodeficiency virus [HIV] infection, history of 
liver disease, alcoholism, and pregnancy)  
 
Repeat measurements if 
 Baseline results are abnormal 
 Patient has symptoms of adverse reactions  
 
There are a number of drug interactions with potentially 
serious consequences. Significant interactions with 
methadone, birth control hormones, and many other 
drugs.  
 
Contraindicated or should be used with caution when 
administered with protease inhibitors (PIs) and 
nonnucleoside reverse transcriptase inhibitors 
(NNRTIs). Reduces levels of many drugs (e.g., PIs, 
NNRTIs, methadone, dapsone, ketoconazole, coumadin 
derivatives, hormonal contraceptive, digitalis, 
sulfonylureas, diazepam, ß-blockers, anticonvulsants, 
and theophylline). 
 
For more information, refer to “Section 7: Drug 
Interactions” on page 45 in “Treatment of Tuberculosis”  
at http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
 
Because information regarding rifamycin drug 
interactions is evolving rapidly, consult the CDC’s 
Division of Tuberculosis “News and Updates” Web page 
at http://www.cdc.gov/tb/default.htm to obtain the most 
up-to-date information.  
 
Colors body fluids orange. 
 
May permanently discolor soft contact lenses. 
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L  Treatment of Tuberculosis Disease 6.22 
Revised 12/04/07 
Anti- Side Effects/ Monitoring Comments 
tuberculosis Adverse Reactions 
Drug 
Rifabutin (RFB)  Rash 
 Hepatitis 
 Fever 
 Thrombocytopenia 
 Orange-colored body fluids 
(secretions, urine, tears) 
 
With increased levels of RFB:  
 Severe arthralgias 
 Uveitis 
 Leukopenia 
 
Complete blood count, platelets, and liver function 
tests (aspartate aminotransferase  [AST], alanine 
aminotransferase [ALT], and serum bilirubin) at 
baseline in selected cases (human 
immunodeficiency virus [HIV] infection, history of 
liver disease, alcoholism, and pregnancy)  
 
Repeat measurements if 
 Baseline results are abnormal 
 Patient has symptoms of adverse reactions 
 
Use adjusted daily dose of RFB and monitor for 
decreased antiretroviral activity and for RFB 
toxicity if RFB taken concurrently with protease 
inhibitors (PIs) or nonnucleoside reverse 
transcriptase inhibitors (NNRTIs) 
 
Although drug interactions are less problematic with 
RFB, they still occur and close monitoring is required. 
 
Contraindicated for HIV-infected patients taking hard-
gel saquinavir or delavirdine; caution is also advised if 
RFB is administered with soft-gel saquinavir. 
 
Similar to rifampin but less potent of an inducer, 
rifabutin reduces levels of many drugs (e.g., PIs, 
NNRTIs, methadone, dapsone, ketoconazole, coumadin 
derivatives, hormonal contraceptive, digitalis, 
sulfonylureas, diazepam, ß-blockers, anticonvulsants, 
and theophylline). 
 
When used with efavirenz, the daily dose of RFB should 
be increased from 300 mg to 450 mg or 600 mg.  
 
May permanently discolor soft contact lenses. 
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Anti- Side Effects/ Monitoring Comments 
tuberculosis Adverse Reactions 
Drug 
Rifapentine 
(RPT) 
Similar to those associated 
with rifampin  
 
Similar to that for rifampin 
 
Drug interactions involving RPT are being investigated 
and are likely to be similar to those of rifampin. RPT is 
an inducer of multiple hepatic enzymes and therefore 
may increase metabolism of coadministered drugs that 
are metabolized by these enzymes. For more 
information, refer to “Section 7: Drug Interactions” on 
page 45 in “Treatment of Tuberculosis” at 
http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
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Anti- Side Effects/ Monitoring Comments 
tuberculosis Adverse Reactions 
Drug 
Pyrazinamide 
(PZA) 
 Gastrointestinal upset 
 Hepatitis 
 Rash 
 Photosensitive dermatitis 
 Hyperuricemia 
 Joint aches 
 Gout (rare) 
 
Clinical monitoring at weeks 2, 4, and 8 
 
If the drug is used in patients with underlying liver 
disease, laboratory and clinical monitoring should 
be increased 
 
Baseline measurements of uric acid  
 
Liver function tests (aspartate aminotransferase  
[AST], alanine aminotransferase [ALT], and serum 
bilirubin) at baseline in selected cases (human 
immunodeficiency virus [HIV] infection, history of 
liver disease, alcoholism, or pregnancy)    
 
Repeat measurements if  
 Baseline results are abnormal 
 Patient has symptoms of adverse reactions 
 
Treat hyperuricemia only if patient has symptoms. 
 
Might make glucose control more difficult in persons 
with diabetes. 
 
Serum uric acid measurements are not recommended 
as a routine but may serve as a surrogate marker for 
compliance.  
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Anti-
tuberculosis 
Drug 
Side Effects/ 
Adverse Reactions 
Monitoring Comments 
Ethambutol 
(EMB) 
 Optic neuritis 
 Rash 
 
Baseline tests of visual acuity (Snellen chart) and 
color discrimination (Ishihara tests) or other 
standard tests 
 
At each monthly visit, patients should be 
questioned regarding possible visual disturbances, 
including blurred vision or scotomata  
 
Monthly testing of visual acuity and color 
discrimination is recommended for  
 Patients taking doses >15–25 mg/kg  
 Patients receiving EMB for >2 months 
 Patients with renal insufficiency 
 
Optic neuritis may be unilateral; check each eye 
separately. 
 
Patients should be instructed to contact their physician 
or public health clinic immediately if they experience a 
change in vision.  
 
EMB should be discontinued immediately and 
permanently if there are any signs of visual toxicity. 
 
Rifamate® 
(INH and RIF)  
Rifater®  
(INH, RIF, PZA) 
See comments under individual 
drugs above 
  
Definitions of abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; EMB = ethambutol; HIV = human immunodeficiency virus; INH = isoniazid; NNRTIs = 
nonnucleoside reverse transcriptase inhibitors; PZA = pyrazinamide; PIs = protease inhibitors; RFB = rifabutin; RIF = rifampin; RPT = rifapentine.  
Sources: CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49 (No. RR-6):26–29, 38–39; ATS, CDC, IDSA. Treatment of tuberculosis. 
MMWR 2003;52(No. RR-11):19–25; CDC. Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide 
for treatment of latent tuberculosis infection—United States. MMWR 2003;52(No. 31):735–736; CDC. Table 5: first-line anti-TB medications. In: Chapter 7: treatment of TB disease. 
Core Curriculum on Tuberculosis (2000) [Division of Tuberculosis Elimination Web site]. Updated November 2001. November 2001. Available at: 
http://www.cdc.gov/tb/pubs/corecurr/index.htm . Accessed July 3, 2006. 
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 Response to Treatment 
For consultation regarding a patient’s response to treatment, contact 602-
364-4750. 
For patients whose sputum cultures are positive before treatment, the best way to 
measure the effectiveness of therapy is to obtain specimens for culture at least monthly 
until the cultures convert to negative. Patients with multidrug-resistant tuberculosis 
(MDR-TB) should have cultures performed monthly for the entire course of treatment. 
In some cases, a patient may not be able to produce a sputum specimen after two 
months of treatment. If the patient has improved clinically and has shown chest 
radiograph improvement, treatment may be continued as if the patient had a negative 
sputum specimen at two months.  
Radiographic evaluations during treatment are of less importance than sputum 
evaluation. However, a chest radiograph at completion of treatment provides a baseline 
for comparison with future films. 
Patients whose cultures have not become negative or whose symptoms do not resolve 
despite three months of therapy should be reevaluated for potential drug-resistant 
disease, as well as for potential failure to adhere to the regimen. If the patient is 
receiving self-administered therapy, the remainder of treatment should be directly 
observed.  
 
If drug susceptibility results show resistance to any of the first-line drugs or 
if the patient remains symptomatic or smear- or culture-positive after three 
months, a tuberculosis (TB) medical expert should be consulted. Contact 
the Arizona Department of Health Services, TB Control Section at 602-
364-4750 immediately. 
In patients with negative sputum cultures before treatment, the major indicators of 
response to therapy are the chest radiograph and clinical evaluation. The intervals at 
which chest radiography should be repeated depend on the clinical circumstances and 
the differential diagnosis that is being considered, but usually should be no more than 
every three months. If the radiograph does not improve after the patient has received 
three months of treatment, the abnormality may be the result of either previous (not 
current) TB or another process.19 
 
 
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L     Treatment of Tuberculosis Disease 6.27 
Revised 12/04/07 
Completion of Therapy 
A full course of therapy (completion of treatment) is determined more accurately if the 
total number of doses ingested is taken into account, as well as the duration of therapy. 
If there are no interruptions in drug administration, six months is usually the minimum 
duration of treatment and accurately indicates the amount of time in which drugs are 
given. However, in human immunodeficiency virus (HIV)-negative, culture-negative 
patients, treatment for four months may be adequate if there is clinical or radiographic 
improvement and no other etiology identified.20 
For consultation regarding the treatment of tuberculosis (TB) in a patient 
with negative cultures, contact the local health department, TB Control 
Section.  
In some cases, either because of drug toxicity or nonadherence to the treatment 
regimen, the specified number of doses cannot be administered within the targeted 
period. In such cases, the goal is to deliver the specified number of doses within a 
recommended maximum time. For example, for a six-month daily regimen, the total 
doses should be administered within nine months of beginning treatment. If treatment is 
not completed within this period, the patient should be assessed to determine the 
appropriate action to take, such as continuing treatment for a longer duration or 
restarting treatment from the beginning. 
Treating a patient for a defined duration, without accounting for the number 
of doses taken, can result in undertreatment. 
Interruptions in treatment may have a significant effect on the duration of therapy. 
Reinstitution of treatment must take into account the extensiveness of the disease (e.g., 
cavitary versus noncavitary disease on chest radiograph, smears and cultures, 
immunologic status), the point in time when the interruption occurred, and the duration of 
the interruption. In general, the earlier in treatment and the longer the duration of the 
interruption, the more serious the effect and the greater the need to restart therapy from 
the beginning.21  
For consultation regarding completion of therapy or considerations for 
retreatment, contact the local health department, TB Control Section. 
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Post-Treatment Evaluation 
Routine follow-up after completion of therapy is not necessary for patients with a 
satisfactory and prompt bacteriologic response to a six- or nine-month regimen that 
included both isoniazid and rifampin.  
The table below describes the clinician’s responsibilities at completion of therapy for 
cases in which the organisms are drug-susceptible and drug-resistant.  
Table 9: CLINICIAN’S RESPONSIBILITIES AT COMPLETION OF THERAPY  
Drug Susceptibility Clinician’s Actions 
Drug-susceptible 
organisms 
Instruct the patient to promptly report the development of any symptoms, particularly 
prolonged cough, fever, or weight loss.  
Organisms resistant to 
isoniazid, rifampin, or 
both 
Individualize follow-up evaluation.22
 
For consultation regarding post-treatment evaluation, contact the local 
health department, TB Control Section. 
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Treatment in Special Situations 
Treatment of tuberculosis (TB) in the following situations requires a high level of 
expertise or close consultation with an expert to provide appropriate management: 
 Drug-resistant TB 
 Human immunodeficiency virus (HIV) infection 
 Liver disease 
 Renal insufficiency and end-stage renal disease (ESRD) 
 TB associated with tumor necrosis factor-alpha (TNF-α) antagonists  
 Culture-negative pulmonary TB 
 Extrapulmonary TB 
 Pregnancy and breastfeeding 
 TB in children 
For consultation regarding treatment in the following situations, contact the 
Arizona Department of Health Services, TB Control Section at 602-364-
4750. 
 
Drug-Resistant Tuberculosis 
 
Treatment of TB caused by drug-resistant organisms should be provided 
by, or in close consultation with, an expert in the management of these 
difficult situations. Second-line regimens often represent the patient’s last 
hope for being cured, and inappropriate management can have life-
threatening consequences.23  
Drug resistance is proven only by drug-susceptibility testing performed in a competent 
laboratory. A patient with a strain of Mycobacterium tuberculosis resistant to both 
isoniazid (INH) and rifampin (RIF) has multidrug-resistant TB (MDR-TB). Refer MDR-TB 
patients immediately to a specialist or seek consultation with a specialized treatment 
center.24  
Acquired drug resistance usually develops when an inadequate drug regimen is 
prescribed (e.g., inappropriate drugs or insufficient dosage) or when there is a combined 
failure of both the patient and the provider to ensure that an adequate regimen is taken. 
A patient with acquired drug resistance may transmit his or her strain to others, who may 
then develop primary drug-resistant TB.25 
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For consultation regarding the treatment of drug-resistant TB, contact the 
Arizona Department of Health Services, TB Control Section at 602-364-
4750. 
Resources 
 ATS, CDC, IDSA. “Treatment of Tuberculosis” (MMWR 2003;52[No. RR-11]:11-12, 
68–70). Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
 CDC. “Drug-Resistant Tuberculosis” (TB Elimination Fact Sheet; accessed April 23, 
2007). Available at: http://www.cdc.gov/tb/pubs/TBfactsheets.htm .   
Human Immunodeficiency Virus Infection 
Management of HIV-related TB is complex and requires expertise in the management of 
both HIV disease and TB. Because HIV-infected patients often take numerous 
medications, some of which interact with antituberculosis medications, clinicians are 
strongly encouraged to consult with experts who treat HIV-related TB. 
It is especially important to use directly observed therapy (DOT) and other adherence-
promoting strategies with patients with HIV-related TB. 
 
The following are contraindicated in HIV-infected patients: 
 Isoniazid-rifapentine (INH-RPT) once weekly  
 Twice-weekly rifampin (RIF)- or rifabutin (RFB)-based regimens in 
patients with CD4+ cell counts of less than 100 per microliter 26 
Patients with HIV-related TB may experience a temporary exacerbation of 
symptoms, signs, or radiographic manifestations (paradoxical reactions) of 
TB while receiving antituberculosis treatment.27 
Resources 
 ATS, CDC, IDSA. “Treatment of Tuberculosis” (MMWR 2003;52[No. RR-11]:9, 50–
55). Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
 ATS, CDC. “Notice to Readers: Updated Guidelines for the Use of Rifamycins for the 
Treatment of Tuberculosis among HIV-infected Patients Taking Protease Inhibitors 
or Nonnucleoside Reverse Transcriptase Inhibitors” (MMWR 2004;53[No. 2]:37). 
Available at: http://www.cdc.gov/mmwr/PDF/wk/mm5302.pdf . 
 CDC. Self-Study Modules on Tuberculosis (Division of Tuberculosis Elimination Web 
site; 1999). Available at:  http://www.phppo.cdc.gov/phtn/tbmodules/Default.htm . 
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 CDC. “Treatment of Drug-Susceptible TB in HIV-Infected Persons” (TB Elimination 
Fact Sheet; March 2003). Available at: 
http://www.cdc.gov/tb/pubs/tbfactsheets/treatmentHIVpositive.htm  
 CDC. “Treating Opportunistic Infections Among HIV-exposed and Infected Children” 
(MMWR 2004;53[No. RR-14]).  Available at: 
http://www.cdc.gov/mmwr/PDF/rr/rr5314.pdf . 
Liver Disease 
Management of TB in patients with unstable or advanced liver disease is difficult. The 
likelihood of drug-induced hepatitis may be greater in these patients. The implications of 
drug-induced hepatitis for patients with marginal hepatic reserve are potentially serious, 
even life-threatening. Also, fluctuations in the biochemical indicators of liver function 
(with/without symptoms) related to the preexisting liver disease confound monitoring for 
drug-induced hepatitis.28 
For all patients with preexisting liver disease, frequent clinical and 
laboratory monitoring should be performed to detect drug-induced hepatic 
injury.29
Resources 
 ATS, CDC, IDSA. “Treatment of Tuberculosis” (MMWR 2003;52[No. RR-11]:11, 65). 
Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
For consultation regarding patients with preexisting liver disease, contact 
the Arizona Department of Health Services, TB Control Section at 602-
364-4750. 
Renal Insufficiency and End-Stage Renal Disease  
Renal insufficiency complicates the management of TB because some antituberculosis 
medications are cleared by the kidneys. Management may be further complicated by the 
removal of some antituberculosis agents via hemodialysis. To facilitate DOT (three times 
per week) and avoid premature removal of the drugs, administer all antituberculosis 
drugs immediately after hemodialysis.30  
Resources 
 ATS, CDC, IDSA. “Treatment of Tuberculosis” (MMWR 2003;52[No. RR-11]:10–11, 
63–65). Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
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Tuberculosis Associated with Tumor Necrosis Factor-
Alpha Antagonists 
TB is a potential consequence of treatment with tumor necrosis factor-alpha (TNF-α) 
antagonists such as the following: 
 Infliximab (Remicade®) 
 Etanercept (Enbrel®) 
 Adalimumab (Humira®) 
These drugs work by blocking TNF-α, an inflammatory cytokine, and are approved for 
treating rheumatoid arthritis and other selected autoimmune diseases. Blocking TNF-α 
can allow TB disease to emerge from latent TB infection (LTBI). Healthcare providers 
should take steps to prevent TB in immunocompromised patients and remain vigilant for 
TB as a cause of unexplained febrile illness.31 
Patients should be screened for risk factors for M. tuberculosis infection 
and tested for infection before initiating immunosuppressive therapies, 
including TNF-α antagonists.32
Resources 
 CDC. “Tuberculosis Associated with Blocking Agents against Tumor Necrosis 
Factor-Alpha—California, 2002–2003” (MMWR 2004;53[No. 30]:83–686). Available 
at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5330a4.htm . 
Culture-Negative Pulmonary Tuberculosis 
A diagnosis of TB should not be ruled out if M. tuberculosis cannot be isolated from 
persons suspected of having pulmonary TB on the basis of clinical features and chest 
radiographic examination. Alternative diagnoses should be carefully considered and 
further appropriate diagnostic studies undertaken in persons with apparent culture-
negative TB.33 
A diagnosis of culture-negative pulmonary TB can be made if all the following conditions 
are met: 
 Initial acid-fast bacilli (AFB) smears and cultures are negative. 
 Clinical or radiographic response occurs within two months of initiation of therapy. 
 No other diagnosis has been established.34 
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After the initial phase (first two months), continue treatment with an additional two 
months of isoniazid and rifampin during the continuation phase to complete a total of 
four months of treatment.35 However, HIV-infected patients with culture-negative 
pulmonary TB should be treated for a minimum of six months.36 
For consultation regarding the treatment of TB in a patient with negative 
cultures, contact the local health department, TB Control Section. 
Resources  
 ATS, CDC, IDSA. “Treatment of Tuberculosis” (MMWR 2003;52[No. RR-11]:10, 61). 
Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
Extrapulmonary Tuberculosis  
The basic principles for treating pulmonary TB also apply to extrapulmonary forms of the 
disease. The addition of corticosteroids is recommended for patients with TB pericarditis 
and TB meningitis. Recommendations concerning duration of therapy are as follows: 
 Use a six-month course of therapy for TB involving any site.37 Exceptions: For bone 
or joint TB, use a six- to nine-month regimen.38 For the meninges, use a 9- to 12-
month regimen.39  
 Consider prolonging therapy for patients with TB in any site that is slow to respond.40 
Note: Affected lymph nodes may enlarge while patients are receiving appropriate 
therapy or after treatment has ended without any evidence of bacteriological relapse. On 
occasion, new nodes can appear during or after treatment as well.41 
For consultation to discuss length of treatment, contact the local health 
department, TB Control Section. 
Resources 
 ATS, CDC, IDSA. “Treatment of Tuberculosis” (MMWR 2003;52[No. RR-11]:10, 56–
61). Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
 Division of Tuberculosis Elimination. Fact Sheets (Division of Tuberculosis 
Elimination Web site; accessed February 2007). Available at: 
http://www.cdc.gov/tb/pubs/TBfactsheets.htm .  
 CDC. Self-Study Modules on Tuberculosis (Division of Tuberculosis Elimination Web 
site; 1999). Available at: http://www.phppo.cdc.gov/phtn/tbmodules/Default.htm . 
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Pregnancy and Breastfeeding 
Because of the risk of TB to the fetus, treatment in pregnant women should be initiated 
whenever the probability of maternal disease is moderate to high. The initial treatment 
regimen should consist of isoniazid (INH), rifampin (RIF), and ethambutol (EMB). As 
pyrazinamide (PZA) generally is not included in the initial treatment regimen, the 
minimum duration of therapy is nine months. Although these drugs cross the placenta, 
they do not appear to have teratogenic effects. 
Breastfeeding should not be discouraged in women being treated with first-line 
antituberculosis agents because the small concentrations of drugs in breast milk do not 
produce toxicity in the nursing newborn. Conversely, drugs in breast milk should not be 
considered an effective treatment for TB in a nursing infant.42 
Pyridoxine supplementation (25 mg/day) is recommended for all women taking INH who 
are either pregnant or breastfeeding.43 
Resources 
 ATS, CDC, IDSA. “Treatment of Tuberculosis” (MMWR 2003;52[No. RR-11]:11, 62–
63). Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
 CDC. Self-Study Modules on Tuberculosis (Division of Tuberculosis Elimination Web 
site; 1999). Available at:  http://www.phppo.cdc.gov/phtn/tbmodules/Default.htm . 
Tuberculosis in Children 
A pediatric patient is a person below six (6) years of age. 
Because of the high risk of disseminated TB in infants and children 
younger than 5 years of age, treatment should be started as soon as the 
diagnosis of TB is suspected.44  
The following recommendations have been developed for children: 
 Regimens recommended for infants, children, and adolescents with TB are generally 
the same as those for adults.  
Exception: Ethambutol (EMB) is not used routinely in children.45 
 Duration of treatment in children is six months.  
Exception: For disseminated disease and TB meningitis, use a 9- to 12- month 
regimen.46 For other exceptions, refer to “Duration of Treatment” in the “Treatment 
Regimens and Dosages” topic in this section. 
 DOT should always be used in treating children.47  
Due to the difficulty of isolating M. tuberculosis in a child with pulmonary TB, the choice 
of drugs for the child is frequently guided by the drug susceptibility test results of the 
presumed source case. If drug-resistant TB is suspected or the source case isolate is 
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L     Treatment of Tuberculosis Disease 6.35 
Revised 12/04/07 
not available, specimens for microbiological evaluation should be obtained via early 
morning gastric aspiration, bronchoalveolar lavage, or biopsy.48  
Resources 
 ATS, CDC, IDSA. “Treatment of Tuberculosis” (MMWR 2003;52[No. RR-11]:9–10, 
55–56). Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
 CDC. Self-Study Modules on Tuberculosis (Division of Tuberculosis Elimination Web 
site; 1999). Available at: http://www.phppo.cdc.gov/phtn/tbmodules/Default.htm . 
 Francis J. Curry National Tuberculosis Center. Pediatric Tuberculosis: An Online 
Presentation (Francis J. Curry National Tuberculosis Center Web site; 2007).  
Available at: http://www.nationaltbcenter.edu/pediatric_tb/ . 
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Resources and References 
Resources 
 ATS, CDC, IDSA. “Treatment of Tuberculosis” (MMWR 2003;52[No. RR-11]). 
Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
 CDC. Core Curriculum on Tuberculosis (2000) [Division of Tuberculosis Elimination 
Web site]. November 2001. Available at 
http://www.cdc.gov/tb/pubs/corecurr/default.htm . 
 CDC. Self-Study Modules on Tuberculosis (Division of Tuberculosis Elimination Web 
site; 1999). Available at: http://www.phppo.cdc.gov/phtn/tbmodules/Default.htm . 
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Introduction 
Purpose 
Use this section to understand and follow national and Arizona guidelines to 
 classify patients with latent TB infection (LTBI) 
 diagnose LTBI 
In the 2005 guideline “Controlling Tuberculosis in the United States: Recommendations 
from the American Thoracic Society, Centers for Disease Control and Prevention, and 
the Infectious Diseases Society of America,” one of the recommended strategies to 
achieve the goal of reduction of TB morbidity and mortality is the identification of persons 
with LTBI at risk for progression to TB disease, and treatment of those persons with an 
effective drug regimen.1 
 
Contacts are mentioned within this section, but their evaluation and follow-
up are covered in more depth in the Contact Investigation section. For 
information on treatment, refer to the Treatment of Latent Tuberculosis 
Infection section. 
 
Policy 
In Arizona: 
 Targeted testing for LTBI should be conducted only among persons in groups with 
identified risk factors for LTBI and/or progression to TB disease.  
 Contacts should be evaluated as described in the Contact Investigation section. 
For roles and responsibilities, refer to the “Roles, Responsibilities, and 
Contact Information” topic in the Introduction. 
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State Laws and Regulations 
Arizona Laws/Rules Regarding Tuberculosis Control 
Arizona Revised Statutes.  Title 36:  Public Health and Safety; Chapter 6:  
Public Health Control; Title 6:  Tuberculosis Control.  (ARS§36-711 
through §36-738)  
ARS§36-711.  Definitions.   
ARS§36-712. Administration by the department.   
ARS§36-714.  Tuberculosis control officer.   
ARS§36-715.  Costs; removals; proceedings.   
ARS§36-716.  Payment of assistance.   
ARS§36-717.  Responsibility for care or treatment by counties.   
ARS§36-718.  Contracting for care of afflicted persons.   
ARS§36-721.  Rules.   
ARS§36-723.  Investigation of tuberculosis cases.   
ARS§36-724.  Voluntary control measures.   
ARS§36-725.  Orders to cooperate; emergency custody.    
ARS§36-726.  Petition for court ordered examination, monitoring, 
treatment, isolation or quarantine.   
ARS§36-727. Hearings; procedure; confidentiality.   
ARS§36-728. Judicial action.   
ARS§36-729. Amended orders for intervention and transport of afflicted 
persons.   
ARS§36-730.  Appointment of guardian or conservator.   
ARS§36-731.  Confinement; selection; jails; prohibition.   
ARS§36-732.  Early release from court ordered treatment.   
ARS§36-733.  Choice of physician and mode of treatment.   
ARS§36-734.  Treatment; exemption.   
ARS§36-735.  Notification of rights.   
ARS§36-736.  Administrative procedures act; judicial review of 
administrative procedures; exemption; appeals.  
ARS§36-737.  Violation; classification.   
ARS§36-738.  Qualified immunity.   
 
Arizona Administrative Code.  Title 9. Chapter 6.  Department of 
Health Services Communicable Diseases and Infestations.   
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Tuberculosis Classification System  
The system for classifying tuberculosis (TB) is based on how the infection and disease 
develop in the body. Use this classification system to help track the status of TB in your 
patients and to allow comparison with other reporting areas.  
 
Table 1: TUBERCULOSIS CLASSIFICATION SYSTEM2  
Class Type Description 
0  No tuberculosis (TB) exposure 
 Not infected 
 No history of exposure 
 Negative reaction to the tuberculin skin test (TST) or 
interferon gamma release assay (IGRA)  
1  TB exposure 
 No evidence of infection 
 History of exposure 
 Negative reaction to the TST or IGRA 
2  TB infection 
 No disease 
 Positive reaction to the TST or IGRA 
 Negative bacteriologic studies (if done) 
 No clinical, bacteriologic, or radiographic evidence of TB 
disease 
3  TB disease 
 Clinically active 
 Mycobacterium tuberculosis complex cultured (if this has 
been done) 
 Clinical, bacteriologic, or radiographic evidence of 
current disease 
4  TB disease 
 Not clinically active 
 History of episode(s) of TB 
 Or 
 Abnormal but stable radiographic findings 
 Positive reaction to the TST or IGRA 
 Negative bacteriologic studies (if done) 
 And 
 No clinical or radiographic evidence of current disease 
5  TB suspect  Diagnosis pending  
Adapted from: CDC. Classification system. In: Chapter 2: transmission and pathogenesis. Core Curriculum on 
Tuberculosis (2000) [Division of Tuberculosis Elimination Web site]. Updated November 2001. Available at: 
http://www.cdc.gov/tb/pubs/corecurr/default.htm . Accessed July 3, 2006. 
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High-Risk Groups  
Certain factors identify persons at high risk for tuberculosis (TB) infection and/or for 
progression to TB disease. Persons in the high-risk groups listed in Table 2: Persons at 
High Risk for Tuberculosis Infection and Progression to Tuberculosis Disease are 
candidates for tuberculin skin testing in Arizona.  
Persons with risk factors from both columns may be at much higher risk than those with 
risk factors in only one column. For example, an individual born in a high-TB-prevalence 
country with HIV infection is at much higher risk of having active TB than a US-born 
individual with HIV infection.  
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Table 2: PERSONS AT HIGH RISK FOR TUBERCULOSIS INFECTION AND 
PROGRESSION TO TUBERCULOSIS DISEASE3 
For Tuberculosis Infection For Progression to Tuberculosis Disease4  
 High-priority contacts such as housemates or 
coworkers or contacts of persons who have smear-
positive pulmonary or laryngeal tuberculosis (TB)  
 Infants, children, and adolescents exposed to adults 
in high-risk categories 
 Recent immigrants (<5 years) from countries with 
high incidence of TB (Asian, African, Latin American, 
and Eastern European countries have TB rates 5–30 
times higher than U.S. rates, and an increasing 
percentage of TB cases here are occurring among 
immigrants from those countries)  
 Recent immigrants from Mexico 
 Migrant workers 
 Persons who have recently spent over 3 months in 
high-incidence countries (such as missionaries from 
the Church of Jesus Christ of Latter-Day Saints) 
 Native Americans 
 Persons with high rates of TB transmission:  
• Homeless persons 
• Injection drug users 
• Persons with human immunodeficiency virus 
(HIV) infection  
• Persons living or working in institutions with 
individuals at risk for TB such as:  
 Hospitals, especially staff in nursing, 
emergency departments, and laboratories  
 Long-term care facilities  
 Homeless shelters 
 Residences for acquired immunodeficiency 
syndrome (AIDS) patients 
 Correctional facilities 
 Persons with HIV infection 
 Infants and children aged <5 years 
 Persons infected with Mycobacterium tuberculosis 
within the previous 2 years 
 Persons with a history of untreated or inadequately 
treated TB disease 
 Persons with radiographic findings consistent with 
previous TB disease 
 Persons who use alcohol or illegal drugs (such as 
injection drugs or crack cocaine)  
 Persons with any of the following clinical conditions 
or other immunocompromising conditions: 
• Silicosis 
• Diabetes mellitus 
• End-state renal disease (ESRD)/chronic renal 
failure, hemodialysis  
• Some hematologic disorders (e.g., leukemias and 
lymphomas) 
• Other malignancies (e.g., carcinoma of head, 
neck, or lung) 
• Body weight ≥10% below idea body weight  
• Prolonged corticosteroid use 
• Use of other immunosuppressive treatments (e.g., 
prednisone or tumor necrosis factor-alpha [TNF- 
α] antagonists) 
• Organ transplantation  
• Gastrectomy 
• Chronic malabsorption syndromes 
• Jejunoileal bypass 
 
Source: Adapted from: CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care 
settings, 2005. MMWR 2005;54(No. RR-17):4–5; CDC. Targeted tuberculin testing and treatment of latent tuberculosis 
infection. MMWR 2000;49(No. RR-6):7–9.  
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Diagnosis of Latent Tuberculosis Infection  
The diagnosis of latent tuberculosis infection (LTBI) has been traditionally been based 
upon results of tuberculin skin testing. However, the QuantiFERON®-TB Gold test (QFT-
G),  a whole-blood interferon gamma release assay (IGRA), is now another option for 
detecting LTBI.  
Use the Mantoux tuberculin skin test (TST) or the QFT-G to test for Mycobacterium 
tuberculosis infection. QFT-G can be used in all circumstances in which the TST is used, 
and the QFT-G usually can be used in place of (and not in addition to) the TST.5 
For information on testing methods available in Arizona, refer to the 
Laboratory Services section. 
Mantoux Tuberculin Skin Testing 
The Mantoux method of tuberculin skin testing is used to detect infection with 
Mycobacterium tuberculosis.   
In general, it takes 2 to 10 weeks after infection for a person to develop a delayed-type 
immune response to tuberculin measurable with the Mantoux tuberculin skin test (TST).6 
During the test, tuberculin is injected into the skin. The immune system of most persons 
with tuberculosis (TB) infection will recognize the tuberculin, causing a reaction in the 
skin. Repeated TSTs do not produce hypersensitivity. 
The size of the measured induration (a hard, dense, raised formation) and the patient's 
individual risk factors should determine whether TB infection is diagnosed.7 Based on 
the sensitivity and specificity of the purified protein derivative (PPD) TST and the 
prevalence of TB in different groups, three cut-points have been recommended for 
defining a positive tuberculin reaction:  
 Greater than or equal to 5 mm 
 Greater than or equal to 10 mm  
 Greater than or equal to 15 mm of induration8   
For more information on cut-points for the TST, see the “Interpretation of 
the Tuberculin Skin Test” topic in this section. 
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Candidates for Mantoux Tuberculin Skin Testing  
The Mantoux TST can be administered to all persons, including pregnant women,9 
persons who have previously been vaccinated with Bacille Calmette-Guérin (BCG),10 
and human immunodeficiency virus (HIV)-infected persons. However, persons with a 
documented prior positive TST do not need another TST, and the Mantoux TST should 
not be administered until four weeks after vaccination with live-virus vaccines.  
If the person being tested is a contact, follow the procedures outlined in 
the Contact Investigation section. 
Pregnancy 
Tuberculin skin testing is entirely safe and reliable for pregnant women, and pregnant 
women at high risk for TB infection or disease should be tested. Screen pregnant 
women for TB infection if they have any of the following conditions:  
 Symptoms suggestive of TB disease 
 HIV infection  
 Behavioral risk factors for HIV  
 Medical conditions other than HIV infection that increase the risk for TB disease  
 Close contact with a person who has pulmonary or laryngeal TB disease 
 Immigration from an area of the world where incidence of TB is high  
Bacille Calmette-Guérin Vaccine 
BCG vaccines are live vaccines derived from a strain of Mycobacterium bovis. Because 
their effectiveness in preventing infectious forms of TB has never been demonstrated in 
the United States, they are not recommended as a TB control strategy in the United 
States, except under rare circumstances. They are, however, used commonly in other 
countries. A history of BCG vaccination is not a contraindication for tuberculin skin 
testing, nor does it influence the indications for a TST. Administer and measure TSTs in 
BCG-vaccinated persons in the same manner as in those with no previous BCG 
vaccination. 
Diagnosis and treatment of LTBI should be considered for BCG-vaccinated persons with 
a TST reaction of equal to or greater than 10 mm induration, especially if they are  
 continually exposed to populations with a high prevalence of TB (e.g., some 
healthcare workers, employees and volunteers at homeless shelters, and workers at 
drug treatment centers); 
 born or have lived in a country with a high prevalence of TB; or 
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 exposed to someone with infectious TB, particularly if that person has transmitted TB 
to others.11 
Evaluate these patients for symptoms of TB. If a patient has symptoms of TB disease, 
obtain chest radiography and (if the patient is coughing) collect sputum specimens. 
Anergy Testing 
Anergy testing is not routinely recommended in conjunction with TST for HIV-infected 
persons in the U.S.12  
Anergy testing is a diagnostic procedure used to obtain information about the 
competence of the cellular immune system. Conditions that cause an impaired cellular 
immune system include HIV infection, severe or febrile illness, measles or other viral 
infections, Hodgkin’s disease, sarcoidosis, live virus vaccination, and corticosteroid or 
immunosuppressive therapy. Persons with conditions such as these may have 
suppressed reactions to a TST even if infected with TB. However, there are no simple 
skin testing protocols that can reliably identify persons as either anergic or nonanergic 
and that have been proven to be feasible for application in public health TB screening 
programs. 
Factors limiting the usefulness of anergy skin testing include the following:  
 Problems with standardization and reproducibility 
 Low risk for TB  associated with a diagnosis of anergy 
 Lack of apparent benefit of treatment for LTBI in groups of anergic HIV-infected 
persons 
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Documented Prior Positive Tuberculin Skin Test 
Persons who have tested positive in the past and can provide documentation of their 
status should not have another TST. Instead, they should have a TB symptom 
assessment questionnaire administered to identify any symptoms of TB disease.13 
Persons who are symptomatic should receive a chest radiograph.   
Live-Virus Vaccines 
The Mantoux TST can be administered in conjunction with all vaccines. However, the 
measles (MMR) vaccine—and possibly mumps, rubella, varicella, and live attenuated 
influenza vaccines—may transiently suppress the response to PPD.14 Therefore, if a 
vaccine containing live virus (e.g., measles, smallpox) has already been given, the TST 
should be deferred until (or repeated) at least four weeks after the vaccine was 
administered.  
When giving the TST and the MMR, one of the following three sequences should be 
used: 
 Apply the TST at same visit as the MMR 
 Delay the TST at least four weeks if the MMR is given first 
 Apply the TST first and then give the MMR when the TST is measured15  
Multiple Puncture Tests  
Multiple puncture tests (MPTs), such as the Tine test, should not be used. The MPTs are 
not reliable because the amount of tuberculin injected intradermally cannot be precisely 
controlled and there is no standard for interpretation. 
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Administration of the Tuberculin Skin Test  
The TST should be placed by a healthcare worker who has received appropriate training 
and is following written protocols. 
Table 3: BEFORE YOU BEGIN TO ADMINISTER A TUBERCULIN SKIN TEST  
Before You Begin to Administer a TST 
Review 
Information 
CDC. Mantoux Tuberculin Skin Test Facilitator Guide at 
http://www.cdc.gov/tb/pubs/Mantoux/guide.htm 
 
Infection control procedures (including hand washing before and after the procedure and the 
use of gloves and a sharps container). 
Gather 
Equipment 
 Gloves 
 Alcohol pads or alternative skin cleanser 
 Safety needle  
 Tuberculin syringe (Do not pre-draw tuberculin into syringes prior to test.) 
 Purified protein derivative (PPD) (Tubersol® or Aplisol®: See the warning in the text below in 
this table.) 
 Sharps container 
 
Note: Opened PPD tuberculin vials must be dated and discarded after 30 days. See the 
package insert for appropriate storage information. 
 
Read the PPD labels carefully before administering a TST. The packaging of 
tetanus toxoid-containing vaccines (TTCVs) is similar to Tubersol® and 
Aplisol®, and all are refrigerated. See the CDC’s “Errors Involving Mix-up of 
Tuberculin Purified Protein Derivative and Vaccine Products” (TB Notes 
Newsletter. 2005;No. 1) at 
http://www.cdc.gov/tb/notes/TBN_1_05/Errors_mix_up.htm . 
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How to Administer a Tuberculin Skin Test 
1. If the patient’s written consent is required, obtain it, per health department 
requirements. 
2. Inject air into the vial air space (not into the solution). Injection of air into the air 
space in the vial prevents creation of negative pressure within the vial, allowing the 
antigen to be withdrawn easily. Injecting air into the solution creates bubbles and 
may interfere with withdrawing the correct amount of antigen.16 
3. The injection should be placed on the palm-side-up surface of the forearm, about two 
to four inches below the elbow. Your local institutional policy may specify the right or 
left forearm for the skin test. The area selected should be free of any barriers to 
placing and reading the skin test, such as muscle margins, heavy hair, veins, sores, 
tattoos, or scars. 
4. After choosing the injection site, clean the area with an alcohol swab by circling from 
the center of the site outward. Allow the site to dry completely before the injection.  
5. Using a disposable tuberculin safety needle and syringe, inject 0.1 ml of PPD 
tuberculin containing 5 tuberculin units (TU) intradermally with the needle bevel 
facing upward. Because some of the tuberculin solution can adhere to the inside of 
the plastic syringe, the skin test should be given as soon as possible after the 
syringe is filled. 
6. The injection should produce a discrete, pale elevation of the skin (a wheal) 6 to 10 
mm in diameter. Note: If a 6- to10-mm wheal is not produced, repeat the test on the 
opposite arm or the same arm, 2 inches from the original site. 
7. Record the date and time of TST administration, location of injection site, dose, 
name of person who administered the test, name and manufacturer of tuberculin 
product used, lot number, expiration date, and reason for testing.17 
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Measurement of the Tuberculin Skin Test  
A trained healthcare worker should read the TST 48 to 72 hours after the intradermal 
injection. Patients should never be allowed to read their own TSTs.18  
 A positive reaction can be measured anytime after 48 hours. 
 If the results appear negative and more than 72 hours have passed, the test should 
be repeated. It can be repeated immediately, or after one week, if two-step testing is 
required.  
 
See the topic titled “Two-Step Tuberculin Skin Testing” in the Infection Control 
section.  
 
Before you measure a TST, review information in the CDC’s Mantoux 
Tuberculin Skin Test Facilitator Guide at 
http://www.cdc.gov/tb/pubs/Mantoux/guide.htm . 
How to Measure a Tuberculin Skin Test 
1. Measure the TST site crosswise to the axis of the forearm. 
2. Induration is a hard, dense, raised formation. Measure only induration hardness and 
not swelling around the site of the injection. Do not measure erythema (redness). A 
TST with erythema, but no induration, is nonreactive.  
3. Record the test result in mm, not as “positive” or “negative.” An exact reading in mm 
may be necessary to interpret whether conversions occur on a subsequent test. 
Record a TST with no induration as “0 mm.” Where there is induration, do not round 
off the reading, but record it exactly as read.  
4. Report adverse reactions to a TST (e.g., blistering, ulcerations, necrosis) to the 
FDA’s MedWatch Program at 1-800-FDA-1088, or via the Internet at 
http://www.fda.gov/medwatch/ . 
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Interpretation of the Tuberculin Skin Test  
TSTs should be interpreted by a trained healthcare worker. Use Table 4 below to 
interpret TSTs.  
Call the medical director regarding TST reactions when interpretation and 
medical follow-up are unclear. 
Before you interpret a TST, review information in the CDC’s Mantoux 
Tuberculin Skin Test Facilitator Guide at 
http://www.cdc.gov/tb/pubs/Mantoux/guide.htm . 
How to Interpret a Tuberculin Skin Test  
Use the table below to determine when a reaction is positive. 
Table 4: POSITIVE TUBERCULIN SKIN TEST REACTIONS 
Induration Size Considered Positive For: 
5 mm or more   Persons with human immunodeficiency virus (HIV) infection/acquired 
immunodeficiency syndrome (AIDS) 
 Recent contacts of an infectious case of tuberculosis (TB) disease 
 Persons with fibrotic lesions on chest radiograph consistent with healed TB 
 Persons with organ transplants or other immunosuppressed persons (such as those 
receiving the equivalent of >15 mg/day of prednisone for >1 month)   
 Persons receiving treatment with tumor necrosis factor-alpha (TNF-α) antagonists 
 
10 mm or more   Foreign-born persons recently arrived (within 5 years) from countries with a high TB 
incidence or prevalence (e.g., most countries in Africa, Asia, Latin America, Eastern 
Europe, Russia, or from refugee camps 
 Persons who inject drugs or use other high-risk substances, such as crack cocaine  
 Alcoholics 
 Residents and employees in high-risk, congregate settings (e.g., correctional 
institutions; long-term residential care facilities, such as nursing homes, mental 
institutions, etc.; hospitals and other healthcare facilities; homeless shelters; and 
refugee camps) 
 Mycobacteriology laboratory personnel 
 Persons with other medical conditions that increase the risk of TB disease 
 Children younger than 5 years of age, or children and adolescents exposed to 
adults in high-risk categories 
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Induration Size Considered Positive For: 
15 mm or more   Persons with no known risk factors for TB 
 
 
When interpreting TST results, be aware of the following.  
Skin test conversions: For persons previously skin tested, an increase in induration of 
10 mm or more within a two-year period is classified as a conversion to positive. 
False-negative reactions may be due to the following: 
 Anergy  
See “Anergy Testing” under “Candidates for Mantoux Tuberculin Skin Testing” 
in this section. 
 Recent TB infection (within the past 10 weeks) 
 Very young age (less than 6 months of age, because the immune system is not fully 
developed) 
 Overwhelming TB disease 
 Vaccination with live viruses (e.g., measles, mumps, rubella, varicella, oral polio, or 
yellow fever).  
TB skin testing should be done either on the same day as vaccination with live 
virus or at least four weeks after vaccination.  
See “Live-Virus Vaccines” under “Candidates for Mantoux Tuberculin Skin 
Testing” in this section. 
 Some viral infections (measles, mumps, chickenpox, or HIV) 
 Corticosteroids or other immunosuppressive agents given for two or more weeks 
False-positive reactions may be due to the following:19 
 Nontuberculous mycobacteria (NTM) or mycobacterium other than tuberculosis 
(MOTT) 
 BCG vaccination  
See “Bacille Calmette-Guérin Vaccine” under “Candidates for Mantoux 
Tuberculin Skin Testing” in this section. 
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Human Immunodeficiency Virus Screening 
The Centers for Disease Control and Prevention (CDC) recommends the following: 
 Routine HIV screening for all patients ages 13–64 seeking health care for any 
reason, without regard to patient’s known risks for HIV infection 
 Annual HIV screening of patients known to be at high risk20 
Follow-Up Activities 
After testing, complete the following tasks: 
 
If the person has signs or symptoms of TB, evaluate for TB disease as 
described in the “Diagnosis of Tuberculosis Disease” topic in the Diagnosis 
of Tuberculosis Disease section. Refer to Table 3: When to Suspect 
Pulmonary Tuberculosis in Adults. 
If the person is a contact, follow the procedures for testing and 
evaluation in the Contact Investigation section. 
If the person is a participant in two-step screening, see the topic titled 
“Two-Step Tuberculin Skin Testing” in the Infection Control section.  
If the TST result is positive, a chest radiograph should be obtained for 
the patient, as specified in the “Chest Radiography” topic in this section.  
Interferon Gamma Release Assays  
An interferon gamma release assay (IGRA) is another method to test for M. tuberculosis 
infection. For patients with a previous documented positive TST reaction, an IGRA can 
be done.  Refer to www.quantiferon.com for available test sites. Refer to the Celestis 
web-site http://cellestis.com/ for additional information.  
Blood assay for Mycobacterium tuberculosis (BAMT) is a general term referring to 
recently developed in vitro diagnostic tests that reveal the presence of infection with M. 
tuberculosis. This term includes, but is not limited to IGRAs. The IGRA currently 
approved by the Food and Drug Administration (FDA) and available on the market is 
QuantiFERON®-TB Gold (QFT-G), which can be used in all circumstances in which the 
TST is used. QFT-G usually can be used in place of the TST.21 Other cytokine-based 
immunoassays are under development and may also become useful in the diagnosis of 
M. tuberculosis infection. Future FDA-licensed products, in combination with CDC-
issued recommendations, may provide additional diagnostic alternatives.22 
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The advantages of IGRA, compared with the TST, are that results can be obtained after 
a single patient visit, and that, because it is a blood test performed in a qualified 
laboratory, the variability associated with skin test reading can be eliminated.23 In 
addition, the QFT-G test appears to be less affected by past BCG vaccination than the 
TST and may eliminate the unnecessary treatment of patients with BCG-related false-
positive results.24 However, the QFT-G test has practical limitations that include the 
need to draw blood and to ensure its receipt in a qualified laboratory in time for testing
For QFT-G tests, the blood must be incubated with the test antigens <12 hours af
collection, while the lymphocytes are viable.
. 
ter 
25 .26 Refer to www.quantiferon.com for 
available test sites. Refer to the Celestis web-site http://cellestis.com/ for additional 
information regarding a.new QuantiFERON®-TB Gold In-Tube (IT) test that has recently 
been approved by the FDA. 
Additional tests, such as chest radiography and bacteriologic examination, are required 
to confirm TB disease. 27 
Persons with a positive QFT-G result or a positive TST result, regardless of symptoms 
and signs, should be evaluated for TB disease before LTBI is diagnosed. At minimum, a 
chest radiograph should be examined for abnormalities consistent with TB disease. 28 
Negative QFT-G results should not be used alone to exclude M. tuberculosis infection in 
persons with symptoms or signs suggestive of TB disease. Medical evaluation of such 
persons should include a history and physical examination, chest radiograph, 
bacteriologic studies, serology for human immunodeficiency virus (HIV), and, when 
indicated, other tests or studies.29 
 
For more information on IGRAs and the QFT-G test, see the CDC’s 
“Guidelines for Using the QuantiFERON®-TB Gold Test for Detecting 
Mycobacterium tuberculosis Infection, United States” (MMWR. 2005;54[No. 
RR-15]) at http://www.cdc.gov/mmwr/pdf/rr/rr5415.pdf  . 
 
For information on laboratories that provide QFT-G testing services for 
Arizona, go to www.quantiferon.com. For supplies to draw and ship the blood 
samples, see the “Specimen Collection and Shipment Supplies” topic in the 
Supplies, Materials and Services section.  
Chest Radiography  
All individuals being considered for LTBI treatment should undergo a chest radiograph to 
rule out pulmonary TB disease. For information on how to classify TB, see the 
“Tuberculosis Classification System” topic at the beginning of this section. Refer to Table 
5 to determine when to obtain a chest radiograph and what follow-up is required for 
chest radiograph results. 
A posterior-anterior radiograph of the chest is the standard view used for the detection 
and description of chest abnormalities in adults. In some instances, other views (e.g., 
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Children younger than 5 years of age should receive posterior-anterior and 
lateral radiographs.30  
 
For more information on chest radiography, refer to the Francis J. Curry 
National Tuberculosis Center’s Radiographic Manifestations of Tuberculosis: A 
Primer for Clinicians (Francis J. Curry National Tuberculosis Center Web site; 
2006) at 
http://www.nationaltbcenter.edu/products/product_details.cfm?productID=EDP-
04 . 
 
For persons recently exposed to TB, follow the procedures for testing and 
evaluation in the Contact Investigation section. 
lateral, lordotic) or additional studies (e.g., computed tomography [CT] scans) may be 
necessary.  
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Table 5: TARGETED TESTING FOR LATENT TUBERCULOSIS INFECTION: WHEN CHEST RADIOGRAPHS ARE REQUIRED AND 
HOW TO FOLLOW UP ON RADIOGRAPHY RESULTS 
Signs or 
Symptoms  
of TB Disease? 
TST or  
IGRA 
Result? 
Recent  
Exposure to 
Infectious 
TB? 
 
Chest Radiograph? 
 
Follow-up Action 
Yes Positive or 
negative  
Yes or no Normal or abnormal  Classify as Class 5. 
 Evaluate for TB disease. Refer to the Diagnosis of Tuberculosis 
Disease section. 
No  Negative  No CXR not recommended unless the 
patient has HIV infection or other forms 
of immunosuppression are present 
 Classify as Class 0.  
 
No  Positive  No Normal  Classify as Class 2.  
 Consider treatment for LTBI. Refer to the Treatment of Latent 
Tuberculosis Infection section. 
   Abnormal: Noncalcified fibrotic lesions 
suggestive of old, healed TB; 
comparison film available and stable  
 Classify as Class 4 or 5.  
 Consider evaluating for TB disease. Refer to the Diagnosis of 
Tuberculosis Disease section. 
   Abnormal: Consistent with TB disease; 
no comparison film 
 Classify as Class 3 or 5.  
 Evaluate for TB disease. Refer to the Diagnosis of Tuberculosis 
Disease section. 
 Definitions of abbreviations: CXR = chest radiograph; HIV = human immunodeficiency virus; IGRA = interferon gamma release assay; LTBI = latent tuberculosis infection; TB = 
tuberculosis; TST = tuberculin skin test. 
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Introduction 
Purpose 
Use this section to understand and follow national and Arizona guidelines to 
 Determine whom to treat for latent tuberculosis infection (LTBI); 
 Select appropriate treatment regimens and dosages; 
 Monitor patients for adverse reactions; 
 Monitor patients’ adherence to treatment; 
 Determine whether and when therapy is completed; and 
 Provide treatment in special situations, such as when a patient is pregnant or has tuberculosis (TB)–human immunodeficiency 
virus (HIV) coinfection. 
Prevention of TB has major public health implications, so it is essential to identify and treat all those with risk factors for TB disease.1 
LTBI is the presence of Mycobacterium tuberculosis organisms (tubercle bacilli), with no symptoms and no radiographic or 
bacteriologic evidence of TB disease.2 A person with LTBI is noninfectious but can develop active TB disease. Persons with 
increased risk for developing TB include those who have had recent infection with M. tuberculosis and those who have clinical 
conditions associated with an increased risk for the progression of LTBI to TB disease.  
To control and prevent TB, our healthcare resources and efforts should be directed to meet the priorities outlined in the 2005 
“Controlling Tuberculosis in the United States: Recommendations from the American Thoracic Society, Centers for Disease Control 
and Prevention, and the Infectious Diseases Society of America.” One of the recommended strategies to achieve the goal of 
reduction of TB morbidity and mortality is the identification and treatment of persons with LTBI at risk for progression to TB.3  
Healthcare providers must communicate the risks and benefits of treatment to their patients and encourage adherence and treatment 
completion. Treatment of LTBI is essential to controlling and eliminating TB in the United States. LTBI treatment substantially 
A R I Z
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reduces the risk that TB infection will progress to disease.4 Depending upon adherence and length of treatment, completing 
treatment for LTBI can reduce the risk of TB disease by 65–90%.5 
Policy  
Treatment should be considered for all persons who are determined to be candidates for the treatment of LTBI.  
 
For roles and responsibilities, refer to the “Roles, Responsibilities, and 
Contact Information” topic in the Introduction. 
  
Whom to Treat 
Determine whom to treat for latent tuberculosis infection (LTBI). Certain groups are at high risk of developing tuberculosis (TB) 
disease once infected, so make every effort to begin appropriate treatment and to ensure those persons complete the entire course 
of treatment for LTBI.6  
 
For a list of high-risk groups by tuberculin skin test (TST) results, see the 
Tuberculin Skin Test Results listings, which follow in this topic. For more 
information on targeted testing, see the Targeted Testing for Latent 
Tuberculosis Infection section.  
 
High-risk contacts (under 5 years of age or immunocompromised) should 
be started promptly on treatment for LTBI. For more information on time 
frames, see the “Time Frames for Contact Investigation” topic in the 
Contact Investigation section.  
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Several treatment regimens are available for the treatment of LTBI, and providers should discuss treatment options with their 
patients.7   
 
For more information on treatment of LTBI, see the “Treatment Regimens 
and Dosages” topic in this section and the Centers for Disease Control and 
Prevention (CDC) publication “Treatment of Latent Tuberculosis Infection 
(LTBI)” (TB Elimination Fact Sheet; April 2006) at 
http://www.cdc.gov/tb/pubs/tbfactsheets/treatmentLTBI.pdf . 
For consultation regarding the treatment of LTBI, contact the local health 
agency, TB program or the Arizona Department of Health Services, TB 
Control Section at 602-364-4750. 
Susceptible and Vulnerable Contacts 
A contact is someone who has been exposed to M. tuberculosis infection by sharing air space with a person with infectious TB.8 
Susceptible contacts are those who are more likely to become ill with TB disease if they are infected, and vulnerable contacts are 
those who could suffer severe morbidity if they had TB disease.9 Persons who are susceptible and/or vulnerable to TB disease are 
candidates for window period treatment, which is treatment for presumptive TB infection during the interval between infection and 
detectable skin test reactivity. The National Tuberculosis Controllers Association (NTCA) and the CDC recommend that the window 
period be estimated at 8 to 10 weeks.10  
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The following contacts with initially negative TST results should receive treatment for LTBI after TB disease has been ruled out by 
clinical examination and chest radiograph:  
1. Contacts younger that 5 years of age (with highest priority given to those under 3 years)  
2. Contacts with human immunodeficiency virus (HIV) infection or who are otherwise immunocompromised 
If the second skin test result is negative and the contact is immunocompetent (including immunocompetent young children) and no 
longer exposed to infectious TB, treatment for LTBI may be discontinued, and further follow-up is not necessary. If the second test is 
negative but the contact is immunocompromised (e.g., with human immunodeficiency virus [HIV] infection), a course of therapy for 
LTBI should be completed. If the second test result is negative but the person remains in close contact with an infectious patient, 
treatment for LTBI should be continued if the contact is  
1. Less than 5 years old;  
2. Aged 5–15 years, at the clinician’s discretion; or 
3. HIV-seropositive or otherwise immunocompromised.11 
 
Persons known to be or suspected of being immunocompromised, such as 
HIV-infected persons, should be given treatment for LTBI regardless of the 
TST reaction.12  
Tuberculin Skin Test Results of 5 mm or More 
Persons in the following high-risk groups are candidates for treatment of LTBI if their skin test result is 5 mm or more: 
 Persons with HIV infection  
 Recent contacts of persons with newly diagnosed infectious TB 
 Persons with fibrotic changes on their chest radiograph that is consistent with old TB 
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 Persons with organ transplants and other immunosuppressed patients (receiving the equivalent of 15 mg or more/day of 
prednisone for at least one month)13  
Tuberculin Skin Test Results of 10 mm or More 
Persons in the following high-risk groups are candidates for treatment of LTBI if their skin test result is greater than or equal to 10 
mm:  
 Foreign-born persons who have recently arrived (within five years) from countries with a high TB incidence or prevalence, or 
persons who have recently traveled to these countries (most countries in Africa, Asia, Latin America, Eastern Europe, and 
Russia) 
 Persons who are alcoholics, who inject drugs, or who use other high-risk substances, such as crack cocaine 
 Residents and employees of high-risk congregate settings, such as correctional institutions, homeless shelters, long-term 
residential care facilities (e.g., nursing homes, mental institutions), hospitals, and other healthcare facilities 
 Mycobacteriology laboratory personnel 
 Persons with medical conditions or undergoing treatments that increase the risk of TB disease (diabetes mellitus, silicosis, recent 
infection with M. tuberculosis within the past two years, bone marrow and organ transplant recipients, prolonged high-dose 
corticosteroid therapy and other immunosuppressive therapy, chronic renal failure, hemodialysis, some hematological disorders 
[e.g., leukemias and Hodgkin’s disease], other specific malignancies [e.g., carcinoma of the head, neck, or lung], chronic 
malabsorption syndromes, weight of 10% or more below ideal body weight, and intestinal bypass or gastrectomy) 
 Children less than 5 years of age and adolescents exposed to adults at high risk for developing TB disease14  
Tuberculin Skin Test Results of 15 mm or More15 
Persons in the following groups may be considered for treatment of LTBI if their skin test result is greater than or equal to 15 mm.  
These groups should be given a lower priority for prevention efforts than the groups already listed above.  
 Persons with no known risk factors for TB disease 
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 Healthcare workers* who are otherwise at low risk for TB disease and who received baseline testing at the beginning of 
employment as part of a TB screening program16 
*  For healthcare workers (HCWs) who are otherwise at low risk for LTBI and progression to TB disease if infected and who received baseline testing at the beginning of employment 
as part of a TB infection-control screening program, a TST result of ≥15 mm (instead of ≥10 mm) is considered to be positive. Although a result of ≥10 mm on baseline or follow-up 
testing is considered a positive result for HCWs for the purposes of referral for medical and diagnostic evaluation, if the TST result is 10–14 mm on baseline or follow-up testing, the 
referring clinician might not recommend treatment of LTBI.17  
 
   
Treatment Regimens and Dosages  
Select appropriate treatment durations, regimens, and dosages. Treatment of latent tuberculosis infection (LTBI) is an essential part 
of the strategy to eliminate tuberculosis (TB) in the United States. Persons with LTBI who are considered at increased risk for TB 
should be offered treatment.18  
There are several treatment regimens available for the treatment of LTBI, and providers should discuss options with patients. 
Persons who are at especially high risk for TB, and either are suspected of nonadherence or are on an intermittent dosing regimen, 
should be treated using directly observed therapy (DOT). This method of treatment is especially appropriate when a household 
member is on DOT for TB disease or in institutions and facilities where a staff member can observe treatment.  
For a list of high-risk groups, see the “Whom to Treat” topic in this section. 
 
High-risk contacts (under 5 years of age or immunocompromised) should 
be started promptly on treatment for LTBI. For more information on time 
frames, see the “Time Frames for Contact Investigation” topic in the 
Contact Investigation section.  
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Regimens 
Identify an appropriate regimen for the patient using the national guidelines provided in Table 1 below. 
Table 1: RECOMMENDED DRUG REGIMENS FOR TREATMENT OF LATENT TUBERCULOSIS INFECTION IN ADULTS19  
Rating* 
(evidence)† 
 
Drug 
Interval and 
Duration 
 
Comments 
HIV– HIV+ 
Daily for 9 
months‡ § 
In HIV-infected patients, INH may be administered 
concurrently with nucleoside reverse transcriptase 
inhibitors (NRTIs), protease inhibitors, or non-nucleoside 
reverse transcriptase inhibitors (NNRTIs). 
A (II) A (II) INH 
Twice weekly 
for  
9 months‡ § 
DOT must be used with twice-weekly dosing. B (II) B (II) 
Daily for 6 
months§ 
This duration of therapy is not indicated for HIV-infected 
persons, those with fibrotic lesions on chest radiographs, 
or children. 
B (I) C (I) INH 
Twice weekly 
for 6 months§ 
DOT must be used with twice-weekly dosing. B (II) C (I) 
RIF Daily for 4 
months in 
adults  
 
Daily for 6 
months in 
children 
RIF is used for persons who are contacts of patients with 
INH-resistant, RIF-susceptible TB. 
Some antiretroviral drugs, such as the protease inhibitors 
and NNRTIs, have interactions with the rifamycins. 
Clinicians should consult Web-based updates or experts 
for the latest specific recommendations.  
The optimal length of RIF therapy in children with LTBI is 
not known; however, the American Academy of Pediatrics 
recommends 6 months of treatment.20  
B (II) B (III) 
Definitions of abbreviations: DOT = directly observed therapy; HIV = human immunodeficiency virus; INH = 
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isoniazid; LTBI = latent tuberculosis infection; RIF = rifampin. 
*  Strength of recommendation: A = Preferred, B = Acceptable alternative, C = Offer when A and B cannot be given. 
†  Quality of evidence: I = Randomized clinical trial data, II = Data from clinical trials that are not randomized or 
were conducted in other populations, III = Expert opinion. 
‡  Recommended regimen for children <18 years of age. 
§  Recommended regimen for pregnant women. 
  Source: CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(No. RR-6):31. 
 
 
 
 
The regimen of rifampin (RIF) and pyrazinamide (PZA) for two months is 
no longer recommended for treatment of LTBI because of its association 
with severe liver injury. For more information, see the CDC’s “Update: 
Adverse Event Data and Revised American Thoracic Society 
(ATS)/Centers for Disease Control and Prevention (CDC) 
Recommendations Against the Use of Rifampin and Pyrazinamide for 
Treatment of Latent Tuberculosis Infection” (MMWR 2003;52[No. 31]:735) 
at http://www.cdc.gov/mmwr/PDF/wk/mm5231.pdf .  
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Dosages 
Once the appropriate regimen has been identified, refer to Table 2 for instructions on dosages for each drug. The information in 
Table 2 is taken from ATS, CDC, and Infectious Diseases Society of America (IDSA) guidelines. 
The following drugs are available in the State of Arizona for treating LTBI. These drugs are provided free of charge by Arizona upon 
approval of the TB Program. 
 Isoniazid (INH) 
 Rifampin (RIF) 
Table 2: RECOMMENDED DOSAGES21,22  
Drug Preparation  Adults/ 
Children 
Daily Twice a Week  
Adults (max.) 5 mg/kg (300 mg) 15 mg/kg (900 mg) INH Tablets (50 mg, 100 mg, 300 
mg); elixir (50 mg/5 ml)  Children 
(max.) 
10–15 mg/kg (300 
mg) 
20–30 mg/kg (900 
mg) 
Adults (max.) 10 mg/kg (600 mg) 10 mg/kg (600 mg) RIF Capsule (150 mg, 300 mg); 
powder may be suspended 
for oral administration Children (max.) 
10–20 mg/kg (600 
mg) 
10–20 mg/kg (600 
mg) 
 Definitions of abbreviations; INH = isoniazid; RIF = rifampin. 
Source: ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):4; CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 
2000;49(No. RR-6):28–29. 
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 The use of INH elixir is discouraged, as it commonly causes diarrhea and 
cramping in children. If children have difficulty taking medications, open 
capsules and crush tablets, and then hide the drugs in soft foods or liquids. 
Possible foods are maple syrup, Nutella, spinach baby food, and chocolate 
whipped cream. Layer the food and drug on a spoon, and teach the child 
to take the contents of the spoon without chewing.23 
Ann Loeffler, M.D. pediatrician and faculty consultant with the Francis J. 
Curry National Tuberculosis Center suggests the following for methods to 
deliver the drugs: 
“Mix with soft vehicle and deliver in one or two spoonfuls – followed by 
food without medicine to clear the palate. The best vehicles seem to be 
strong flavored and darkly colored.  
• Chocolate sauce,  pudding, fudge sauce, ice cream, etc.  
• Jelly or marmalade ( the texture hides the powder granularity 
• Apple sauce or berry-sauce (better to hide the red rifampin color) 
• Nutella or peanut butter  
• Cream cheese or chili con carne  
• Whatever the family can make work.” 
For information on ordering drugs, see the Supplies, Materials, and 
Services section. 
 
For consultation regarding the treatment of LTBI in persons who have 
been in contact with a case who is resistant to drugs in the recommended 
regimens, contact the Arizona Department of Health Services, TB Control 
Section at 602-364-4750. 
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Side Effects and Adverse Reactions 
The patient should be monitored by a registered nurse and/or clinician or case manager at least monthly for signs and symptoms of 
adverse reactions until treatment is completed. If a patient is symptomatic, the provider should be consulted and the patient 
monitored more frequently. Chemistries and complete blood count (CBC), aspartate aminotransferase (AST)/alanine 
aminotransferase (ALT), or other tests based on specific drugs should be done periodically. See Table 4: Monitoring and 
Interventions for Side Effects and Adverse Reactions in this section. 
As is true with all medications, combination chemotherapy for tuberculosis is associated with a predictable incidence of adverse 
effects, some mild, some serious.24  
Adverse effects are fairly common and often manageable. Although it is important to be attuned to the potential for adverse effects, it 
is at least equally important that the drugs with the highest evidence rating not be stopped without adequate justification.25 However, 
adverse reactions can be severe, and thus, it is important to recognize adverse reactions that indicate when a drug should not be 
used. Mild adverse effects can generally be managed with symptomatic therapy; whereas with more severe effects, the offending 
drug or drugs must be discontinued.26 In addition, proper management of more serious adverse reactions often requires expert 
consultation.27 
Monitor patients for side effects and adverse reactions following the basic monitoring steps listed below.  
Basic Monitoring Steps  
1. All healthcare workers providing treatment for latent tuberculosis infection (LTBI) should be familiar with the American Thoracic 
Society (ATS)/Centers for Disease Control and Prevention (CDC) guidelines.  
a. All jurisdictions should follow the national monitoring guidelines identified in the current treatment guidelines for treatment of 
LTBI, “Targeting Tuberculin Testing and Treatment of Latent Tuberculosis Infection,” pages 26–29 at 
http://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf . 
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b. It is also important to check for guideline updates posted on the CDC’s Division of Tuberculosis Elimination home page at 
http://www.cdc.gov/tb/default.htm and the list of guidelines by date at 
http://www.cdc.gov/tb/pubs/mmwr/Maj_guide/List_date.htm .  
2. While on treatment, all patients should be evaluated in person, at baseline (before starting treatment), and then at least every 
months for side effects and adverse reactions.  
3. The common side effects of and adverse reactions to drugs used to treat for LTBI are listed in Table 3: Reporting Reactions to 
Antituberculosis Medications. Educate patients to stop the medicine and promptly report any of the symptoms or signs listed in 
Table 3 or any unexplained illness to the prescribing clinic immediately. 
a. If a patient reports a potentially serious adverse reaction, call the patient’s provider immediately and alert the state TB 
program by calling the Arizona TB Control Program at 602-364-4750.  
b. If a patient reports a potentially less severe side effect, call the patient’s provider immediately and monitor the patient.  
4. If you suspect that an antituberculosis drug may be causing a particular side effect or adverse reaction: 
a. Refer to Table 4: Monitoring and Interventions for Side Effects and Adverse Reactions below.  
b. Consult with the patient’s provider and contact the Arizona TB program for more information by calling 602-364-4750. 
5. If you suspect that an antituberculosis drug may be interacting with other medications that the patient is taking, refer to pages 45–
47 in the “Treatment of Tuberculosis” (MMWR 2003; 52[No. RR-11]) at http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
6. Document the following patient information: 
a. Review of symptoms, side effects, and adverse reactions (and any labs that were drawn)  
b. Education given 
c. Refill provided 
d. Description of any problems encountered and action taken for that visit 
e. Next appointment 
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Reporting Reactions  
The table below is intended for use by a healthcare worker who performs case management services. The healthcare worker should 
instruct the patient to report to the provider the side effects and adverse reactions listed in Table 3. 
If a patient reports to a healthcare worker a potentially serious adverse reaction, the healthcare worker should call the patient’s 
provider immediately and alert the Arizona TB Program by calling 602-364-4750. 
If a patient reports to a healthcare worker a potentially less severe side effect, the healthcare worker should call the patient’s provider 
immediately and monitor the patient.  
TABLE 3: REPORTING REACTIONS TO ANTITUBERCULOSIS MEDICATIONS28 
Potentially Serious  
Adverse Reactions* 
Less Severe  
Signs and Symptoms* 
Immediately report the following signs and symptoms 
or other abnormalities or unexpected events to the 
patient’s provider. These signs and symptoms 
suggest side effects, including hepatotoxicity: 
 Jaundice  
 Dark urine 
 Vomiting 
 Abdominal pain  
 Fever  
 Visual changes  
 Marked clinical rash 
In consultation with the provider, instruct the patient 
to stop TB medications until evaluated by the 
provider.  
Report the following signs and symptoms to the 
patient’s provider within 24 hours:  
 Anorexia 
 Nausea 
 Malaise 
 Peripheral neuropathy: tingling or burning sensation 
in hands or feet 
 Rashes  
 
 
* These lists are not all-inclusive. For a complete list, refer to the current guidelines for treatment of TB, 
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L           Treatment of Latent Tuberculosis Infection      8.14 
REVISED 12/04/07  
“Treatment of Tuberculosis” (MMWR 2003;52[No. RR-11]) at http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
Source: California Department of Health Services(CDHS)/California Tuberculosis Controllers Association(CTCA). TB case management—core components. CDHS/CTCA Joint 
Guidelines [CTCA Web site]. 1998:9. Available at: http://www.ctca.org/guidelines/index.html . Accessed July 11, 2006.  
The two-month regimen of rifampin and pyrazinamide is no longer 
recommended due to serious and fatal hepatitis associated with this 
regimen.29  
At present, the Division of Tuberculosis Elimination (DTBE) urges health departments, hospices, hospitals, jails, prisons, and private 
medical offices to report all severe adverse events (e.g., liver injury, pancreatitis, metabolic acidosis, anaphylaxis, seizure, severe 
dermatitis) leading to hospitalization or death of a person receiving treatment for LTBI that occurred after January 1, 2004, to DTBE 
by calling 404-639-8401. Also, if not done previously, please call the Arizona TB Program by calling 602-364-4750 to report severe 
adverse events. 
Monitoring for Side Effects and Adverse Reactions by Antituberculosis Drug 
Refer to Table 4: Monitoring and Interventions for Side Effects and Adverse Reactions to  
 Identify the side effects and adverse reactions associated with particular antituberculosis drugs 
 Determine how to monitor for side effects and adverse reactions 
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Table 4: MONITORING AND INTERVENTIONS FOR SIDE EFFECTS AND ADVERSE REACTIONS30,31,32 
Antituberculosis 
Drug 
Side Effects/ 
Adverse Reactions 
Monitoring Comments 
Isoniazid (INH)  Rash 
 Hepatic enzyme elevation 
 Hepatitis 
 Peripheral neuropathy 
 Mild central nervous system 
effects 
 
Clinical monitoring monthly 
 
Liver function tests (aspartate aminotransferase  
[AST], alanine aminotransferase [ALT], and serum 
bilirubin) at baseline in selected cases ((human 
immunodeficiency virus [HIV] infection, history of 
liver disease, alcoholism, and pregnancy)  
 
Repeat measurements if 
 Baseline results are abnormal 
 Patient is pregnant, in the immediate postpartum 
period, or at high risk for adverse reactions 
 Patient has symptoms of adverse reactions  
 
Hepatitis risk increases with age and alcohol 
consumption. 
 
Pyridoxine (vitamin B6, 10–25 mg/d) might prevent 
peripheral neurophathy and central nervous system 
effects. 
 
Serum concentrations of phenytoin, disulfiram 
(Antabuse), and carbamazepine may be increased in 
persons taking INH. Measure serum concentrations of 
phenytoin and carbamazepine in patients receiving INH 
(with or without rifampin), and adjust the dose if 
necessary. 
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Antituberculosis 
Drug 
Side Effects/ 
Adverse Reactions 
Monitoring Comments 
Rifampin (RIF)  Rash 
 Gastrointestinal upset  
 Hepatitis 
 Fever 
 Bleeding problems 
 Thrombocytopenia 
 Renal failure 
 Flu-like symptoms 
 Orange-colored body fluids 
(secretions, urine, tears) 
 
Complete blood count, platelets, and liver function 
tests (aspartate aminotransferase  [AST], alanine 
aminotransferase [ALT], and serum bilirubin) at 
baseline in selected cases (human 
immunodeficiency virus [HIV] infection, history of 
liver disease, alcoholism, and pregnancy)  
 
Repeat measurements if 
 Baseline results are abnormal 
 Patient has symptoms of adverse reactions  
 
There are a number of drug interactions with potentially 
serious consequences. Significant interactions with 
methadone, birth control hormones, and many other 
drugs.  
 
Contraindicated or should be used with caution when 
administered with protease inhibitors (PIs) and 
nonnucleoside reverse transcriptase inhibitors 
(NNRTIs). Reduces levels of many drugs (e.g., PIs, 
NNRTIs, methadone, dapsone, ketoconazole, coumadin 
derivatives, hormonal contraceptive, digitalis, 
sulfonylureas, diazepam, ß-blockers, anticonvulsants, 
and theophylline). 
 
For more information, refer to “Section 7: Drug 
Interactions” on page 45 in “Treatment of Tuberculosis” 
at http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
 
Because information regarding rifamycin drug 
interactions is evolving rapidly, consult the CDC’s 
Division of Tuberculosis “News and Updates” Web page 
at http://www.cdc.gov/tb/default.htm to obtain the most 
up-to-date information.  
 
Colors body fluids orange. 
 
May permanently discolor soft contact lenses. 
A R I Z
REVI
Adherence 
Monitor patients for adherence to self-administered latent tuberculosis infection (LTBI) 
treatment regimens at least every month throughout treatment.33 It is difficult to identify 
who will and who will not be adherent.34 If patients do not take medicine as directed, the 
effectiveness of the regimen decreases, and the patient will be at greater risk of 
progressing to disease in the future and of infecting others.  
Monthly Assessment of Adherence 
At each visit, the clinician should assess adherence by doing the following: 
1. Ask patients how many doses they have missed since their last refill. If patients are 
asked, “Did you take all your pills last month?” the natural inclination is to agree and 
say “yes” even if they did not.  
2. Have patients bring their bottle of medicine to the refill appointment, and count how 
many pills are left. 
3. If adherence problems are identified, include patients in the problem-solving process. 
a. Ask patients why they think that doses are missed and what could be done 
better: change the time of day, the location where they keep or take their pills, 
etc. 
b. Find out if there are barriers to obtaining refills in a timely manner that could be 
corrected. 
c. Review with patients what they believe is their risk of developing tuberculosis 
(TB) if medicine is not taken. Provide education again, as needed. 
d. Mutually agree on a plan to improve adherence. 
e. Praise patients for cooperation. 
4. If adherence seems to be good, praise patients. 
 
For information on what to include in a patient education session, see the 
Patient Education section. 
Directly Observed Therapy  
Patients in the following high-risk groups are strongly recommended for directly 
observed therapy (DOT). 
 DOT is mandatory for any intermittent regimen. 
 DOT is strongly encouraged for those with the greatest risk for progressing to 
tuberculosis (TB) disease: 
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• Young children who are recent contacts to infectious cases.  
• Human immunodeficiency virus (HIV)-infected persons. 
For more information, see the “Directly Observed Therapy” topic in the 
Case Management section.  
 
For more information on adherence strategies for different developmental 
stages, see Appendix C in the New Jersey Medical School National 
Tuberculosis Center’s Management of Latent Tuberculosis Infection in 
Children and Adolescents: A Guide for the Primary Care Provider (New 
Jersey Medical School Global Tuberculosis Institute Web site; 2004) at 
http://www.umdnj.edu/globaltb/downloads/products/PediatricGuidelines.pdf. 
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L         Treatment of Latent Tuberculosis Infection 8.19 
REVISED 12/04/07 
Completion of Therapy 
Determine whether and when therapy is completed based on the total number of doses 
administered, not on the duration of therapy. When patients have had lapses in therapy 
but are still able to complete the recommended number of doses in the allotted time 
period, encourage them to complete therapy.  
Assess patients who will not complete appropriate therapy within the time frame 
specified to determine whether or not to restart treatment. If the decision is made to 
retreat the patient, then restart the entire regimen and follow the recommended 
treatment plan of therapy. Specific factors to consider when determining whether to 
restart treatment include the following: 
 Individual’s risk for developing tuberculosis (TB) disease 
 Total number of doses of latent tuberculosis infection (LTBI) treatment administered 
 Time elapsed since the last dose of treatment for LTBI 
 Patient adherence issues (previous attempts at completion, willingness to continue, 
etc.) 
Give nonadherent patients at very high risk of developing TB disease every opportunity 
to complete treatment for LTBI. Consider these patients for intermittent therapy with 
directly observed therapy (DOT), and evaluate the use of incentives and enablers.35  
Treatment of LTBI in contacts is considered a priority in TB control activities. Make every 
effort to assure completion of treatment in contacts.  
All contacts who are being treated for infection should be seen face-to-face by a 
healthcare provider at least every month or more often. Incentives and enablers are 
recommended as aids to adherence, and the healthcare provider should educate the 
patient about TB, its treatment, and the signs of adverse drug effects at each patient 
encounter.36 
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Table 5 describes the duration of therapy and the number of doses that patients are 
required to take to complete therapy and the time frame within which the total number of 
doses must be administered for completion of therapy.  
Table 5: RECOMMENDED REGIMENS FOR COMPLETION OF THERAPY37 
Regimen Age Duration 
of Therapy 
Number of 
Doses 
Must be Administered 
Within 
INH daily Adult and 
child 
9 months 
 
270 
 
12 months 
INH daily Adult 6 months 180 9 months 
INH twice 
weekly 
Adult and 
child 
9 months 
 
76 
 
12 months 
INH twice 
weekly 
Adult 6 months 52 9 months 
RIF daily Adult  
 
Child 
4 months 
 
6 months 
120 
 
180 
6 months 
 
9 months 
Definitions of abbreviations: INH = isoniazid; RIF = rifampin. 
 Sources: CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(No. RR-6):26–
27; CDC. Regimens. In: Chapter 6: treatment of LTBI. Core Curriculum on Tuberculosis (2000) [Division of Tuberculosis 
Elimination Web site]. Updated November 2001. Available at: http://www.cdc.gov/tb/pubs/corecurr/index.htm . Accessed 
February 1, 2007  
Make every effort to encourage patients to adhere to the LTBI treatment regimen. 
However, if a patient has failed three attempts to complete treatment, no further effort 
may be merited. The healthcare provider should contact patients who interrupt therapy 
and are at high risk of developing TB disease (for example, contacts of patients with 
infectious TB, human immunodeficiency virus (HIV)-infected patients, or TB Class 4 
patients) for reevaluation.38  
 
For consultation regarding completion of therapy and considerations to 
examine when restarting treatment in noncompliant patients, contact the 
Arizona, TB Control Section at 602-364-4750. 
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Treatment in Special Situations 
Human Immunodeficiency Virus and Latent 
Tuberculosis Infection 
 
Treatment of latent tuberculosis infection (LTBI) in a person with human 
immunodeficiency virus (HIV) infection can be extremely complicated. 
Before treatment is initiated, contact the Arizona, TB Control Section at 
602-364-4750 for consultation.  
HIV infection is the strongest known risk factor for the progression of LTBI to 
tuberculosis (TB) disease. HIV-infected persons with LTBI are 100 times more likely to 
progress to TB disease than are those patients without HIV infection. Coinfected HIV 
and LTBI patients have a 7 to 10 percent yearly risk of developing TB disease. Patients 
with only LTBI have a 10 percent lifetime risk of developing TB disease.  
 
High-risk contacts (less than 5 years of age or immunocompromised) 
should be started promptly on treatment for LTBI. For more information on 
time frames, see the “Time Frames for Contact Investigation” topic in the 
Contact Investigation section. 
Resources 
 CDC. “TB Guidelines: HIV/AIDS” (DTBE Web site; accessed February 2007). 
Available at:  
http://www.cdc.gov/tb/pubs/mmwr/Maj_guide/HIV_AIDS.htm .  
 ATS, CDC. “Targeted Tuberculin Testing and Treatment of Latent Tuberculosis 
Infection” (MMWR 2000;49[No. RR-6]:33). Available at:  
http://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf . 
 CDC. “Prevention and Treatment of Tuberculosis among Patients Infected with 
Human Immunodeficiency Virus: Principles of Therapy and Revised 
Recommendations” (MMWR 1998;47(No. RR-20). Available at: 
http://www.cdc.gov/mmwr/PDF/rr/rr4720.pdf . 
 CDC. “Updated Guidelines for the Use of Rifabutin or Rifampin for the Treatment and 
Prevention of Tuberculosis among HIV-infected Patients Taking Protease Inhibitors 
or Nonnucleoside Reverse Transcriptase Inhibitors” (MMWR 2000;49[No. 9]:185). 
Available at: http://www.cdc.gov/mmwr/PDF/wk/mm4909.pdf  
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Pregnancy and Breastfeeding 
Pregnancy has minimal influence on the pathogenesis of TB or the likelihood of LTBI 
progressing to disease. Pregnant women should be targeted for testing only if they have 
a specific risk factor for LTBI or for progression of LTBI to disease. Extensive use of INH 
during pregnancy has shown that although it readily crosses the placental barrier, the 
drug is not teratogenic, even when given during the first four months of gestation. 
Pregnant women taking INH should receive pyridoxine supplementation. 
Breastfeeding is not contraindicated when the mother is being treated for LTBI. 
However, infants whose breastfeeding mothers are taking INH should receive 
supplemental pyridoxine. Note that the amount of INH provided by breast milk is 
inadequate for treatment of the infant.39 
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Resources and References 
Resources 
Whom to Treat 
 CDC. “Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection” 
(MMWR 2000;49[No. RR-6]). Available at: 
http://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf . 
 CDC. Core Curriculum on Tuberculosis (2000) [Division of Tuberculosis Elimination 
Web site]. Updated November 2001. Available at: 
http://www.cdc.gov/tb/pubs/corecurr/default.htm . 
Treatment Regimens and Dosages 
 CDC. “Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection” 
(MMWR 2000;49[No. RR-6]). Available at: 
http://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf  
 CDC. “Update: Adverse Event Data and Revised American Thoracic Society 
(ATS)/Centers for Disease Control and Prevention (CDC) Recommendations Against 
the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis 
Infection” (MMWR 2003;52[No. 31]). Available at: 
http://www.cdc.gov/tb/pubs/mmwr/mmwr_updates.htm . 
 CDC. Core Curriculum on Tuberculosis (2000) [Division of Tuberculosis Elimination 
Web site]. Updated November 2001. Available at: 
http://www.cdc.gov/tb/pubs/corecurr/default.htm . 
Side Effects and Adverse Reactions 
 CDC. “Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection” 
(MMWR 2000;49[No. RR-6]:26–29, 38–39). Available at: 
http://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf . 
 National Tuberculosis Controllers Association–National Tuberculosis Nurse 
Consultant Coalition. Tuberculosis Nursing: A Comprehensive Guide to Patient Care 
(Atlanta, GA;1997:47–51, 63–64). 
 CDC. Module 4: “Treatment of Tuberculosis and Tuberculosis Infection” (Self-Study 
Modules on Tuberculosis [Division of Tuberculosis Elimination Web Site]; 1999:15–
17, 30–32). Available at: http://www.phppo.cdc.gov/phtn/tbmodules/Default.htm . 
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Adherence 
 CDC. Module 9: “Patient Adherence to Tuberculosis Treatment” (Self-Study Modules 
on Tuberculosis. Division of Tuberculosis Elimination Web Site; 1999). Available at: 
http://www.phppo.cdc.gov/phtn/tbmodules/modules6-9/Default.htm . 
 
This module is entirely devoted to assessing and promoting adherence. It covers the 
many areas that need to be addressed, such as: 
• Case management: assigning responsibility to the healthcare worker 
• Communication and problem-solving skills 
• Education of the patient 
• Using interpreters when needed 
• Using incentives (rewards) and enablers (things that remove barriers for patients) 
• Using directly observed therapy (DOT) 
 CDC. Improving Patient Adherence to Tuberculosis Treatment. (1994) 
 National Tuberculosis Controllers Association–National Tuberculosis Nurse 
Consultant Coalition. Tuberculosis Nursing: A Comprehensive Guide to Patient Care 
(Atlanta, GA; 1997:69–84). 
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Introduction 
Purpose 
Tuberculosis (TB) case management describes the activities undertaken by the 
jurisdictional public health agency and its partners to ensure successful completion of 
TB treatment and cure of the patient.1 Case management is a system in which a 
specific health department employee is assigned primary responsibility for the patient, 
systematic regular review of patient progress is conducted, and plans are made to 
address any barriers to adherence.2  
Use this section to understand and follow national and Arizona’s guidelines to 
 Conduct initial assessments; 
 Develop treatment plans for case management activities; 
 Conduct monthly ongoing assessments;  
 Monitor adverse reactions to anti-tuberculosis medications and monitor toxicity;    
 Monitor bacteriologic and clinical improvement; 
 Verify completion of therapy; 
 Evaluate case management activities; 
 Provide directly observed therapy (DOT); 
 Use incentives and enablers to improve adherence to therapy; and 
 Understand when and how to use legal orders, if necessary, for adherence to 
therapy. 
One of the four fundamental strategies to achieve the goal of TB control in the United 
States is the early and accurate detection, diagnosis, and reporting of TB cases, 
leading to initiation and completion of treatment. Completion of a full course of 
standard therapy is essential to prevent treatment failure, relapse, and the 
development of drug resistance.3  
One reason for failure to complete standard treatment is that patients frequently fail to 
adhere to the lengthy course of treatment. Poor adherence to treatment regimens 
might result from difficulties with access to the healthcare system, cultural factors, 
homelessness, substance abuse, lack of social support, rapid clearing of symptoms, 
or forgetfulness.4  
These adverse outcomes are preventable by case-management strategies provided 
by TB control programs, including use of DOT.5 It is strongly recommended that the 
initial treatment strategy utilize patient-centered case management with an adherence 
plan that emphasizes DOT.6 It is essential to provide patient-centered case 
management in which treatment is tailored and supervision is based on each patient’s 
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clinical and social circumstances.7 Programs utilizing DOT as the central element in a 
comprehensive, patient-centered approach to case management (enhanced DOT) 
have higher rates of treatment completion than less intensive strategies.8 
Policy  
Although some patients may undergo most of their evaluation and treatment in 
settings other than a local public health agency, a local public health agency should 
undertake the major responsibility for monitoring and ensuring the quality of all TB-
related activities in the community as part of its duties to protect the public health.9  
Effective TB case management requires administrative commitment and support. This 
includes education, staff training, and ensuring adequate funding to maintain program 
activities.10 It is recognized that local public health agencies differ in their staffing and 
organization and that no set of guidelines can cover all the situations that may arise 
relating to case management.11   
For roles and responsibilities, refer to “Roles, Responsibilities, and Contact 
Information” topic in Chapter 1 Introduction. 
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 State Laws and Regulations 
Arizona Laws/Rules Regarding Tuberculosis Control 
Arizona Revised Statutes.  Title 36:  Public Health and Safety; Chapter 
6:  Public Health Control; Title 6:  Tuberculosis Control.  (ARS§36-711 
through §36-738)  
ARS§36-711.  Definitions.   
ARS§36-712. Administration by the department.   
ARS§36-714.  Tuberculosis control officer.   
ARS§36-715.  Costs; removals; proceedings.   
ARS§36-716.  Payment of assistance.   
ARS§36-717.  Responsibility for care or treatment by counties.   
ARS§36-718.  Contracting for care of afflicted persons.   
ARS§36-721.  Rules.   
ARS§36-723.  Investigation of tuberculosis cases.   
ARS§36-724.  Voluntary control measures.   
ARS§36-725.  Orders to cooperate; emergency custody.    
ARS§36-726.  Petition for court ordered examination, monitoring, 
treatment, isolation or quarantine.   
ARS§36-727. Hearings; procedure; confidentiality.   
ARS§36-728. Judicial action.   
ARS§36-729. Amended orders for intervention and transport of afflicted 
persons.   
ARS§36-730.  Appointment of guardian or conservator.   
ARS§36-731.  Confinement; selection; jails; prohibition.   
ARS§36-732.  Early release from court ordered treatment.   
ARS§36-733.  Choice of physician and mode of treatment.   
ARS§36-734.  Treatment; exemption.   
ARS§36-735.  Notification of rights.   
ARS§36-736.  Administrative procedures act; judicial review of 
administrative procedures; exemption; appeals.  
ARS§36-737.  Violation; classification.   
ARS§36-738.  Qualified immunity.   
 
Arizona Administrative Code.  Title 9. Chapter 6.  Department of 
Health Services Communicable Diseases and Infestations.   
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Initial Assessment 
Conduct initial assessments of tuberculosis (TB) patients to gather data that will form 
the basis for TB treatment and care. It is essential to gather data to determine the 
clinical and social issues and circumstances of relevance to the patient and to assess 
each situation objectively to determine the appropriateness of the planned 
intervention. Many professionals involved in the patient’s care contribute to the 
assessment data, and the case manager gathers assessment data from many 
sources, including community agencies, primary care providers, schools, and other 
healthcare facilities.12   
 When the patient with TB is a child, the case manager should involve 
both the child and family in the assessment process.13 
 
 To document assessment data, use the appropriate form in the 
Chapter on Forms 
Cultural Sensitivity and Language Issues 
In the initial assessment, consider cultural sensitivity and language issues. To improve 
the validity and quality of the assessment information, healthcare workers need to be 
culturally sensitive in approaching each patient. A medical interpreter may be needed 
for patients whose primary language is not English.  
  
 For more information on cultural sensitivity, refer to the Participant’s 
Workbook for Session 4: “Working with Culturally Diverse 
Populations” in DOT Essentials: The DOT Trainer’s Curriculum 
(Francis J. Curry National Tuberculosis Center Web site; 2003) at 
http://www.nationaltbcenter.edu/catalogue/epub/index.cfm?uniqueID
=2&tableName=DOTE .  
  
 For assistance with language issues, see the National Health Law 
Program and The National Council on Interpreting Health Care’s 
Language Services Resource Guide for Health Care Providers 
(National Health Law Program Web site; October 2006) at 
http://www.healthlaw.org/library.cfm?fa=download&resourceID=8992
8&appView=folder&print . 
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  
 For more information on using interpreters, see the Interpretation 
Services lesson in Module 9: “Patient Adherence to Tuberculosis 
Treatment” of the CDC’s Self-Study Modules on Tuberculosis 
(Division of Tuberculosis Elimination Web site; 1999) at 
http://www.phppo.cdc.gov/phtn/tbmodules/modules6-9/m9/9-12.htm 
. 
Patient’s Medical Records 
The case manager needs all medical records in order to provide case management 
and recommend a treatment plan. Prior to the visit with the patient, the case manager 
should ensure that a copy of all of the patient’s medical records (from hospitals, 
clinics, and other healthcare providers) and chest radiographs are available to the 
treating physician. Without the medical records, the physician may not be able to 
make the correct judgments in medical management.14  
Assessment Site 
The case manager (or designee) should make an initial hospital visit within one 
business day of a referral or case report to assess the condition of the patient and 
begin the contact investigation. 
If the patient is hospitalized, conduct the initial assessment during the patient’s 
hospitalization. If the patient is not hospitalized, conduct the initial assessment at the 
first clinic visit or during a home visit within three business days after discharge.  
Discharge Planning 
  
 Patients who are diagnosed with TB during a hospitalization will 
require discharge planning. The case managers should ensure that 
appropriate discharge planning occurs for all patients with TB, to 
prevent transmission in the community and interruption in 
treatment.15 
Initial Assessment Activities 
To complete an initial assessment, perform the following activities: 
 Visit the patient’s home  
 Obtain or review demographic information 
 Ascertain the extent of TB illness 
 Obtain and review the patient’s health history 
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 Determine infectiousness or potential infectiousness 
 Evaluate the patient’s knowledge and beliefs about TB 
 Initiate treatment, if not initiated during hospital stay   
 Monitor the TB medication regimen  
 Identify any barriers or obstacles to adherence 
 Review psychosocial status 
 Identify and document a good history of the patient’s social network 
 Gather information for a possible contact investigation 
Visit the patient’s home. During the patient’s TB treatment, at least one or more 
home visits are required. Home visits are useful for confirming the patient’s address, 
particularly for patients at high risk for default from treatment. Information gathered at 
the patient’s home is often more revealing than assessments performed in the clinical 
or health department settings and can lead to a more accurate understanding of the 
patient’s lifestyle (for example, seeing a child’s shoes or toys when a child was not 
named in the contact investigation).16 Several home visits may be needed, because 
usually not all of the necessary information is gathered from the patient and his or her 
family at one time. 
Obtain or review demographic information, including the name, address, telephone 
number(s), birth date, Social Security number, and health insurance provider’s name, 
address, and identifying information.17 
Ascertain the extent of TB illness, including acuity and length of symptoms, 
bacteriology and radiographic findings, laboratory analyses, tuberculin skin test 
results, nutritional status, vital signs, and baseline weight (without shoes or excess 
clothing). Assess temperature, pulse, and respiration if the patient appears ill or the 
history suggests illness. Blood pressure evaluations are valuable, especially if the 
patient has no primary care provider.  
The responsible physician and/or program medical consultant should be consulted 
within one business day of receipt of a suspect report. Within seven business days of 
a case report, a tuberculin skin test should be placed, measured, and interpreted; and 
a chest radiograph should be taken and interpreted. Also within seven business days 
of a case report, a minimum of three consecutive sputum specimens of good quality 
should be collected 8–24 hours apart (with at least one being an early morning 
specimen) and submitted to the laboratory.  
  
 In the case of pulmonary TB in children younger than 5 years of age, 
posterior-anterior and lateral chest radiographs are important in the 
initial diagnosis.18 Adults who are suspected of TB or who are active 
cases usually need only an initial posterior-anterior chest 
radiograph. 
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Obtain and review the patient’s health history to determine concurrent medical 
problems, including human immunodeficiency virus (HIV) disease or risk factors, 
country of birth, sexual history, allergies, or medications that may interfere with TB 
drugs. The case manager should obtain the names, addresses, and telephone 
numbers of the patient’s primary care provider and any specialists involved in his or 
her medical care, previous hospitalizations, allergies, and current medications. It is 
important to know the history of treatment for TB infection and/or disease, especially 
for patients who are treatment failures or have a relapse of TB disease, as they are at 
a higher risk for developing multidrug-resistant TB (MDR-TB). It is also important to 
determine what the patient perceives as his or her most important medical/health 
problem. The date of the last menstrual period and contraceptive use should be 
obtained from female patients.19  
  
 Some antituberculosis medications are contraindicated when a 
patient is taking birth control pills. For more information, see the 
“Side Effects and Adverse Reactions” topic in the Treatment of 
Tuberculosis Disease section. 
Determine infectiousness or potential infectiousness. To determine where and 
whom to initiate contact investigation, the initial assessment should gather information 
to define the start and end dates of the period of infectiousness. This assessment 
should include the duration and frequency of symptoms, especially cough, and a 
review of the radiographic findings. If the patient is infectious or potentially infectious, 
the case manager should have an understanding of the period of infectiousness. The 
parameters of a contact investigation, including the need for repeating the tuberculin 
skin test for contacts that were initially negative, can then be determined.20 
  
 In the case of a child with TB who is younger than 5 years, the 
contact investigation should focus on determining the source case of 
TB, since young children are not likely to transmit TB. Dates of 
exposure and most recent information concerning the infectiousness 
of the source case should be documented.  
 For more information on the period of infectiousness and contact 
investigations, see the Contact Investigation section. 
Evaluate the patient’s knowledge and beliefs about TB, including a history of TB in 
family and/or friends and the response to treatment. The case manager can assess 
TB knowledge by interviewing the patient regarding TB transmission, pathogenesis, 
and symptoms. Patient education should be based on current knowledge and ability to 
comprehend written, visual, and/or verbal information.21  
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  It is important to interview both the child and parent or guardian in 
their own language when assessing TB knowledge; however, 
adolescents should be given the opportunity to speak to a healthcare 
provider alone. Keep in mind that parents who have misinformation or 
cultural bias about TB may affect their children’s understanding of the 
disease.22 Use age-appropriate educational materials and methods, 
especially in working with children. When dealing with a school-aged 
child, it is important to explain that TB is treatable, and with the 
adolescent, it may be necessary to constantly reaffirm 
confidentiality.23  
Initiate treatment. A clinician should initiate medical treatment within one business 
day of positive acid-fast bacilli (AFB) sputum smear results (unless there is evidence 
that the AFB is not M. tuberculosis complex, e.g., by direct test of sputum) or a 
presumptive diagnosis. A clinician should complete medical evaluations within seven 
days of a referral. Within one business day of receipt of medical orders which 
document drugs, dose, route, frequency, and duration, the case manager should order 
drugs. The case manager then should initiate treatment within one business day of 
receiving the drugs.  
Monitor the TB medication regimen. The case manager should ensure that 
medications and dosages are prescribed according to current American Thoracic 
Society (ATS)/Centers for Disease Control and Prevention (CDC) guidelines. If the 
initial assessment occurs during the patient’s hospitalization, the case manager should 
ensure that the ingestion of the TB medication is observed by a nurse. It is important 
to ensure that hospitals order and give the right doses and are observing patients 
taking medications. Since the outpatient phase of treatment will involve giving TB 
medications at one time, hospitals should be discouraged from splitting dosages for 
two reasons: (1) taking medications more than once a day creates an expectation for 
the patient that will have to change after discharge from the hospital, and (2) tolerance 
to the full dosage cannot be assessed while in the hospital. The patient’s tolerance to 
TB medications should be noted, and interactions with other medications should be 
determined prior to the patient starting TB medications.24  
 
For more information on treatment regimens and dosages contact the 
Arizona Department of Health Services TB Control at 602-364-4750 or see 
the Treatment of Tuberculosis Disease section. Additional information can 
be obtained by contacting the Heartland National TB Center at 800-839-
5864. 
If the medications will be given to a child in a school or daycare setting, 
parental authorization must be obtained. 
Identify any barriers or obstacles to adherence in taking TB medications and 
keeping physician or clinic appointments. This includes such issues as language, 
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availability of transportation, the patient’s preference for place and time of directly 
observed therapy (DOT), and the ability to swallow pills. Many adolescents and adults 
who have difficulty swallowing pills are embarrassed to report this to the healthcare 
provider. It may be necessary to teach people how to take pills, or it may be necessary 
to crush the pills and put them in food, such as pudding or applesauce. In addition, the 
case manager should determine the need for enablers and identify incentives that will 
be most valuable to the patient. 
Review psychosocial status to identify unmet needs, the use of alcohol and/or illegal 
drugs, and any pre-existing psychiatric diagnoses.25  
Identify and document a good history of the patient’s social network. This is 
important to identify and document in the event that the patient does not return for 
follow-up. The case manager needs to verify the patient/family’s address, evaluate 
residential stability, and assess potential for homelessness. Determine the patient’s 
residence(s) during the past year, particularly any congregate living situations, such as 
prison, jail, homeless shelter, nursing home, boarding home, or foster care. Establish 
the patient’s occupation and/or student status, and document the name and address 
of business or school. The name and location of a child’s babysitter, other caretakers, 
daycare center, and/or school should be noted. In order to identify those who have 
shared common air space with the infectious, untreated patient with TB, it is 
necessary to have an understanding of the patient’s social and recreational activities 
and how he/she spends leisure time. This includes time spent at bars, floating card 
games, circuit parties, faith-based functions, and other venues.  
Gather information for a possible contact investigation. A contact investigation 
should begin within three days of a case/suspect report and be completed within 10 
days. 
 
For more information, see the Contact Investigation section. 
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Treatment Plan  
When sufficient information has been gathered by members of the healthcare team to 
assess a patient’s needs and problems, the case manager should develop a treatment 
plan for each patient with confirmed or suspected tuberculosis (TB). The plan should 
combine both medical management of the patient and nursing interventions. Due to 
the length of TB treatment (from 6 to 24 months), the plan must include intermediate 
and expected outcomes. 
To ensure that therapy is completed, a treatment plan should be based on data 
collected by the healthcare team and must be designed to meet the patient’s medical 
and personal needs. Treatment of a patient with TB is most successful within a 
comprehensive framework that addresses both clinical and social issues of relevance 
to the patient. Patient-centered care is essential to provide because it tailors treatment 
and bases supervision on each patient’s clinical and social circumstances. 
Each patient’s management plan should be individualized to incorporate measures 
that facilitate adherence to the drug regimen, such as social service support, treatment 
incentives and enablers, housing assistance, referral for treatment of substance 
abuse, and coordination of TB services with those of other providers.26 
In the initial management strategy, regardless of the source of supervision, always 
include an adherence plan that emphasizes directly observed therapy (DOT), in which 
patients are observed as they ingest each dose of anti-tuberculosis medications, to 
maximize the likelihood of completion of therapy.27 
The case manager is responsible for the overall plan, including documentation, 
monitoring the patient response, interventions, intermediate and expected outcomes, 
and initiating changes in the plan to reflect changes in circumstances.28 The treatment 
plan should be reviewed and updated at least monthly during reviews of clinical 
progress.29 
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Treatment Plan Components  
 
The components of a treatment plan include the following: 
 Patient’s verified address and contact information 
 Assignment of responsibilities: case manager, clinical supervisor (nurse, physician, 
or physician assistant), DOT workers, other caregivers (outreach workers, nurses), 
and person managing the contact investigation 
 Patient educator’s name and dates of education sessions 
 Method for prevention of transmission: no isolation, airborne infection isolation, 
home isolation, legal order for isolation 
 Planned course of anti-tuberculosis drug therapy 
 Estimated date of completion of treatment 
 Test results from initial medical evaluation 
 Medical history 
 Diagnosis 
 Monitoring activities and schedule to assess response to therapy 
 Baseline tests and monitoring activities and schedule to detect potential side 
effects and adverse reactions 
 Potential drug interactions 
 Potential treatment adherence obstacles 
 Personal service needs 
 Referrals for social services 
 Means of ensuring successful completion of treatment (DOT, incentives, enablers) 
 Location(s) where DOT will be administered 
 Approvals and signatures of the attending physician, local public health agency 
representative, and the patient 
 Intermediate and expected outcomes30 
  
 For a list of intermediate and expected outcomes, see Module 2: 
“Fundamentals of TB Case Management,” pages 23–25 in the New 
Jersey Medical School National Tuberculosis Center’s Tuberculosis 
Case Management for Nurses: Self-Study Modules (New Jersey 
Medical School Global Tuberculosis Institute Web site) at 
http://www.umdnj.edu/globaltb/products/tbcasemgmtmodules.htm 
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Planning Activities  
To complete planning, perform the following activities: 
 Establish the treatment plan 
 Establish time frames in the treatment plan to monitor the plan and patient 
response  
 Negotiate and adjust the treatment plan 
Establish the treatment plan, ensuring that all the components are included. The 
case manager should ensure that the treatment plan is useful and meaningful. It 
becomes the internal standard of care for the patient as well as the performance 
standard for the case manager. Good planning will allow the patient to experience TB 
care and treatment along the healthcare continuum and prevent duplication and 
fragmentation of services. The plan should be discussed and validated with all team 
members and the patient.31 DOT should be the standard of care for all TB cases and 
suspects. 
Establish time frames in the treatment plan to monitor the plan and patient 
response. Monitoring should be done at least every monthly at the patient’s home, 
ambulatory clinic, health department, or private physician’s office. Each component of 
the plan should be reviewed to ensure that it is an accurate accounting of the patient’s 
problems, required tests, and interventions. To track progress toward outcomes, 
document all treatment activities and their dates: medications taken, tests and results, 
patient visits, monitoring activities, side effects, adverse reactions, education sessions, 
social service referrals, incentives, enablers, isolation status changes, and patient 
problems.32   
Negotiate and adjust the treatment plan as needed, to meet new realities. Since 
patient circumstances are usually fluid and personnel resources often change over 
time, it is essential that the plan be negotiated with the patient and changed to adjust 
to new situations. The adjusted plan should be discussed with the team members, as 
well as the patient.33 
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Implementation Activities 
To begin implementation of the treatment plan, perform the following activities: 
 Refer the patient to other healthcare providers, social service agencies, or 
community organizations as needed 
 Evaluate and locate needed services relating to TB treatment 
 Negotiate a plan for DOT or self-administration evaluation 
 Coordinate strategies to improve adherence 
 
Refer the patient to other healthcare providers, social service agencies, or 
community organizations, as needed. The referral process requires the case 
manager to locate and coordinate accessible, available, and affordable resources for 
the patient. After the referral is made, the case manager should monitor the patient’s 
adherence to the referral and obtain the consultation or follow-up report in writing. 
Immediate intervention may be necessary if the patient or the referring agency 
experiences difficulty.34 All patients with suspected or proven TB should be assessed 
for HIV risk and offered counseling and voluntary testing for HIV, with referral for HIV 
treatment services when necessary. Referrals to medical specialists for conditions that 
would endanger the patient and/or affect the outcome of treatment should be made as 
soon as possible. The patient should be sent to an emergency department if the 
condition is serious when assessed by the case manager. The case manager should 
follow up a referral to obtain medical information and determine whether the 
necessary medical intervention has been completed. 
Evaluate and locate needed services relating to the TB treatment. This may 
include laboratory, auditory, or visual acuity testing; additional radiographs; or other 
tests required specifically for the patient. It is important to schedule or assist the 
patient in scheduling appointments and to monitor the patient’s adherence to the 
appointment and the results. An understanding of the patient’s financial resources and 
health insurance coverage is important. Lack of financial resources or health 
insurance will affect the patient’s willingness to keep appointments, which may be 
critical to his or her health. The case manager may need to discuss essential services 
with insurance companies or other healthcare providers to obtain the most cost-
effective, quality service.35 Help should be provided to reinforce a patient’s efforts to 
receive financial assistance and treatment for psychosocial, alcohol-related, and drug-
related conditions. 
Negotiate a plan for DOT or self-administration evaluation. DOT should be the 
standard of care for all patients. The case manager should ensure the plan is suitable 
for the patient’s needs and achievable by the healthcare provider(s) and then have the 
patient sign a DOT agreement. Due to the length of TB treatment, the patient’s 
circumstances may change. The case manager needs to verify that the time and place 
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for DOT administration originally agreed upon is still agreeable to the patient and 
provider. It also may be necessary to coordinate the arrangements for DOT with 
outside organizations, such as school nurses or drug treatment center nurses.36  
Coordinate strategies to improve adherence. The case manager must have 
knowledge of and proficiency in strategies to improve patient adherence, understand 
the importance of developing and maintaining a therapeutic relationship, and be 
familiar with the principles and practices of behavioral contracting and behavioral 
modification. Collaboration with team members is essential to obtain as much 
information as possible about strategies to improve adherence of individual patients 
and elicit opinions, attitudes, and feelings expressed by the patient. To be effective, 
incentives and enablers should be meaningful and specific for a particular patient.37 
Incentives and enablers should be considered for use with all patients. 
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Ongoing Assessment and Monitoring 
Conduct ongoing assessments and monitor patients at least every month, either in an 
ambulatory clinic setting, local public health agency, or private physician’s office. 
Schedule additional assessments throughout the month for patients experiencing 
problems, or are non-adherent to directly observed therapy (DOT) or follow-up 
appointments.38  
There are countless stories from nurses and outreach workers reinforcing the fact that 
not all information is obtained from the patient or family at one time. Therefore, the 
case manager must ensure that the list of contacts is updated from time to time and 
determine the need for further testing. It is also important to review the status of the 
contact investigation to ensure that timelines and standards are followed. Also, 
checking for the accuracy of previously gathered information should occur throughout 
the patient’s TB treatment.39  
 
  
 For ongoing assessment and monitoring, refer to the sample forms 
located in the forms section. For the reporting schedule, see Table 3: 
Required Reports in the “Required Reports from Local Public Health 
Agencies to the Arizona’s Tuberculosis Program” topic in the 
Surveillance section. 
Ongoing Assessment Activities 
To complete an ongoing assessment, perform the following activities: 
 Monitor the clinical response to treatment 
 Determine human immunodeficiency virus (HIV) status and the risk factors for HIV 
disease, and refer the patient for treatment, if indicated 
 Review the treatment regimen 
 Ensure that medications are ordered and given at the correct time, and in the 
correct dosage 
 Monitor the side effects of and adverse reactions to medication 
 Assess adherence daily and monthly, and identify positive and negative 
motivational factors influencing adherence 
 Determine the unmet educational needs of the patient 
 Educate the patient about the TB disease process 
 Advocate for the patient with team members and other service providers 
 Review the status of the contact investigation, if one was started 
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Monitor the clinical response to treatment by reviewing vital signs, weight, 
bacteriology reports, and radiographic results, including drug susceptibility results and 
TB symptoms, and comparing them to previous documented findings. This review is 
an important measurement of clinical improvement, worsening, or stabilization of the 
patient’s condition. The case manager should collect a sputum sample for acid-fast 
bacilli (AFB) sputum smear and culture every month until sputum smear conversion. 
Thereafter, sputum samples should be collected every month until there are two 
negative cultures. If a patient is on DOT, no further specimen collected is indicated 
unless the patient becomes symptomatic. A clinician should complete a medical 
evaluation every month until treatment is completed, and periodically based on patient 
condition or review of diagnostic information, patient chart, and chest radiographs. If 
the patient’s condition is worsening, interview the patient to determine the potential 
cause(s) for the worsening condition. List all bacteriological reports in chronological 
order, and correlate them with the patient’s current symptoms history and chest 
radiograph report to ensure accuracy. Also, conduct this review at conversion as 
evidence for the improving condition of the patient.40  
 Inconsistencies should trigger additional questions, such as the 
possibility of laboratory contamination. Bring these questions 
immediately to the attention of the physician and manager. 41 
  
 A child’s clinical response to treatment may not be as significant as 
that of an adult. Therefore, it is important to reinforce what the 
expected response to treatment should be for the individual child 
during the course of treatment. 42  
Determine HIV status and the risk factors for HIV disease, and refer the patient 
for treatment, if indicated. It is important for patients to understand the correlation 
between TB and HIV disease. The case manager should ensure that HIV counseling 
and testing are done at the beginning of TB treatment, if the HIV status is not 
previously known. If the patient refuses HIV testing, an assessment of the risk factors 
for HIV should be completed.43 If a patient refuses, voluntary HIV testing and 
counseling should continue to be offered periodically throughout treatment.  
 
If the parents of a young child with TB refuse to permit the child to be HIV tested, the 
parents should be interviewed regarding the child’s risk of HIV disease, including 
neonatal transmission.44  
Review the treatment regimen to verify that the physician’s orders are clear and 
concise. One of the case manager’s primary responsibilities is to ensure that the 
patient completes treatment according to the physician’s orders. It is also important to 
ensure that the plan is specific for the individual patient and follows the principles of 
TB treatment.45  
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Ensure that medications are ordered and given at the correct time, and in the 
correct dosage. Review the patient’s treatment plan and chart, and correct the 
medications as necessary. 
Monitor the side effects of and adverse reactions to medication. Review 
laboratory findings and contact the treating physician if abnormal results are 
obtained.46 The patient should be monitored by a registered nurse and/or clinician or 
case manager every one to two weeks for signs and symptoms of adverse reactions 
until treatment is completed. If a patient is symptomatic, the provider should be 
consulted and the patient monitored more frequently. Chemistries and complete blood 
count (CBC), aspartate aminotransferase (AST)/alanine aminotransferase (ALT), or 
other tests based on specific drugs should be done periodically per orders from the 
provider. See Table 8: Monitoring and Interventions for Side Effects and Adverse 
Reactions in the Treatment of Tuberculosis Disease section.  
 
  
 If a child is taking TB medications at school, communicate at a 
minimum on a monthly basis with designated staff to determine 
whether the child is experiencing medication side effects or adverse 
reactions.47 
Assess adherence daily and monthly, and identify positive and negative 
motivational factors influencing adherence. An assessment of adherence needs to 
occur at each patient encounter. If the case manager is not involved in providing DOT, 
a notification system should alert him or her if the patient misses a DOT dose or if 
there is suspicion of non-adherence if the case is on self-administered therapy. If a 
DOT dose is missed, the patient should be contacted the same day or the next 
business day and the issue escalated to the case manager’s supervisor. Direct 
observation provides immediate information on poor adherence and adverse effects. 
The key to a successful DOT program is the timely use of this information in order to 
promptly identify and respond to potential barriers to adherence, missed doses, and 
potential adverse treatment effects. It is important not to send a mixed message to a 
patient by not promptly responding to missed DOT doses.  A preventable interruption 
in treatment can be avoided if the case manager is notified immediately, rather than 
when the monthly DOT rate is calculated. Regularly monitor the effectiveness of 
enhancement methods (i.e., incentives, enablers, behavioral contracting, or behavior 
modification).48 Policies and procedures must be in place to establish the expected 
monthly rate of DOT adherence. The case manager should review the monthly 
adherence rate to ensure that patients achieve the expected adherence rate. DOT 
should be initiated if adherence is compromised, as evidenced by missed pill pick-up 
appointments, inaccurate pill counts, etc., in persons at high risk of developing TB 
disease. 
The case manager should ensure that the patient is informed about the consequences 
of non-adherence, including legal interventions. Changes in the patient’s attitude 
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toward the healthcare worker should be noted and verified with the patient.49  
 
Determine the unmet educational needs of the patient regarding transmission, 
diagnosis, and treatment of TB. Identify the concerns and anxieties regarding 
diagnosis, and need for further education. The educational needs of the patient/family 
may vary throughout the course of treatment. Patient education also will vary 
depending on beliefs about TB treatment, acceptance of the diagnosis, coping 
mechanisms, cultural values, and the accuracy of the information they have already 
received. The case manager should explore the effect the diagnosis has on the 
patient’s relationships with other family members, coworkers, and social contacts so 
that appropriate, culturally sensitive information can be provided.50 
Educate the patient about the TB disease process during the course of TB 
treatment. Provide instruction relevant for the patient’s level of education or ability to 
learn, and address healthcare beliefs that are in conflict with educational information. 
The case manager should ensure that education is provided in the patient’s primary 
language and that it is culturally appropriate.51 The case manager should provide 
patient and family education every month and until satisfactory recall is obtained.  
 
For more information, see the Patient Education section. 
Advocate for the patient with team members and other service providers when 
necessary. The case manager should demonstrate respect and understanding of the 
patient’s cultural beliefs and values, and prevent team members from imposing their 
own values or belief systems on the patient. The case manager should be able to 
communicate the patient’s fears/anxieties, likes/dislikes, and needs/wants to the team 
members in a nonjudgmental manner. The case manager must also have an 
understanding of the team members, and mediate, negotiate, and resolve differences 
of opinion regarding the patient and interventions.52 
Review the status of the contact investigation, if one was initiated. It has been 
found that patients may not initially reveal the names of all close contacts. Over time, 
many more individuals are often identified.53 A contact investigation should begin 
within three days of a case/suspect report and be completed within 10 days. The 
investigation should be repeated if for any reason the index patient becomes AFB 
sputum smear positive again during treatment and there has been sufficient exposure 
for the skin-test-negative persons to become infected.  
Monitoring Side Effects and Adverse Reactions  
Assess and document side effects and adverse reactions to antituberculosis 
medications and monitor toxicity. The patient should be monitored by a registered 
nurse and/or clinician or case manager every one to two weeks for signs and 
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symptoms of adverse reactions until treatment is completed. If a patient is 
symptomatic, the provider should be consulted and the patient monitored more 
frequently. Chemistries and CBC, AST/ALT, or other tests based on specific drugs 
should be done periodically per orders from the provider See Table 8: Monitoring 
and Interventions for Side Effects and Adverse Reactions in the Treatment of 
Tuberculosis Disease section.  
As is true with all medications, combination chemotherapy for tuberculosis is 
associated with a predictable incidence of adverse effects, some mild, some serious.54  
Adverse effects are fairly common and often manageable. Although it is important to 
be attuned to the potential for adverse effects, it is at least equally important that first-
line drugs not be stopped without adequate justification.55 However, adverse reactions 
can be severe, and thus, it is important to recognize adverse reactions that indicate 
when a drug should not be used. Mild adverse effects can generally be managed with 
symptomatic therapy, whereas with more severe effects, the offending drug or drugs 
must be discontinued. In addition, proper management of more serious adverse 
reactions often requires expert consultation. 56 
 Instruct patients to report the side effects and adverse reactions listed 
in the “Side Effects and Adverse Reactions” topic in the Treatment of 
Tuberculosis Disease section. 
 To record information from monitoring for side effects and adverse 
reactions, refer to the sample forms in the forms section. 
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Activities to Monitor for Side Effects and  
Adverse Reactions  
To monitor for side effects and adverse reactions, perform the following activities: 
 Educate the patient and family to report side effects and adverse reactions 
 Assess the patient for side effects and adverse reactions 
 Ensure patient contact information is updated monthly for effective case 
management 
Educate the patient and family to report side effects and adverse reactions. The 
case manager reinforces prior patient teaching and continues to educate the patient 
and family about TB medications, signs and symptoms of adverse effects, and the 
importance of continued treatment and uninterrupted drug therapy. Case managers 
should be familiar with all TB medications, their side effects, contraindications, and 
drug interactions.57  
Assess the patient for adverse reactions and side effects. For patients on self-
administered therapy, the case manager ensures that patients are assessed for 
adverse effects to TB medications at least every month and at each visit. If the patient 
is on DOT or pill counts, staff should assess patients for side effects and adverse 
reactions on each visit by performing a symptom review. If indicated, (such as fatigue, 
rash, poor appetite, nausea, bloating, vomiting, abdominal pain, jaundiced, dark urine, 
light stools, or neurological problems), order liver function tests and monitor their 
results. The case manager should be aware of complications in patients on 
medications by maintaining close communication with outreach staff .58    
Monitoring Bacteriologic Improvement 
Assess and document response to treatment. The case manager should collect sputa 
for AFB sputum smear and culture every month until sputum smear conversion. 
Thereafter, a sputum sample should be collected every month until there are two 
negative cultures. If a patient is on DOT, no further specimen collection is indicated 
unless the patient becomes symptomatic. 59 
To record information from monitoring for bacteriologic and clinical 
improvement refer to the sample forms in the forms section.  
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Activities to Monitor for  
Bacteriologic and Clinical Improvement  
To monitor for response to treatment, perform the activities described below.  
For more information on discontinuing isolation, see the Infection Control 
section. 
Acid-Fast Bacilli Sputum Smear Negative 
If a patient is AFB sputum smear negative, place laboratory reports promptly in the 
patient’s chart. If previously AFB sputum smear positive and now AFB sputum smear 
negative on three separate consecutive days, consider discontinuing isolation.60   
Acid-Fast Bacilli Sputum Smear Positive 
If a patient is AFB sputum smear positive and  
 Prior positive: Place a report in the patient’s chart. Repeat sputum smears every 
month until three consecutive negative sputum smears have been documented 
from different days.  
 Has new AFB sputum smear positive results and is diagnosed with 
pulmonary TB: Notify the TB controller and provider and initiate isolation. Repeat 
sputa smears at appropriate intervals (and at least every monthly until three 
consecutive negative sputa smears have been documented from different days.61 
 
Culture-Positive Pulmonary Tuberculosis  
For patients with culture-positive pulmonary TB, collect two or more sputum 
specimens every month for smears and cultures until persistently negative cultures 
are documented. 62 
 
Continued Positive Sputum Smears or Positive Cultures 
If sputum smears are positive after two months, call the ADHS TB Control 
Section at 602-364-4750. 
A patient with continued AFB sputum smear positive results or positive cultures should 
be evaluated for treatment failure if sputum specimen(s) remain bacteriologically 
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positive (i.e., culture positive and/or AFB sputum smear positive) after three months of 
treatment or become bacteriologically positive after initially converting to negative.  
The case manager should initiate the evaluation of the patient and notify his or her 
supervisor within one day after obtaining documentation of a positive/suspect TB 
case. The case manager should do the following:  
1. Review and confirm the patient’s medication compliance. 
2. Place the patient on DOT, if not already on DOT. 
3. Reconfirm the appropriateness of the medication regimen, based on drug 
susceptibility results and other considerations.  
4. If additional anti-tuberculosis drugs are added to the treatment regimen, ensure 
that at least two new drugs that the patient has not been treated with previously 
are used.  
5. Consider serum drug levels.  
6. Repeat cultures and repeat drug susceptibility testing.63   
Culture Negative or No Specimens 
If a patient is culture negative or no specimens were collected:  
1. Review the medications that the patient was on at the time TB medications were 
started, particularly other antibiotics.  
2. If applicable, obtain follow-up chest radiograph reports to determine improvement.  
3. Review the patient’s symptoms for improvement, if applicable. 
4. Review the patient’s tuberculin skin testing information (retesting may be 
appropriate if initially negative or test if not initially done), and discuss this with the 
patient’s provider.  
5. Review information with the provider regarding his or her reasons for continuing 
TB medications.  
6. Discuss the above findings with the manager or the ADHS TB Control Section, if 
necessary at 602-364-4750 to determine if the patient is to be reported as a case. 
Verification of Isolate Drug Susceptibility Results 
The case manager should obtain and promptly document all positive cultures and 
respective drug susceptibility results.  
1. If a patient’s TB organism is pan-susceptible: Follow the recommended treatment 
regimen.  
2. If a patient’s TB organism is drug resistant:     
a. Notify the provider for adjustment of medications  
b. Confirm the appropriateness of regimen within one day of provider notification 
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c. If the regimen is inappropriate, immediately notify the clinician and the 
manager or the ADHS TB Control Section, if necessary at 602-364-
4750.  
d.  Initiate DOT  
3. If isoniazid-resistant or multidrug-resistant TB (MDR-TB):  
a. Place contacts on appropriate latent TB infection (LTBI) treatment regimens. 
Treatment of LTBI caused by drug-resistant organisms should be provided by, 
or in close consultation with, an expert in the management of these difficult 
situations. For patients with MDR-TB, refer to the instructions on multidrug-
resistant tuberculosis provided below.  
b. Contact ADHS TB Control Section at 602-364-4750 for consultation 
regarding the treatment of drug-resistant TB  
 
Multidrug-Resistant Tuberculosis 
If a patient has MDR-TB, the case manager should:  
1. Notify his or her supervisor and the ADHS TB Control Section at 602-364-
4750, and the patient’s provider the same day that MDR-TB findings are 
reported/known.  
2. Confirm initiation of an appropriate regimen within one day. If the provider is 
unwilling to institute an appropriate regimen, notify the case manager’s supervisor 
and the ADHS TB Control Section at 602-364-4750 on the same day. 
3. For consultation regarding the treatment of drug-resistant TB, contact  the 
ADHS TB Control Section at 602-364-4750 
4. Initiate transfer of patient care to a more appropriate provider, if necessary. 
The case manager, with TB clinician/ADHS TB Control Section at 602-364-4750 
should confer with the provider and arrange transfer of the case to a provider with 
experience/expertise in the management of MDR-TB. The case manager must 
document transfer of care and ongoing follow-up.  
5. Obtain appropriate medications from suppliers.  
6. Initiate DOT and maintain accurate DOT records. If the patient is non-adherent 
with DOT, the case manager must document attempts to correct the situation and 
notify his or her supervisor.  
7. Provide   
a. Patient education, including information regarding second-line TB drugs;  
b. Attempts to provide DOT at the patient’s convenience;  
c. Use of incentives and enablers; and 
d. Legal orders.  
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Clinical Response to Treatment  
The case manager should monitor/evaluate a patient’s clinical response to treatment. 
Some indicators are: 
1. Lessening or resolution of TB symptoms  
2. Weight gain  
3. Progressive improvement in the chest radiograph, if pulmonary TB disease is 
diagnosed and repeat radiographs are ordered 
 
Isolation  
If a patient is isolated, ensure and document the patient’s adherence to respiratory 
isolation. 64 
For more information on isolation and quarantine, refer to the Infection 
Control section. 
 
Closing a Case 
If the patient is not to be reported as case, notify the provider that the patient is closed 
to TB control program services. The patient can be closed to TB Registry.  
For more information on closing a case, see the “Completion of Therapy” 
topic in this section. 
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Completion of Therapy  
The case manager should verify completion of therapy. Completion of therapy is 
essential to ensure that the patient is cured. It is also Arizona’s and the Centers for 
Disease Control and Prevention (CDC) goal and important measurement of the 
effectiveness of tuberculosis (TB) control efforts. Verification of completion of therapy 
and a completed contact investigation are the responsibility of the case manager.  
 
  
 To record verification and closure information, use the RVCT 
Completion of Therapy Form. 
 
Verifying Adequate Course of Treatment 
Most cases of active TB can be successfully treated using the standard short course 
(six months) of therapy. The case manager is responsible for considering the following 
conditions to ensure that the patient has received an adequate course of therapy. 
 If culture remains positive beyond two months of treatment, reasons for 
persistent positive cultures should be examined and treatment adjusted/prolonged.  
 For TB involving the bones or joints or tuberculous meningitis: These are 
exceptions to the standard six-month course. See “Duration of Treatment” in the 
“Treatment Regimens and Dosages” topic in the Treatment of Tuberculosis 
Disease section.  
 HIV-negative, culture-negative patients: See “Duration of Treatment” in the 
“Treatment Regimens and Dosages” topic in the Treatment of Tuberculosis 
Disease section.  
 Relapse of TB following treatment for TB with pan-susceptible organisms. 
Treatment may be prolonged to nine months or more. (Current drug susceptibility 
testing must be performed and the regimen adjusted if resistance has 
developed.)65 
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Calculating Completion of Therapy 
So that doses missed due to nonadherence or other treatment interruptions are still 
given after treatment is resumed, the 2003 revised TB treatment guidelines 
“Treatment of Tuberculosis” (MMWR 2003;52[No. RR-11]) at 
http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf recommend basing the completion of 
treatment on the number of doses of directly observed therapy (DOT) received rather 
than on the chronological passage of time (e.g., six months).66  

 For the total number of doses recommended for completion of 
regimens using first-line drugs, refer to the “Treatment Regimens and 
Dosages” topic in the Treatment of Tuberculosis Disease section.  
Closures Other than Completion of Therapy 
 
 Moved: All attempts should be made by the case manager to obtain the new or 
forwarding address. If this new address is within the original jurisdiction, the case 
should be transferred, as per the local public health agency protocol. If the new 
address is in another jurisdiction, the Arizona TB Program should be notified and 
procedures followed as described in the Transfer Notifications section. Cases 
should be closed as “moved” only if a new address is obtained.  
 For information on whom to alert when a case will move or has 
moved, refer to the Transfer Notifications section.  
 Not TB: If the completed diagnostic evaluation determined that the diagnosis of 
TB is not substantiated and another diagnosis is established, the case is closed as  
“Not TB.” 
 Lost: If three documented good faith attempts to locate the patient fail, the case 
should be closed as “Lost.”  
 Died: If the patient expired prior to completion of therapy, the case is closed as 
“Died.”67 Continue to follow up with contacts. 
Ensure that the contact investigation on the case is also completed. For 
more information, see the Contact Investigation Chapter. 
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L  Case Management 9 . 2 8  
R e v i s e d  1 2 / 0 4 / 0 7  
 
 
Evaluation  
Evaluate case management activities. Patient care is never complete without the 
evaluation component. In tuberculosis (TB) case management, the achievement of 
desired outcomes must be evaluated so that services and activities can be improved 
and TB treatment goals achieved. Evaluation is the outcome of the case management 
process and should be continuous and ongoing.  
Evaluation activities answer the following questions:  
 Were the TB treatment plan and control activities implemented in a timely manner? 
 Were intermediate and expected outcomes achieved?  
 Was the patient satisfied with services or care?  
 Were the case manager and the team members satisfied with the plan and 
outcomes?  
 
There are cohort review forms available on the Washington State 
Department of Health’s Website at 
http://www.doh.wa.gov/cfh/tb/guidelines.htm 
Evaluation Activities   
To evaluate case management, perform the following activities: 
 Monitor the multidisciplinary care plan at least every month 
 Identify strengths or weaknesses in the healthcare system 
 Conduct a cohort analysis at least every three months 
 Monitor the regulatory reporting mechanism and the contact investigation 
Monitor the treatment plan at least every month, or more frequently depending on 
the complexity of treatment and patient variables. Review the appropriateness of 
interventions, as well as dates when intermediate and/or expected outcomes were 
achieved. Pay attention to how rapidly the treatment plan was changed when the need 
was identified. If the treatment plan has remained unchanged, determine the reason 
why.68  
Identify strengths or weaknesses in the healthcare system that negatively or 
positively affect the expected outcome. A good evaluation will lead to positive changes 
for the patient and others.  
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Conduct a cohort analysis at least every month to identify variances or common 
elements among the group. Cohort review is a “systematic review of the management 
of TB patients with TB disease and their contacts.”69 With the information learned from 
the evaluation, the case manager can make changes to improve patient care 
outcomes.70  
Monitor reports to ensure that the TB case reports are accurate and updated 
according to state standards and that the contact investigation is complete.71   
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Directly Observed Therapy 
Provide directly observed therapy (DOT), as required. DOT means that a healthcare 
worker or other designated individual trained by the local health jurisdiction watches 
the patient swallow every dose of the prescribed TB drugs (“supervised swallowing”). 
A family member should not be designated to observe therapy. A dose of medication 
that is delivered to a patient, an address, or a mailbox or left with a family member, 
friend, or acquaintance is a dose of self-administered therapy (SAT) and should be 
designated as such. 
DOT is a component of case management that helps to ensure that patients receive 
effective treatment and adhere to it. The American Thoracic Society (ATS), the 
Centers for Disease Control and Prevention (CDC), and Arizona recommend that 
every tuberculosis (TB) patient be considered for DOT.72 DOT is implemented 
because 
 DOT is the most effective strategy for making sure that patients take their 
medicines; 
 DOT can lead to reductions in relapse and acquired drug resistance;73 and 
 Directly observing each dose provides immediate information on poor adherence 
and adverse effects, information that cannot readily be obtained from patients 
treated with SAT. 
Candidates for Directly Observed Therapy 
DOT should be the standard of care for all TB cases and suspects. In Arizona many 
public health agencies, DOT is the standard of care. That is, it is their goal to place all 
patients on DOT regardless of the patient’s circumstances because it has been shown 
to be such an important treatment tool.74 Consider DOT for all patients with TB 
disease, and ensure that medications are delivered by DOT for the following patients: 
 All patients being treated for active TB disease 
 Patients with multidrug-resistant TB (MDR-TB)  
 Immunocompromised persons on treatment for LTBI 
 Pediatric contacts on treatment for LTBI 
 Household contacts on treatment for LTBI  
How to Deliver Directly Observed Therapy 
Who Can Deliver Directly Observed Therapy? 
 Usually TB clinic personnel, such as a nurse or other healthcare worker 
 Staff at other healthcare settings, such as outpatient treatment centers 
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 Other responsible persons, such as school personnel, employers, others trained 
by the local health jurisdiction 
Who Cannot Deliver Directly Observed Therapy? 
 Family members75 
Principles of Directly Observed Therapy 
 The healthcare worker should watch the patient swallow each dose of medication. 
 Use DOT with other measures to promote adherence. 
 DOT can be given anywhere the patient and healthcare worker agree upon, 
provided the time and location are convenient and safe.76,77 
Directly Observed Therapy Tasks 
1. Deliver medication. 
2. Check for side effects and adverse reactions. 
 
  
 For more information, see the “Ongoing Assessment and Monitoring” 
topic in this section and the “Side Effects and Adverse Reactions” 
topic in the Treatment of Tuberculosis Disease section. 
3. Verify medication. 
4. Watch the patient take pills. 
  
 Healthcare workers should watch for tricks or techniques some 
patients may use to avoid swallowing medication, such as hiding pills 
in the mouth and spitting them out later, hiding medicine in clothing, 
or vomiting the pills after leaving the clinic. 
 If it is necessary to make sure that the patient swallows the pills, the 
healthcare worker may have to check the patient’s mouth, or ask the 
patient to wait for a half hour before leaving the clinic so the 
medication can dissolve in the patient’s stomach.78 
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5. Document the visit.  
 
 Refer to the forms section for a sample DOT form 
Another sample of DOT form from Snohomish County in the State of 
Washingtion. The location is 
http://www.doh.wa.gov/cfh/TB/2004_guidelines/case_management/Snohomis
h%20DOT%20Form.pdf 
  
 
6. As necessary and appropriate, do the following: 
a. Provide patient education 
b. Help the patient keep appointments 
c. Connect the patient with social services and transportation 
d. Draw upon familiarity with the patient’s home environment to identify 
household contacts 
e. Offer incentives and/or enablers to encourage adherence79  
 For more information, refer to the Patient Education section and the 
“Incentives and Enablers” topic in this section. 
Adherence to Directly Observed Therapy 
Patient Education 
The case manager should ensure that education is provided in the patient’s primary 
language and is culturally appropriate.80  
  
 For more information, see the Patient Education section. For points to 
use to explain to the patient why DOT is important, refer to the CDC’s 
Questions and Answers About TB 2005. Active TB Disease: What is 
directly observed therapy? (Division of Tuberculosis Elimination Web 
site; 2005) at http://www.cdc.gov/tb/faqs/qa_TBDisease.htm . 
Children with Tuberculosis 
To facilitate DOT adherence of children with TB, the case manager needs to be 
familiar with the childhood developmental stages, including important events, and 
utilize strategies in consideration of these stages.  
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  For more information on adherence strategies for different 
developmental stages, see Appendix C in the New Jersey Medical 
School National Tuberculosis Center’s Management of Latent 
Tuberculosis Infection in Children and Adolescents: A Guide for the 
Primary Care Provider (New Jersey Medical School Global Tuberculosis 
Institute Web site; 2004) at: 
http://www.umdnj.edu/globaltb/downloads/products/PediatricGuidelines.pdf
.  
Agreements 
It may be useful to develop a letter of agreement or acknowledgment between the 
patient and the DOT worker. Some jurisdictions have successfully used these as a 
method of ensuring adherence to therapy. The DOT worker and the patient negotiate 
dates, places, and times for DOT services to be provided, and both sign a document 
stating such agreements. Included in the agreement could be language specifying 
what consequences may result in the event that the client violates the terms of the 
contract.81  
Incentives and Enablers 
Incentives and enablers may be appropriate to help patients adhere to DOT.  
 For more information, see the “Incentives and Enablers” topic in this 
section.  
Missed Directly Observed Therapy Dose 
 If a DOT dose is missed, the patient should be contacted on the same 
day or on the next business day and the issue escalated to the case 
manager’s supervisor. 
It is important not to send a mixed message to patients by delaying the response to 
missed DOT doses. After telling patients that TB treatment is so important for their 
health and the health of the community, you cannot delay in responding to the failure 
to be available for DOT.  
A missed dose needs to be seen as an opportunity to identify barriers to adherence 
and work with patients to find ways to successfully complete treatment. The key to a 
successful DOT program is the use of immediate information on poor adherence, side 
effects, and adverse reactions in order to promptly identify and respond to potential 
barriers to adherence, missed doses, and potential adverse treatment effects. This 
approach has been referred to as enhanced DOT—the use of a patient-centered 
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approach to promptly identify and address barriers to treatment completion through 
use of incentives, enablers, and education efforts appropriate to the individual patient. 
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Incentives and Enablers 
Use incentives and enablers to enhance adherence to therapy.82 Incentives and 
enablers are used to improve patient attitudes and to foster good health behaviors.83 
They help patients stay with and complete treatment.84 
Incentives are small rewards given to patients to encourage them to either take their 
own medicines or keep their clinic or field directly observed therapy (DOT) 
appointments. 85 Enablers are those things that make it possible or easier for the 
patients to receive treatment by overcoming barriers such as transportation difficulties. 
Eligible Patients 
The following patients may receive incentives and/or enablers: 
• Patients qualify for incentives and enablers as needed. 
Available Incentives and Enablers  
The following incentives and enablers are available in Arizona: 
Table 1: AVAILABLE INCENTIVES AND ENABLERS 
Incentives Enablers 
 Food and beverages 
 Movie passes 
 Restaurant/fast food vouchers 
 
 Transportation 
• Bus pass 
• Cab fare 
 Childcare 
 Obtaining and transporting specimens for the 
patient 
 Assisting the client to get medication refills 
 Rent assistance 
 Assisting the client to complete paperwork to get 
food/housing assistance 
 Assisting the client to get substance treatment 
 To obtain incentives and enablers, see the “Incentives and Enablers” 
topic in the Supplies, Materials, and Services section.  
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State Laws and Regulations 
   
For Arizona laws and rules on tuberculosis (TB), see the following:  
ARS§36-725.  Orders to cooperate; emergency custody.    
ARS§36-726.  Petition for court ordered examination, monitoring,                   
treatment, isolation or quarantine.   
ARS§36-727. Hearings; procedure; confidentiality.   
ARS§36-728. Judicial action.   
ARS§36-729. Amended orders for intervention and transport of afflicted persons.              
ARS§36-730.  Appointment of guardian or conservator.   
ARS§36-731.  Confinement; selection; jails; prohibition.   
ARS§36-732.  Early release from court ordered treatment.   
ARS§36-733.  Choice of physician and mode of treatment.   
ARS§36-734.  Treatment; exemption.   
ARS§36-735.  Notification of rights.   
ARS§36-736.  Administrative procedures act; judicial review of                                           
administrative procedures; exemption; appeals.  
ARS§36-737.  Violation; classification.   
ARS§36-738.  Qualified immunity.   
          
Arizon Administrative Code.  Title 9. Chapter 6.  Department of  Health Services 
Communicable Diseases and Infestations.   
R9-3-303 Child Care Group Homes 
R9-5-301 Child Care Facilities 
R9-10-206 Hospitals Health Care Institutions: Licensing  
R9-10-207 Medical Staff 
R9-10-229 Infection Control 
R9-10-503 Adult Day Health Care Facilities personnel 
R9-10-706 Assisted Living Facilities – Personnel Qualifications and                            
Records 
R9-10-805 Hospice Staff 
R9-10-905 Nursing Care Institutions Staff 
R9-10-1103 Home Health Agencies Personnel 
R9-10-1404 Recovery Care Centers, Personnel 
R9-10-1704 Outpatient Surgical Centers 
R2-20-204 Behavioral Health Service Agencies: Licensure  
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Understand when and how to use legal orders, if necessary, for adherence to therapy. 
Non-adherent adults with pulmonary TB pose the greatest threat to the health of a 
community. It is the local public health agency’s responsibility to ensure that 
compliance is maintained, treatment is completed, and the risk of transmission to 
others is eliminated. These responsibilities require that TB staff members be 
innovative and always “go the extra mile” to see that patients take their medicine as 
prescribed. The public health mandate and good judgment dictate that program staff 
should go to every extent possible to fulfill the job responsibilities outlined above 
before resorting to legal action.86   
Progressive Interventions 
Have an intervention plan that goes step-by-step from voluntary participation to 
involuntary confinement as a last resort. Refer to Figure 1: Progressive 
Interventions for Non-adherent Patients. Progressive intervention should begin with 
learning the possible reasons for non-adherence and addressing the identified 
problems using methods such as directly observed therapy (DOT), incentives, and 
enablers. The patient should be told orally and in writing of the importance of adhering 
to treatment, the consequences of failing to do so, and the legal actions that will have 
to be taken if the patient refuses to take medication.87  
Before legal measures are taken against a patient who has been taking TB drugs on a 
self-administered basis, DOT should be offered to the patient.88  
Use a DOT agreement form and home isolation form with a patient who is likely to 
comply with treatment requirements. With a patient who may need more 
encouragement to adhere to treatment, complete a voluntary orders form. Voluntary 
orders are not legal orders but serve to clarify the mutual understanding between the 
patient and the local public health agency and provide written proof that treatment 
requirements were communicated to the patient and that the patient agreed to them. 
 
 
See the sample forms section. To ensure that they are effective, a state’s 
voluntary orders forms should be developed in collaboration with court 
personnel.  
If the patient does not adhere to DOT voluntarily, the next step may be court-ordered 
DOT. An optional step toward other legal orders, court-ordered DOT can be 
successful in convincing a patient that his or her TB treatment is an important public 
health priority. Involuntary confinement or isolation for inpatient treatment should be 
viewed as the step of last resort, to be used only when all other options fail. However, 
when a patient with infectious TB refuses treatment and voluntary isolation, 
emergency detention to isolate the person is appropriate.89  
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Under normal circumstances, patients with extra-pulmonary TB do not transmit the 
disease to others, and, therefore, these persons usually cannot be legally ordered to 
take their medications. However, their personal health is endangered if they choose 
not to be treated. They should be educated regarding the possibility of their disease 
spreading to the lungs and becoming infectious to others. For additional information 
contact the Arizona Department of Health Services TB Program at 602-364-4750. 
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Figure 1: PROGRESSIVE INTERVENTIONS FOR NONADHERENT PATIENTS 90 
Definitions of abbreviations: DOT = directly observed therapy; TB = tuberculosis. 
Source: CDC. Module 9: Patient Adherence to Tuberculosis Treatment. Self-Study Modules on Tuberculosis [Division 
of Tuberculosis Elimination Web site]. 1999:28. 
 
 Criteria for starting isolation and discontinuing isolation are provided 
in the Infection Control section.  
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Resources and References 
General Case Management Resources 
 CDC. Module 4: “Treatment of Tuberculosis Infection and Disease” (Self-Study 
Modules on Tuberculosis [Division of Tuberculosis Elimination Web site]; 1999). 
Available at: http://www.phppo.cdc.gov/phtn/tbmodules/modules1-5/m4/4-toc.htm . 
 CDC. Module 9: “Patient Adherence to Tuberculosis Treatment “(Self-Study Modules 
on Tuberculosis [Division of Tuberculosis Elimination Web site]; 1999). Available at:  
http://www.phppo.cdc.gov/phtn/tbmodules/modules6-9/m9/9-toc.htm . 
 California Department of Health Services (CDHS)/California Tuberculosis Controllers 
Association (CTCA). “TB Case Management—Core Components” (CDHS/CTCA 
Joint Guidelines [CTCA Web site]; May 11, 1998). Available at:  
http://www.ctca.org/guidelines/IIA6casemgmt.pdf . 
 New Jersey Medical School National Tuberculosis Center. Tuberculosis Case 
Management for Nurses: Self-Study Modules (New Jersey Medical School Global 
Tuberculosis Institute Web site). Available at:  
http://www.umdnj.edu/globaltb/products/tbcasemgmtmodules.htm . 
Directly Observed Therapy Resources 
 CDC. Chapter 7: “Treatment of TB Disease” (Core Curriculum on Tuberculosis 
(2000) [Division of Tuberculosis Elimination Web site]; Updated November 2001). 
Available at: http://www.cdc.gov/tb/pubs/corecurr/Chapter7/Tableofcontents.htm . 
 CDC. Module 9: “Patient Adherence to Tuberculosis Treatment” (Self-Study Modules 
on Tuberculosis [Division of Tuberculosis Elimination Web site]; 1999). Available at: 
http://www.phppo.cdc.gov/phtn/tbmodules/modules6-9/m9/9-toc.htm  
 Francis J. Curry National Tuberculosis Center. Directly Observed Therapy (DOT) 
Training Curriculum for TB Control Programs (Francis J. Curry National Tuberculosis 
Center Web site; 2003). Available at: 
http://www.nationaltbcenter.edu/catalogue/epub/index.cfm?uniqueID=1&tableName=
DOTE . 
Incentives and Enablers Resources 
 CDC. “Adherence” in Chapter 7 “Treatment of TB Disease” (Core Curriculum on 
Tuberculosis (2000) [Division of Tuberculosis Elimination Web site]; Updated 
November 2001). Available at: 
http://www.cdc.gov/tb/pubs/corecurr/Chapter7/Chapter_7_Adherence.htm . 
 CDC. Module 9: “Patient Adherence to Tuberculosis Treatment” (Self-Study Modules 
on Tuberculosis [Division of Tuberculosis Elimination Web site]; 1999). Available at: 
http://www.phppo.cdc.gov/phtn/tbmodules/modules6-9/m9/9-toc.htm . 
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Legal Orders Resources 
 CDC. Module 9: “Patient Adherence to Tuberculosis Treatment “(Self-Study Modules 
on Tuberculosis [Division of Tuberculosis Elimination Web site]; 1999). Available at: 
http://www.phppo.cdc.gov/phtn/tbmodules/modules6-9/m9/9-toc.htm . 
 New Jersey Medical School National Tuberculosis Center. Implementing Legal 
Interventions for the Control of Tuberculosis (New Jersey Medical School Global 
Tuberculosis Institute Web site; 2005). Available at: 
http://www.umdnj.edu/globaltb/products/legalinterventions.htm . 
 State of Washington. Washington State TB Guidelines—Revised (Washington State 
Department of Health; October 2004). Available at: 
http://www.doh.wa.gov/cfh/TB/guidelines.htm . 
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Introduction 
Purpose 
A contact investigation is the process of identifying, examining, evaluating, and treating 
all persons who are at risk for infection with Mycobacterium tuberculosis due to recent 
exposure to a newly diagnosed or suspected case of pulmonary, laryngeal, or pleural 
tuberculosis (TB).  
The primary goal of a contact investigation is to  
 Identify persons who were exposed to an infectious case of TB 
 Ensure that contacts receive  
• Testing for M. tuberculosis infection;  
• Screening for TB disease;  
• Medical evaluation, if indicated; 
• Prompt initiation of treatment for latent tuberculosis infection (LTBI) if at high risk 
(younger than 5 years of age or immunocompromised); and 
• Complete, standard course of treatment, unless medically contraindicated.1  
Secondary goals of a contact investigation are to  
 Stop transmission of M. tuberculosis by identifying persons with previously 
undetected infectious TB; and 
 Determine whether a TB outbreak has occurred (in which case, an expanded 
outbreak investigation should ensue).2 
Use this section to understand and follow national and Arizona’s guidelines to do the 
following: 
 Decide when to initiate a contact investigation 
 Understand the time frames for key contact investigation activities 
 Estimate the infectious period  
 Conduct index patient interviews 
 Assign priorities to contacts 
 Complete contact evaluation, treatment, and follow-up 
 Determine when to expand a contact investigation 
 Manage data and evaluate contact investigations 
 Conduct an outbreak investigation 
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Except in rare cases, every case of TB begins as a contact to a person with active 
pulmonary, laryngeal, or pleural TB disease. For this reason, the Centers for Disease 
Control and Prevention (CDC) has identified contact investigations (i.e., seeking and 
evaluating contacts) as a fundamental strategy for the prevention and control of TB. To 
control and prevent TB, our healthcare resources and efforts in Arizona should be 
directed to meeting the priorities outlined in the 2005 “Controlling Tuberculosis in the 
United States: Recommendations from the American Thoracic Society, Centers for 
Disease Control and Prevention, and the Infectious Diseases Society of America.” One 
of the recommended strategies to achieve the goal of reduction of TB morbidity and 
mortality is prompt identification of contacts of patients with infectious TB and timely 
treatment of those at risk with an effective drug regimen.3 National recommendations for 
contact investigations are provided in the CDC’s “Guidelines for the Investigation of 
Contacts of Persons with Infectious Tuberculosis: Recommendations from the National 
Tuberculosis Controllers Association and CDC, and Guidelines for Using the 
QuantiFERON®-TB Gold Test for Detecting Mycobacterium tuberculosis Infection, United 
States” (MMWR 2005; 54[No. RR-15]: 1–49). 
One of the major challenges to successful control of TB is in protecting contacts of 
persons with infectious TB and in preventing and responding to TB outbreaks.4 
Reducing the risk of TB among contacts through the development of better methods of 
identification, evaluation, and management would lead to substantial personal and public 
health benefits and facilitate progress toward eliminating TB in the United States.5 
The evaluation of contacts of cases of infectious TB is one of the most productive 
methods of identifying adults and children with LTBI at high risk for progression to TB 
disease and persons in the early stages of TB disease. Contact investigations, therefore, 
serve as an important means of detecting TB cases and at the same time identify 
persons in the early stage of LTBI, when the risk for progression to TB disease is high 
and the benefit of treatment is greatest.6 A study showed that improvements in contact 
investigations might have prevented 17 (10%) of 165 pediatric TB cases in California in 
1994.7  
Policy  
A contact investigation is recommended for the following forms of suspected or 
confirmed TB because they are likely to be infectious:  
Pulmonary, laryngeal, or pleuropulmonary disease with either  
 Pulmonary cavities;  
 Respiratory specimens that have acid-fast bacilli (AFB) on microscopy;  
 Especially both.8 
Persons with AFB sputum smear negative results are less likely to be infectious, but are 
still capable of infecting others.    
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For roles and responsibilities, refer to the “Roles, Responsibilities, and 
Contact Information” topic in the previous chapter. 
 
Forms 
 
For each investigation, complete the ADHS Prevention Registry Form on 
the reporting schedule in Table 3: Required Reports in the “Required 
Reports from Local Public Health Agencies to the Arizona Tuberculosis 
Program” topic in the Surveillance section. Forms are available in the 
sample forms section.  
Persons with AFB sputum smear negative results are less likely to be infectious, but are 
still capable of infecting others. 
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Structure of a Contact Investigation 
Basic Steps of a Contact Investigation 
A successful contact investigation requires the careful gathering and evaluation of 
detailed information, often involving many people. In general, contact investigations 
follow a process that includes these steps: 
1. Preinterview preparation 
2. Index patient interviews  
3. Field investigation  
4. Risk assessment for Mycobacterium tuberculosis transmission  
5. Decision about priority of contacts  
6. Evaluation of contacts  
7. Treatment and follow-up for contacts  
8. Decision about whether to expand testing  
9. Evaluation of contact investigation activities9,10 
Although these steps are presented in sequence above, it is important to remember that 
contact investigations do not always follow a predetermined sequence of events.11 
Contact Investigation Plan  
The investigation plan starts with information gathered during interviews and site visits. It 
should include a registry of the contacts, their assigned priorities, and a written timeline. 
The timeline sets expectations for monitoring the progress of the investigation, and it 
informs public health officials about whether additional resources are needed for finding, 
evaluating, and treating the high- and medium-priority contacts.  
 
For more information on timelines, see Table 2: Time Frames for 
Investigating the Index Patient and the Sites of Transmission and 
Table 3: Time Frames for Contact Evaluation and Treatment in this 
section’s topic “Time Frames for Contact Investigation.” 
The plan is a pragmatic work in progress and should be revised if additional information 
indicates a need to expand a contact investigation. It is part of the permanent record of 
the overall investigation for later review and program evaluation.12  
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Decision to Initiate a Contact Investigation 
Factors Predicting Transmission of Tuberculosis 
Decide when to initiate a contact investigation using the criteria provided in this topic. 
Competing demands restrict the resources that can be allocated to contact 
investigations. Therefore, public health officials must decide which contact investigations 
are more significant and which contacts to evaluate first.  
The index patient is the first patient that comes to the investigator’s attention as an 
indicator of a potential public health problem. Whether or not to investigate an index 
patient depends on factors predicting transmission. See Table 1: Index Patient Factors 
Increasing Transmission Risk. In addition, other information about the index patient, 
such as social habits or workplace environments, can influence the investigative 
strategy.13  
Table 1. INDEX PATIENT FACTORS INCREASING TRANSMISSION RISK 14  
Characteristics of the Index Patient Behaviors of the Index Patient 
• Pulmonary, laryngeal, or pleuropulmonary 
tuberculosis (TB) 
• Positive acid-fast bacilli sputum smear results 
• Cavitation on chest radiograph 
• Adolescent or adult patient 
• Lack of treatment or ineffective treatment of TB 
disease 
• Frequent coughing 
• Sneezing 
• Singing 
• Close social network 
Source: CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from 
the National Tuberculosis Controllers Association and CDC, and Guidelines for using the QuantiFERON®-TB Gold test 
for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005;54(No. RR-15):4. 
 
Anatomical Site of Disease  
Ordinarily, patients with pulmonary or laryngeal tuberculosis (TB) are the only ones who 
can transmit their infection. For contact investigations, pleural disease is grouped with 
pulmonary disease because sputum cultures can yield Mycobacterium tuberculosis even 
when no lung abnormalities show on radiography. Rarely, extrapulmonary TB causes 
transmission during medical procedures, such as autopsy and embalming, that release 
aerosols.  
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Sputum Bacteriology 
The relative infectiousness increases when the sputum culture results are positive, and 
increases further when the acid-fast bacilli (AFB) sputum smear results are also 
positive.15 The significance of results from respiratory specimens other than 
expectorated sputum, such as bronchial washings or bronchoalveolar lavage fluid, is 
undetermined. Expert opinion recommends that these specimens be regarded as 
equivalent to sputum.  
Radiographic Findings 
Patients who have lung cavities observed on a chest radiograph are more infectious 
than patients with noncavitary disease. This is an independent predictor after 
bacteriologic findings are taken into account. The significance of small lung cavities that 
are detectable with computerized tomography (CT), but not with plain radiography, is 
undetermined.  
Isolated instances of highly contagious endobroncheal TB in severely 
immunocompromised patients who temporarily had normal chest radiographs have 
contributed to outbreaks. The number and relative significance of such instances is 
unknown, but in one case series with human immunodeficiency virus (HIV)-infected TB 
patients, 3% who had positive AFB sputum smears had normal chest radiographs at the 
time of diagnosis. 
Social Characteristics 
Social issues can influence transmission. To assess the risk of transmission, it is 
important to consider the index patient’s social factors, such as a close social network, 
residential setting or homelessness, employment, work setting, non-work-related 
activities, recent arrival from a foreign country, substance abuse, and intravenous  
drug use.  
Age 
Transmission from children younger than 10 years of age is unusual, although it has 
been reported in association with those pulmonary forms of disease typically seen in 
adults. Contact investigations to evaluate transmission from pediatric cases should not 
be undertaken, except for those unusual cases. However, children younger than 5 years 
with TB, regardless of the site of disease, should have a contact investigation to identify 
the source case. A source-case investigation seeks the source of recent M. tuberculosis 
infection, perhaps newly diagnosed TB disease. TB disease in children younger than 5 
years typically indicates that the infection is recent. Young children usually do not 
transmit TB to others, and their contacts are unlikely to be infected because of exposure 
to them.  
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Human Immunodeficiency Virus Status 
This evaluation needs to be done promptly since progression to active TB may occur 
within weeks of exposure among individuals with acquired immunodeficiency syndrome 
(AIDS). HIV-infected TB patients with low CD4 T-cell counts frequently have chest 
radiographic findings that are not typical of pulmonary TB.16 In particular, they are more 
likely to have mediastinal adenopathy and less likely to have upper-lobe infiltrates and 
cavities. The atypical radiographic findings increase the potential for delayed diagnosis, 
which increases transmission. However, HIV-infected patients who have pulmonary or 
laryngeal TB on average are only as contagious as similar patients who are not HIV 
infected. Contacts to HIV-infected index TB cases are also more likely to be HIV 
infected. Therefore, for all persons who were exposed to HIV-infected TB cases (or 
those with risk factors for HIV) and whose infection status is unknown, HIV counseling 
and testing is recommended.17 Regardless of known HIV status, HIV counseling should 
always be recommended for all patients as a part of the screening process.18 
After Starting Chemotherapy 
TB patients rapidly become less contagious while under treatment. This has been 
corroborated by measuring the number of viable M. tuberculosis organisms in sputa and 
by observing infection rates in household contacts. However, the exact rate of decrease 
cannot be predicted for individual patients, and an arbitrary determination is required for 
each.  
Treatment After Exposure to Drug-Resistant Tuberculosis 
Drug susceptibility results for the M. tuberculosis isolate from the index 
patient (i.e., the presumed source of infection) are absolutely necessary for 
selecting the treatment regimen. 
Resistance to only isoniazid (INH) leaves the option of four months of daily rifampin 
(RIF), but additional resistance to RIF constitutes multidrug-resistant TB (MDR-TB). If 
this is the case, all the potential regimens are poorly tolerated to some extent, while 
none of these regimens have been tested fully for efficacy. Therefore, a consultation with 
a physician having expertise in this area is strongly recommended for selecting a 
regimen and managing the care of contacts. Monitor contacts who are suspected to be 
infected with multidrug-resistant M. tuberculosis for two years after exposure.  
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Deciding to Initiate a Contact Investigation 
Consider a contact investigation for any patient with confirmed or suspected pulmonary, 
laryngeal, or pleuropulmonary TB. Refer to Figure 1 to help determine whether to start a 
contact investigation. 
Figure 1: DECISION TO INITIATE A CONTACT INVESTIGATION19 
 
 
Definitions of abbreviations: AFB = acid-fast bacilli; C/W = consistent with; CXR = chest radiograph; TB = tuberculosis. 
* Use time frames from the middle column of Table 2 in the “Time Frames for Contact Investigation” topic. 
† Use time frames from the right-hand column of Table 2 in the “Time Frames for Contact Investigation” topic. 
Source: CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from 
the National Tuberculosis Controllers Association and CDC, and guidelines for using the QuantiFERON®-TB Gold test 
for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005;54(No. RR-15):5. 
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In general, a contact investigation should be promptly initiated for an AFB sputum 
smear-positive pulmonary TB suspect. However, many AFB sputum smear-positive 
suspects may turn out to have nontuberculous mycobacteria (NTM) instead of M. 
tuberculosis. An approved nucleic acid amplification (NAA) test for M. tuberculosis can 
be used to avoid unnecessary contact investigations for suspects with NTM, particularly 
in patients who are at low risk for TB.    
If AFB are not detected by microscopy of three sputum smears, an investigation is still 
recommended if the chest radiograph shows cavities in the lung. Small parenchymal 
cavities that can be detected only by computerized imaging techniques (e.g., computed 
tomography [CT], computerized axial tomography [CAT] scan, or magnetic resonance 
imaging [MRI] of the chest) are not included in these guidelines.  
When sputum samples have not been collected, either because of an oversight or the 
patient’s inability to expectorate, results from other types of respiratory specimens (e.g., 
gastric aspirates or bronchoalveolar lavage) may be interpreted in the same way as in 
the above recommendations. However, whenever feasible, sputum samples for each 
case should be collected before or while initiating chemotherapy.  
A contact investigation can still be considered for high-risk contacts of suspects with 
non-cavitary disease and negative AFB sputum smears. The decision depends on the 
amount of resources that can be allocated and on whether goals are being met for 
higher priority contact investigations.  
Contact investigations generally should not be initiated around index patients who have 
suspected TB disease and minimal diagnostic findings in support of pulmonary TB. 
Possible exceptions can be found during outbreak investigations, especially when 
vulnerable or susceptible contacts are found, or during a source-case investigation. 
Outbreak investigations and source-case investigations are explained briefly below. 
 Outbreak Investigation: Definitions for TB outbreaks are relative to the local 
context. Outbreak cases can be distinguished from other cases only when some 
association in time, location, patient characteristics, or M. tuberculosis attributes 
(e.g., drug resistance or genotype) becomes apparent. In low-incidence jurisdictions, 
any temporal cluster will cause suspicion regarding an outbreak. In places where 
cases are more common, clusters can be obscured by the baseline incidence rate 
until suspicion is triggered by a noticeable increase, a sentinel event (e.g., pediatric 
cases), or related M. tuberculosis isolates.  
For more information on outbreak investigations, see the “Outbreak 
Investigation” topic in this section. 
 Source-Case Investigation: A source-case investigation seeks the source of recent 
M. tuberculosis infection, perhaps newly diagnosed TB disease. A source case or 
patient is the original source of infection for secondary cases or contacts. The source 
case can be, but is not necessarily, the index patient.  
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For more information on source-case investigations, see the CDC’s 
“Guidelines for the Investigation of Contacts of Persons with Infectious 
Tuberculosis Cases” (MMWR 2005;54[No. RR-15]: 31) at 
http://www.cdc.gov/mmwr/pdf/rr/rr5415.pdf . 
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Time Frames for Contact Investigation 
Use this topic to understand the time frames for key contact investigation activities. A 
suspected or confirmed case of tuberculosis (TB) becomes designated an “index patient” 
when that person is the first patient to appear as an indicator of a potential public health 
problem. An investigation is launched because of an index patient, and the investigation 
often starts with an interview of the index patient.  
Information about the Index Patient  
and Transmission Sites 
Comprehensive information about an index patient is the foundation of a contact 
investigation. This information includes the disease characteristics, the onset date of the 
illness, names of contacts, exposure locations, and current medical factors, such as 
initiation of effective treatment and drug susceptibility results.  
The infectiousness of the index patient determines the recommended time frames for 
pursuing the investigation. Indications of infectiousness include symptoms (such as 
cough, fever, weight loss, and night sweats), a positive acid-fast bacilli (AFB) sputum 
smear, a positive nucleic acid amplification (NAA) test, cavitary disease, or an abnormal 
chest radiograph consistent with TB.  
Refer to Table 2: Time Frames for Investigating the Index Patient and the Sites of 
Transmission for the recommended time frames for index patient interviews and visits 
to the residence transmission sites.  
 
Some readers confuse prioritizing an investigation with prioritizing follow-
up of individual contacts within an investigation. The following explains the 
difference between the two: 
 The time priority for investigating the index patient and transmission 
sites is determined by the infectiousness of the index patient. 
Indications of infectiousness include positive AFB sputum smear 
results as well as symptoms, positive NAA test results, and chest 
radiographs showing cavitary disease or abnormalities consistent with 
TB.  
 Priority-ranking contacts for follow-up within an investigation is based 
on the characteristics of the index patient as well as the duration and 
circumstances of the exposure, and the vulnerability/susceptibility of 
the contacts to disease from Mycobacterium tuberculosis infection. 
For information on how to determine which contacts are high, medium, and 
low priority, see the “Contact Priorities” topic in this section. 
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Table 2: TIME FRAMES FOR INVESTIGATING THE INDEX PATIENT AND THE SITES OF 
TRANSMISSION20 
 Suspects Expected to Be Cases of Tuberculosis  
 
Activity 
Suspects with Indications of 
Infectiousness  
Suspects Without Indications 
of Infectiousness 
First Index Patient Interview 
Number of days following notification 
within which the index patient should be 
interviewed in person (i.e., not by 
telephone) 
≤1 Business Day of Reporting ≤3 Business Days of 
Reporting 
Residence Visit 
Number of days following the first index 
patient interview within which the place 
of residence of the index patient should 
be visited 
≤3 Business Days After First 
Interview 
3 Business Days After First 
Interview 
Field Investigation 
Number of days following initiation of the 
contact investigation within which all 
potential settings for transmission should 
be visited 
5 Business Days After the 
Start of the Investigation 
 
5 Business Days After the 
Start of the Investigation  
Index Patient Reinterviews 
Length of time after the first interview 
within which the index patient should be 
reinterviewed one or more times for 
clarification and additional information 
1 or 2 Weeks After First 
Interview 
1 or 2 Weeks After First 
Interview 
 
Reassessment of Index Patient 
Information about the index patient should be reassessed at least weekly until drug-susceptibility results are available 
for the Mycobacterium tuberculosis isolate or for 2 months following notification, whichever is longer. 
Source: CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from 
the National Tuberculosis Controllers Association and CDC, and guidelines for using the QuantiFERON®-TB Gold test 
for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005;54(No. RR-15):7–8. 
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Contact Evaluation and Treatment 
In addition to the investigation of the index patient and transmission sites, a contact 
investigation also involves contact follow-up. Refer to Table 3: Time Frames for 
Contact Evaluation and Treatment to monitor the progress of the investigation and 
determine whether additional resources are needed for finding, evaluating, and treating 
the high- and medium-priority contacts. 
 
Priority-ranking contacts for investigation is based on the likelihood of 
infection and the potential hazard to the individual contact if infected.21 For 
information on how to determine which contacts are high-, medium-, or 
low-priority, see the “Contact Priorities” topic in this section. 
Table 3: TIME FRAMES FOR CONTACT EVALUATION AND TREATMENT22 
 
 
Type of Contact 
 
Business Days from 
Listing of a Contact to 
Initial Encounter* 
Business Days from 
Initial Encounter to 
Completion of 
Medical Evaluation† 
Business Days 
from Completion of 
Medical Evaluation 
to Start of 
Treatment 
5 Business Days 10 Business Days High-Priority Contact 
Index patient with positive acid-fast 
bacilli (AFB) sputum smear results or 
cavitary disease on chest radiograph 
3 Business Days After 
Being Listed in the 
Investigation23 
5 Business Days 
Children and high-risk contacts can develop 
complicated tuberculosis (TB) within a few 
weeks of infection. 
High-Priority Contact 
Index patient with negative AFB sputum 
smear results  
3 Business Days After 
Being Listed in the 
Investigation24 
10 Business Days 10 Business Days 
Medium-Priority Contact 
Regardless of AFB sputum smear or 
culture result 
3 Business Days After 
Being Listed in the 
Investigation25 
10 Business Days  10 Business Days 
* “Encounter” means a face-to-face meeting, which gives the public health worker a chance to determine whether the contact is 
generally healthy or ill. The initial encounter also provides opportunities to administer a tuberculin skin test (TST) and to schedule 
further evaluation. 
† The medical evaluation is complete when the contact’s status relative to Mycobacterium tuberculosis infection or TB disease has 
been determined. A normal exception to this schedule is the delay in waiting for final mycobacteriology results, but this applies to 
relatively few contacts. 
Source: Adapted from CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: 
recommendations from the National Tuberculosis Controllers Association and CDC. MMWR 2005;54(No. RR-15):9. 
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Ongoing Management Activities 
Ongoing contact follow-up includes testing, medical evaluation, and treatment. 
Information from contact follow-up guides decisions about whether to expand a contact 
investigation. Refer to Table 4: Overview of Ongoing Management Activities and 
Maximum Time Frames to monitor the progress of ongoing contact follow-up and to 
determine when to decide whether to expand the investigation. 
Table 4: OVERVIEW OF ONGOING MANAGEMENT ACTIVITIES AND MAXIMUM TIME 
FRAMES26 
Activity Purpose Maximum Time Interval 
Review all documentation To ensure that contact list is 
complete 
Ongoing 
Review and assess completeness 
of each contact’s medical follow-
up and treatment plan 
To ensure appropriate and 
complete medical follow-up 
5 business days after each 
contact’s medical evaluation is 
completed* 
Review and assess the timeliness 
of initiating the treatment plan 
To avoid delays in treatment 
initiation, particularly in high-risk 
contacts 
10 business days after each 
contact’s medical evaluation is 
completed* 
Determine if transmission occurred To decide whether to expand 
investigation  
At completion of follow-up testing, 
or if secondary cases are identified 
Obtain and review drug-
susceptibility results 
To determine if contacts are 
receiving appropriate treatment for 
latent tuberculosis infection (LTBI) 
1 to 2 months after the index 
patient’s initial sputum collection 
date 
Repeat tuberculin skin test (TST) if 
contact is initially TST-negative 
To determine if contact has 
converted (TB Class I to TB  
Class II) 
8 to 10 weeks after each contact’s 
initial TST or last exposure to the 
index patient† 
Reevaluate contacts who were 
initially TST-negative and started 
on LTBI treatment (Window Period 
Treatment for a TB Class I 
Contact) 
To determine if treatment for LTBI 
should be continued 
8 to 10 weeks after each contact’s 
initial TST or last exposure to the 
index patient before the end of the 
infectious period† 
Assess contacts’ adherence with 
medical follow-up and TB 
medication 
To remove barriers and ensure 
timely and complete evaluation 
and follow-up 
Monthly, at time of each visit  
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Activity Purpose Maximum Time Interval 
Ensure contacts are monitored for 
adverse reactions and toxicity of 
LTBI treatment regimens  
To prevent development of 
adverse effects and toxicity from 
drug regimens  
At least monthly while on LTBI 
treatment 
Evaluate problems and concerns 
that arise and may delay or 
hamper contact investigation 
To remove barriers and ensure 
timely and complete evaluation 
and follow-up 
Whenever problems are identified 
Collect and analyze data to 
evaluate the contact investigation 
To provide epidemiologic analysis 
of investigations and to measure 
performance using indicators that 
reflect performance objectives27 
Ongoing 
Collect data to complete the 
Aggregate Reports for 
Tuberculosis Program Evaluation 
(ARPE) form 
To report on investigation to the 
Centers for Disease Control and 
Prevention 
Ongoing 
*  The medical evaluation is complete when the contact’s status relative to Mycobacterium tuberculosis infection or TB disease 
has been determined. A normal exception to this schedule is the delay in waiting for final mycobacteriology results, but this 
applies to relatively few contacts. 
† Third TST: In rare circumstances, an infectious index patient with advanced disease can stay infectious for several months. In 
these circumstances, the second TST for negative contacts should be performed in the usual time frame (8 to 10 weeks). This 
will identify any contacts who have already converted so they can be evaluated for treatment. However, any household 
members who remain TST negative and have continued exposure to the infectious index patient should have a third TST 8 to 
10 weeks after the index patient becomes noninfectious. This is especially true for contacts who are infants in a household 
where a resident is culture positive after 3 months or has multidrug-resistant TB. For example, a household member with 
continued exposure to an infectious index patient had a negative second TST on 3/12/2007. The last date the index patient 
was infectious was 3/5/2007. The household member should have a third TST 8 to 10 weeks from 3/5/2007. For consultation 
regarding the appropriateness of a third TST, call the Arizona Department of Health at 602-364-4750.  
Source: Adapted from: California Department of Health Services (CDHS)/California Tuberculosis Controllers Association 
(CTCA).  Contact investigation guidelines. CDHS/CTCA Joint Guidelines [CTCA Web site]. November 12, 1998:18. 
Available at: http://www.ctca.org/guidelines/IID1contactinvestigation.pdf . Accessed July 6, 2006.  
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Infectious Period 
Determine the infectious period to focus the investigation on those contacts most likely 
to be at risk for infection and to set the time frame for testing contacts. 
The infectious period is the time frame in which potential exposure to others may have 
occurred while the patient was infectious or able to transmit tuberculosis (TB).28 The 
start of the infectious period cannot be determined with any current methods, so a 
practical estimation is necessary. From expert opinion, an assigned start three months 
prior to TB diagnosis is recommended for the more infectious patients. Some 
circumstances may indicate an even earlier start, which should be used instead. The 
clearest example is when the patient or the patient’s associates were aware of 
protracted illness, which can exceed one year in extreme examples.  
Assemble information from the index patient interview and other sources to estimate the 
infectious period. Helpful details are the approximate dates that TB symptoms were 
noticed, bacteriology results, and the extent of disease—especially the presence of large 
lung cavities, which imply prolonged illness as well as infectiousness.   
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Use Table 5: Guide for Estimating the Beginning of the Period of Infectiousness to 
determine the start of the infectious period. 
Table 5: GUIDE FOR ESTIMATING THE BEGINNING OF THE PERIOD OF 
INFECTIOUSNESS29 
Index Patient Characteristics 
Tuberculosis  
Symptoms 
Positive Acid-Fast 
Bacilli  Sputum 
Smear Results 
Cavitary Chest 
Radiograph 
Yes No Yes No Yes No 
 
 
Recommended Beginning 
of Likely Period of 
Infectiousness 
9   9  9 3 months prior to symptom 
onset or first positive finding 
consistent with tuberculosis 
(TB) disease (whichever is 
longer) 
9  9  9  3 months prior to symptom 
onset or first positive finding 
consistent with TB disease 
(whichever is longer) 
 9  9  9 4 weeks prior to date of 
suspected diagnosis 
 9 9  9  3 months prior to first 
positive finding consistent 
with TB 
Source: California Department of Health Services Tuberculosis Control Branch; California Tuberculosis Controllers 
Association. Contact investigation guidelines. Berkeley, CA: California Department of Health Services; 1998; in CDC. 
Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National 
Tuberculosis Controllers Association and CDC, and guidelines for using the QuantiFERON®-TB Gold test for detecting 
Mycobacterium tuberculosis infection, United States. MMWR 2005;54(No. RR-15):7. 
 
For the purposes of contact investigation, the end of potential exposure to the infectious 
case determines the end of the infectious period. The potential for transmission is 
reduced by the initiation and duration of treatment, the index patient’s response to 
treatment, and/or the application of effective infection control measures.   
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In general, for the purposes of contact investigation, the infectious period is closed 
when exposure to contacts has ended OR when all three of the following criteria are 
met:  
1. The index patient is receiving effective treatment (as demonstrated by 
Mycobacterium tuberculosis susceptibility results) for at least two weeks. 
2. The index patient has diminished symptoms. 
 The index patient exhibits mycobacteriologic response (e.g., decrease in grade of 
sputum smear positivity detected on sputum-smear microscopy).30,31 
Take careful note of the following exceptions: 
 Multidrug-resistant TB (MDR-TB):  MDR-TB can extend infectiousness if the 
treatment regimen is ineffective.  
 Signs of infectiousness: Any index patient with signs of extended infectiousness 
should be continually reassessed for recent contacts. 
 Susceptible contacts: Apply more stringent criteria for setting the end of the 
infectious period if particularly susceptible contacts are involved.  
 
A patient with pulmonary or laryngeal TB returning to a congregate living 
setting or to any setting in which susceptible persons might be exposed 
should meet the following criteria for noninfectiousness.  
1. Have had three consecutive AFB-negative results from sputum 
specimens collected 8 to 24 hours apart, with at least one being an early 
morning specimen, and 
2. Have been on antituberculosis therapy for two weeks, and 
3. Diminished symptoms.   
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Index Patient Interviews 
Conduct index patient interviews to set the direction for the contact investigation, identify 
contacts, provide opportunities for the patient to learn about tuberculosis (TB) and its 
control, and help the public health worker learn how to provide treatment and specific 
care for the patient. 
In index patient interviews, gather information about the index patient’s medical history, 
treatment needs, residence, transmission sites, dates and times at specific transmission 
sites, and contacts at specific sites. Use the information from these interviews to decide 
whether to start a contact investigation, establish its priority relative to other 
investigations, and determine the scope of the investigation.  
There should be an initial interview and one or two reinterviews before discharge from 
the hospital, or within one to two weeks if the initial interview is at home, to obtain further 
information and answer additional questions.32  
 
TB Interviewing for Contact Investigation: A Practical Resource for the 
Healthcare Worker (New Jersey Medical School Global Tuberculosis 
Institute Web site; 2004) at 
http://www.umdnj.edu/globaltb/products/tbinterviewing.htm offers specific 
suggestions on how to prepare for and conduct the interviews.33  
 
Record information on the index patient and contacts on the ADHS 
Prevention Registry Form available in the forms section. 
Pre-interview Preparation 
Gather information on the patient and the circumstances of the illness to prepare for the 
first interview.  
Consult these sources:  
 Current medical record 
 Physician who reported the case 
 Infection control nurse (if the patient is hospitalized)  
The Privacy Rule in the Health Insurance Portability and Accountability Act (HIPAA) 
permits disclosure of medical record information to public health authorities.34 
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General Guidelines for Interviewing an Index Patient 
1. Discuss confidentiality and privacy in frank terms to help the patient decide how to 
share information, and revisit these topics several times during the interview to stress 
their importance. Emphasize confidentiality, but inform the patient that relevant 
information may need to be shared with other health department staff or other 
persons who may assist in congregate settings to most efficiently ascertain which 
contacts need to be evaluated. Inform the patient that it will be necessary for visits to 
be made at sites such as the home, workplace/school, or leisure establishments to 
assess the shared air environment to accurately structure the contact investigation.35  
2. Conduct the interviews in the patient’s language, using a medical interpreter if the 
patient does not speak English.   
3. Conduct the interviews in a culturally competent manner.  
 
 
For more information on cultural sensitivity, refer to the Participant’s 
Workbook for Session 4: “Working with Culturally Diverse Populations” in 
the Directly Observed Therapy Training Curriculum for TB Control 
Programs (Francis J. Curry National Tuberculosis Center Web site; 2003) 
at 
http://www.nationaltbcenter.edu/catalogue/epub/index.cfm?uniqueID=2&t
ableName=DOTE . 
 
For assistance with language issues, see the Language Services 
Resource Guide for Health Care Providers (The National Health Law 
Program Web site; 2006) at 
http://www.healthlaw.org/library.cfm?fa=download&resourceID=89928&a
ppView=folder&print . 
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Field Investigation 
A field investigation includes visiting the patient's home or shelter, workplace (if any), 
and the other places where the patient said he or she spent time while infectious. The 
field investigation is important and should be done even if the patient interview has 
already been conducted. The purpose of the field investigation is to identify contacts and 
evaluate the environmental characteristics of the place in which exposure occurred. The 
field investigation may provide additional information for the risk assessment and identify 
additional contacts.36  
During field visits, the healthcare worker should do the following: 
 Observe environmental characteristics, such as room size, crowding, and 
ventilation, to estimate the risk of tuberculosis (TB) transmission: air volume, exhaust 
rate, and circulation predict the likelihood of transmission in an enclosed space. In 
large indoor settings, the degree of proximity between contacts and the index patient 
can influence the likelihood of transmission. The most practical system for grading 
exposure settings is to categorize them by size (e.g., “1” being the size of a vehicle 
or car, “2” the size of a bedroom, “3” the size of a house, and “4” a size larger than a 
house). The volume of air shared between an infectious TB patient and contacts 
dilute the infectious particles. Local circulation and overall room ventilation also dilute 
infectious particles, but both factors have to be considered because they can redirect 
exposure into spaces that were not visited by the index patient.37  
 Identify additional contacts (especially children) and their locating information, 
such as phone numbers and addresses. 
 Look for evidence of other contacts that may not be present at the time of the visit  
(for example, pictures of others who may live in or visit the house, shoes of others 
who may live in the house, or toys left by children).  
 Interview and skin test high- and medium-priority contacts that are present and 
arrange for reading of the results. 
 Educate the contacts about the purpose of a contact investigation, the basics of 
transmission, the risk of transmitting Mycobacterium tuberculosis to others, and the 
importance of testing, treatment, and follow-up for TB infection and disease. 
 Refer contacts who have TB symptoms to the health department for a medical 
evaluation, including sputum collection.38  
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For field investigation, use the ADHS Prevention Registry Form available 
in the sample form section. 
Healthcare workers should remember to follow infection control precautions while visiting 
a potentially infectious TB patient at home or in any other location. These precautions 
may include wearing a personal respirator.39  
For more information on infection control, see the Infection Control section. 
Another critical consideration during field investigations is safety. Healthcare workers 
should become familiar with policies and recommendations of local law enforcement 
agencies and health department administration regarding personal safety. Current 
information on local high-risk areas for crime can be very valuable in planning and 
conducting safe field visits.  
General safety precautions that are recommended for the healthcare worker include the 
following:  
 Wearing an identity badge with a current photo  
 Working in pairs when visiting a potentially dangerous area  
 Informing someone of your itinerary and expected time of return, especially if you 
anticipate problems40  
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Contact Priorities 
Assign priorities to contacts, using the registry of contacts compiled from the index 
patient interviews, site visits, interviews with contacts, and information from other 
persons involved in the investigation. The Centers for Disease Control and Prevention 
(CDC) defines the three levels of contact priorities as follows: 
 High-priority contacts 
 Medium-priority contacts 
 Low-priority contacts 
Contact priorities are determined by the likelihood of infection and the potential hazards 
to the individual contact if infected.41 Priority-ranking contacts for investigation is based 
on the characteristics of the index patient, the duration and circumstances of the 
exposure, and the vulnerability/susceptibility of the contacts to disease from 
Mycobacterium tuberculosis infection.42  
Use the assigned priorities to allocate resources to complete all investigative steps for 
the high- and medium-priority contacts.43 Dividing contacts into these three levels 
provides a system for public health staff to reach high-priority contacts first, and then 
medium-priority contacts, and then low-priority contacts. The priority scheme directs 
resources to the following essential actions: 
1. Find contacts who are secondary active tuberculosis (TB) cases. 
2. Find contacts who have recent M. tuberculosis infection—the most likely to benefit 
from treatment. 
3. Select contacts who are most likely to progress to TB disease if they are infected 
(i.e., susceptible contacts) or who could suffer severe morbidity if they had TB 
disease (i.e., vulnerable contacts).44  
 
 
Timely initiation of treatment is especially important for susceptible and 
vulnerable contacts. Refer to Table 3: Time Frames for Contact 
Evaluation and Treatment in the “Time Frames for Contact Investigation” 
topic. 
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Use the tables on the following pages to assign priorities to contacts to the following: 
 Table 6: Prioritization of Contacts to Smear-Positive or Cavitary Cases  
 Table 7: Prioritization of Contacts to Smear-Negative Cases  
 Table 8: Prioritization of Contacts to Cases with Negative Bacteriologic Results 
and Abnormal Chest Radiographs Not Consistent with Tuberculosis  
Index Patient with Positive Acid-Fast Bacilli Sputum 
Smear Results or Cavitary Tuberculosis  
Use Table 6 to prioritize contacts to smear-positive or cavitary index patients.  
Table 6: PRIORITIZATION OF CONTACTS TO SMEAR-POSITIVE OR CAVITARY 
CASES45 
High-Priority Contacts Medium-Priority Contacts Low-Priority Contacts 
• Household contacts 
• Contacts <5 years old 
• Contacts with human 
immunodeficiency virus (HIV) 
infection or other  
immunocompromising 
condition 
• Contacts with exposure during 
a medical procedure such as 
bronchoscopy, sputum 
induction, or autopsy 
• Contacts with exposure in a 
congregate setting 
• Contacts whose exposure 
exceeds duration/environment 
limits per unit time established 
by the health department for 
high-priority contacts*  
• Contacts not in high-priority 
groups 
• Contacts 5–15 years old 
• Contacts whose exposure 
exceeds duration/environment 
limits per unit time established by 
the health department for 
medium-priority contacts* 
 
• Contacts not in high-priority 
groups  
• Contacts not in medium-priority 
groups 
 
 
* Observe environmental characteristics, such as room size, crowding and ventilation, to estimate the risk of 
tuberculosis (TB) transmission: air volume, exhaust rate, and circulation predict the likelihood of transmission in an 
enclosed space.  In large indoor settings, the degree of proximity between contacts and the index patient can 
influence the likelihood of transmission.  The most practical system for grading exposure settings is to categorize 
them by size (e.g., “1” being the size of a vehicle or car, “2” the size of a bedroom, “3” the size of a house, and “4” 
a size larger than a house).  The volume of air shared between an infectious TB patient and contacts dilutes the 
infectious particles.  Local circulation and overall room ventilation also dilute infectious particles, but both factors 
have to be considered because they can redirect exposure into spaces that were not visited by the index patient.46  
Source: CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from 
the National Tuberculosis Controllers Association and CDC. MMWR 2005;54 (No. RR-15):12. 
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Index Patient with Negative Acid-Fast Bacilli Sputum 
Smear Results  
Use Table 7 to prioritize contacts to smear-negative index patients. 
Table 7: PRIORITIZATION OF CONTACTS TO SMEAR-NEGATIVE CASES 47 
High-Priority Contacts Medium-Priority Contacts Low-Priority Contacts 
• Contacts <5 years old 
• Contacts with human 
immunodeficiency virus (HIV)  
infection or other 
immunocompromising 
conditions 
• Contacts exposed during a 
medical procedure such as 
bronchoscopy, sputum 
induction, or autopsy 
 
• Contacts not in high-priority 
groups 
• Household contacts 
• Contacts exposed in a 
congregate setting 
• Contacts whose exposure 
exceeds duration/environment 
limits per unit time established by 
the by the local TB control 
program for medium-priority 
contacts  
 
• Contacts not in high-priority 
groups  
• Contacts not in medium-priority 
groups 
 
 
* Observe environmental characteristics, such as room size, crowding and ventilation, to estimate the risk of 
tuberculosis (TB) transmission: air volume, exhaust rate, and circulation predict the likelihood of transmission in an 
enclosed space.  In large indoor settings, the degree of proximity between contacts and the index patient can 
influence the likelihood of transmission.  The most practical system for grading exposure settings is to categorize 
them by size (e.g., “1” being the size of a vehicle or car, “2” the size of a bedroom, “3” the size of a house, and “4” 
a size larger than a house).  The volume of air shared between an infectious TB patient and contacts dilutes the 
infectious particles.  Local circulation and overall room ventilation also dilute infectious particles, but both factors 
have to be considered because they can redirect exposure into spaces that were not visited by the index patient. 48 
Source: CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from 
the National Tuberculosis Controllers Association and CDC. MMWR 2005;54(No. RR-15):13. 
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Index Patient with Negative Bacteriologic Results and 
Abnormal Chest Radiographs Not Consistent with 
Tuberculosis 
Use Table 8 to prioritize contacts to a suspected case of pulmonary TB who is acid-fast 
bacilli (AFB) sputum smear negative, nucleic acid amplification (NAA) negative, and 
culture negative, and who has abnormal chest radiographs not consistent with TB 
disease. 
Table 8: PRIORITIZATION OF CONTACTS TO CASES WITH NEGATIVE 
BACTERIOLOGIC RESULTS AND ABNORMAL CHEST RADIOGRAPHS NOT 
CONSISTENT WITH TUBERCULOSIS 49 
High-Priority Contacts Medium-Priority Contacts Low-Priority Contacts 
 • Household contacts 
• Contacts <5 years old 
• Contacts with human 
immunodeficiency virus (HIV)  
infection or other medical risk 
factor 
• Contacts exposed during a 
medical procedure such as 
bronchoscopy, sputum induction, 
or autopsy 
• Contacts not in medium-priority 
groups 
 
 
Source: CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from 
the National Tuberculosis Controllers Association and CDC. MMWR 2005;54(No. RR-15):14. 
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Contact Evaluation, Treatment, and  
Follow-up 
Complete evaluation, treatment, and follow-up for high- and medium-priority contacts, as 
specified in your contact investigation plan. The Centers for Disease Control and 
Prevention (CDC) recommends the following: 
 Provide each high- and medium-priority contact an initial assessment that includes a 
face-to-face encounter in which an impression of each contact’s general health is 
formed and a tuberculin skin test (TST) is usually administered.  
 Medically evaluate each high- and medium-priority contact to determine whether 
tuberculosis (TB) disease or latent tuberculosis infection (LTBI) is present or absent.  
 Timely initiation of treatment is especially important for high-priority contacts 
and for contacts likely to progress to TB disease if they are infected (i.e., 
susceptible contacts) or contacts who could suffer severe morbidity if they 
had TB disease (i.e., vulnerable contacts). For recommended time frames, refer to 
Table 3: Time Frames for Contact Evaluation and Treatment in the “Time Frames 
for Contact Investigation” topic. 
 Use the same diagnostic methods for all contacts, except when they have medical or 
constitutional conditions making TB more likely or more difficult to diagnose. A 
contact’s country of origin and Bacille Calmette-Guérin (BCG) vaccination are not 
included in algorithms for diagnosis or treatment. Interpret a positive TST in a 
foreign-born or BCG-vaccinated person as evidence of recent Mycobacterium 
tuberculosis infection in contacts of persons with infectious cases. Evaluate these 
contacts for TB disease and offer them a course of treatment for LTBI.50 
Use the tables on the following pages to determine the evaluation activities for contacts 
in these different risk groups and priority rankings: 
 Table 9: Immunocompromised Contacts and Children Younger than 5  
 Table 10: Immunocompetent Adults and Children 5 and Older (High- and 
Medium-Priority Contacts)  
  Table 11: Contacts with Prior Positive Tuberculin Skin Tests  
 
 
For the evaluation of low-priority contacts, see the “When to Expand a 
Contact Investigation” topic.   
 
During the contact evaluation, treatment, and follow-up, use the ADHS 
Prevention Registry Report available in the forms section. 
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For time frames, see the “Time Frames for Contact Investigation” topic in 
this section. To arrange follow-up with public health officials in other 
jurisdictions for out-of-area contacts, see the Transfer Notifications 
section.51 
Immunocompromised Contacts and Children under 5 
Use Table 9 to select evaluation, treatment, and follow-up activities for contacts who are 
immunocompromised and/or under 5 years old. 
Evaluate contacts who are immunocompromised or under 5 years of age with medical 
history, physical examination, chest radiograph, and tuberculin skin test (TST) or 
interferon gamma release assay (IGRA). Based on the results of these evaluations, take 
the actions in Table 9. 
 
Timely initiation of treatment is especially important for these contacts. 
Refer to Table 3: Time Frames for Contact Evaluation and Treatment in 
the “Time Frames for Contact Investigation” topic. 
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Table 9: EVALUATION, TREATMENT, AND FOLLOW-UP OF IMMUNOCOMPROMISED 
CONTACTS AND CHILDREN UNDER 5 YEARS OLD52 
If evaluation or test results  
show that a contact has 
 
Then take this action or these actions 
Symptoms consistent with TB disease  
and/or 
Abnormal chest radiograph 
Fully evaluate for TB disease 
1st TST* ≥5 mm 
 
Complete a full course of treatment for LTBI 
1st TST  <5 mm 
and 
≥8 weeks since last exposure  
• If not HIV-infected, no further evaluation required 
 
• If HIV-infected, no further evaluation required; consider 
a full course of treatment for LTBI 
1st TST  <5 mm 
and 
 <8 weeks since last exposure 
Begin treatment for LTBI and retest 8–10 weeks post 
exposure 
2nd TST  ≥5 mm Complete a full course of treatment for LTBI 
 
 
 
 
 
No symptoms 
consistent with 
TB disease 
and  
normal chest 
radiographs 
2nd TST  <5 mm • If not HIV-infected, no further evaluation required 
 
• If HIV-infected, no further evaluation required; consider 
a full course of treatment for LTBI 
Definitions of abbreviations: HIV = human immunodeficiency virus; IGRA = interferon gamma release assay; LTBI = latent 
tuberculosis infection; TB = tuberculosis; TST = tuberculin skin test. 
*  Note: An IGRA may be used in place of a TST. 
Source: CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from 
the National Tuberculosis Controllers Association and CDC, and guidelines for using the QuantiFERON®-TB Gold test 
for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005;54(No. RR-15):15–16. 
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Immunocompetent Adults and Children 5 and Older 
(High- and Medium-Priority Contacts) 
Use Table 10 to select evaluation, treatment, and follow-up activities for high- and 
medium-priority contacts who are immunocompetent and/or 5 years of age or older.  
Evaluate high- and medium-priority contacts who are immunocompetent and/or 5 years 
of age or older, with medical history, exposure history, and tuberculin skin test (TST) or 
interferon gamma release assay (IGRA). Based on the results of these evaluations, take 
the actions in Table 10. 
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Table 10: EVALUATION, TREATMENT, AND FOLLOW-UP OF IMMUNOCOMPETENT 
ADULTS AND CHILDREN 5 YEARS AND OLDER (HIGH- AND MEDIUM-PRIORITY 
CONTACTS)53 
If evaluation or test results show that a 
contact has 
Then take this action or these actions 
Symptoms consistent with TB disease Fully evaluate for TB disease 
No symptoms 
consistent with 
TB disease 
1st TST* ≥5 mm 
 
Evaluate with a physical examination and CXR: 
• If CXR abnormal, fully evaluate for TB disease 
• If CXR normal, complete a full course of treatment for 
LTBI 
No symptoms 
consistent with 
TB disease 
1st TST <5 mm 
and 
8–10 weeks since last 
exposure  
No further evaluation or treatment required 
No symptoms 
consistent with 
TB disease 
1st TST <5 mm 
and 
 <8 weeks since last 
exposure 
Retest 8–10 weeks post exposure 
No symptoms 
consistent with 
TB disease 
2nd TST ≥5 mm Evaluate with a physical examination and CXR: 
• If CXR abnormal, fully evaluate for TB disease 
• If CXR normal, complete a full course of treatment for 
LTBI 
No symptoms 
consistent with 
TB disease 
2nd TST <5 mm No further evaluation or treatment required 
Definitions of abbreviations: CXR = chest radiograph; IGRA = interferon gamma release assay; LTBI = latent tuberculosis 
infection; TB = tuberculosis; TST = tuberculin skin test. 
*  Note: An IGRA may be used in place of a TST. 
Source: CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from 
the National Tuberculosis Controllers Association and CDC, and guidelines for using the QuantiFERON®-TB Gold test 
for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005;54(No. RR-15):17. 
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Contacts with Prior Positive Tuberculin Skin Tests  
Use Table 11 to select evaluation, treatment, and follow-up activities for contacts who 
have prior positive TSTs. 
For contacts with prior positive TSTs, evaluate them with medical and exposure history. 
Based on these histories, take the actions in Table 11. 
Table 11: EVALUATION, TREATMENT, AND FOLLOW-UP OF CONTACTS WITH PRIOR 
POSITIVE TUBERCULIN SKIN TESTS 54 
If evaluation or test results show that a 
contact has 
Then take this action or these actions 
 
Symptoms consistent with TB disease Fully evaluate for TB disease 
No symptoms 
consistent with 
TB disease 
Immunocompromised  
or  
<5 years old 
Evaluate with a physical examination and CXR: 
• If CXR or physical examination is indicative of TB disease, 
fully evaluate for TB disease 
• If results are not indicative of TB disease:  
 If contact previously completed treatment, consider 
retreatment 
 If treatment not completed previously, complete a full 
course of LTBI treatment 
No symptoms 
consistent with 
TB disease 
Immunocompetent  
and  
≥5 years old 
 
• If contact previously completed treatment for LTBI, no further 
evaluation or treatment required 
 
• If contact has not completed treatment for LTBI, consider 
treatment for LTBI 
Definitions of abbreviations: CXR = chest radiograph; LTBI = latent tuberculosis infection; TB = tuberculosis. 
Source: CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from 
the National Tuberculosis Controllers Association and CDC, and guidelines for using the QuantiFERON®-TB Gold test 
for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005;54(No. RR-15):19. 
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When to Expand a Contact Investigation  
Guidelines for Expanding an Investigation 
Determine when to expand a contact investigation using the following guidelines: 
1. Do not include lower-priority contacts unless objectives for high- and medium-priority 
contacts are being met.  
2. Consider the extent of recent transmission.  
3. Consider expanding the scope (e.g., number of contacts) of an investigation if any 
one or more of the following criteria are met:  
a. Unexpectedly large rate of tuberculosis (TB) infection or disease in high-priority 
contacts: 10% or at least twice the rate of a similar population without recent 
exposure, whichever is greater 
 
Since the background prevalence of tuberculosis infection in adult foreign-born 
populations from high-incidence countries often exceeds 30%, it is important to 
stratify the infection rates by country of birth and/or length of residence and by 
age. For example, household contacts with a positive tuberculin skin test (TST) 
results are more likely to be infected recently (or as a result of exposure to the 
index patient) if the contacts are U.S.-born children rather than adults born in 
high-incidence countries.  
b. Evidence of second-generation transmission (i.e., from TB patients who were 
infected after exposure to the source patient) 
c. TB disease in any contacts who had been assigned low priority  
d. Infection in any contacts younger than 5 years old  
e. Contacts with change in TST status from negative to positive  
 When results from an investigation indicate that it should be expanded, but 
resources are insufficient, seek assistance from the next higher public health 
administrative level.  
In general, without evidence of recent transmission, do not expand an investigation to 
lower-priority contacts. When program evaluation objectives have not been met, expand 
a contact investigation only in exceptional circumstances, generally involving highly 
infectious cases with high rates of infection among contacts or evidence for secondary 
cases and secondary transmission. Derive the strategy for expanding an investigation 
from the data obtained from the investigation to that point in time. Without data from the 
initial contact investigation to support evidence of transmission, there is little support to 
expand to lower-priority contacts. As in the initial investigation, review the incoming 
results of the expanded investigation at least weekly to reassess the strategy.  
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Sometimes the result from an investigation indicates a need for expansion, but 
resources do not permit this. In these situations, seek consultation and assistance from 
the next higher level in public health administration (e.g., the county health department 
consults with the state health department). Consultation offers an objective review of 
strategy and results, additional expertise, and the potential for personnel or funds for 
meeting needs.  
 
Contact the Arizona Department of Health Services TB Program at 602-
364-4750 to consult about expanding a contact investigation. 
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Low-Priority Contacts  
Use Table 12 to select evaluation, treatment, and follow-up activities for low-priority 
contacts.  Evaluate low-priority contacts with medical and exposure history. Based on 
these histories, take the actions in the Table 12. 
Table 12: EVALUATION, TREATMENT, AND FOLLOW-UP OF  
LOW-PRIORITY CONTACTS 55 
 
If evaluation or test results show  
that a contact has 
 
Then take this action or these actions: 
Symptoms consistent with TB disease Fully evaluate for TB disease 
No symptoms 
consistent with 
TB disease 
8–10 weeks since last 
exposure  
Evaluate with a TST 
No symptoms 
consistent with 
TB disease 
<8 weeks since last 
exposure  
Wait 8–10 weeks after last exposure, and then evaluate with a 
TST 
No symptoms 
consistent with 
TB disease 
1st TST* ≥5 mm 
 
Evaluate with physical examination and CXR: 
• If CXR is abnormal, fully evaluate for TB disease 
• If CXR is normal, consider treatment for LTBI 
No symptoms 
consistent with 
TB disease 
1st TST <5 mm 
 
No further evaluation or treatment required 
Definitions of abbreviations: CXR = chest radiograph; IGRA = interferon gamma release assay; LTBI = latent tuberculosis 
infection; TB = tuberculosis; TST = tuberculin skin test. 
*  Note: An IGRA may be used in place of a TST. 
Source: CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from 
the National Tuberculosis Controllers Association and CDC, and guidelines for using the QuantiFERON®-TB Gold test 
for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005;54(No. RR-15):22. 
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Data Management and Evaluation of 
Contact Investigations  
Data collection related to contact investigations has three broad purposes:  
1. Management of care and follow-up of individual index patients and contacts  
2. Epidemiological analysis of an investigation in progress and overall investigations  
3. Program evaluation via performance indicators that reflect performance objectives 
Reasons Contact Investigation Data Are Needed  
Comprehensive Care 
For each index patient and the associated contacts, a broad amount of demographic, 
epidemiological, historical, and medical information are needed for providing 
comprehensive care. The care for these individuals can extend to longer than a year in 
some instances, so the information builds stepwise and has numerous longitudinal 
elements (e.g., clinic visits attended, treatment doses administered, and bacteriological 
response to treatment).  
Timeline Objectives 
Many of these data elements also contribute to the other reasons for collecting data. 
Data on some process steps are necessary for monitoring whether the contact 
investigation is keeping to the timeline objectives (e.g., how soon after listing is the 
tuberculin skin test (TST) administered to a contact).  
Completion of Investigation 
When aggregated, the data from an investigation inform public health officials as to 
whether the investigation is on time and complete. The analysis of data also contributes 
to reassessments of the strategy used in the investigation (e.g., was the infection rate 
greater for contacts believed to have more exposure?).  
Reassessment of Strategy 
The data from a completed investigation and all investigations in a fixed period (e.g., six 
months) show the achievements in meeting program objectives, such as observance of 
timelines and completion of therapy for infected contacts. These core measurements for 
program evaluation, however, cannot directly show why objectives were not met. If the 
data are structured and stored in formats allowing detailed retrospective review, then the 
reasons for problems can be studied.  
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CDC’s “Framework of Program Evaluation in Public Health” (MMWR 
1999;48[No. RR-11]), at 
ftp://ftp.cdc.gov/pub/Publications/mmwr/rr/rr4811.pdf , is recommended for 
assessing the overall activities of contact investigations. 
Approach 
Follow a systematic, consistent approach to data collection, organization, analysis, and 
dissemination.  
1. Collect specific data elements on index patients and their contacts. The data 
elements should permit calculation of program performance indices.  
2. Collect data on standardized (paper or electronic) forms.  
3. Supply data definitions and formats for use by persons who collect, use, and 
interpret contact investigation data.  
4. Whenever feasible, use data definitions and formats that are standard among 
jurisdictions.  
5. Store data electronically for quick analysis of interim results.  
6. Implement policies for data management that enable quick analysis of interim 
results.  
7. Implement policies for data management and storage that specify the assignment of 
responsibilities.  
8. Implement training and policies for data accuracy, completeness, and security.  
9. Periodically summarize and review data during a particular contact investigation and 
for overall contact investigations.  
10. Evaluate programs for contact investigation activities at least annually. Evaluation is 
an integral part of TB program responsibility.  
11. Beyond standard data elements shown in these guidelines, specific additional 
elements can contribute to local program management.  
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Index Patient and Contact Data  
Use the Report of Verified Case of Tuberculosis Form to collect the data each 
index patient and the ADHS Prevention Registry Form to collect the data on 
individual contacts.  
Evaluation of a Contact Investigation  
Statewide contact investigation data are compiled and summarized by the Arizona TB 
Program and provided to the Centers for Disease Control and Prevention (CDC) for 
national surveillance purposes.  The data are also used to evaluate local and state 
program activities.  The Arizona TB Program provides summarized contact investigation 
data to the CDC using the Aggregate Report for Program Evaluation (ARPE) form. 56  In 
addition, the CDC’s Framework for Program Evaluation in Public Health is 
recommended for assessing the overall activities of contact investigations. 57  
 
For information about the ARPE form, see the CDC’s Aggregate Reports 
for Tuberculosis Program Evaluation: Training Manual and User’s Guide. 
(Atlanta, GA: US Department of Health and Human Services, CDC; 2005) 
at http://www.cdc.gov/tb/pubs/PDF/ARPEs_manual.pdf . 
 
For more information on using this evaluation framework, see the CDC 
Program Evaluation Workgroup’s Web site at 
http://www.cdc.gov/eval/framework.htm . 
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Outbreak Investigation 
If data from a contact investigation or surveillance indicate a potential outbreak, conduct 
an outbreak investigation. A tuberculosis (TB) outbreak warns of potential extensive 
transmission. An outbreak implies that 1) a TB patient was contagious, 2) contacts were 
exposed significantly, and 3) the interval since exposure has been sufficient for infection 
to progress to disease. An outbreak investigation involves several overlapping contact 
investigations, with a surge in the need for public health resources. More emphasis on 
active case finding is recommended, which sometimes means that more contacts than 
usual should have chest radiographs and specimen collection for mycobacteriology. 
Definition of a Tuberculosis Outbreak 
Definitions for TB outbreak are relative to the local context. Outbreak cases can be 
distinguished from other cases only when certain associations in time, location, patient 
characteristics, or Mycobacterium tuberculosis attributes (e.g., drug resistance or 
genotype) become apparent. In low-incidence jurisdictions, any temporal cluster is 
suspicious for an outbreak. A working definition of a potential TB outbreak is helpful for 
planning and response, and may include any of the following six criteria:  
Criteria based on surveillance and epidemiology:  
1. An increase has occurred above the expected number of TB cases 
2. During and because of a contact investigation, two or more contacts are identified as 
having TB disease, regardless of their assigned priority (i.e., high, medium, or low 
priority) 
3. Any two or more cases occurring within one year of each other are discovered to be 
linked, and the linkage is established outside a contact investigation (e.g., two 
patients who received a diagnosis of TB disease outside a contact investigation are 
found to work in the same office and only one or neither of the persons was listed as 
a contact to the other) 
4. A genotype cluster leads to discovery of one or more verified transmission links that 
were missed during a contact investigation within the prior two years 
Criteria based on program resources:  
 Transmission is continuing despite adequate control efforts by the TB control 
program  
 Contact investigation associated with increased cases requires additional outside 
help 
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Deoxyribonucleic Acid Genotyping 
Deoxyribonucleic acid (DNA) genotyping is a laboratory technique used by public health 
officials during a TB outbreak to distinguish between different strains of M. tuberculosis 
and to help assess the likelihood of TB transmission. Characterization of M. tuberculosis 
with DNA genotyping is a powerful tool for the following: 
1. Surveillance of potential outbreaks  
2. Confirming TB cases linked by traditional epidemiologic methods  
3. Identifying clusters of patients infected with genetically related or identical strains of 
M. tuberculosis and determining common sources of infections  
4. Guiding contact investigations and the appropriate use of preventive therapy  
5. Identifying laboratory cross-contamination as the cause of misdiagnosis  
When used to track the transmission of a specific strain, DNA genotyping can help 
assess the effectiveness of TB control programs, a particularly useful methodology for 
areas with low TB incidence as the United States approaches TB elimination. 
Confirm the linkage between cases by genotyping results if isolates have been obtained. 
An outbreak increases the urgency of investigations and will put greater demands on the 
health department. Therefore, corroborate a suspected linkage between cases by 
genotyping results before intensifying an investigation. An epidemiologic investigation is 
required for determining probable transmission linkages even if genotypes match. 
Any secondary case that is unexpectedly linked to a known index patient represents a 
potential failure in the contact investigation; in such cases, reassess the original 
investigation to determine whether the strategy for finding contacts was optimal and 
whether the priorities were valid. If a secondary case occurred because treatment for a 
known contact with latent tuberculosis infection (LTBI) was not started or completed, 
then review the strategies for treatment and completion. 
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Resources and References 
Resources 
 
 California Department of Health Services (CDHS)/California Tuberculosis Controllers 
Association (CTCA).  “Contact Investigation Guidelines” (CDHS/CTCA Joint 
Guidelines; 1998). Available at: 
http://www.ctca.org/guidelines/IID1contactinvestigation.pdf . 
 CDC. Aggregate Reports for Tuberculosis Program Evaluation: Training Manual and 
User’s Guide (Atlanta, GA; 2005). Available at: 
http://www.cdc.gov/tb/pubs/PDF/ARPEs_manual.pdf . 
 CDC. Effective TB Interviewing for Contact Investigation: Self-Study Modules. 
(Atlanta, GA; 2006). Available at: 
http://www.cdc.gov/tb/pubs/Interviewing/default.htm.  
 CDC. “Guidelines for the Investigation of Contacts of Persons with Infectious 
Tuberculosis: Recommendations from the National Tuberculosis Controllers 
Association and CDC” (MMWR 2005;54 [No. RR-15]). Available at:  
http://www.cdc.gov/mmwr/pdf/rr/rr5415.pdf . 
 CDC. “Goal II: accelerate the decline“ (CDC’s Response to Ending Neglect: The 
Elimination of Tuberculosis in the United States). Available at: 
http://www.cdc.gov/tb/pubs/iom/iomresponse/goal2.htm . 
 CDC Evaluation Workgroup. Framework for Program Evaluation (CDC Web site). 
Available at: http://www.cdc.gov/eval/framework.htm .  
 New Jersey Medical School National Tuberculosis Center. Performance Guidelines: 
A Supervisor’s Guide for the Development and Assessment of TB Field Investigation 
Skills (New Jersey Medical School Global Tuberculosis Institute Web site; 2004). 
Available at: http://www.umdnj.edu/globaltb/products/performanceguide.htm . 
 New Jersey Medical School National Tuberculosis Center. Performance Guidelines 
for Contact Investigation: The TB Interview (New Jersey Medical School Global 
Tuberculosis Institute Web site). Available at: 
http://www.umdnj.edu/globaltb/products/tbinterview.htm . 
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Introduction 
Purpose 
Use this section to  
 Get contact information for laboratories; 
 Determine which tests are available and the tests’ turnaround times; and 
 Identify which laboratory can perform a specific test. 
The diagnosis of tuberculosis (TB), management of patients with the disease, and public 
health TB control services rely on accurate laboratory tests. Laboratory services are an 
essential component of effective TB control, providing key information to clinicians (for 
patient care) and public health agencies (for control services).1 
Policy  
Public health laboratories should ensure that clinicians and public health agencies within 
their jurisdictions have ready access to reliable laboratory tests for diagnosis and 
treatment of TB.2 
Effective TB control requires timely, complete, and accurate communication among the 
laboratory system, TB control program, and healthcare provider.3 
 
For roles and responsibilities, refer to the “Roles, Responsibilities, and 
Contact Information” topic in the Introduction. 
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State Laws and Regulations 
Arizona Laws/Rules Regarding Tuberculosis Control 
Arizona Revised Statutes.  Title 36:  Public Health and Safety; Chapter 6:  
Public Health Control; Title 6:  Tuberculosis Control.  (ARS§36-711 
through §36-738)  
ARS§36-711.  Definitions.   
ARS§36-712. Administration by the department.   
ARS§36-714.  Tuberculosis control officer.   
ARS§36-715.  Costs; removals; proceedings.   
ARS§36-716.  Payment of assistance.   
ARS§36-717.  Responsibility for care or treatment by counties.   
ARS§36-718.  Contracting for care of afflicted persons.   
ARS§36-721.  Rules.   
ARS§36-723.  Investigation of tuberculosis cases.   
ARS§36-724.  Voluntary control measures.   
ARS§36-725.  Orders to cooperate; emergency custody.    
ARS§36-726.  Petition for court ordered examination, monitoring, 
treatment, isolation or quarantine.   
ARS§36-727. Hearings; procedure; confidentiality.   
ARS§36-728. Judicial action.   
ARS§36-729. Amended orders for intervention and transport of afflicted 
persons.   
ARS§36-730.  Appointment of guardian or conservator.   
ARS§36-731.  Confinement; selection; jails; prohibition.   
ARS§36-732.  Early release from court ordered treatment.   
ARS§36-733.  Choice of physician and mode of treatment.   
ARS§36-734.  Treatment; exemption.   
ARS§36-735.  Notification of rights.   
ARS§36-736.  Administrative procedures act; judicial review of 
administrative procedures; exemption; appeals.  
ARS§36-737.  Violation; classification.   
ARS§36-738.  Qualified immunity.   
 
Arizona Administrative Code.  Title 9. Chapter 6.  Department of 
Health Services Communicable Diseases and Infestations.   
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 Laboratory Contact Information 
To locate and contact a laboratory, refer to Table 1: Laboratory Contact Information. 
For the list of the tests performed at each laboratory, refer to Table 2: Available 
Laboratory Tests. 
Table 1: LABORATORY CONTACT INFORMATION 
Roles and Responsibilities Contact Information 
State Laboratory  
Provides consultation as needed and  
 
Arizona State Laboratory 
250 N. 17th Avenue 
Phoenix, AZ 85007 
(602) 542-1188 
(602) 542-0760 Fax 
Private Laboratories 
To be used as determined by specific contracts 
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Available Laboratory Tests 
The following laboratory tests are available: 
Table 2: AVAILABLE LABORATORY TESTS  
Test Laboratory Turnaround Time  
Diagnosis 
QuantiFERON®-TB Gold  
(QFT-G) 
    Contact Maricopa Medical Center at:     
602-344-5240 
  
    For additional sites go to: 
www.quantiferon.com 
    Up to two weeks 
    Acid-fast (AFB) bacilli smear     Arizona State Laboratory Within 24 hours from receipt 
in laboratory4
Culture Arizona State Laboratory Mycobacterial growth 
detection by culture within 
14 days from date of 
specimen collection 
Identification of cultured 
mycobacteria within 21 days 
from date of specimen 
collection5,6  
Drug susceptibility Arizona State Laboratory Within 30 days from date of 
specimen collection7,8  
Nucleic acid amplification 
(NAA) test 
Arizona State Laboratory Within 2 days from date of 
specimen collection9,10 
 
Treatment Monitoring 
Hepatic enzymes or up to 8 
clinical, multichannel chem 
panel (that includes aspartate 
aminotransferase [AST], 
alanine aminotransferase 
[ALT], lactate dehydrogenase 
[LDH], total and direct bilirubin, 
alkaline phosphatase, uric acid, 
and calcium) 
Contracted laboratory     varies 
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Test Laboratory Turnaround Time  
Uric acid  Contracted laboratory varies 
Complete blood count (CBC) 
and platelets 
Contracted laboratory varies 
Kidney function Contracted laboratory varies 
 Epidemiologic Monitoring 
Genotyping Arizona State Laboratory sends the 
specimen out to the appropriate 
laboratory 
varies 
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Laboratories should report positive smears or positive cultures, and primary healthcare 
providers should report suspected or confirmed cases of TB to the health department, as 
specified in the “Reporting Tuberculosis” topic in the Surveillance section (Chapter 2.11). 
Prompt reporting allows the health department to organize treatment and case 
management services and to initiate a contact investigation as quickly as possible.11 
For information on reporting, see the “Reporting Tuberculosis” topic in the 
Surveillance section. 
 
For laboratory services available in Arizona contact the Arizona TB Control 
Program at 602-364-4750.   
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Specimen Collection  
Sputum is phlegm from deep in the lungs. The important characteristics needed in 
sputum specimens are freshness and actual sputum, rather than saliva. An early 
morning specimen is best, so when collecting a set of three sputum specimens, at least 
one of them should be an early morning specimen.  
To isolate mycobacteria from clinical materials successfully, handle specimens carefully 
after collection. For optimal results, collect specimens in clean, sterile containers and 
keep them in conditions that inhibit the growth of contaminating organisms, since most 
specimens will contain bacteria other than mycobacteria.12  
Refer to Table 3 to review the methods used to collect various specimens and the type 
of specimens obtained for pulmonary tuberculosis (TB).  
 
During procedures in which aerosols may be produced, use appropriate 
respiratory protection and environmental controls. For more information, refer 
to the CDC’s “Guidelines for Preventing the Transmission of Mycobacterium 
tuberculosis in Health-care Settings, 2005” (MMWR 2005;54[No. RR-17]) at  
http://www.cdc.gov/mmwr/pdf/rr/rr5417.pdf . 
Table 3: SPECIMEN COLLECTION METHODS AND TYPES  
FOR PULMONARY TUBERCULOSIS 
Pulmonary Tuberculosis  
Collection Method Specimen Type 
Spontaneous sputum collection occurs when the 
patient can cough up sputum without extra assistance. 
 5–10 ml of sputum from deep in the lung 
Induced sputum collection should be considered if a 
patient needs assistance in bringing up sputum.* 
 5–10 ml of sputum from deep in the lung 
Gastric aspirates can be submitted for the diagnosis of 
pulmonary tuberculosis (TB) in young children who 
cannot produce sputum (make sure to alkalinize the 
specimen) 
 50 ml of gastric contents 
Bronchoscopy can be used in the following situations:  
 If a patient cannot produce sputum by the above 
three methods13 or 
 If a patient has a substantial risk of drug-resistant TB 
and has initial routine studies that are negative14 or 
 In a patient in whom there is suspicion of 
endobroncheal TB15 or 
 Bronchial washings 
 Bronchoalveolar lavage 
 Transbronchial biopsy 
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 If a variety of clinical specimens for the diagnosis of 
pulmonary TB or other possible diseases need to be 
obtained 
* It is important to specify if the sputum is induced or not, because induced sputum is “more watery” and appears to 
be just saliva. Some laboratories may throw out induced sputum and report it as an inadequate specimen. 
Refer to Table 4 for collection methods and specimen types for extrapulmonary TB. 
Table 4: SPECIMEN COLLECTION METHODS AND TYPES 
FOR EXTRAPULMONARY TUBERCULOSIS 
Extrapulmonary Tuberculosis  
Collection Method Specimen Type 
Extrapulmonary specimen collection from tissue and 
other body fluids can be submitted for the diagnosis of 
extrapulmonary tuberculosis. 
Examples of tissues 
(biopsy)* 
 Lymph node 
 Pleural 
 Bone/joint 
 Kidney 
 Peritoneal 
 Pericardial 
 
Examples of  
fluids 
 Pleural 
 Cerebrospinal  
 Blood 
 Urine 
 Synovial 
 Peritoneal 
 Pericardial 
* Do not place specimens in formalin. 
How to Perform Spontaneous Sputum Collection at a 
Healthcare Facility 
1. Collect the specimen in a specialized room or booth designed for cough-inducing 
procedures. 
2. Instruct the patient on how to collect the sputum sample.  
a. Put a mark at the 5 ml level on the sputum tube (if not already marked) to show 
the patient the minimum amount of sputum needed. (Most laboratories consider 
5 to 10 ml an adequate amount.)  
b. Review with the patient how to collect sputum.  
3. Make sure the specimen container and laboratory requisition are filled out completely 
before shipping.  
a. On the specimen container, record the patient name and the date and time of 
collection. 
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b. Use the appropriate laboratory form.  
 
It is especially important to specify if the sputum is induced or not, 
because an induced sputum generally is “more watery” and appears to be just 
saliva. Some private laboratories may throw out the specimen and report it as 
an “inadequate specimen.”  
4. Make sure the specimen and laboratory requisition are packaged into appropriate 
shipping containers, per laboratory instructions.  
Refer to the “Specimen Collection and Shipment Supplies” topic in the 
Supplies, Materials, and Services section, and see the “Specimen Shipment 
topic,” which follows. 
5. If possible, send the specimen on the day it is collected. If this is not possible, 
refrigerate the specimen until it is sent on the next day.  
6. Do not keep specimens to send all three on the same day.  
7. Use the most rapid transport to the laboratory: yourself, courier, overnight carrier, or 
US mail.  
 
Make every effort to submit specimens to the laboratory within 24 hours of 
collection. Normal flora can overgrow any mycobacteria in the specimen and 
make it unusable. If specimens cannot be submitted within 24 hours, keep in 
mind that most laboratories will not run a specimen over five days old. Know 
how long it takes the specimen to get to the laboratory from the time it leaves 
your hands, and submit specimens accordingly. 
How to Direct a Patient to Perform Spontaneous 
Sputum Collection at Home 
If a patient will be collecting sputum specimens at home, provide the following guidance. 
1. Put a mark at the 5 ml level on the sputum tubes (if not already marked) to show the 
patient the minimum amount of sputum needed. (Most laboratories consider 5 to 10 
ml an adequate amount.)  
2. Review with the patient how to collect sputum.  
3. Make arrangements for a healthcare worker to pick up the specimen or for the 
patient, a family member, or a friend to drop off the specimen. 
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Induced Sputum Collection at a Healthcare Facility  
If the patient cannot produce sputum spontaneously, then make arrangements for an 
induced sputum to be collected at a facility. Facilities where sputum can be collected 
include the respiratory therapy department of a local hospital, TB clinic, or laboratory. 
Facilities should have appropriate respiratory protection, environmental controls, and 
policies and procedures. 
How to Collect Gastric Aspirates  
The following are basic guidelines for collecting gastric aspirates: 
 Collect the specimen after the patient has fasted for 8 to 10 hours and, preferably, 
while the patient is still in bed.  
 Collect a specimen daily for three days.  
 Make sure the specimen is alkalinized at the time of collection. 
 
For additional information on how to collect a gastric aspirate and prepare the 
specimen for transport, see the guide and Francis J. Curry National 
Tuberculosis Center’s online video Pediatric TB: A Guide to the Gastric 
Aspirate (GA) Procedure at  
http://www.nationaltbcenter.edu/products/product_details.cfm?productID=ONL
-06 . 
Bronchoscopy or Collection of Extrapulmonary 
Specimens 
If TB staff are consulting with physicians before the specimens are collected, the 
physician should be reminded to send part of the specimen (not in formalin) to the 
microbiology laboratory for acid-fast bacilli (AFB) smear and culture, in addition to any 
other tests or pathology examinations the physician plans to obtain. In addition, a post-
bronchoscopy sputum specimen should be sent for AFB smear and culture. 
 Bronchoscopy: Refer the patient to a local specialist.  
 Extrapulmonary specimens: These specimens will be collected by the physician 
performing the diagnostic work-up.  
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Specimen Shipment 
There are three main categories of transportation methods: medical couriers, ground 
transportation, and air transportation. Category B Infectious Substances (raw diagnostic 
specimens, such as sputum, blood, or tissue) can be mailed through the US Postal 
Service (USPS), shipped by private carrier (e.g., Federal Express, Airborne Express, 
etc.), or transported by a medical courier. Pure mycobacterial cultures (or culture 
isolates suspected of being mycobacteria) are Category A Infectious Substances and 
can be transported only by a medical courier or shipped by private carrier as dangerous 
goods. Category A Infectious Substances cannot be mailed through the US Postal 
Service. Each category requires different packaging requirements to provide increased 
levels of protection against leaks and contamination.  
Shipment of dangerous goods by USPS is regulated by the US Department of 
Transportation. Specific shipping instructions from the Centers for Disease Control and 
Prevention (CDC) can be found in the publication by the US Department of Health and 
Human Services (DHHS) Public Health Mycobacteriology: A Guide for the Level III 
Laboratory. Packaging and shipment of specimens by USPS should meet the following 
regulations: 
 Public Health Service/CDC: 42 CFR, Part 72—Interstate Shipment of Etiologic 
Agents at http://www.cdc.gov/od/ohs/biosfty/shipregs.htm  
 USPS: 39 CFR and USPS Domestic Mail Manual C023.1.1, International Mail 
Manual 135, and USPS Publication 52 
 US Department of Transportation: 49 CFR, Parts 171–180 (August 14, 2002) at  
http://www.access.gpo.gov/nara/cfr/waisidx_04/49cfrv2_04.html  
 The Department of Labor, Occupational Safety and Health Administration (OSHA): 
29 CFR 1910.103016 
For shipments by private carriers, follow International Air Transportation Association 
(IATA) instructions. Mycobacterium tuberculosis pure cultures are defined as infectious 
substances/etiologic agents when shipped by private carrier and must be shipped in 
packaging approved by the United Nations (UN), according to IATA Packing Instruction 
602. Diagnostic specimens are defined as human or animal specimens, including 
excreta, secreta, blood and its components, tissue, tissue fluids, and cultures of 
nontuberculous mycobacteria being transported for diagnostic or investigational 
purposes. Diagnostic specimens must be packaged according to IATA Packing 
Instruction 650.17  
Refer to the shipping regulations that are listed under “Resources and References” at 
the end of this section. Personnel who handle, package, and ship infectious materials 
must be trained in these procedures.  
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For more information, contact the State of Arizona Laboratory at (602) 542-
1188. 
 
To obtain specimen collection and transport supplies, see the topic on 
“Specimen Collection and Shipment Supplies” in the Supplies, Materials, and 
Services section. 
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Resources and References 
Resources for Laboratory Services 
Detailed descriptions of recommended laboratory tests; recommendations for their 
correct use; and methods for collecting, handling, and transporting specimens have 
been published.  
For more information on laboratory testing for tuberculosis (TB), see the following: 
 ATS, CDC, IDSA. “Controlling Tuberculosis in the United States: Recommendations 
from the American Thoracic Society, CDC, and the Infectious Diseases Society of 
America” (MMWR 2005;54[No. RR-12]). Available at: 
http://www.cdc.gov/mmwr/PDF/rr/rr5412.pdf . 
 ATS, CDC, IDSA. “Diagnostic Standards and Classification of Tuberculosis in Adults 
and Children” (Am J Respir Crit Care Med 2000;161[4 Pt 1]). Available at:   
http://www.cdc.gov/tb/pubs/PDF/1376.pdf . 
 National Committee for Clinical Laboratory Standards. Susceptibility Testing of 
Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard 
[Document no. M24-A] (Wayne, PA; 2003).  
Resources for Specimen Collection and Shipment 
 CDC. “Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in 
Health-care Settings, 2005” (MMWR 2005;54[No. RR-17]). Available at:  
http://www.cdc.gov/mmwr/pdf/rr/rr5417.pdf . 
 CDC. Public Health Mycobacteriology: A Guide for the Level III Laboratory (Atlanta, 
GA; 1985). 
 Francis J. Curry National Tuberculosis Center. Pediatric TB: A Guide to the Gastric 
Aspirate (GA) Procedure (Francis J. Curry National Tuberculosis Center Web site). 
Available at:  
http://www.nationaltbcenter.edu/products/product_details.cfm?productID=ONL-06 . 
 International Air Transport Association (IATA). IATA Web site. Available at: 
http://www.iata.org/index.htm . 
 National Jewish Medical and Research Center. How to Mail Specimens and Cultures 
to the National Jewish Mycobacteriology Laboratory (Denver, CO: March 2005). 
 National Jewish Medical and Research Center. Instructions (for Patients) for 
Collecting and Mailing Sputum Specimens (Denver, CO: March 2005). 
 National Tuberculosis Controllers Association—National Tuberculosis Nurse 
Consultant Coalition. Tuberculosis Nursing: A Comprehensive Guide to Patient Care 
(Atlanta, GA; 1997):39–42.  
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 US Department of Transportation. Hazardous Materials: Revision to standards for 
infectious substances. Part III 49 CFR Part 171. Federal Register (August 14, 2002).   
 USPS. Mailing Standards of the United States Postal Service: Domestic Mail Manual 
(USPS Web site). Available at: http://pe.usps.com/  
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Introduction 
Purpose 
Use this section to  
 Determine what information to cover in education sessions; 
 Educate patients about tuberculosis (TB); 
 Educate patients about latent TB infection (LTBI); and 
 Identify which forms to use to document education efforts. 
 An important part of helping patients take their medicine is educating them about TB. 
This means talking to them about the cause of TB, the way TB is spread, how TB is 
diagnosed, and their specific treatment plan.1 Patients cannot be expected to adhere to 
treatment recommendations if they are not educated about TB and how it is treated, and 
patients who understand these concepts are more likely to adhere to treatment.  
Patients with LTBI need to understand that they are infected with TB, that they may have 
specific risks for progressing to TB disease, and that they can take precautions to 
protect themselves, their family, and their friends. Patients with TB disease need to 
understand the seriousness of the disease and why it is important to adhere to 
treatment. In order to prevent relapse and drug resistance, clinicians must prescribe an 
adequate regimen and make sure that patients adhere to treatment.2 To ensure 
completion of treatment, the public health department should thoroughly educate the 
patient, monitor the patient’s adherence, and use incentives and enablers.3,4,5 
Policy 
The Arizona Department of Health Services uses the CDC guidelines in regards to the 
content for TB education that should be provided to patients with TB disease and LTBI 
(see resources at the end of this chapter).  
 
For roles and responsibilities, refer to the “Roles, Responsibilities, and 
Contact Information” topic in the Introduction. 
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General Guidelines  
Table 1: GUIDELINES FOR THE EDUCATIONAL PROCESS 
When Educating Tuberculosis Patients 
Do Don’t 
 Find out what patients know and believe about 
tuberculosis (TB). Reinforce and provide correct 
TB information, and educate them of any 
misconceptions. 
 Use good skills to interview and influence patients, 
and to problem solve. 
 Go through the educational material with patients. 
Use language appropriate to their level of 
understanding. If necessary, use an interpreter.  
 
 Flood patients with information about TB and its 
effects without allowing them to participate in the 
discussion. 
 Hand out pamphlets and brochures to patients 
without going through the materials with them. 
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Education Topics  
During the initial assessment, directly observed therapy (DOT) appointments, and 
monthly monitoring, educate the patient as needed on the topics that follow. 
For more information on case management activities, see the Case 
Management section. 
Language and Comprehension Barriers 
In the initial assessment, assess for and address any potential language and 
comprehension barriers. 
1. Assess the patient’s ability to speak and understand instructions, including potential 
barriers, such as not speaking English as primary language, deafness, speech 
deficit, or learning disability. 
2. Assess literacy in the patient’s primary language. 
3. Provide all instructions and communications in the appropriate language. 
4. Use interpreters, visuals, or other educational methods to promote understanding. 
5. Provide educational materials appropriate to the patient’s language and reading 
level. 
6. Make referrals to an appropriate service and notify it of any language and 
comprehension concerns. 
 
For more information on cultural sensitivity, refer to the Participant’s 
Workbook for Session 4: “Working with Culturally Diverse Populations” in 
the Directly Observed Therapy Training Curriculum for TB Control 
Programs (Francis J. Curry National Tuberculosis Center Web site; 2003) 
at 
http://www.nationaltbcenter.edu/catalogue/epub/index.cfm?uniqueID=2&t
ableName=DOTE . 
 
For assistance with language issues, see the Language Services 
Resource Guide for Health Care Providers (The National Health Law 
Program Web site; 2006) at 
http://www.healthlaw.org/library.cfm?fa=download&resourceID=89928&a
ppView=folder&print . 
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Medical Diagnosis 
In the initial interviews with the patient, provide information about TB and the patient’s 
treatment plan. During DOT appointments and monthly monitoring, confirm and reinforce 
the patient’s understanding of these topics.  
1. Discuss the difference between TB disease and TB infection. 
2. Explain the signs and symptoms of TB, how TB is transmitted, prevention activities, 
and treatment. 
3. Explain that TB is both treatable and preventable.  
4. Explain the importance of completion of treatment. 
5. Discuss diagnostic procedures used to make diagnosis of TB, such as chest 
radiography, sputum microscopy, and tuberculin skin testing. Stress the importance 
of testing and follow-up.       
6. Discuss the current medical treatment plan and rationale. Have the patient sign the 
treatment plan and a DOT agreement. 
7. Explain the need for regular medical monitoring and follow-up during the disease 
process. Discuss how treatment will be monitored (i.e., sputum, blood tests, vision 
screening, weight check, etc.). Encourage the patient to be an active participant in 
care and treatment. 
8. Discuss the roles of the patient (engage in treatment), the health department (case 
management, monitoring, contact tracing, and supervision of treatment), and the 
private provider (treatment and monitoring). Encourage the patient to contact the 
case manager for issues and problems that arise during treatment. 
9. Explain the risk of treatment relapse or failure and the need to complete treatment to 
prevent relapse.   
10. Explain the signs and symptoms of possible relapse or failure, and encourage the 
patient to report them immediately to the case manager. 
Contact Investigation 
When a contact investigation is necessary, educate the index patient about the process 
and confidentiality.  
1. Discuss the contact investigation process. 
2. Reinforce the confidentiality of investigation, but warn the patient of the potential for 
contacts to guess the patient’s identity. 
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Isolation  
If isolation is necessary, educate the patient about how to take proper precautions. 
1. Explain isolation precautions and restrictions, if appropriate. Have the patient sign an 
isolation agreement. 
2. Explain the behavior changes needed for infection control. Discuss permitted and 
prohibited activities, limiting and excluding visitors, covering the mouth and nose 
when coughing and sneezing, and using a mask. 
3. Explain the home environmental changes needed for infection control. Discuss 
ventilation and sunlight. Explain how to dispose of items soiled with potentially 
infectious material.   
4. Discuss the requirements for release from isolation. Advise the patient that clearance 
is contingent upon clinical condition and continued compliance with the treatment 
regimen.    
Side Effects and Adverse Reactions 
Educate all patients on antituberculosis medications about the medications’ potential 
side effects and adverse reactions. 
1. Explain the names, dosages, and rationale for the drug treatment plan as well as the 
importance of treatment. 
2. Explain the common side effects and methods to improve symptoms. 
3. Explain signs and symptoms of drug toxicity. 
4. Direct the patient on what actions to take if side effects or signs and symptoms of 
toxicity appear. 
5. Explain potential effects of alcohol and/or drug use on treatment and the increased 
risk for side effects and toxicity. 
 
For more information on side effects and adverse reactions, see the “Side 
Effects and Adverse Reactions” topic in the Treatment of Tuberculosis 
Disease section or the Treatment of Latent Tuberculosis Infection section. 
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Adherence 
If a patient has the potential for not adhering to the treatment plan, educate the patient 
about the importance of treatment, the patient’s responsibilities during treatment, and the 
consequences of nonadherence. 
1. Explain the importance of treatment and follow-up for active TB. 
2. Explain the importance of regular monitoring visits. 
3. Discuss the treatment plan and expectations. Advise the patient on the patient’s 
responsibilities and expected behavior regarding treatment compliance and follow-up 
activities. Have the patient sign the treatment plan and a DOT agreement. 
4. Advise the patient on laws regarding TB disease and isolation.   
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Patient Education Materials  
The Centers for Disease Control and Prevention (CDC) offers the following patient 
education materials online (as of January 2007).  
 Get the Facts About TB Disease 
http://www.cdc.gov/tb/pubs/pamphlets/TB_disease_EN_rev.pdf 
 Protect Your Friends and Family from TB: The TB Contact Investigation 
http://www.cdc.gov/tb/pubs/pamphlets/TB_contact_investigation.pdf   
 Questions and Answers About TB 2005  
http://www.cdc.gov/tb/faqs/pdfs/qa.pdf 
 Staying on Track with TB Medicine 
http://www.cdc.gov/tb/pubs/pamphlets/TB_trtmnt.pdf 
 Stop TB  
http://www.cdc.gov/tb/pubs/Posters/images/StopTB.pdf 
 Tuberculosis: General Information  
http://www.cdc.gov/tb/pubs/tbfactsheets/tb.htm 
 Tuberculosis: Get the Facts!  
http://www.cdc.gov/tb/pubs/pamphlets/TBgtfctsEng.pdf 
 What You Need to Know About TB Infection 
http://www.cdc.gov/tb/pubs/pamphlets/TB_infection.pdf  
 What You Need to Know About the TB Skin Test 
http://www.cdc.gov/tb/pubs/pamphlets/TB_skin_test.pdf 
 
For other sources of patient education materials, consult the resources at the end of this 
section. 
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Resources and References 
Resources 
Patient Education Information for Healthcare Workers 
 CDC. “Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection” 
(MMWR 2000;49[No. RR-6]). Available at: 
http://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf ; and Updates available at: 
http://www.cdc.gov/tb/pubs/mmwr/mmwr_updates.htm   
 ATS, CDC, IDSA. “Treatment of Tuberculosis” (MMWR 2003;52[No. RR-11]). 
Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf . 
 CDC. Self-Study Modules on Tuberculosis (Division of Tuberculosis Elimination Web 
site; 1999). Available at: http://www.phppo.cdc.gov/phtn/tbmodules/Default.htm . 
• Module 9: “Patient Adherence to Tuberculosis Treatment.” Available at: 
http://www.phppo.cdc.gov/phtn/tbmodules/modules6-9/Default.htm . 
• Module 4: “Treatment of Tuberculosis Infection and Disease, Adherence to 
Treatment.” Available at: http://www.phppo.cdc.gov/phtn/tbmodules/modules1-
5/Default.htm . 
 CDC. TB Elimination: Now Is the Time! 2007 (Division of Tuberculosis Elimination 
Web site; 2007). Available at: http://www.cdc.gov/tb/pubs/nowisthetime/default.htm .  
Patient Education Materials for Patients 
 CDC. TB Education and Training Resources [TB Education and Training Resources 
Web site]. Available at: http://www.findtbresources.org/scripts/index.cfm . 
 CDC, Division of Tuberculosis Elimination. Education and Training Materials 
[Division of Tuberculosis Elimination Web site]. Available at:  
http://www.cdc.gov/tb/pubs/default.htm . 
 Minnesota Department of Health. Tuberculosis: Patient Education Materials 
[Minnesota Department of Health Web site]. Available at: 
http://www.health.state.mn.us/divs/idepc/diseases/tb/brochures.html . 
 University of Washington Harborview Medical Center. Patient Education Resources: 
All Languages [EthnoMed Web site]. Available at: 
http://ethnomed.org/ethnomed/patient_ed/index.html#tuberculosis .    
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 Introduction 
Purpose 
Use this section to  
 Determine what information and which records should be treated with confidentiality; 
 Identify state policy for maintaining patient confidentiality; 
 Take measures to ensure TB patients’ confidentiality; and 
 Determine when it is permissible to share information for public health reasons. 
The protection of private patient information is commonly referred to as confidentiality. 
Confidentiality involves the protection of information revealed during patient–healthcare 
worker encounters, including all written or electronic records of these encounters. 
Confidentiality is an essential issue in many different aspects of tuberculosis (TB) 
control. Healthcare workers need to be aware of confidentiality issues that are relevant 
to patient–healthcare worker encounters, as well as to the collection, management, and 
sharing of information gathered on TB patients.1 
Policy 
Healthcare workers should keep patient information in confidence and divulge it only 
with the permission of the patient, except as otherwise required by law.2 
For roles and responsibilities, refer to the “Roles, Responsibilities, and 
Contact Information” topic in the Introduction. 
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State Laws and Regulations 
Arizona Laws/Rules Regarding Tuberculosis Control 
Arizona Revised Statutes.  Title 36:  Public Health and Safety; Chapter 6:  
Public Health Control; Title 6:  Tuberculosis Control.  (ARS§36-711 
through §36-738)  
ARS§36-711.  Definitions.   
ARS§36-712. Administration by the department.   
ARS§36-714.  Tuberculosis control officer.   
ARS§36-715.  Costs; removals; proceedings.   
ARS§36-716.  Payment of assistance.   
ARS§36-717.  Responsibility for care or treatment by counties.   
ARS§36-718.  Contracting for care of afflicted persons.   
ARS§36-721.  Rules.   
ARS§36-723.  Investigation of tuberculosis cases.   
ARS§36-724.  Voluntary control measures.   
ARS§36-725.  Orders to cooperate; emergency custody.    
ARS§36-726.  Petition for court ordered examination, monitoring, 
treatment, isolation or quarantine.   
ARS§36-727. Hearings; procedure; confidentiality.   
ARS§36-728. Judicial action.   
ARS§36-729. Amended orders for intervention and transport of afflicted 
persons.   
ARS§36-730.  Appointment of guardian or conservator.   
ARS§36-731.  Confinement; selection; jails; prohibition.   
ARS§36-732.  Early release from court ordered treatment.   
ARS§36-733.  Choice of physician and mode of treatment.   
ARS§36-734.  Treatment; exemption.   
ARS§36-735.  Notification of rights.   
ARS§36-736.  Administrative procedures act; judicial review of 
administrative procedures; exemption; appeals.  
ARS§36-737.  Violation; classification.   
ARS§36-738.  Qualified immunity.   
 
Arizona Administrative Code.  Title 9. Chapter 6.  Department of 
Health Services Communicable Diseases and Infestations.   
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Health Insurance Portability and  
Accountability Act (HIPAA) 
Confidentiality of patient information has long been a requirement in the healthcare field 
and now has its own set of regulations, the Health Insurance Portability and 
Accountability Act (HIPAA) Privacy Rule. The new regulations protect the privacy of 
certain individually identifiable health data, referred to as protected health information 
(PHI). PHI is individually identifiable health information that is transmitted or maintained 
in any form or medium (e.g., electronic, paper, or oral), but excludes certain educational 
and employment records. 
Centers for Disease Control and Prevention  
Guidance on HIPAA 
The Centers for Disease Control and Prevention (CDC) published the report “HIPAA 
Privacy Rule and Public Health: Guidance from CDC and the US Department of Health 
and Human Services” (MMWR 2003;52 [S-2]:1–12 at 
http://www.cdc.gov/mmwr/preview/mmwrhtml/su5201a1.htm), to provide guidance in 
implementing the HIPAA requirements. In this report, the US Department of Health and 
Human Services (DHHS) recognized the importance of sharing PHI to accomplish 
essential public health objectives and to meet certain other societal needs (e.g., 
administration of justice and law enforcement).  
Covered entities—which are health plans, healthcare clearinghouses, and healthcare 
providers who transmit health information in electronic form in connection with certain 
transactions—are permitted by the Privacy Rule to do the following: 
 Share PHI for specified public health purposes. For example, covered entities may 
disclose PHI, without individual authorization, to a public health authority legally 
authorized to collect or receive the information for the purpose of preventing or 
controlling disease, injury, or disability. 
 Make disclosures that are required by other laws, including laws that require 
disclosures for public health purposes.3 
Arizona HIPAA Policies 
 
Click on the following link for information regarding the Arizona Department of Health 
Services HIPAA web-link: http://www.azdhs.gov/its/hipaa/index.htm 
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National Guidelines  
The following guidelines for protecting tuberculosis (TB) patients’ confidentiality are 
adapted from the National Tuberculosis Controllers Association’s (NTCA’s) and Centers 
for Disease Control and Prevention’s (CDC’s) “Guidelines for the Investigation of 
Contacts of Persons with Infectious Tuberculosis: Recommendations from the National 
Tuberculosis Controllers Association and CDC” (MMWR 2005;54[No. RR-15]). 
To create a consent form, refer to the CDC’s form “Example of an Authorization 
for Disclosure of Medical Record Information” at 
http://www.phppo.cdc.gov/phtn/tbmodules/modules6-9/m7/7-11.htm#fig7.1 . 
Table 1: HOW TO PROTECT CONFIDENTIALITY  
Conducting All 
Activities 
 Make every attempt to ensure patient confidentiality. 
Training  Participate in training on maintaining confidentiality and obtaining informed consent in 
accordance with local/state laws. 
Interviewing  
Patients 
 Interview the tuberculosis (TB) patient in a private setting. 
 Inform the patient about confidentiality rights. 
 Explain to a human immunodeficiency virus (HIV)-infected patient that HIV status will be 
kept confidential. 
 Consult with the patient to identify boundaries for confidentiality and obtain oral consent 
for any breaches in confidentiality.  
 If written consent is required, present the consent form to the patient in an appropriate 
manner, and retain a copy in the patient’s medical record. If consent is refused, the TB 
program should develop a plan of action.  
Conducting 
Site 
Investigations 
 Plan site investigation procedures in advance of any visit, in consultation with and with 
the consent of the index patient, if possible.  
 Obtain agreement to maintain confidentiality from any site personnel who receive 
information about the identity of the index patient. 
Communicating 
with the Press 
 Maintain confidentiality in communications with the press. 
Breaching 
Confidentiality 
 Breach confidentiality only with approval of TB program administrators and with the 
consent of the TB patient, when possible. 
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Resources and References 
Resources 
 CDC. “HIPAA Privacy Rule and Public Health: Guidance from CDC and the US 
Department of Health and Human Services” (MMWR 2003;52[S-2]). Available at: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/su5201a1.htm . 
 CDC. Module 7: “Confidentiality in Tuberculosis Control” (Self-Study Modules on 
Tuberculosis. Division of Tuberculosis Elimination Web site; 1999). Available at: 
http://www.phppo.cdc.gov/phtn/tbmodules/modules6-9/Default.htm . 
 United States Department of Health and Human Services. “Health Insurance 
Portability and Accountability Act of 1996.” (Public Law 104-191 Web site). Available 
at: http://www.aspe.hhs.gov/admnsimp/pl104191.htm . 
 United States Department of Health and Human Services. “Office for Civil Rights—
HIPAA” [Office for Civil Rights Web site]. Available at: http://www.hhs.gov/ocr/hipaa/ . 
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Services. MMWR 2003;52(S-2):1. 
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Introduction 
Purpose 
Use this section to do the following: 
 Notify public health agency staff in another jurisdiction that a person is moving (or 
has moved) to their jurisdiction who is a  
• Verified or suspected case of tuberculosis (TB) disease; 
• High-priority contact to a smear-positive Class 3 or Class 5 pulmonary case, 
contact to a smear-negative Class 3 pulmonary case, or contact to a highly 
suspect Class 5 pulmonary case; 
• Documented convertor who has initiated treatment for latent tuberculosis infection 
(LTBI);  
• Class 2 or Class 4 patient who has initiated treatment for LTBI; or 
• Close associate to a Class 3 index case with clinical presentation consistent with 
recently acquired disease in a source-case investigation or close associate to a 
child with LTBI in a source-case investigation. 
 Follow up on notifications. 
 Make CURE-TB referrals for TB patients and contacts who move between the U.S. 
and Mexico; 
 Enroll mobile TB patients in the TBNet tracking and referral service. 
Making sure that TB patients complete their evaluation and treatment is a critical 
element of TB control.TPD1DPT Some patients receiving treatment for TB disease in the United 
States move from one jurisdiction to another before completing treatment. Notifying the 
receiving local and/or state jurisdiction of a patient’s impending arrival will prevent care 
from being interrupted and improve treatment outcome.  
The term transfer notification refers to a referral or follow-up report. Before the patient 
moves, or as soon as it becomes apparent that a patient has moved, the referring 
jurisdiction provides a referral to the receiving jurisdiction. After the patient has moved, 
the receiving jurisdiction then provides the referring jurisdiction with a follow-up report.  
Policy 
The Arizona Department of Health Services is responsible for coordination of transfer 
notifications between states and other local jurisdictions within the state. The local public 
health jurisdiction should notify the state public health department when a patient plans 
or requests to transfer to another jurisdiction. The receiving and referring jurisdictions 
should stay in communication until final dispensation of the patient is known. T 
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For roles and responsibilities, refer to the chapter on “Roles, Responsibilities, 
and Contact Information”  
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TTWhen to Initiate a Notification 
For a definition of tuberculosis (TB) patient classifications, see the 
“Tuberculosis Classification System” T Ttopic in the Diagnosis of Tuberculosis 
Disease section. 
Table 1: TRANSFER NOTIFICATIONS AND FOLLOW-UPS TPD2DPT 
Referral Type When to Initiate Notes 
Verified and suspected 
cases of tuberculosis 
(TB) disease  
When notified that a Class 3 or 5 
patient is moving or has moved from 
the area for 30 days or more  
May also initiate to coordinate directly 
observed therapy (DOT) while patient is 
visiting another area. 
Contacts After identifying a: 
 High-priority contact to a smear-
positive Class 3 or Class 5 
pulmonary case  
 Contact to a smear-negative Class 
3 pulmonary case  
 Contact to a highly suspect Class 
5 pulmonary case 
Send individual referrals for each 
contact. 
Latent TB Infection 
(LTBI) converters 
When notified that a documented 
convertor who has initiated treatment 
is moving or has moved from the 
area for 30 days or more 
 
LTBI reactors When notified that a Class 2 or 4 
patient who has initiated treatment is 
moving or has moved from the area 
for 30 days or more 
 
Source case 
investigation for TB 
disease 
After identifying a close associate to 
a Class 3 index case with clinical 
presentation consistent with recently 
acquired disease  
Use primarily for associates to children 
under 5 years of age with TB disease. A 
younger age cut-off may be advisable 
because the focus would be on more 
recent transmission. TPD3DPT 
Source case 
investigation for LTBI  
After identifying a close associate to 
a child with LTBI 
Use primarily for associates to children 
under 2 years of age with LTBI. TPD4DPT 
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Follow-Up Type  When to Initiate Notes 
Final disposition When final status and/or outcome is 
known  
 
Source: NTCA. Interjurisdictional Tuberculosis (TB) Notification—National Tuberculosis Controllers Association 
Recommendations. Smyrna, GA: March 2002:1–5.  
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How to Issue a Notification 
How a notification is made depends upon whether the transfer occurred: 
 TInside the United States 
 Outside the TUnited States T 
Transfers Inside the United States 
T ransfers Within Arizona TRefer to Table 2: TReferrals in the United States. T 
T ransfers Between States: T An interjurisdictional tuberculosis (TB) notification system 
has been set up by the National Tuberculosis Controllers Association (NTCA) to facilitate 
and standardize communication between states. This system will enhance continuity and 
completeness of care, and improve outcome evaluation of verified cases. PD5DP Refer to 
Table 2: Referrals in the United States. 
The local health departments and the State of Arizona, Department of Health Services 
should take the following steps to send a referral to notify another jurisdiction to which a 
patient has moved or another jurisdiction in which a contact/associate is identified. 
Table 2: REFERRALS IN THE UNITED STATES TPD6DPT 
Action Transfers Within Arizona Transfers Between States 
Make a referral The public health agency from which the 
patient is transferring should do the 
following as soon as possible:  
 Call the Arizona Department of Health 
Services at 602-364-4750. 
 Copy the updated, complete local 
public health file on the patient, and 
send the copy to the jurisdiction  
receiving the patient 
 Call the patient’s private provider and 
arrange for transfer of the patient’s 
records to the receiving physician (or 
to the jurisdiction receiving the patient 
if no receiving physician is 
designated) 
The public health agency from which the 
patient is transferring should do the 
following as soon as possible:  
 Call the Arizona Department of Health 
Services at 602-364-4750. 
 Fill out the NTCA’s “Interjurisdictional 
Tuberculosis Notification” form* 
 Mail and fax the form to the Arizona 
Department of Health Services, TB 
Control Section at:  
• Mail: 150 N. 18PthP Avenue, Suite 140 
Phoenix, AZ.  85007 
• Fax: 602-364-3267 
If more information is needed, the Arizona 
Department of Health Services will 
request it from the public health agency 
from which the patient is transferring  
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Action Transfers Within Arizona Transfers Between States 
Provide records to 
patient 
The public health agency from which the 
patient is transferring should provide the 
patient a copy of the treatment records 
 
The public health agency from which the 
patient is transferring should provide the 
patient a copy of the referral and 
treatment records 
 
Send the referral 
form 
Not necessary Use the TNTCA’s “TInterjurisdictional TB 
Notification Follow-Up” formP†  P 
*  The NTCA’s “Interjurisdictional Tuberculosis Notification” form is available online at  
HTUhttp://bluewinkle.com/ntca/themes/connections/ntca_files/IJ_Form_Page1.pdf UHT 
P
†
P  NTCA’s T “ TInterjurisdictional TB Notification Follow-Up” form is available online at  
HTUhttp://bluewinkle.com/ntca/themes/connections/ntca_files/IJ_Form_Page2_Followup.pdf UHT 
Source: NTCA. Interjurisdictional Tuberculosis (TB) Notification–National Tuberculosis Controllers Association 
Recommendations. Smyrna, GA: March 2002:1–5. 
 
 
 
For more information on completing the NTCA forms, see the NTCA’s 
TInterjurisdictional Tuberculosis (TB) Notification—National Tuberculosis 
Controllers Association Recommendations T (NTCA Web site; March 2002) at 
HTUhttp://bluewinkle.com/ntca/themes/connections/ntca_files/IJ_Instructions.pdfUHT. 
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Transfers Outside the United States 
Centers for Disease Control and Prevention  
International Notifications 
The Arizona Department of Health Services is responsible for international transfer 
notifications. The local health jurisdiction should notify the state health department when 
a patient moves outside the country.  
Local healthcare agency staff: The information below is provided for your 
information only. State program staff will fill out these forms. 
A process for international notification of TB cases has been developed by the CDC to 
provide information to TB control staff in the country of the patient’s destination.TPD7DPT The 
CDC notification process covers the following regions:  
 African Region 
 Americas Region 
 Eastern Mediterranean Region 
 European Region 
 Southeast Asia Region 
 Western Pacific and East Asia Region 
In Arizona send these referrals directly to the destination country and the Arizona 
Department of Health Services, TB Control Section as soon as possible after receiving 
information about the patient’s move or identifying a contact/associate.   
T o make an international referral through CDC:  
1. Complete the International Tuberculosis Notification Form 
HTUhttp://www.cdc.gov/nchstp/tb/pubs/international/PDF/internat_proces.pdf UTH 
2. Forward a copy of the notification by fax to the destination country and the Arizona 
Department of Health Services, TB Control Section. For contact information, see the 
CDC Website at HTUhttp://www.cdc.gov/nchstp/tb/pubs/international/international.htm UTH 
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3. Provide the patient with  
a. A copy of the referral and treatment records. 
b. Enough medication for one week if the patient is going out of the country. 
CURE-TB: Transfers to Mexico 
Instead of the CDC notification, make referrals through CURE-TB 
( HTUhttp://www.curetb.orgUTH), a referral program for TB patients and their contacts moving 
between the U.S. and Mexico. This program provides direct guidance to patients and 
facilitates the exchange of information between providers in both countries. Services are 
available to patients and providers all over the U.S. and Mexico. PD8D P 
Referrals accepted by the CURE-TB program include the following: 
 TPatients T with suspected or confirmed TB disease who are moving or spending more 
than one month in Mexico 
 TContacts who move T between the U.S. and Mexico 
 TContacts living in MexicoT who have been exposed to a confirmed case living in the 
U.S. 
 TSource case findingT for an index case in the U.S. when there is reasonable 
suspicion of TB disease in a person living in Mexico 
 TRequests for a patient’s clinical historyT while living in Mexico, if sufficient locating 
information regarding the Mexican provider is supplied 
 T he T local health department or the Arizona Department of Health Services initiates a 
CURE-TB referral within as soon as possible after receiving information about the 
patient’s move or identifying a contact/associate.  
T o make a CURE-TB referral: 
1. Complete the CURE-TB Referral Form 
( HTUhttp://www2.sdcounty.ca.gov/hhsa/documents/BinationalReferralForm111.pdf UTH)   
2. Forward a copy of the referral form by fax to CURE-TB and the Arizona Department 
of Health Services  
a. The CURE-TB fax number is 1-619-692-8020. CURE-TB can be reached by 
telephone at 1-619-542-4011 or 1-619-542-4015. 
b. There is a Binational Card available from Immigration Custom Enforcement (ICE) 
and the local health departments for deportees. This card gives the deportees 
information on how to contact CURE-TB for assistance. 
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L  Transfer Notifications 14.10 
Revised 12/04/07 
3. Provide the patient with:  
a. The CURE-TB telephone numbers to call (1-800-789-1751 in the U.S.; 001-800-
789-1751 in Mexico) for questions about their care or about accessing care on 
either side of the border; PD9DP  
b. A copy of the referral and treatment records;  
c. A one-week supply of medication for patients going out of the country.  
TBNet: International Transfers in Mobile, Underserved Populations  
TBNet (HHTUhttp://www.migrantclinician.org/network/tbnet UHTH) is a multinational TB patient 
tracking and referral project for mobile, underserved populations. Although the program 
was originally created for migrant farm workers, it is expanding to include any patient 
who might be mobile during their treatment, such as the homeless, immigration 
detainees, or prison parolees.PD10D P 
TBNet offers the following services:  
 TPortable, wallet-sized treatment records. T TBNet supplies TB clinics with records 
that summarize a patient’s TB treatment and can easily be carried by the patient.  
 T oll-free line (1-800-825-8205) for healthcare providers and patients. THealthcare 
providers from the U.S. or Mexico can call to request an up-to-date copy of medical 
records of patients enrolled in TBNet. Patients can call for help with locating 
treatment facilities at their next destination.  
T The local health department or the Arizona Department of Health Services Tinitiates a 
TBNet referral as soon as possible after the start of treatment.   
 
T o enroll a patient in TBNet: 
1. Call the TBNet Program Manager, at 1-800-825-8205 to begin the referral process. 
2. Complete the TBNet Patient History and Brief Medical Information Form. 
( HTUhttp://www.migrantclinician.org/_resources/TBNet_Pt_History___Med_Info.pdf UTH)  
3. Fax the form and copies of the chest radiograph and all laboratory reports to TBNet 
at 1-512-327-6140. PD11D P 
4. Provide the patient with the portable, wallet-sized treatment record and TBNet’s toll 
free number (1-800-825-8205).  
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Introduction 
Use this section find out what resources are available and how to access them.  
The Arizona Tuberculosis Program has resources available to assist local agencies. The 
following tables explain the resources that are available and how to obtain them: 
 Table 1: Mantoux Tuberculin Skin Testing 
 Table 2: Interferon Gamma Release Assay  
 Table 3: Chest Radiographs 
 Table 4: Specimen Collection and Shipment 
 Table 5: Antituberculosis Medications  
 Table 6: Incentives and Enablers 
 Table 7: Medical Interpretation Services 
 Table 8: Healthcare Staff Training and Education 
 
For information on obtaining laboratory tests, see the Laboratory Services 
section. 
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Mantoux Tuberculin Skin Testing Supplies 
Table 1: MANTOUX TUBERCULIN SKIN TESTING SUPPLIES 
Availability  Mantoux Tuberculin Skin Testing is available at: 
• Every local health agency 
 
How to Obtain  Order Mantoux Tuberculin Skin Testing supplies through your approved supplier:  
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Interferon Gamma Release Assay  
Table 2: INTERFERON GAMMA RELEASE ASSAY  
Availability and 
Contact 
information 
Interferon Gamma Release Assay: 
 The only place available in Arizona that is doing Quantaferon is Maricopa Integrated 
Health System (MIHS).  
  Contact MIHS at 602-344-5240 for further information or go to 
www.quantiferon.com  
.  
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Chest Radiographs 
Table 3: CHEST RADIOGRAPHS 
Availability  In the following circumstances: 
 Chest Radiographs are available at your provider’s office or the local health agencies 
as needed 
Table 4: SPECIMEN COLLECTION AND SHIPMENT 
Availability  The State TB laboratory provides the following specimen supplies at no charge: 
 Specimen containers 
 Packaging for shipment 
How to Obtain  To order these supplies from the state laboratory:  
 
 Call (602) 542-1188 
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Antituberculosis Medications  
Table 5: ANTITUBERCULOSIS MEDICATIONS 
Availability  In the following circumstances:  
When a patient has been diagnosed with tuberculosis and does not have any insurance 
medication for tuberculosis can be obtained at the local health agency. 
 
The local health agencies provides the following antituberculosis medications at no 
charge: 
 Isoniazid (INH) 
 Rifampin (RIF) 
 Rifapentine (RPT) 
 Ethambutol (EMB) 
 Pyrazinamide (PZA) 
 
Note: Pyridoxine (vitamin B-6) is also provided to patients who have conditions 
associated with neuropathy such as nutritional deficiency, diabetes, human 
immunodeficiency virus (HIV) infection, renal failure, alcoholism, and pregnant/ 
breastfeeding women. Second-line antituberculosis medications are provided for 
patients with drug-resistant TB.  
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Incentives and Enablers 
Table 6: INCENTIVES AND ENABLERS 
Availability and 
Cost 
In the following circumstances:  
The local health agencies may provide the following incentives/enablers for people with 
tuberculosis in certain situations: 
 Incentives  
 Food and beverages 
 
Enablers 
 Transportation (bus pass, cab fare, car 
battery, gas)  
 Obtaining and shipping specimens for 
the patient 
 Assisting the patient with getting 
medication refills 
 Assisting the patient with completing 
paperwork to get food/housing 
assistance 
 Assisting the patient with getting 
substance treatment 
A R I Z O N A  T U B E R C U L O S I S  P R O G R A M  M A N U A L  Supplies, Materials, and Services 1 5 . 7  
Revised 12/04/07 
Medical Interpretation Services 
Table 7: MEDICAL INTERPRETATION SERVICES 
Availability  In the following circumstances:  
The local health agencies have medical interpretation services at no charge to the 
patient who has been diagnosed with tuberculosis. 
 
For other patients, other agencies may fund interpretation services, or interpretation 
services may be obtained on a fee-for-service basis. 
How to Obtain  The following may be helpful to obtain Medical Interpretation Services 
 Diversity Rx page on Interpreter Associations: 
http://diversityrx.org/HTML/MOASSO.htm  
 Yellow pages under "Translators & Interpreters"  
 Medicaid-funded interpreters 
 State refugee services program  
 Local community organizations 
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Healthcare Staff Training and Education 
Table 8: HEALTHCARE STAFF TRAINING AND EDUCATION 
Availability and 
Cost 
The local health agencies and/or the Department of Health Services, TB Control Section 
give free training and education based on need and availability of staff.  
 
How to Obtain  For more information, call the local health agency or the Arizona Department of Health 
Services at 602-364-4750. 
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Introduction 
Purpose 
Use this section to understand and follow national and Arizona guidelines to 
 Review the hierarchy of infection control measures and know where to go for further 
information; 
 Alert local public health staff to the basic differences between masks and respirators; 
 Estimate patients’ infectiousness and determine when patients are noninfectious; 
 Determine when to isolate patients, when to discharge them from hospitals, and 
when to permit them to return to work, school, or other settings; 
 Review how to implement infection control measures in residential settings, patient 
care facilities, and transportation vehicles; 
 Consult with facilities that are implementing infection control measures, including 
two-step testing. 
 
In the 2005 guidelines, “Controlling Tuberculosis in the United States: 
Recommendations from the American Thoracic Society, Centers for Disease Control 
and Prevention, and the Infectious Diseases Society of America,” one of the 
recommended strategies to achieve the goal of reduction of tuberculosis (TB) morbidity 
and mortality is the identification of settings in which a high risk exists for transmission of 
Mycobacterium tuberculosis and application of effective infection control measures.1 
As TB continues to decline in most areas of the U.S., it is crucial that state and local 
public health agencies provide facilities with epidemiological data on TB, as well as 
education and guidance in developing effective TB infection control programs.  
Infection control measures are fundamental to reducing the spread of communicable 
diseases such as TB.  Transmission of M. tuberculosis from person to person can occur 
in many locations, such as home, work, school, and healthcare facilities.2 It is impossible 
to prevent all exposure; however, the goal is to reduce the amount of transmission. 
Each agency’s or facility’s program should include a hierarchy of administrative controls, 
environmental controls, and personal respiratory protection.  Because each patient care 
setting and patient’s home is different, each program will incorporate a different 
combination of control activities. The extent to which each agency or facility implements 
its control activities is based on the results of its risk assessment. In areas where TB 
rates are lower, the TB risk is lower, and this should affect which elements of the TB 
infection control plan are utilized.  
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Policy  
Three main areas of infection control that need to be addressed by state and local public 
healthcare agencies are TB control in 
1. Healthcare facilities, where persons with infectious TB disease would seek care;3,4  
2. Congregate settings and residential facilities, whose residents are at increased risk 
for TB disease;5,6  
3. The patient’s home. 
 
To accomplish TB control activities, each local public healthcare agency should do the 
following: 
1. Familiarize staff with the current Centers for Disease Control and Prevention (CDC) 
infection control guidelines for healthcare providers and settings.  
2. Develop an infection control program for the county or state TB staff, focusing on 
a. Assignment of responsibility for program; 
b. Risk assessment; 
c. Persons (if anyone) who need baseline testing, including TB screening and 
counseling; 
d. Education and training; 
e. Case management (if direct patient care is provided).  
3. Designate a staff person to guide facilities that may need to set up TB infection 
control programs.  
 
For roles and responsibilities, refer to the “Roles, Responsibilities, and 
Contact Information” topic in the Introduction. 
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State Laws and Regulations 
Arizona Laws/Rules Regarding Tuberculosis Control 
Arizona Revised Statutes.  Title 36:  Public Health and Safety; Chapter 6:  
Public Health Control; Title 6:  Tuberculosis Control.  (ARS§36-711 
through §36-738)  
ARS§36-711.  Definitions.   
ARS§36-712. Administration by the department.   
ARS§36-714.  Tuberculosis control officer.   
ARS§36-715.  Costs; removals; proceedings.   
ARS§36-716.  Payment of assistance.   
ARS§36-717.  Responsibility for care or treatment by counties.   
ARS§36-718.  Contracting for care of afflicted persons.   
ARS§36-721.  Rules.   
ARS§36-723.  Investigation of tuberculosis cases.   
ARS§36-724.  Voluntary control measures.   
ARS§36-725.  Orders to cooperate; emergency custody.    
ARS§36-726.  Petition for court ordered examination, monitoring, 
treatment, isolation or quarantine.   
ARS§36-727. Hearings; procedure; confidentiality.   
ARS§36-728. Judicial action.   
ARS§36-729. Amended orders for intervention and transport of afflicted 
persons.   
ARS§36-730.  Appointment of guardian or conservator.   
ARS§36-731.  Confinement; selection; jails; prohibition.   
ARS§36-732.  Early release from court ordered treatment.   
ARS§36-733.  Choice of physician and mode of treatment.   
ARS§36-734.  Treatment; exemption.   
ARS§36-735.  Notification of rights.   
ARS§36-736.  Administrative procedures act; judicial review of 
administrative procedures; exemption; appeals.  
ARS§36-737.  Violation; classification.   
ARS§36-738.  Qualified immunity.   
 
Arizona Administrative Code.  Title 9. Chapter 6.  Department of 
Health Services Communicable Diseases and Infestations.   
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Hierarchy of Infection Control Measures 
There are three types of infection control measures. The first are administrative controls, 
which are primarily aimed at early identification, isolation, and appropriate treatment of 
infectious patients. The second are environmental controls, which focus on preventing 
the spread and reducing the concentration of infectious droplet nuclei in the air.7 The 
third is personal respiratory protection, which may provide additional protection for 
healthcare workers in high-risk settings such as isolation rooms and cough-inducing or 
aerosol-generating suites. 
The activities described below are more relevant to infection control in healthcare or 
residential facilities. Home settings are discussed separately in the “Residential Settings” 
topic in this section.  
Administrative Controls  
Administrative control measures are the first of three levels of measures designed to 
reduce the risk of tuberculosis (TB) transmission. Administrative controls are the first 
level of infection control because they include a variety of activities to identify, isolate, 
and appropriately treat persons suspected of having TB disease.  
An effective TB infection control plan contains measures for reducing the spread of 
TB that are appropriate to the risk of a particular setting.8  Every healthcare setting 
should have a TB infection control plan that is part of an overall infection control 
program.9 A written TB infection control plan helps to ensure prompt detection, airborne 
precautions, and treatment of persons who have suspected or confirmed TB disease.10   
 In TB infection control programs for settings in which patients with suspected 
or confirmed TB disease are expected to be encountered, develop a written TB 
infection control plan that outlines a protocol for the prompt recognition and initiation 
of airborne precautions for persons with suspected or confirmed TB disease, and 
update it annually.11   
 In TB infection control program for settings in which patients with suspected 
or confirmed TB disease are NOT expected to be encountered, develop a written 
TB infection control plan that outlines a protocol for the prompt recognition and 
transfer of persons who have suspected or confirmed TB disease to another 
healthcare setting. The plan should indicate procedures to follow to separate persons 
with suspected or confirmed infectious TB disease from other persons in the setting 
until the time of transfer. Evaluate the plan annually, if possible, to ensure that the 
setting remains one in which persons who have suspected or confirmed TB disease 
are not encountered, and that they are promptly transferred.12 
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Administrative Activities13 
Key activities to reduce the risk of transmission include the following: 
1. Assign responsibility to a specific person for designing, implementing, evaluating, 
and maintaining a TB infection control program for that facility. 
2. Conduct a risk assessment. The risk level of a particular facility will affect the 
extent of all other activities and will result in each facility having a different plan.  
3. Develop, implement, and enforce policies and procedures to ensure early 
identification, evaluation, and treatment of infectious cases of TB. 
4. Provide prompt triage and management in the outpatient setting of patients who 
may have infectious TB. 
5. Initiate promptly and maintain TB isolation for persons who may have infectious 
TB and are admitted to an inpatient setting. 
6. Plan effectively for the discharge of the patient, coordinating between the local 
public health agency and the healthcare provider. 
7. Implement environmental controls. Develop, install, maintain, and evaluate the 
effectiveness of engineering controls. 
8. Implement a respiratory protection program. Develop, initiate, install, maintain, 
and evaluate the effectiveness of the respiratory protection program.    
9. Implement precautions for cough-inducing procedures. Develop, implement, 
and enforce policies and procedures to ensure adequate precautions when 
performing cough-inducing procedures. 
10. Educate and train healthcare workers about TB. 
11. Counsel and screen healthcare workers. Develop and implement counseling and 
screening program for healthcare workers about TB disease and latent TB infection 
(LTBI). 
12. Evaluate promptly possible episodes of TB transmission.       
13. Coordinate activities between the state and local public healthcare agencies. 
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Environmental Controls  
TB is caused by an organism called Mycobacterium tuberculosis. When a person with 
infectious TB disease coughs or sneezes, tiny particles called droplet nuclei that contain 
M. tuberculosis are expelled into the air.14 Environmental controls are used to prevent 
the spread and reduce the concentration of infectious droplet nuclei.15 Each facility 
should use different combinations of environmental controls, based on the results of its 
risk assessment. 
It is important to note, however, that without strong administrative controls, 
environmental controls are ineffective because cases would not be recognized or 
managed appropriately.  
Table 1 describes the three main types of environmental controls. 
 
Table 1: THREE TYPES OF ENVIRONMENTAL CONTROLS 
Most Effective 
Control 
    
Ventilation 
 Controls direction of air flow to prevent contamination of air in areas 
surrounding a person with infectious tuberculosis (TB) 
 Dilutes and removes contaminated air  
 Exhausts contaminated air to the outside 
 
Supplementary 
Controls 
High-efficiency particulate air (HEPA) filtration 
 Cleans the air of infectious droplet nuclei  
 
Ultraviolet germicidal irradiation (UVGI) 
 Kills or inactivates TB bacilli in the air 
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Personal Respiratory Protection  
Although administrative controls and environmental controls are most effective in 
controlling the spread of TB, they do not eliminate the risk of transmission entirely. 
Personal respiratory protection, the third level of infection control, is also used in higher-
risk settings. 
The purpose of a respirator is to reduce exposure by filtering out TB bacilli from the room 
air before the air is breathed into a person’s lungs. Respirators used for TB control 
should be approved for TB use by the National Institute for Occupational Safety and 
Health (NIOSH). 
It is recommended that healthcare provider staff and visitors use personal respiratory 
protective equipment in settings that may be at higher risk for TB transmission, such as 
the following: 
 Rooms where infectious TB patients are being isolated  
 Areas where cough-inducing or aerosol-generating procedures are performed 
 Other areas, which should be identified in the facility’s risk assessment, where 
administrative and environmental controls are not likely to protect persons from 
inhaling infectious droplet nuclei 
It is important to note that the precise level of effectiveness (of respiratory protection) in 
protecting healthcare workers from M. tuberculosis transmission in healthcare settings 
has not been determined.16  
 
Surgical-type masks are to be used by persons who are infectious or are 
suspected cases of TB disease when they are out of TB respiratory 
isolation. The purpose of the mask is to reduce transmission by reducing 
the number of TB bacilli coughed out into the room air. The infectious 
patient should not wear a respirator. For more information, see Table 2: 
Using Masks and Respirators. 
When TB respirators are used, a respiratory protection program should be developed 
and enforced.1,17 For more information respiratory protection programs, see the Centers 
for Disease Control and Prevention’s (CDC’s) “Guidelines for Preventing the 
Transmission of Mycobacterium tuberculosis in Health-care Settings, 2005” (MMWR 
2005;54[No. RR-17]:75–79) at http://www.cdc.gov/mmwr/pdf/rr/rr5417.pdf . 
The new CDC guidelines recommend that healthcare facilities conduct annual training 
regarding multiple topics for healthcare workers (HCWs), including the nature, extent, 
and hazards of TB disease in the healthcare setting. The training can be conducted in 
conjunction with other related training regarding infectious disease associated with 
airborne transmission.  
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In addition, training topics should include the following: 
1. Risk assessment process and its relation to the respirator program, including signs 
and symbols used to indicate that respirators are required in certain areas and the 
reasons for using respirators 
2. Environmental controls used to prevent the spread and reduce the concentration of 
infectious droplet nuclei 
3. Selection of a particular respirator for a given hazard (See “Selection of Respirators” 
on p. 78 of the CDC guidelines.) 
4. Operation, capabilities, and limitations of respirators 
5. Cautions regarding facial hair and respirator use  
6. Occupational Health and Safety Administration (OSHA) regulations regarding 
respirators, including assessment of employees' knowledge  
Trainees should be provided opportunities to handle and wear a respirator until they 
become proficient. Trainees should also be provided with copies or summaries of lecture 
materials for use as references and instructions to refer all respirator problems 
immediately to the respiratory program administrator.18 
A fit test is used to determine which respirator fits the user adequately and to ensure that 
the user knows when the respirator fits properly. Fit testing provides a means to 
determine which respirator model and size fits the wearer best and to confirm that the 
wearer can don the respirator properly to achieve a good fit. Periodic fit testing for 
respirators used in TB environments can serve as an effective training tool in conjunction 
with the content included in employee training and retraining.19  
The CDC recommends that, after a risk assessment to validate the need for respiratory 
protection, a healthcare facility should perform fit testing during the initial respiratory 
protection program training and periodically thereafter in accordance with federal, state, 
and local regulations.20  The frequency of periodic fit testing should be supplemented by 
the occurrence of 1) risk for transmission of M. tuberculosis, 2) facial features of the 
wearer, 3) medical condition that would affect respiratory function, 4) physical 
characteristics of respirator, or 5) model or size of the assigned respirator.21 
The OSHA also developed its own TB Rule, although it was withdrawn in 2003.  
However, OSHA has addressed TB in their general respiratory protection requirements, 
which includes the need for the following:  
 Respiratory protection program  
 Amended medical evaluation 
 Training and recordkeeping 
 Annual fit testing  
 Fit checking 
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 For regulations in your area, refer to state and local regulations and contact your local 
OSHA office. A directory of OSHA offices may be found at http://www.osha-
slc.gov/html/RAmap.html.22 
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Who Should Use a Mask or Respirator 
Using masks and respirators properly can reduce transmission of Mycobacterium 
tuberculosis and exposure to TB.  Refer to Table 2: Using Masks and Respirators to 
determine when to use masks and respirators. 
Table 2: USING MASKS AND RESPIRATORS23 
Mask 
(a regular "surgical" mask*) 
Respirator  
(NIOSH-approved, N-95 or higher*) 
Purpose  
To reduce transmission by capturing infectious droplet 
nuclei that an infectious patient releases before they 
get into the air. 
Purpose 
To reduce exposure by filtering infectious droplet 
nuclei out of the air, before the wearer breathes the air 
into their lungs. 
Who should wear a mask? 
 Patients with infectious TB or suspected infectious 
TB 
Who should wear a respirator? 
 Staff 
 Visitors to TB isolation rooms (keep these visitors to 
a minimum) 
A patient should wear a mask 
In a hospital setting when: 
 Suspected of having infectious TB and not yet 
placed in respiratory isolation 
 Leaving a respiratory isolation room for any reason 
Note: Infectious patients should NOT wear masks 
when in their TB isolation rooms. 
 
In a health clinic setting when: 
 Not in a TB isolation room 
 Returning to the clinic for evaluation 
A staff person or visitor should wear a respirator 
In a hospital or clinic setting when: 
 Entering a TB isolation room 
 Performing cough-inducing or aerosol-generating 
procedures 
 Unlikely to be protected by administrative or 
environmental controls 
 
A patient should wear a mask 
In a transportation setting when: 
 Traveling in a vehicle with other persons 
A staff person or visitor should wear a respirator 
In some transportation settings when: 
 Riding in a vehicle with a patient with infectious TB 
In the patient’s home: 
 
Note: Infectious patients do NOT need to wear a mask 
when they are in their homes. 
A staff person or visitor* should wear a respirator 
In a patient’s home when: 
 Visiting the infectious patient inside a 
home/residence 
 
*Note: There should NOT be any visitors (excluding 
protected healthcare workers) to the home until the 
patient is released from TB isolation. 
Definition of abbreviations:  NIOSH = National Institute for Occupational Safety and Health; TB = tuberculosis. 
* There are some devices, such as the 3M 1860,  which are both N95 respirators and surgical masks. 
Source: CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 2005. 
MMWR 2005;54(No. RR-17):38–40.  
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Two-Step Tuberculin Skin Testing 
Two-step testing is used to improve the interpretation of tuberculin skin tests (TSTs), 
especially in persons who need to receive serial tests. Two-step testing should be used 
for the initial skin testing of adults who will be retested periodically, such as healthcare 
workers.24  
In some persons who are infected with Mycobacterium tuberculosis, delayed-type 
hypersensitivity to tuberculin may wane over the years. When these persons are skin 
tested many years after their infection, they may have a negative reaction.  
However, the skin test may have stimulated (boosted) their ability to react to tuberculin, 
causing a positive reaction to subsequent tests. This boosted reaction may be 
misinterpreted as a new infection. The booster phenomenon may occur at any age, but 
its frequency increases with age and is highest among older persons. Boosted reactions 
may occur in persons infected with nontuberculous mycobacteria or in persons who 
have had a prior Bacille Calmette-Guérin (BCG) vaccination. 
A positive reaction to the second test should be interpreted as evidence for infection with 
M. tuberculosis. On the basis of this second test result, the person should be classified 
as previously infected and cared for accordingly. This would not be considered a skin 
test conversion.  
If the first and second test results are negative, the person should be classified as 
uninfected. In these persons, a positive reaction to any subsequent test is likely to 
represent new infection with M. tuberculosis (a skin test conversion). 
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Schedule apppointments for two-step testing as shown below.  
Refer to the topics on administration, measurement, and interpretation of the 
tuberculin skin test in the section on Finding and Diagnosing Tuberculosis 
Disease and Latent Tuberculosis Infection. 
  
Table 3: FOUR APPOINTMENT SCHEDULE FOR TWO-STEP TESTING 
Appointments Tasks 
First appointment Apply the first tuberculin skin test (TST). 
Second appointment 
48 to 72 hours after applying the 
first TST 
Measure the reaction. 
 If the reaction is negative, schedule a third appointment. 
 If the reaction is positive, do not repeat the TST. Obtain a chest 
radiograph. 
Second or third appointment 
1 to 3 weeks after measurement 
of the first TST 
Re-apply the TST. 
 Use the same dose and strength of tuberculin. Inject the tuberculin on the 
other forearm, or at least 5 cm from the original test site.  
 If the reaction is negative and the patient returns over a week after the first 
TST was applied, apply the second TST. 
Third or fourth appointment 
48 to 72 hours after applying the 
second TST 
Measure the reaction. 
 If the reaction is negative, classify the individual as uninfected. 
 If the reaction is positive, obtain a chest radiograph. 
 
For more information on two-step testing, refer to the CDC’s “Guidelines for 
Preventing the Transmission of Mycobacterium tuberculosis in Health-care 
Facilities, 2005” (MMWR 2005;54[No. RR-17]) at 
http://www.cdc.gov/mmwr/pdf/rr/rr5417.pdf . 
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Isolation  
To reduce disease transmission, a patient with tuberculosis (TB) disease may need to 
be isolated or have activities restricted.  
Isolation: Isolation is used when people are ill. Isolation of people who have a specific 
illness separates them from healthy people and restricts their movement to stop the 
spread of that illness. Isolation allows for the focused delivery of specialized health care 
to people who are ill, and it protects healthy people from getting sick. People in isolation 
may be cared for in their homes, in hospitals, or at designated healthcare facilities. 
Isolation is a standard procedure used in hospitals today for patients with TB and certain 
other infectious diseases. In most cases, isolation is voluntary; however, many levels of 
government (federal, state, and local) have the basic legal authority to compel isolation 
of sick people to protect the public.25 
Restricted Activities: Until determined to be noninfectious, the patient is not permitted 
to return to work, school, or any social setting where the patient could expose individuals 
to airborne bacteria.  
Quarantine: Although TB control programs have used the word “quarantine” 
interchangeably with “isolation” and “restricted activities,” the word “quarantine” properly 
used is not a term applicable to TB control. Quarantine applies to people who have been 
exposed and may be infected but are not yet ill. Separating exposed people and 
restricting their movements is intended to stop the spread of illness. Quarantine is not an 
appropriate TB control measure for asymptomatic, exposed individuals. 26 
 
For information on diagnosis and laboratory tests, refer to the sections on 
diagnosis of tuberculosis disease and latent tuberculosis infection. For 
information on guidelines for infection control in the patient’s residence, 
group settings, and during transportation of a patient, see the subtopics 
that follow. 
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Estimating Infectiousness 
In general, patients who have suspected or confirmed TB disease and who are not on 
antituberculosis treatment should be considered infectious if characteristics include the 
following: 
 Presence of cough 
 Cavitation on chest radiograph 
 Positive acid-fast bacilli (AFB) sputum smear result 
 Respiratory tract disease with involvement of the lung or airways, including larynx 
 Failure to cover the mouth and nose when coughing 
 Undergoing cough-inducing or aerosol-generating procedures (e.g., sputum 
induction, bronchoscopy, airway suction) 27 
If a patient with one or more of these characteristics is on standard multidrug therapy 
with documented clinical improvement, usually in connection with smear conversion over 
several weeks, the risk of infectiousness is reduced.28  
Determining Noninfectiousness 
Use the following criteria as general guidelines to determine when during therapy a 
patient with pulmonary TB disease has become noninfectious. Decisions about infectivity 
of a person on treatment for TB should depend on the extent of illness and the specific 
nature and circumstances of the contact between the patient and exposed persons. 
These guidelines can and should be modified on a case-by-case basis by a qualified 
public health officer or health officer. 
 Patient has negligible likelihood of multidrug-resistant TB (no known exposure to 
multidrug-resistant tuberculosis and no history of prior episodes of TB with poor 
compliance during treatment). 
 Patient has received standard multidrug antituberculosis therapy for two to three 
weeks. (For patients with AFB sputum smear results that are negative or rarely 
positive, threshold for treatment is four to seven days.) 
 Patient has demonstrated complete adherence to treatment (e.g., is receiving directly 
observed therapy). 
 Patient has demonstrated evidence of clinical improvement (e.g., reduction in the 
frequency of cough or reduction of the grade of the AFB sputum smear result). 
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 All close contacts of the patient have been identified, evaluated, advised, and, if 
indicated, started on treatment for latent TB infection. This criterion is critical, 
especially for children younger than 5 years of age and persons of any age with 
immunocompromising health conditions such as human immunodeficiency virus 
(HIV) infection. 
 While in hospital for any reason, patients with pulmonary TB should remain in 
airborne infection isolation until they  
• Are receiving standard multidrug antituberculosis therapy;  
• Have demonstrated clinical improvement;  
• Have had three consecutive AFB-negative smear results of sputum specimens 
collected eight to 24 hours apart, with at least one being an early morning 
specimen. 
 
Hospitalized patients returning to a congregate setting (e.g., a homeless shelter or 
detention facility) should have three consecutive AFB-negative smear results of 
sputum specimens collected more than eight hours apart before being considered 
noninfectious.29 
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Airborne Infection Isolation  
in a Healthcare Facility 
In airborne infection isolation (AII), the patient is placed in an AII room, usually within a 
hospital or healthcare facility. The main characteristics of an AII room (for new or 
renovated buildings) are that it has negative air pressure relative to the hall and 12 or 
more air exchanges per hour, of which at least two exchanges are outside air. For 
existing structures, six or more air exchanges per hour are acceptable.30  
The decisions to initiate and discontinue isolation should be made in consultation with 
the TB Control Department at the local health agency or the TB Control Officer at the 
Arizona Department of Health Services at 602-364-4750. Isolation decisions should be 
made on a case-by-case basis.  
When to Initiate Airborne Infection Isolation  
Suspected cases of laryngeal or pulmonary TB should be isolated immediately, before 
AFB sputum smear results are available.  
Initiate TB AII precautions for any patient who meets the criteria in Table 4.  
Table 4: INITIATION OF AIRBORNE INFECTION ISOLATION31 
Criteria for Initiation of Airborne Infection Isolation  
The patient has signs or symptoms of 
pulmonary, laryngeal, or multidrug-resistant 
tuberculosis (MDR-TB) disease 
OR  The patient has documented infectious  
pulmonary, laryngeal tuberculosis (TB) disease or 
MDR-TB disease 
         AND 
 The patient has not completed treatment  
Source: CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. 
MMWR 2005;54(No. RR-17):16, 44. 
 
 
 
Patients with suspected or confirmed MDR-TB should remain in an AII 
room throughout their hospitalization or until culture conversion is 
documented, regardless of sputum smear results. 
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When to Discontinue Airborne Infection Isolation  
 
Prior to discontinuing isolation, call the local health agency. High-risk 
patients should be carefully evaluated before discontinuing isolation. 
Hospitalized patients with suspected or confirmed MDR-TB should remain 
in an AII room throughout their hospitalization. 
 
Suspected Tuberculosis Disease 
For patients placed in AII due to suspected infectious TB disease of the lungs, airway, or 
larynx, AII can be discontinued when the criteria in Table 5 are met.  
Table 5: DISCONTINUATION OF AIRBORNE INFECTION ISOLATION OF SUSPECTED 
CASES OF TUBERCULOSIS32  
Criteria for Discontinuing Airborne Infection Isolation: 
Suspected Case of Tuberculosis of the Lungs, Airway, or Larynx 
Infectious tuberculosis (TB) disease is 
considered unlikely 
AND Either  
 Another diagnosis is made that explains the 
clinical syndrome 
OR  
 The patient has 3 negative acid-fast bacilli (AFB) 
sputum smear results* has been on treatment 
delivered as directly observed therapy, and has 
demonstrated clinical improvement 
*   Each of the 3 sputum specimens should be collected 8 to 24 hours apart, and at least 1 should be an early morning specimen 
(because respiratory secretions pool overnight). Generally, this will allow patients with negative AFB sputum smear results to 
be released from AII in 2 days.33  
While in hospital for any reason, patients with pulmonary TB should remain in airborne infection isolation until they (1) are 
receiving standard multidrug antituberculosis therapy; (2) have demonstrated clinical improvement; and (3) have had 3 
consecutive AFB-negative smear results of sputum specimens collected 8 to 24 hours apart, with at least 1 being an early 
               morning specimen.34  
Because patients with TB disease who have negative AFB sputum smear results can still be infectious, patients with 
suspected disease who meet the above criteria for release from AII should not be released to an area where other patients 
with immunocompromising conditions or children <5 years are housed.35  
Sources: CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. 
MMWR 2005;54(No. RR-17):16, 43; ATS, CDC. Controlling tuberculosis in the United States: recommendations from 
the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR 2005;54(No. RR-12):9 
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Confirmed Tuberculosis Disease 
A patient with drug-susceptible TB of the lung, airway, or larynx who is on standard 
multidrug antituberculosis treatment and who has had a significant clinical and 
bacteriologic response to therapy (e.g., reduction in cough, resolution of fever, and 
progressively decreasing quantities of AFB on smear results) is probably no longer 
infectious. However, because culture and drug susceptibility results are not usually 
known when the decision to discontinue AII is made, all patients with confirmed TB 
disease should remain in AII while hospitalized until all the criteria in Table 6 are met.36  
Table 6: DISCONTINUATION OF AIRBORNE INFECTION ISOLATION OF CONFIRMED 
CASES OF TUBERCULOSIS37   
Criteria for Discontinuing Airborne Infection Isolation:  
Hospitalized Patients with Confirmed, Drug-Susceptible Tuberculosis  
of the Lungs, Airway, or Larynx  
 The patient has had 3 consecutive negative acid-fast bacilli (AFB) sputum smear results collected 8 to 24 hours 
apart, with at least 1 being an early morning specimen 
        AND 
 The patient has received standard multidrug antituberculosis treatment by directly observed therapy (DOT)  
        AND 
 The patient has demonstrated clinical improvement 
Source: CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. 
MMWR 2005;54(No. RR-17):43. 
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Hospital Discharge 
The decisions to discharge an AFB sputum smear-positive patient or an MDR-TB patient 
should be made in consultation with the TB Control Department at the local health 
agency or the TB Control Officer at the Arizona Department of Health Services at 602-
364-4750.  
Drug-Susceptible Tuberculosis Disease 
If a hospitalized patient who has suspected or confirmed drug-susceptible TB disease is 
deemed medically stable (including patients with positive AFB sputum smear results 
indicating pulmonary TB disease), the patient can be discharged from the hospital before 
converting AFB sputum smear results to negative if all the criteria in Table 7 are met.38  
Table 7: HOSPITAL DISCHARGE OF DRUG-SUSCEPTIBLE CASES OF 
TUBERCULOSIS39   
Criteria for Hospital Discharge to Home: 
Patients with Suspected or Confirmed Drug-Susceptible Tuberculosis  
 A specific plan exists for follow-up care with the local TB control program 
        AND 
 The patient has been started on a standard multidrug antituberculosis treatment regimen and directly observed 
therapy (DOT) has been arranged 
        AND 
 No children aged <5 years or persons with immunocompromising conditions are present in the household  
        AND 
 All immunocompetent household members have been previously exposed to the patient  
        AND 
 The patient is willing to not travel outside the home except for healthcare-associated visits until the patient has 
negative acid-fast bacilli (AFB) sputum smear results 
Source: CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. 
MMWR 2005;54(No. RR-17):43–44. 
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Multidrug-Resistant Tuberculosis Disease 
Patients with suspected or confirmed MDR-TB disease should remain in the hospital in 
AII until they meet all three of the criteria in Table 8. 
Table 8: HOSPITAL DISCHARGE OF MULTIDRUG-RESISTANT CASES OF 
TUBERCULOSIS 
Criteria for Hospital Discharge to Home:  
Patients with Suspected or Confirmed Multidrug-Resistant TB  
 The patient has had 3 consecutive negative acid-fast bacilli (AFB) sputum smear results collected 8 to 24 hours 
apart, with at least 1 being an early morning specimen 
        AND 
 An appropriate treatment regimen has been devised and initiated 
        AND 
 Suitable arrangements have been made so that the regimen can be continued and properly monitored on an 
outpatient basis, specifically by directly observed therapy (DOT)  
 
Release Settings 
Patients with suspected or confirmed infectious TB disease should not be released to 
healthcare settings or homes where the patient can expose others who are at high risk 
for progressing to TB disease if infected, such as HIV-infected persons or young 
children.40 Hospitalized patients returning to a congregate setting (e.g., a homeless 
shelter or detention facility) should have three consecutive AFB-negative smear results 
of sputum specimens collected more than eight hours apart before being considered 
noninfectious.41  
Patients who have positive AFB sputum smear results should not be directly discharged 
from the hospital to any of the following living environments:  
 Congregate living site (e.g., shelter, nursing home, jail, prison, group home, another 
hospital) 
 Living situation where infants and young children also reside  
 Living situation where immunosuppressed persons (e.g., HIV-infected persons or 
those taking cancer chemotherapy) also reside  
 Living situation where home health aides or other social service providers will be 
present in the home for several hours a day to care for the person or family member 
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Residential Settings 
Patients suspected of having infectious tuberculosis (TB) either are diagnosed during an 
outpatient workup, or if admitted to a hospital, are often sent home after starting 
treatment. Patients are sent home, even though they may still be infectious, because 
they are most likely to transmit TB to household members before TB has been 
diagnosed and treatment has started. However, TB patients and members of their 
household can take steps to prevent the spread of TB in their home until the patient 
becomes noninfectious.42,43 
Administrative Controls in the Patient’s Home 
Have a policy and procedure for managing infectious patients at home. To standardize 
care, the following information should be included: 
1. Definition of key terms: Infectious case and noninfectious case 
2. Treatment of cases at home whenever possible: Treat patients at home if their 
condition does not otherwise require hospitalization.  
3. Window period treatment policy: Ensure that candidates for window period 
treatment in the home have completed their evaluation and are on medication before 
they are discharged home (or as soon as possible if they were not hospitalized).  
4. Education: Educate infectious patients, family, care providers, and close contacts 
regarding the purpose of isolation, their responsibility to adhere to the isolation 
requirements, and the consequences of not voluntarily complying with isolation.  
5. Home isolation agreements: Have infectious cases in isolation sign a home 
isolation agreement. This document should include any legal consequences should 
they fail to voluntarily comply.  
 
 
Refer to the sample “Home Isolation Agreement” in the Appendix.  
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Environmental Controls in the Patient’s Home 
Generally, there are no special engineering recommendations. However, patients and 
their families can be advised to do the following: 
 Have tissues available for patients to cover their mouths and noses when coughing 
or sneezing. 
 Keep windows and doors open (weather permitting) to increase the ventilation and 
dilution of infectious droplet nuclei in the house.  
 If a sputum sample needs to be collected at home, do so in a well-ventilated area 
away from other residents (e.g., bathroom with an exhaust fan). If possible, collect 
the sputum in an outdoor area away from open windows or doors. 
Respiratory Protection in the Patient’s Home 
Patient: Mask 
 Patients do not need to wear masks at home. 
 Give patients regular surgical-type masks and advise them to wear them at medical 
appointments until they are no longer infectious.  
 
For more information on the criteria for noninfectiousness, see the 
“Determining Noninfectiousness” topic in this section. 
 
 Do not give patients respirators (N-95 or higher). 
Healthcare Worker: Respirator  
 Healthcare workers should wear respirators when entering the home or a closed 
area to visit with infectious patients. 
 The respirators should be National Institute for Occupational Safety and Health 
(NIOSH)-approved (N-95 or higher).  
 Healthcare workers should be provided with respirators after appropriate education 
and testing. 
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Other Residential Settings 
Motels 
Homeless persons with infectious TB may be housed in a motel that has outside access 
to rooms (not via hallways).  
The motel manager must be advised of the following: 
1. The patient is in respiratory isolation.  
2. The manager should report to local public health agency staff if the manager 
becomes aware that the patient does not stay in the room or has guests.  
3. The manager should advise motel staff that they are not to enter the room while the 
patient resides at the motel. (Arrangements should be made that once a week, the 
patient sets out linens that need to be replaced. The staff can knock on the door and 
leave the linens for the patient to make his or her own bed.)  
4. Upon release from isolation, the room should be aired out for one day before staff 
enter to clean. Afterwards, routine cleaning done between guests is sufficient, and 
there are no additional special cleaning requirements.  
5. Local public health agency staff will be delivering medication to the patient (specify 
the frequency).  
6. Arrangements have been made for food delivery to the patient. 
Healthcare Facilities or Residential Settings 
1. Patients with infectious TB should be in appropriate respiratory isolation (airborne 
infection isolation rooms) when housed in healthcare facilities or residential settings. 
2. If a facility does not have the capability to provide appropriate respiratory isolation, 
the patient should be transferred to a facility that can accommodate respiratory 
isolation until the patient is noninfectious. Once noninfectious, the person may return 
to the original facility. 
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Return to Work, School, or Other Social Settings 
The decision of when to allow a patient to return to work, school, or other social settings 
should be made in consultation with the TB Control Department at the local health 
agency or the TB Control Officer at the Arizona Department of Health Services at 602-
364-4750. 
The decision to permit a patient to return to work, school, or other social settings is 
based on the following:  
 The characteristics of the patient with TB disease (e.g., whether the patient is likely 
to adhere to the regimen and follow treatment instructions) 
 The characteristics of the TB disease itself (e.g., multidrug-resistant versus drug-
susceptible TB, AFB sputum smear-positive versus smear-negative, cavitary versus 
noncavitary)   
 The duration of current treatment (e.g., the patient has received standard multidrug 
antituberculosis therapy for two-to-three weeks or, if the patient AFB sputum smear 
that are negative or rarely positive, the threshold for treatment is four-to-seven 
days)44   
 The environment(s) to which the patient will be returning  
Prior to notifying a patient that he or she is able to return to work or school, call 
the TB Control Department at the local health agency or the TB Control Officer at 
the Arizona Department of Health Services at 602-364-4750. 
 
Drug-Susceptible Tuberculosis Disease 
Patients with drug-susceptible TB are no longer considered infectious if they meet all the 
criteria in Table 9.  
Table 9: RETURN TO WORK, SCHOOL, AND OTHER SETTINGS OF DRUG-
SUSCEPTIBLE CASES OF TUBERCULOSIS45   
Criteria for Return to Work, School, or Other Social Settings: 
Patients with Suspected or Confirmed Drug-Susceptible Tuberculosis  
 The patient is on adequate therapy 
        AND 
 The patient has had a significant clinical response to therapy 
        AND 
 The patient has had 3 consecutive negative acid-fast bacilli (AFB) sputum smear results collected 8 to 24 hours 
apart, with at least 1 being an early morning specimen  
Source: CDC. Infectiousness. Core Curriculum on Tuberculosis (2000) November 2001. 
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Multidrug-Resistant Tuberculosis (MDR-TB) Disease 
Regardless of their occupation, patients known or likely to have pulmonary MDR-TB may 
be considered for return to work or school only if they meet all four of the criteria in Table 
10. 
Table 10: RETURN TO WORK, SCHOOL, AND OTHER SETTINGS OF MULTIDRUG-
RESISTANT CASES OF TUBERCULOSIS  
Criteria for Return to Work, School, or Other Social Settings: 
Patients with Suspected or Confirmed Multidrug-Resistant TB   
 The resolution of fever and the resolution, or near resolution, of cough has occurred 
        AND 
 The patient is on current treatment with an antituberculosis regimen to which the strain is known or likely to be 
susceptible* 
        AND 
 The patient has had 3 consecutive negative acid-fast bacilli (AFB) sputum smear results collected 8 to 24 hours 
apart, with at least 1 being an early morning specimen  
        AND 
 The patient has had a negative culture for Mycobacterium tuberculosis  
*In addition, directly observed therapy (DOT) must be done for patients with MDR-TB. 
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Tuberculosis Infection Control  
in Patient Care Facilities 
Patients with suspected tuberculosis (TB) may present for care in many different 
settings. The Centers for Disease Control and Prevention (CDC) has written a 
comprehensive set of guidelines for TB infection control in acute care hospitals and 
other medical settings.46  In addition to the CDC guidelines, various professional 
organizations or state regulations may have guidelines for managing TB patients.  
The main focus in establishing a TB infection control program at a patient care facility is 
to: 
1. Assign responsibility for managing the program to a designated staff position; 
2. Perform and establish a TB risk assessment for the facility; and 
3. Develop the TB infection control plan based on the level of TB risk identified in the 
assessment. 
The main purpose for having an effective TB infection control plan in a facility is to 
assure that the activities necessary for TB control are addressed and that policies and 
procedures are developed to protect the healthcare workers, other patients, and visitors 
in the facility. 
Table 11: Guidelines for Tuberculosis Infection Control lists references that provide 
the information needed to conduct a TB risk assessment and write a TB infection control 
plan to establish policies and procedures for TB control activities inpatient care facilities.  
 
Call the TB Control Department at the local health agency or the TB Control 
Officer at the Arizona Department of Health Services at 602-364-4750.if you have 
any questions when consulting with institutions on infection control measures. 
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Table 11: GUIDELINES FOR TUBERCULOSIS INFECTION CONTROL 
Guidelines for Tuberculosis Infection Control 
 
The following settings are addressed in the “Guidelines for Preventing the Transmission of Mycobacterium 
tuberculosis in Health-care Facilities, 2005” (MMWR 2005;54[No. RR-17])  at http://www.cdc.gov/mmwr/pdf/rr/rr5417.pdf 
Some settings have additional guidelines as noted below.  
 
Inpatient Settings 
 Emergency departments and urgent care settings 
 Intensive care units 
 Surgical suits 
 Laboratories 
 Bronchoscopy suites 
 Sputum induction and inhalation therapy rooms 
 Autopsy suites and embalming rooms 
 
Outpatient Settings 
 Tuberculosis (TB) treatment facilities 
 Medical settings in correctional facilities: Prevention and Control of Tuberculosis in Correctional Facilities. (ACET) 
(MMWR 1996;45[No. RR-8]) at http://www.cdc.gov/nchstp/tb/pubs/mmwrhtml/Maj_guide/Correctional.htm  
 Medical offices and ambulatory care settings 
 Dialysis units 
 
Nontraditional Facility-Based Settings 
 Homeless shelter clinics: Prevention and Control of Tuberculosis Among Homeless Persons (ACET) (MMWR 
1992;41[No. RR-5]) at  http://www.cdc.gov/mmwr/preview/mmwrhtml/00019922.htm 
 Emergency medical services 
 Home-based healthcare and outreach settings 
 Long-term care facilities (e.g., hospices, skilled nursing facilities): Prevention and Control of Tuberculosis in 
Facilities Providing Long-Term Care to the Elderly (MMWR 1990;39[No. RR-10]) at 
http://www.cdc.gov/mmwr/preview/mmwrhtml/00001711.htm 
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Transportation Vehicles 
To prevent the transmission of M. tuberculosis while transporting patients, follow the 
respiratory precautions identified below. 
Patient Self-Transport  
1. The car windows should be opened, and any recirculating air controls should be 
turned off. 
2. If possible, only household members should accompany the patient. Any members of 
the patient’s household who accompany the patient do not need to wear surgical 
masks. 
3. If the only source for transport is a friend or relative who is not a member of the 
patient’s household: 
a. The person accompanying the patient should be given a respirator (N-95) to 
wear during transport (due to the confined space and lack of ongoing exposure). 
b. The patient should sit in the back seat and wear a surgical mask. 
c. The car windows should be opened, and any recirculating air controls should be 
turned off. 
4. The patient should wear a surgical mask after leaving the vehicle.47 
Transport by Healthcare Workers 
1. Healthcare workers should wear respiratory protection (N-95) while in the vehicle. 
2. The patient should wear a surgical mask and sit in the back seat. 
3. The car windows should be opened, and any recirculating air controls should be 
turned off. 48 
Transport by Emergency Medical Services 
Emergency medical services staff have specialized vehicles that may have the ability to 
separate the driver’s compartment from the transport compartment and rear exhaust 
fans. Recommendations for these vehicles and staff are addressed in the Centers for 
Disease Control and Prevention (CDC) “Guidelines for Preventing the Transmission of 
Mycobacterium tuberculosis in Health-care Facilities, 2005” (MMWR 2005;54[No. RR-
17]:25–26, 88, 127) at http://www.cdc.gov/mmwr/pdf/rr/rr5417.pdf . 
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Resources and References 
Resources 
 CDC. “Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in 
Health-care Settings, 2005” (MMWR 2005;54[No. RR-17]) at 
http://www.cdc.gov/mmwr/pdf/rr/rr5417.pdf  
 CDC. “Guidelines for Environmental Infection Control in Health-care Facilities“ 
(MMWR 2003;52[No. RR-10]) at http://www.cdc.gov/mmwr/PDF/rr/rr5210.pdf   
 CDC. Interactive Core Curriculum on Tuberculosis at 
http://www.cdc.gov/nchstp/tb/webcourses/CoreCurr/index.htm  
 CDC. “Respiratory Protection in Health-Care Settings” (TB Elimination Fact Sheet 
April 2006) at http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/rphcs.pdf  
 CDC. Module 4: “Treatment of TB Infection and Disease” (Self-Study Modules on 
Tuberculosis 1999) at http://www.phppo.cdc.gov/phtn/tbmodules/modules1-5/m4/4-
m-04b.htm  
 CDC. Module 5: “Infectiousness and Infection Control” (Self-Study Modules on 
Tuberculosis 1999) at http://www.phppo.cdc.gov/phtn/tbmodules/modules1-
5/Default.htm 
 NIOSH. “Respiratory Protection” [ Web page] at  
http://www.cdc.gov/niosh/npptl/topics/respirators/  
 OSHA. “Tuberculosis: OSHA Standards” [Web page] at 
http://www.osha.gov/SLTC/tuberculosis/standards.html  
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Prevention Registry Form 
       (Primary Use: Record information on Contacts and Targeted and Other Testing Clients) 
 
DEMOGRAPHICS 
 
Date Entered into Registry: ___/___/____    Provider Code _______    Provider Group ______________    Clinic Name ____________________________________ 
                    (see provider code list)        (generated by the software)            (only applicable in limited, special  investigation situations) 
 
Event ID:___________   Local  ID/ ADC #: _________________   Other ID: ______________________________________  County:__________________________ 
(generated by Registry)        (ex: Medical Record # or Booking #)                          (for local information)           (of current residence) 
 
Last Name: ___________________________   First Name: ____________________  Initial  ____   A.K.A.: _______________________________________________ 
 
Street Address: ___________________________________________________________  City: _____________________   State:  ______  ZIP Code: _____________ 
                   
Telephone (include area code): Home: ___________________________     Work: _______________________________    Other: _____________________________  
 
Mailing Address (if different than Street Address): ______________________________________ City: _________________   State:  ______  ZIP Code: __________ 
 
Service Origin Date ___/___/_____  Date of Birth: ___/___/_____             This Client  is/was a TB Suspect                   Start         Stop         Change / Update 
     (1st date of initial contact)     
Gender Race Ethnicity Reason For Testing Population Risk Residence Country of Birth 
 Female 
 Male 
 White 
 Asian  
 Native Hawaiian or  
    Pacific Islander 
 Black or African  
   American 
 American Indian or  
   Alaska Native 
Tribe ________________ 
 Other ______________ 
 Hispanic or  
   Latino 
 Not Hispanic 
    or Latino 
 Unknown 
These reasons should be 
considered sequentially. 
 Contact Investigation 
 Symptoms/Diagnostic 
 Immigrant 
 Refugee 
 Day Care/School 
 Screening 
 Work Requirement 
 Public Relations 
 CDC Special Project 
    _______________ 
   (CDC project code) 
 Referred 
 Reactor Associate 
 Local Special Project 
 None 
 Low Income 
 Migrant Worker 
 Foreign Born 
 Health Care 
   Worker 
 Correction Facility 
    Worker 
 Frequent visitor to  
    a high risk country 
 Other_________ 
 Private residence 
 Homeless/Shelter 
 Jail/Prison  
    Inmate 
 Nursing Home / 
    Long Term Care 
 Treatment Center 
 Other _________ 
 United States 
 Mexico 
  Other _____________ 
 
  Entered U.S. 
  ___/___/___ 
 
MEDICAL HISTORY 
Diabetes Chemical Use HIV Status Lung Disease G.I./G.U. Cancer/Chemo Hepatitis Medications 
  None Known 
  Diet Only 
  Oral Meds 
  Insulin 
  Uncontrolled 
  None Known 
  Injected Drugs 
  Other Drugs 
  Excess Alcohol 
    >2 Drinks/Day 
    Binge Drinking 
  Current Tobacco 
    Amt. ________    
  Unknown 
  Negative 
  Positive 
  Undetermined 
  Result Pending 
Test Offered: 
  Yes 
  No 
  Refused 
  None Known 
  Asthma 
  Silicosis 
  Pneumonia 
  Other 
   ___________ 
  None Known 
  Gastrectomy 
  Intestinal Bypass 
  Pregnancy 
 EstDD ___/___/___ 
  Post-partum 
  End stage renal 
   disease 
  Under Ideal Wt. 
  None Known 
  Leukemia/ 
    Lymphomas/ 
    Malignancies 
  Immuno- 
    suppressive 
    Therapy 
  Other 
    ___________ 
  None 
    Known 
  Hep A 
  Hep B 
  Hep C 
  Unknown 
    Type 
  None Known 
  Corticosteroids 
  AntiConvulsants 
  Immunosuppressants 
  Birth Control 
  AntiRetroviral 
  Other ___________ 
  Allergies 
    ________________ 
 
CURRENT CLINICAL STATUS 
Prior TB Therapy Symptoms Skin Test Results Chest X-Ray Laboratory Tests 
  None Known 
  Prior Prevention 
  Incomplete PT 
  Undergoing PT 
  Active TB 
   Year _________ 
  Hx BCG 
   Year _________ 
  None 
  Prod. Cough 
  S.O.B. 
  Weight Loss 
  Night Sweats 
  Hemoptysis 
  Fever 
  Other 
 ____________ 
Wt.(lb)______ 
Wt(kg)______ 
At Current Evaluation: 
Date PPD1 placed: ___/___/____ 
Date PPD1 read: ___/___/____  
Results PPD1:_____ mm 
(record results in millimeters only) 
Date PPD2 placed: ___/___/____ 
Date PPD2 read: ___/___/____  
Results PPD2:_____ mm 
(record results in millimeters only) 
 
Last Known Neg. Test  ___________ 
 
Known Positive Reactor:     
  KPR    Date___/___/____ 
Results(mm)______       
 
Quantiferon Testing: 
Date Blood Drawn ___/___/____ 
Final Results:  
               Positive     
               Negative 
               Indeterminate 
               Conditionally Positive  
At Current Evaluation: 
Date X-Ray ___/___/____ 
  Normal 
      Within Normal Limits 
      Limited to calcified granuloma 
  Abnormal 
      Perihilar adenopathy 
      Evidence of old inactive TB 
      Suspect active tuberculosis 
        Status:   Stable    Worsening 
                       Improving 
  Other ___________________ 
  Not Done/Refused 
 
Additional Chest X-Ray: 
Date X-Ray ___/___/____ 
Results:   Normal      Abnormal        
 If abnormal, Status:   Stable   
                                    Worsening   
                                    Improving 
  Other ___________________ 
Source of specimen: __________________ 
          Date            Smear          Culture 
1) ___/___/____     Pos ___+     Pos    
                               Neg              Neg  
                               Not done      Not done 
                               Pending        Pending 
2) ___/___/____     Pos ___+     Pos  
                               Neg              Neg 
                               Not done      Not done 
                              Pending        Pending 
3) ___/___/____     Pos ___+     Pos  
                               Neg              Neg  
                               Not done      Not done 
                               Pending        Pending 
Other _______________________ 
 
Blood Work 
date: ___/___/____  results: ____________ 
date: ___/___/____  results: ____________ 
date: ___/___/____  results: ____________ 
date: ___/___/____  results: ____________ 
date: ___/___/____  results: ____________ 
 
Questions about this Form?                 Arizona Department of Health Services 
Call: (602) 364-4750 or Fax: (602) 364-3267              Tuberculosis Control Program 
 
ASSOCIATED CASES/SOURCE CASE INVESTIGATIONS 
Information about the TB Case/Suspect Source Case Investigation 
Complete this section if the reason for testing is Contact Investigation: 
For non AZ cases, complete the following:   Non AZ Case     
For AZ cases, complete the following: 
TIMS # (State Case #)______________  Year Counted________  
TB Case’s Last Name:______________________________________ 
TB Case’s First Name:______________________________________   
TB Case’s D.O.B.___/___/____     Date TB Case was Interviewed ___/___/____ 
Date TB Case was Reported to the LHD ___/___/____ 
Type of Contact:   Close      Casual   
Relationship of Contact to TB Case:   Household    Work    Social    Other:___________ 
Last date contact was exposed to TB case (may differ with each contact): ___/___/____ 
Sputum Smear (TB case)    Sputum Culture (TB case)          
               Positive                          Positive                                    TB Ruled Out 
               Negative                        Negative 
               Not Done                       Not Done 
If contact to a second TB case within the same year, list that second TB case’s  
TIMS # (State Case#):_____________  & Name: ________________________________ 
Complete this section if the reason for testing is Reactor Associate 
(which includes child converters and other source case investigations): 
 
Record below information about the person for whom the source case 
investigation is being done: 
 
Last Name:_____________________________________ 
 
First Name:_______________  D.O.B.___/___/____ 
 
Reason for source case investigation: 
__________________________________________________________ 
__________________________________________________________ 
__________________________________________________________ 
__________________________________________________________ 
__________________________________________________________ 
 
CURRENT THERAPY 
Reason for Therapy Therapy  Duration Therapy Started 
Select choice from a or b but not from 
both. 
a. For the choices listed below, complete 
at least the Therapy, Duration, and 
Therapy Started Sections: 
   These reasons should be considered 
sequentially. 
  Contact, to recent TB case/suspect 
  Converter (only if documented negative  
   TST within last 2 years) 
  Medical High Risk 
  Old TB Disease 
  Reactor 
  Suspect Active TB 
  Transferred in for completion of therapy 
 
b. If this choice is selected, do not 
complete the Therapy, Duration, and 
Therapy Started sections: 
   Not a candidate for  therapy 
Select choice from a or b but not 
from both. 
a. Medication: 
Also complete the Duration and 
Therapy Started Sections 
  Isoniazid (INH) 
  Rifampin (RIF) 
  RIF/PZA (LTBI therapy, only) 
  Pyrazinamide (PZA) 
  Ethambutol (EMB) 
  Other  ____________ 
Is this a Change in Therapy? 
  Change in Therapy 
               OR 
b. Medication was not started 
because: 
  Not Recommended 
  Therapy Refused 
  Therapy Deferred-Also enter 
the Anticipated Start Date 
Select the recommended duration 
of therapy only if medication was 
started. 
           2 Months 
           4 Months 
           6 Months 
           9 Months 
           12 Months 
 
 
Method(s) used to deliver Therapy: 
  DOPT (LTBI) 
  DOT (Suspects) 
  Self Admin. 
  Both 
 
 
For suspects, only, is suspect 
improving on therapy for TB 
disease? 
  Yes         No 
Enter medication start date only if 
medication was actually started. 
Initial Start Date: ___/___/____  
Provider: ___________________ 
 
                        OR 
 
If medication was recommended but 
deferred, enter the anticipated medication 
start date here.  
Anticipated Start Date: ___/___/____ 
 
Signature: _______________________ 
 
case manager: ____________________ 
 
ordering  
physician:   _________________________ 
 
OUTCOME 
Classification ReStart and Stopped Therapy Date(s) and Reason(s) for Stop Comments: 
All contacts/clients/suspects 
must be classified; please select 
the choice that best describes 
the outcome of the evaluation.  
 
  0 (Not Exposed, Not  
        Infected) 
  1 (Exposed, Not Infected) 
  2 (Newly Infected, No  
       Current Disease) 
  2K (Known Positive Reactor, 
           No Current Disease) 
  2P (Infected, Provider  
          Diagnosed) 
  3 (TB Clinically Active)  
        RVCT Required 
  3M (Disease, not      
            Tuberculosis)  
  If MOTT:________________ 
  4 (TB Not Clinically Active) 
  5 (Tuberculosis Suspected) 
  6 (Client did not Return  to  
        Complete Evaluation) 
  7 (Education Only, No 
Evaluation) 
 
Please enter the date that the 
classification became final. 
 
Date Classification final: 
___/___/____ 
 
 Use these field(s) only if the client has a break in therapy.  
   Start Date          Stop Date               Reason                Provider 
___/___/____    ___/___/____   _______________    __________ 
___/___/____    ___/___/____   _______________    __________   
___/___/____    ___/___/____   _______________    __________   
 
Enter the final therapy stop date and reason below. 
Final Therapy Stop Date: ___/___/____  Provider: ___________ 
Final Reason Therapy was Stopped:  
  Completed Therapy  
  Patient Choice (AMA)  
  Moved  
  Adverse Reaction  
  Lost  
  Died of TB Disease  
  Died / Other  
  Not Infected  
  Provider Decision  
  Active TB Disease 
  Released from prison 
  Transferred to another prison  
                                                        
If the Client leaves from your jurisdiction, please complete the 
following: 
Address Moved/Released/Transferred to:  
__________________________________________ 
 
__________________________________________ 
 
__________________________________________ 
Date moved/released/transferred ____/____/______ 
 
__________________________________________________ 
 
__________________________________________________ 
 
__________________________________________________ 
 
__________________________________________________ 
 
__________________________________________________ 
 
__________________________________________________ 
 
__________________________________________________ 
 
__________________________________________________ 
 
__________________________________________________ 
 
__________________________________________________ 
 
__________________________________________________ 
 
__________________________________________________ 
 
__________________________________________________ 
 
__________________________________________________ 
 
__________________________________________________ 
 
Signature:____________________________________________                                                           (Chart Format ADHS Rev 5A: 6/05) 
Optional Information 
 
Last Name: ___________________________   First Name: ____________________  Initial  ____  Date of Birth: ___/___/_____ Local  ID/ADC #: _______________ 
 
Telephone: ______________   Mailing Address: ______________________________________  City: ________________   State:  ______  ZIP Code: _____________ 
 
CLIENT MANAGEMENT 
date 
____/____/____ 
____/____/____ 
____/____/____ 
____/____/____ 
____/____/____ 
____/____/____ 
____/____/____ 
____/____/____ 
____/____/____ 
____/____/____ 
____/____/____ 
____/____/____ 
____/____/____ 
____/____/____ 
____/____/____ 
____/____/____ 
____/____/____ 
____/____/____ 
 
medications/comments 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
adverse reactions reported 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
Next Clinic Appointment    Reason for next Appt. 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
date: ____/____/______      ____________________ 
 
 
ANNUAL SKIN TESTS   
 In order for clients who receive annual skin tests to be counted in the Standard Reports, the following must be done. Change the 
Service Origin Date (located in the Demographics Section on page 1) to the date of the current service. Move the skin testing information 
currently in the Skin Test Results Section (located in the Current Clinical Status Section on page 1) to this Section. Enter the current skin 
testing information into the now empty Skin Test Results Section (located in the Current Clinical Status Section on page 1). 
TB Skin Test #1 
Pt. Signature: ___________________ 
  Copy of Informed Consent to Pt. 
  Screening Questionnaire Completed 
Date PPD placed: ___/___/____ 
Lot #: ________ Initials: __________ 
Date PPD read: ___/___/____  
Results PPD:_____ mm 
Initials: __________ 
 
TB Skin Test #2 
Pt. Signature: ___________________ 
  Copy of Informed Consent to Pt. 
  Screening Questionnaire Completed 
Date PPD placed: ___/___/____ 
Lot #: ________ Initials: __________ 
Date PPD read: ___/___/____  
Results PPD:_____ mm 
Initials: __________ 
 
TB Skin Test #3 
Pt. Signature: ___________________ 
  Copy of Informed Consent to Pt. 
  Screening Questionnaire Completed 
Date PPD placed: ___/___/____ 
Lot #: ________ Initials: __________ 
Date PPD read: ___/___/____  
Results PPD:_____ mm 
Initials: __________ 
 
TB Skin Test #4 
Pt. Signature: ___________________ 
  Copy of Informed Consent to Pt. 
  Screening Questionnaire Completed 
Date PPD placed: ___/___/____ 
Lot #: ________ Initials: __________ 
Date PPD read: ___/___/____  
Results PPD:_____ mm 
Initials: __________ 
TB Skin Test #5 
Pt. Signature: ___________________ 
  Copy of Informed Consent to Pt. 
  Screening Questionnaire Completed 
Date PPD placed: ___/___/____ 
Lot #: ________ Initials: __________ 
Date PPD read: ___/___/____  
Results PPD:_____ mm 
Initials: __________ 
 
TB Skin Test #6 
Pt. Signature: ___________________ 
  Copy of Informed Consent to Pt. 
  Screening Questionnaire Completed 
Date PPD placed: ___/___/____ 
Lot #: ________ Initials: __________ 
Date PPD read: ___/___/____  
Results PPD:_____ mm 
Initials: __________ 
TB Skin Test #7 
Pt. Signature: ___________________ 
  Copy of Informed Consent to Pt. 
  Screening Questionnaire Completed 
Date PPD placed: ___/___/____ 
Lot #: ________ Initials: __________ 
Date PPD read: ___/___/____  
Results PPD:_____ mm 
Initials: __________ 
 
TB Skin Test #8 
Pt. Signature: ___________________ 
  Copy of Informed Consent to Pt. 
  Screening Questionnaire Completed 
Date PPD placed: ___/___/____ 
Lot #: ________ Initials: __________ 
Date PPD read: ___/___/____  
Results PPD:_____ mm 
Initials: __________ 
 
 
EDUCATION FOR CLIENTS WITH POSITIVE TB SKIN TEST 
Please check all educational information presented/given to client (initial and date each item presented/given, if desired) 
 
  Information on “What Having a Positive TB Skin Test Means” 
  Need for medical evaluation, including a Chest X-Ray 
  TB disease vs. TB infection 
  Risk Factors for progression to TB disease 
  Need for treatment of latent TB infection 
  Medication(s), length of treatment, and side effects 
  Need for monthly face-to-face evaluation 
  Completion of Treatment for Latent TB Infection card given 
 
 
 
 
Questions about this Form?                 Arizona Department of Health Services 
Call: (602) 230-5936 or Fax: (602) 263-4956              Tuberculosis Control Program 
County/Nation Specific Information 
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YAVAPAI COUNTY TB CASE/SUSPECT HOME ASSESSMENT SUMMARY 
 
Initial Assessment  DATE: ___/___/___                  TIMS/RVCT  ____________________________________ 
 
Patient’s Name__________________________________________  DOB ___/___/___    Social Security #  ______-____-________ 
 
AKA/Legal _____________________________________  Parent/Guardian (if applicable) _________________________________   
 
Where Patient Interviewed: _______________________________  Language _________________ Translator?  YES   NO    
 
Support Person ____________________  Phone (____)______-_________ 
 
Emergency Contact/Address _______________________________________________________  Phone (____)______-_________ 
 
Health Insurance:  ___________________________________  Type:  PPO   HMO   Medicare   
 
 Prior Authorization needed  YES   NO           Phone  _______________________________________ 
 
Housing:  House   Apt   Nsg Home   Shelter   Hotel/Motel    Institution Name/Address _____________________________________ 
 
Shares Sleeping Space:  YES   NO    Ventilation:    GOOD   POOR      Household Contacts?  YES   NO   # ____________________ 
 
Medical Risks of Contacts:  YES   NO  Explain ___________________________ Children:  YES   NO   # ______ Ages _________ 
 
__________________________________________________________________________________________________________ 
BARRIERS TO COMPLIANCE:  NONE  ____   LEVEL OF UNDERSTANDING RE:  TB:  Good ____   Needs Education ____ 
 
Transient Living Situation Psychiatric Problems Family Non-acceptance 
Homeless @ Assessment Alcohol Problems:  Current        Past Language Difficulties 
Homeless w/in past year Non-injecting drug use @ Dx Inaccessible Medical Resource 
Unsanitary Living Situation Type:  ________________________ Long Work Hours 
Chronic Incarceration Injection drug use w/in Past Year Transportation Problems 
Incarceration w/in Past Year Type:  ________________________ Inadequate Finances 
Correctional Facility @ Dx Recovery/Rehab w/in Past year Poor Nutrition 
Type:  Fed    State    City    County Resistance to Treatment Lack of Nutritious Food 
Resident Long Term Care @ Dx Resistance to DOT  
Type:  Hospital   Nsg Home    Psych Cultural Non-Acceptance of TB  
 
Immigration status upon US entry:  Refugee                 Student Visa    Immigrant        Class A     Class B1      Class B2        H1/H4  
Political Asylum     Tourist Visa      Undocumented    Parolee    Other:_______________ 
 
Actions Taken:  Masks:  YES  NO            Sputums to be Collected:  YES   NO               Needs Provided for:  YES   NO   
              Sent for Induction:  YES   NO  Where: _________________________________________ 
 
Recommend Discharge to Home:  YES    NO     Discharge to another Facility:  YES   NO         Isolation:  YES   NO  Type:________ 
 
DOT Recommended:  YES   NO  Reason: ______________________ Start Date: ______________ DOT Location: ______________ 
 
Initial Assessment Identified Needs/PLAN: _______________________________________________________________________ 
 
___________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________ 
 
PHN Signature/Date:  _________________________________________________________________________________________ 
YAVAPAI COUNTY COMMUNITY HEALTH SERVICES 
TB CONTROL PROGRAM 
 
TRATAMIENTO DE ISONIAZID PARA LA INFECCIÓN DE TB 
 
El doctor ha comprobado su expediente.  Su reacción a la prueba de la piel de TB y sus medios de la radiografía del  
pecho usted tiene infección de TB (LTBI).  LTBI significa que están durmiendo los gérmenes de TB.  Usted no es 
enfermo.  Usted no puede pasar los gérmenes a otros.   El doctor recomienda que usted toma el isoniazid (INH) para 
esta infección.   INH reducirá su riesgo de convertirse enfermo con enfermedad de TB en el futuro. Los gérmenes de 
TB son muy fuertes.  Muchos gérmenes mueren enseguida después de usted comienzan a tomar su medicina, pero 
algunos permanecen vivo en su cuerpo un largo plazo.   El oficial del control de TB ordenó INH por 9 meses.  
 
Los efectos secundarios a INH incluyen: 
• Dolor del estómago, calambres, náusea, o un malestar estomacal 
• Dolores o el calambres en sus dedos o dedos del pie 
• Orina oscura 
• Pérdida de apetito 
• Erupción/picazón 
• Vomito 
• Piel y/o ojos amarillos 
 
La mayoría de la gente puede tomar INH sin ninguno de estos problemas. 
 
Antes de comenzar el INH, necesitaremos saber si usted tiene o ha tenido enfermedad del riñón, diabetes, o 
problemas del hígado.  Traiga una lista de todas las medicaciones que usted está tomando actualmente.  Si usted es 
embarazado o que intenta conseguir embarazada, por favor, déjenos saber. 
 
Esté enterado que usted no debe beber alcohol mientras que toma esta droga 
 
Muchas veces el doctor pedirá la vitamina B6 para ser tomado junto con el INH. 
 
Usted puede necesitar examen de sangre para probar su hígado al principio del tratamiento.   Las pruebas del hígado 
serán hechas, según lo necesitado, durante el tratamiento.  No hay honorario a usted para esta prueba. 
 
Si usted ve a un doctor o a dentista por cualquier razón mientras que usted está tomando INH, dígale que usted esta 
tomando INH para la infección de TB y no para la enfermedad de TB.  Puede llamar al Departamento de Salud al  
928-442-5559, si tienen preguntas. 
 
Cómo tomar INH:  Tome su INH al mismo tiempo diario.  Si usted se olvida de una dosis, NO TOME UNA DOSIS 
ADICIONAL.  INH trabaja tomado lo más mejor posible en un estómago vacío; usted puede tomar con el alimento 
si es necesario prevenir dolores del estómago.  Evite de tomar a antiácidos 2 horas antes de tomar INH y 1 hora 
después.   
 
INH es dado gratuitamente por Yavapai County.  Usted necesitará visitar la clínica cada mes.   Las visitas son para 
comprobar y saber si hay cualquier problema con tomar el INH y conseguir otra botella del medicamento.   
 
Para comenzar el tratamiento de INH: 
En Cottonwood                                                                           En Prescott: 
639-8132                                                                                  771-3134 
 
 
Si usted tiene preguntas o problemas, llame: 
En Cottonwood                                                                     En Prescott: 
Kay Beddall, RN en 649-5058                                                    Jo Ann French, RN en 771-3134  
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TB CONTROL PROGRAM 
SAMPLE LETTER FOR LTBI 
 
ISONIAZID TREATMENT FOR TB INFECTION 
 
 
The doctor has checked your record.  Your reaction to the TB skin test and your chest x-ray means you have TB 
infection (LTBI).  LTBI means the TB germs are sleeping.  You are not sick.  You can’t pass the germs to others.   
The doctor recommends that you take isoniazid (INH) for this infection.   INH will reduce your risk of becoming 
sick with TB disease in the future. The TB germs are very strong.  Many germs die just after you start taking your 
medicine, but some stay alive in your body a long time.   The TB Control Officer has order INH for 9 months.  
 
Side effects to INH include: 
• Stomach pain, cramps, nausea, or an upset 
stomach 
• Aches or tingling in your fingers or toes 
• Dark urine 
• Loss of appetite 
• Rash/itching 
• Vomiting 
• Yellow skin and/or eyes 
 
Most people can take INH without any these problems. 
 
Before starting the INH, we will need to know if you have or have ever had kidney disease, diabetes, or liver 
problems.  Bring a list of all the medications you are currently taking.  If you are pregnant or trying to get pregnant, 
please let us know. 
 
Be aware that you should not drink alcoholic while taking this drug 
 
Many times the doctor will order vitamin B6 to be taken along with the INH. 
 
You may need to have blood drawn to test your liver at the beginning of treatment.   Liver tests will be done, as 
needed, during treatment.  There is no fee to you for this testing. 
 
If you see a doctor or dentist for any reason while you are taking INH, tell them that you are taking INH for TB 
infection and not for TB disease.  They can call Communicable Disease at the Health Department, at 928-771-3134, 
if they have questions. 
 
How to take INH:  Take your INH at the same time every day.  If you forget a dose, DO NOT TAKE AN EXTRA 
DOSE.  INH works best taken on an empty stomach; you may take with food if needed to prevent stomach pains.  
Avoid taking anti-acids 2 hour before taking INH and 1 hour after.   
 
INH is given free of charge by Yavapai County.  You will need to visit the clinic each month.   The visits are to 
check for any problems with taking the INH and to get another bottle of pills.   
 
To start INH treatment contact: 
       
 
 
If you have questions or problems, call: 
      
 
 
 
 
 
 
Template from YAVAPAI COUNTY COMMUNITY HEALTH SERVICES 
 
Revised:  12/4/07 
YAVAPAI COUNTY COMMUNITY HEALTH SERVICES 
TB CONTROL PROGRAM 
 
RCULOSIS (TB) 
ografía del pecho 
érmenes de TB.  
e usted tome un 
 enfermo con TB en 
uchos gérmenes mueren en seguida después de que usted 
com manecen vivos en su cuerpo por un largo plazo.   El oficial del 
cont es.  
 
undarios de la isoniacida pueden incluir: 
calambres, náusea, o malestar estomacal 
n sus dedos  
• Pérdida de apetito 
s problemas. 
e o ha tenido enfermedad del riñón, diabetes, o 
problemas del hígado.  Traiga una lista de todos los medicamentos que usted está tomando actualmente.  Si usted 
ina B6 junto con la isoniacida 
 
 Las pruebas del 
ta prueba. 
Si usted vaya a un doctor o dentista por cualquier razón mientras que usted esté tomando la isoniacida, dígale que 
e llamar al 
TRATAMIENTO DE ISONIACIDA PARA LA INFECCIÓN DE TUBE
 
El doctor ha comprobado su expediente.  Su reacción a la prueba de la piel de TB y su radi
muestran que usted tiene infección latente de TB.  Latente significa que están durmiendo los g
Usted no está enfermo.  Usted no puede pasar los gérmenes a otros.   El doctor recomienda qu
medicamento llamado isoniacida para esta infección.   Isoniacida reducirá su riesgo de ponerse
el futuro. Los gérmenes de TB son muy fuertes.  M
ience a tomar  el medicamento, pero algunos per
rol de TB ordenó que usted tome isoniacida por 9 mes
Los efectos sec
• Dolor del estómago, 
lores o el calambres e• Do
• Orina oscura 
• Sarpullio o picazón de la piel 
• Vómitos 
• Piel amarilla y/o ojos amarillos 
 
La mayoría de la gente puede tomar la isoniacida sin ninguno de esto
 
Antes de comenzar la isoniacida, necesitaremos saber si usted tien
está embarazada o  está intentando estar embarazada, por favor, déjenos saberlo. 
 
Esté enterado que usted no debe beber alcohol mientras que tome este medicamento. 
 
Muchas veces el doctor recitará que tome la vitam
Al principio del tratamiento, es posible que necesite un  examen de sangre para probar su hígado.  
hígado serán hechas durante el tratamiento según sea necesario.  No hay costo a usted para es
 
usted está tomando isoniacida para la infección de TB y no para la enfermedad de TB.  Pued
Departamento de Salud al  928-442-5559, si tienen preguntas. 
 
Cómo tomar la isoniacida:  Tome la isoniacida al mismo tiempo diario.  Si usted se olvida de una dosis, NO TOME 
UNA DOSIS ADICIONAL.  Es mejor que t a isoniacidaome l  con un estómago vacío.  Sin embargo, usted puede 
tom olo ómago.  Evite de tomar antiácidos 2 horas antes de 
tomar la isoniacida y 1 hora después.   
avapai County.  Usted necesitará visitar a la clínica cada 
mes  isoniacida, y también para conseguirle 
otra botella del medicamento.   
 
Para comenzar el tratamiento de isoniacida, llame: 
En Cottonwood                                                  En Prescott: 
639-8132                                                                771-3134 
 
 
Si usted tiene preguntas o problemas, llame: 
En Cottonwood                                                   En Prescott: 
Kay Beddall, RN en 649-5058                            Jo Ann French, RN en 771-3134  
 
arla con comida si sea necesario prevenir d res del est
 
Se le proporcionará la isoniacida sin ningún costo por Y
.   Las visitas son para averiguar si hay cualquier problema al tomar la
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YAVAPAI COUNTY COMMUNITY HEALTH SERVICES 
TB CONTROL PROGRAM 
 
RCULOSIS (TB) 
ografía del pecho 
érmenes de TB.  
e usted tome un 
 enfermo con TB en 
uchos gérmenes mueren en seguida después de que usted 
com manecen vivos en su cuerpo por un largo plazo.   El oficial del 
cont es.  
 
undarios de la isoniacida pueden incluir: 
calambres, náusea, o malestar estomacal 
n sus dedos  
• Pérdida de apetito 
s problemas. 
e o ha tenido enfermedad del riñón, diabetes, o 
problemas del hígado.  Traiga una lista de todos los medicamentos que usted está tomando actualmente.  Si usted 
ina B6 junto con la isoniacida 
 
 Las pruebas del 
ta prueba. 
Si usted vaya a un doctor o dentista por cualquier razón mientras que usted esté tomando la isoniacida, dígale que 
e llamar al 
TRATAMIENTO DE ISONIACIDA PARA LA INFECCIÓN DE TUBE
 
El doctor ha comprobado su expediente.  Su reacción a la prueba de la piel de TB y su radi
muestran que usted tiene infección latente de TB.  Latente significa que están durmiendo los g
Usted no está enfermo.  Usted no puede pasar los gérmenes a otros.   El doctor recomienda qu
medicamento llamado isoniacida para esta infección.   Isoniacida reducirá su riesgo de ponerse
el futuro. Los gérmenes de TB son muy fuertes.  M
ience a tomar  el medicamento, pero algunos per
rol de TB ordenó que usted tome isoniacida por 9 mes
Los efectos sec
• Dolor del estómago, 
lores o el calambres e• Do
• Orina oscura 
• Sarpullio o picazón de la piel 
• Vómitos 
• Piel amarilla y/o ojos amarillos 
 
La mayoría de la gente puede tomar la isoniacida sin ninguno de esto
 
Antes de comenzar la isoniacida, necesitaremos saber si usted tien
está embarazada o  está intentando estar embarazada, por favor, déjenos saberlo. 
 
Esté enterado que usted no debe beber alcohol mientras que tome este medicamento. 
 
Muchas veces el doctor recitará que tome la vitam
Al principio del tratamiento, es posible que necesite un  examen de sangre para probar su hígado.  
hígado serán hechas durante el tratamiento según sea necesario.  No hay costo a usted para es
 
usted está tomando isoniacida para la infección de TB y no para la enfermedad de TB.  Pued
Departamento de Salud al  928-442-5559, si tienen preguntas. 
 
Cómo tomar la isoniacida:  Tome la isoniacida al mismo tiempo diario.  Si usted se olvida de una dosis, NO TOME 
UNA DOSIS ADICIONAL.  Es mejor que t a isoniacidaome l  con un estómago vacío.  Sin embargo, usted puede 
tom olo ómago.  Evite de tomar antiácidos 2 horas antes de 
tomar la isoniacida y 1 hora después.   
avapai County.  Usted necesitará visitar a la clínica cada 
mes  isoniacida, y también para conseguirle 
otra botella del medicamento.   
 
Para comenzar el tratamiento de isoniacida, llame: 
En Cottonwood                                                  En Prescott: 
639-8132                                                                771-3134 
 
 
Si usted tiene preguntas o problemas, llame: 
En Cottonwood                                                   En Prescott: 
Kay Beddall, RN en 649-5058                            Jo Ann French, RN en 771-3134  
 
arla con comida si sea necesario prevenir d res del est
 
Se le proporcionará la isoniacida sin ningún costo por Y
.   Las visitas son para averiguar si hay cualquier problema al tomar la
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TB CONTROL PROGRAM 
SAMPLE TEMPLATE 
Med Start for TB Infection 
 
Medications currently taking 
Prescribed and OTC 
Medical treatments  
 
Risk of advancing to TB disease 
 
Benefits of treatment for this client 
 
Length of Treatment         4   6   9   
                                             Months 
Alcohol use S/S  of  TB 
No           Yes 
      Adverse reactions of treatment 
Stop medication and call if any of the 
following occur Taking INH Taking RIF 
        Rash related to medication intake Tingling/burning in hands and feet Weakness lasting >3 days 
        Loss of appetite no reason  Fever lasting >3 days 
        Tiredness for no reason  Joint Pain 
        Weight loss for no reason  Easy bruising 
        Stomach pain  Easy bleeding 
        Jaundice  Orange colored tears, sweat 
        Nausea  Staining of contacts 
        Vomiting   
        Dark urine   
        If you become pregnant    
Method of birth control (RIF) 
 
Today’s                        
 Weight 
 Blood draws 
Refill procedure 
 
Health Clearance 
 
Questions? 
 
Handouts given 
 
⁯ Completed TB history card given to client 
Name __________________________ 
Date of birth  _____________ 
⁯ Medication given  Lot # _________ Exp Date ___/___ 
⁯ Appointment for refill Date __________Time ______ 
⁯ Consent signed to be scanned                    Site ______ 
⁯ CC Consent to client 
⁯ CC Med Start to client 
 
_________________________________     ___________ 
TEMPLATE FROM YAVAPAI COUNTY COMMUNITY HEALTH SERVICES 
 
TB CONTROL PROGRAM 
SAMPLE TEMPLATE 
TEMPLATE FROM YAVAPAI COUNTY COMMUNITY HEALTH SERVICES 
 
Nurse                                                                             Date 
Interjurisdictional Follow-up Form 
 
 
 
 
 
 
30 day status:   located   not located 
Return to:  
     
 Name  Fax number 
     
 Jurisdiction  Phone number 
Patient name  Date of birth  / /  
 Last First Middle 
 
New address  
 Number Street/Apt. City State Zip Code 
New telephone ( )  Sex   Male   Female 
  Case: (Send  RVCT F/U2 to reporting jurisdiction) 
   Completed:  / /    Moved to: city county state  
   Died   Lost (after initially located)  Never located 
  Uncooperative or refused  Not TB  Other  
 
 Suspect: 
If verified,  and original jurisdiction 
submits RVCT, complete case 
outcome above. 
  Verified by lab  Verified by clinical 
  Verified by provider  Not verified 
  Other:  
 
 Contact: 
  No follow-up performed  Never located  
  Evaluated: □ Class II □ Class III □Class IV □No infection 
   Started treatment  Continuing treatment  Other:_________________ 
 
 LTBI/Convertor: 
  No follow-up performed  Never located  Started treatment 
   Continuing treatment  Other:_________________ 
Interjurisdictional Tuberculosis Notification 
Referring 
Jurisdiction  city county  state  Date sent  / /  
Contact person  Phone ( )  FAX ( )  
 
  Verified case→State where reported:  RVCT# (attach RVCT)  Not reported  
  Suspect case  Close contact  Reactor LTBI  Convertor  Source case investigation 
 
 
Patient name  Sex   Male  Female 
 Last First Middle 
Date of birth  / /  Interpreter needed?  No      Yes, specify language  
New address   Hispanic  No  Yes 
 Number/Street/Apt. Race    White  Black  Asian 
     Am.Indian/Nat.Alaskan. 
 City/State/ZipCode  Other:  
New telephone ( )  Date of expected arrival   / /  
New health provider:   Unknown  Known (name, address, phone)   
Insurance source:  None  Medicaid  Private  Medicare  Other  
Emergency contact: Name  Phone  
 
Laboratory information for    this referred case/suspect  index case for this contact  not applicable 
Date Specimen type Smear Culture Susceptibility Chest X-ray Other pertinent labs 
       
       
       
       
Site(s) of disease:   Pulmonary   Other(s) specify all  
Date 1st negative smear  / /   Not yet Date 1st negative culture  / /   Not yet 
TB skin test #1:Date  / /  Result  mm TB skin test #2: Date  / /  Result mm 
 
Contact/LTBI Information TB Skin test   Not Done 
TST #1  Date  / /  Result  mm TST#2  Date  / /  Result mm 
CXR    Not Done Date  / /   Normal  Other:  
Last known exposure to index case  / /  Place/intensity of exposure:  
 
Medications π this referred case/suspect π this referred contact/LTBI 
Drug Dose Start date Stop date 
    
    
    
    
    
    
 
 
Comments  
Planned completion date  / /  
DOT   No  Yes: start date  / /  
 Daily  1x W  2x W  3x W 
Last DOT  Date  / /  
Adherence problems/significant drug side effects:
  
  
  
  
  
Case Follow-Up In 30 days report to referring jurisdiction if located or not located and report final outcome. 
Other Follow-Up   Follow-up requested (form attached)  No follow-up requested 
TB CONTACT INVESTIGATION REPORT             CASE MANAGER: 
INDEX CASE: ________________________INFECTIOUSNESS OF CASE:      SPUTUM SMEAR+          SPUTUM CX+        CAVITY ON CXR 
STATE CASE #: ________________________         PAN SENITIVE          RESISTANT TO: ___________________________________ 
DOB: __/__/__  DATE ASSIGNED: ___________________________              
INFECTIOUS PERIOD:___________TO___________  GROUP NAME/ CONTACT PERSON: _________________________________________ 
% OF INFECTIVITY OF HIGH RISK CONTACTS:______________     REASON CI NOT EXPANDED: _________________________________ 
 
 
 
 
Contact Name/ Address/ Phone  
 
 
DOB 
Age 
Sex 
Race// Ethnicity 
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Date of 
Last 
Exposure 
 
Country 
of Birth 
Date of 
Arrival in 
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P
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Date Initial 
PPD’s mm’s 
 
 
 
Date F/U PPD 
mm’s 
 
 
 
CXR Date Results 
 
 
 
Medications Start  
and Stop Dates 
R
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Start __/__/__ 
Stop__/__/__ 
INH             RIF 
Other 
  
  
 
 
 
      
 
 
      
Start __/__/__ 
Stop__/__/__ 
INH             RIF 
Other 
  
  
 
 
 
      
 
 
            
Start __/__/__ 
Stop__/__/__ 
INH             RIF 
Other 
  
  
 
 
 
      
 
 
      
Start __/__/__ 
Stop__/__/__ 
INH             RIF 
Other 
  
  
 
 
 
      
 
 
      
Start __/__/__ 
Stop__/__/__ 
INH             RIF 
Other 
  
  
 
 
 
      
 
 
      
Start __/__/__ 
Stop__/__/__ 
INH             RIF 
Other 
  
Race: 
W-White 
B- Black 
A- Asian/ 
Pacific 
Islander 
I- American 
Indian 
O- Other 
Ethnicity: 
H- Hispanic 
N- Non- Hispanic 
U- Unknown 
 
 
Medical Risks: 
1- Diabetes 
2- Substance Use 
3- HIV 
4- Lung 
5- Kidney/ G.I. 
6- Cancer Imm Supp 
7- Hepatitis 
8- Hx of TB Disease 
Symptoms: 
0- None 
1- Prod. Cough 
2- S.O.B. 
3- Weight Loss 
4- Night Sweats 
5- Hemoptysis 
6- Fever/ Chills 
CXR: 
1- Normal 
2- Limited to calcified granulomas 
 3- Abnormal 
4- Perihilar adenopathy 
5- Evidence of old TB 
6- Suspect active TB 
Reason Why Therapy  
was Stopped: 
1- Completed Therapy 
2- Patient Choice 
(AMA) 
3- Moved 
4- Adverse Reaction 
5- Lost 
6- Died of TB Disease 
7- Died/ Other 
8- Not Infected 
9- Provider Decision 
10- Active TB Disease 
11- Released from Prison 
12- Transferred to 
 another prison 
Outcome: 
0- Not  Exposed/ Not 
Infected 
1- Exposed, Not Infected 
2- Newly Infected, No 
Current Disease 
2K- Known Positive 
Reactor, No Disease 
2p- Infected- Provider 
3- TB Clinically Active (TVCT 
Required) 
3M- Disease not TB 
4- TB Not Clinically Active 
5- Tuberculosis Suspect 
6- Client did not Return to Complete 
Evaluation 
 
Name: ___________________ 
DOB: ____________________ 
PID No: __________________ 
Sex:   Male    Female 
                                       Maricopa County Public Health Department 
Tuberculosis Program CXR Flow Sheet 
1645 Roosevelt Street 
Phoenix, AZ 85006 
   
 
 
TB Site     Pulmonary     Extra Pulmonary  __  Suspect ______             Other _ 
            
 INITIAL     CXR #1 MNTH#__ MNTH#__ MNTH#__ MNTH#__ MNTH#__ MNTH#__ 
Date         
Normal         
Primary Complex         
Abnormal-
Cavitry       
 
 
Abnormal-Non 
Cavitry 
C/W Tuberculosis 
        
Abnormal not 
C/W Tuberculosis       
 
 
         
Stable         
Worse         
Improved         
Comments         
CT Scan         
 
 
 
 
Page I Created 9/7/07 
                    Created on 12/7/2007 7:50:00 AM  
                                       Maricopa County Public Health Department 
Tuberculosis Program Laboratory Flow Sheet 
1645 Roosevelt Street 
Phoenix, AZ 85006 
   
TB Site   Pulmonary                       Mycobacteriology:      Sputum      ____________ 
Name: ___________________ 
DOB: ____________________ 
PID No: __________________ 
Sex:   Male    Female 
                Extra Pulmonary                 Bx/BAL    ______ 
______    Suspect                  Other   __________________        
                Other           Sensitivities:      Pansensitive          Resistant: ____________ 
__________________________________________________________________________________________ 
Date Ordered             
Weight             
            Visual            L   
Acuity           R                
Color Vision             
T.Bilirubin             
Alk. 
Phosphatase             
ALT             
AST             
HIV             
BUN             
Creatnine             
Glucose             
Uric Acid             
WBC             
HCT             
Platelet             
PMN             
Cocci Serology             
QFT-G             
Other             
             
             
             
             
             
             
 
Name: ___________________ 
DOB: ____________________ 
PID No: __________________ 
Sex:   Male    Female 
                                        Maricopa County Public Health Department 
 Tuberculosis Program Medication Flow Sheet 
 1645 Roosevelt Street 
 Phoenix, AZ 85006 
   
 
 
Medication/Dosage: I = Isoniazid_____      mg  SM = Streptomycin__________mg___________________ 
                                    R = Rifampin            mg  PZA = Pyrazinamide  mg_________________ 
                                    E = Ethambutol         mg                Other________________________________________ 
                                    B6 = Pyridoxine          mg       _____________ 
Drug Allergy:     NKA     Specify Allergy to Drug or Food:     _____________ 
TB Site       Pulmonary                       Mycobacteriology:     Sputum      _______ 
                            Extra Pulmonary               Bx/BAL_________________________ 
                              Other   _____________________  Suspect___________________________ 
  AGENT METHOD 
DATE WEEK INH RIF EMB PZA B6 SM Other M-F 2 x wk 
Total 
Dosages 
Missed 
Dosages Comments 
 1             
 2             
 3             
 4             
 5             
 6             
 7             
 8             
 9             
 10             
 11             
 12             
 13             
 14             
 15             
 16             
 17             
 18             
 19             
 20             
 21             
 22             
 23             
 24             
 25             
 26             
 
Page I Created 9/7/07 
Name: ___________________ 
DOB: ____________________ 
PID No: __________________ 
Sex:   Male    Female 
 
Maricopa County Public Health Department 
Tuberculosis Program Medication Flow Sheet 
1645 Roosevelt Street 
Phoenix, AZ 85006 
 
 
Medication/Dosage: I = Isoniazid_____      mg  SM = Streptomycin__________mg____________________  
   R = Rifampin            mg  PZA = Pyrazinamide __________________________  
B6 = Pyridoxine           mg______ Other____________mg_________________________ 
                                    E = Ethambutol         mg      ____________________________________________ 
Drug Allergy:    NKA     Specify Allergy to Drug or Food:      ________ 
_____________________________________________________________________________      
  AGENT METHOD 
DATE MONTH INH RIF EMB PZA B6 SM Other M-F 
2 x 
wk 
Total 
Dosages 
Missed 
Dosages Comments 
 7             
 8             
 9             
 10             
 11             
 12             
 13             
 14             
 15             
 16             
 17             
 18             
 19             
 20             
 21             
 22             
 23             
 24             
CATCH UP DOSAGES 
       b       
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                                        Maricopa County Public Health Department 
 Tuberculosis Program Mycobacteriology Flow Sheet 
 1645 Roosevelt Street 
 Phoenix, AZ 85006 
   
Page I Created 9/7/07 
 
 
Drug Allergy:     NKA     Specify Allergy to Drug or Food:     _____________ 
TB Site       Pulmonary                       Mycobacteriology:     Sputum      _______ 
                            Extra Pulmonary                Bx/BAL________________________ 
                            Suspect  _____________________               Other___________________________ 
_____________  Other_______________________________________________________________________ 
 
Mycobacteriology 
Date Rx Week Source Spec. Number 
SMEAR 
(+)          (-)
CULTURE 
(+)         (-) Sensitive Resistant Histology 
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
Name: ___________________ 
DOB: ____________________ 
PID No: __________________ 
Sex:   Male    Female 
 
COUNTY and TRIBE DON and TB NURSE COORDINATORS as of 11/30/2007  
Arizona Department of Health Services 
Tuberculosis Control Program 
1 
 
Apache County Health Department   Jennifer Foote, RN   
PO Box 1952, Springerville 85938   928-333-2415 
       djfoote@co.apache.az.us 
 
 
Cochise County Health Department                 Cindy Berry, RN 
1415 W. Melody Lane, Bldg A, Bisbee 85603  520-432-9468 
       cberry@co.cochise.az.us 
 
 
Coconino County Health Department   Linus Nienstadte, MPH 
2625 N. King St, Flagstaff 86004   928-522-7892 
       lnienstadte@coconino.az.gov 
 
 
Gila County Health Department   Lorraine Dalrymple, RN, DON  
1400 E. Ash, Globe 85501    Susan Koepf, RN  
       928-402-8807  
                 928-402-8808 
       ldalrymp@co.gila.az.us                
       skoepf@co.gila.az.us 
                                                                                                                       
Graham County Health Department   Kellie Konrad, RN 
826 W. Main, Safford 85546    928-428-0110 
       kkonrad@graham.az.gov   
 
 
Greenlee County Health Department    Michelle Scott, RN, DON Debbie Breshears, LPN 
PO Box 936, Clifton, 85533          928-865-2601   928-865-2601 
       928-865-2505   928-865-2505 
       mscott@co.greenlee.az.us dbreshears@co.greenlee.az.us 
    
               
La Paz County Health Department   Diana Grazier, RN, DON    
1112 Joshua Ave, Ste 204, Parker 85344   928-669-1100     
       dgrazier@co.la-paz.az.us 
         
         
Maricopa County Health Department   Walter Palmer, MPH    
1645 E. Roosevelt, Phoenix 85006   602-506-6643       
       walterpalmer@mail.maricopa.gov          
 
 
Mohave County Health Department   Christy Bronston, RN, DON 
PO Box 7000, Kingman 86401    928-753-0714 x4281 
       christine.bronston@co.mohave.az.us 
 
 
 
 
COUNTY and TRIBE DON and TB NURSE COORDINATORS as of 11/30/2007  
Navajo County Health Department   Tracy Letcher, RN, DON   
251 N. Penrod Rd #1, Show Low 85901   928-532-6050     
         tracy.letcher@co.navajo.az.us     
 
 
Navajo Nation TB Program    Sarah Yazzie 
Gallup Indian Medical Center     505-722-1589 
Public Health Nursing Department #39   s.yazzie@nndoh.org 
PO Box 1337, Gallup, NM 87301 
 
 
Pima County Health Department    Anne Davis, RN 
150 W. Congress, Tucson 85701   520-740-8613 
       anne.davis@pima.gov 
 
 
Pinal County Health Department   Graham Briggs   Artie Cordova 
P.O. Box 2945, Florence, 85232    520-866-7056   520-866-7362 
       graham.briggs@pinal.az.us  artie.cordova@pinal.az.us 
  
 
Santa Cruz County Health Department   Gail Randolph, RN DON 
91 E. La Castellana Drive, Nogales 85621   520-375-5046 
       gairan@mariposachc.net 
 
 
Tohono O’odham Health Department   Lavina Harris, LPN 
PO Box 810, Sells 85634    520-383-6200 
       lavina.harris@tonation-nsn.gov 
 
 
Yavapai County Health Department   JoAnn French, RN 
1090 Commerce Dr, Prescott 86305   928-442-5499 
       jo.ann.french@co.yavapai.az.us 
 
 
Yuma County Health Department    Maria Nunez, RN 
2200 W. 28th St, Yuma 85364    928-317-4585   
       maria.nunez@co.yuma.az.us 
Arizona Department of Health Services 
Tuberculosis Control Program 
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                                       Maricopa County Public Health Department 
Tuberculosis Program Summary Sheet 
1645 Roosevelt Street 
Phoenix, AZ 85006 
 
TB Site   Pulmonary                Mycobacteriology:           Sputum         Allergies:  
               Extra Pulmonary               Bx/BAL   
    Suspect                Other   ______         
               Other              Sensitivities:      Pansensitive          Resistant: ______ 
                                         Date     Date       Date        Date       Date       Date       Date        Date    
  Created on 1/2/2008 8:09:00 AM 
Action Items          
Repeat Sputum          
Repeat Blood Work          
Provider Visits          
Repeat CXR          
Visual Acuity          
Color Vision          
Temp/Weight/VS/Ht          
DOT          
Precautions (Mask or Universal)          
Taxi          
Other          
ACTION ITEMS Date Collected Date Started Date Due Date Completed Date 
Sent
RVCT Pages 1&2      
RVCT Follow-up Report 1      
RVCT Follow-up Report 2 completed & sent      
ADHS Form Completed      
ACTION ITEMS Yes No Results Date Completed Provider 
Notified
TST Results      
Initial W/U completed      
HIV Testing done      
Contact Investigation/Source Case 
Investigation 
     
Culture Report Positive      
Sensitivity Report Received      
Ethambutol stopped?      
On treatment 8 weeks (specify date), 
Should PZA be stopped? 
     
Sputum Conversion Date      
Discharge: (6 months course -26 wks) 
                  (9months course-39 wks)      
Post Rx Follow-up @ 6mon 
                                @ 18 mon      
Name: ___________________ 
DOB: ____________________ 
PID No: __________________ 
Sex:   Male    Female 
  Created on 1/2/2008 8:09:00 AM 
 
Texas Department of State Health Services 
TB Case and Suspect Management Plan 
 
 
Patient’s Name:        Initial Report Date:      
              
Nurse Case Manager:       Case Management Team:     
               
                                       
Directions:  Blank boxes indicate week(s) TB service is to be provided.  Document date and initials of the provider in the appropriate box 
when the task is completed. Document comments in progress notes.   
Action:                                                                                                        
Interval: 
0 
Begin
2 
Wks
4 
Wks
8 
Wks 
12 
Wks 
16 
Wks
20 
Wks
24 
Wks
26 
Wks
Date /    / /    / /    / /    / /    / /    / /    / /    / /    / 
Responsibility   Assign nurse case manager; establish team; document 
in client’s record 
         
Obtain medical history; document on TB-202          
Obtain release (L-30); request previous medical records          
MD evaluation          
RN evaluation          
Mantoux skin test (if not previously done)          
Chest X-ray          
Supervised sputum for AFB smear/culture according to 
protocol 
         
HIV screening for risk factors; counseling and testing          
Medical 
Evaluation 
Nutritional assessment 
 
         
Drug regimen according to protocol or specific order          
Initiate DOT on all cases/suspects:  Daily X2 weeks, 
2X/week (Mon/Thurs or Tues/Fri) or 3X/week 
(Mon/Wed/Fri) til completion of adequate therapy; 
document DOT on TB-206  
         
Pyrazinamide X2 months and ethambutol X2 months 
(or until susceptibilities are reported and client’s 
organism is known to be pan sensitive) 
         
Vitamin B6 (if pregnant, diabetic, at risk for peripheral 
neuropathy) 
         
Treatment 
Obtain Informed Consent form TB-411 (TB-411A, if 
Spanish speaking, only) initially and for any drugs 
added to regimen. 
         
Consultation Obtain expert consult for drug resistant cases, 
complicated adult/pediatric cases or client who remains 
symptomatic or sputum positive after 2 months therapy; 
written consult in client record 
         
Clinical assessment according to protocol; document 
(TB-205 and progress note as appropriate) 
         
Visual acuity (Snellen) and color discrimination 
(Ishihara Plates) initially and monthly if on EMB or 
rifabutin; document (TB-205) 
         
Toxicity/ 
Clinical 
Assessment 
Hearing sweep check initially and monthly if on 
amikacin, capreomycin, kanamycin or streptomycin; 
document (TB-205) 
         
 
TB-201 TB Case and Suspect Management Plan for Outpatient Care – 01/06  (Continued on Reverse) 
TB Case and Suspect Management Plan for Outpatient Care 
 
Action:                                                                                                   
Interval: 
0 
Begin
2 
Wks
4 
Wks
8 
Wks
12 
Wks 
16 
Wks 
20 
Wks
24 
Wks
26 
Wks
Date /    / /    / /    / /    / /    / /    / /    / /    / /    / 
Issue Order to Implement Measures for a Client With 
Tuberculosis form TB-410 (TB-410A, if Spanish 
speaking, only) on all cases/suspects  
         
Follow-up missed appointments within 1 working 
day; initiate court-ordered management according to 
TDH policy (see TB Policy Manual, Section 5) and 
notify Regional office 
         
Adherence 
Evaluate barriers to treatment          
Conduct site visit to assess living situation; isolate 
from congregate living situation and exclude from 
work or school, if infectious 
         Isolation 
Allow to return to work/school following 2 wks 
appropriate therapy, 3 consecutive negative smears 
on different days and an improvement of symptoms 
         
Education Appropriate client education provided initially and 
monthly per protocol; written instructions and review 
of medication side effects, monthly and document on 
TB-203 
         
Interview case/suspect and contacts; plan contact 
investigation using the “Concentric Circle” approach 
         
Initiate contact investigation within 3 working days; 
interview and evaluate (skin test/reading, CXR, 
medical evaluation) within 7 days; document on  
TB-340 
         
Expand contact investigation if >30% of close high-
risk contacts have positive Mantoux skin tests 
         
Provide second skin test 8-10 weeks after break in 
contact with the case to all contacts who were skin 
test negative on the initial test; document on TB-340  
         
Public Health/ 
Contact 
Investigation  
Provide education and counseling for contacts          
Report suspect/case to state designated case registry 
within 1 working day of notification 
         
Submit TB-400A and TB-400B (all data fields 
complete) within 7 days of diagnosis; submit  
TB-400B at least quarterly and at the time of closure 
         
Reporting 
Submit TB-340 within 14 working days of initiating 
contact investigation and after second testing of 
negative contacts is complete 
         
Clinical supervisor or TB Program Manager reviews 
and evaluates contact investigation 
         Quality 
Assurance 
Review Team review of client record           
Social Services Enroll in Medicaid, if eligible; make appropriate 
referrals to drug/alcohol treatment programs and refer 
for HIV services, if necessary 
         
 
 
PRINTED NAME:          SIGNATURE:           INITIALS:       
 
 
PRINTED NAME:          SIGNATURE:           INITIALS:       
 
 
PRINTED NAME:          SIGNATURE:           INITIALS:       
 
 
PRINTED NAME:          SIGNATURE:           INITIALS:       
 
TB-201 TB Case and Suspect Management Plan for Outpatient Care – 01/06 
Texas Department of State Health Services 
Tuberculosis Education/Counseling Record 
 
NAME: __________________________________________________     D.O.B.: _____ /_____ /_____    SS#: _____ /____ /______    
 
Comments: 
 
 
 
 
 
 
 
Initial 
Visit 
1 Mo 
Date 
2 Mo 
Date 
3 Mo 
Date 
4 Mo 
Date 
5 Mo 
Date 
6 Mo 
Date 
7 Mo 
Date 
8 Mo 
Date 
9 Mo 
Date 
Instructions: 
υ  Provide appropriate Education/Counseling to ALL TB  clients.  
υ  Each client must have an education/counseling plan based on 
individual assessment and need. 
υ  This tool serves as a guideline but education/counseling should 
not be limited to this information only. 
υ  Initial each box as education/counseling is performed.  
υ  The ( Υ) indicates when instruction should occur.  
υ  Standardized printed materials (in client’s preferred language, 
if available) are provided to client on the initial visit. 
υ  All staff providing client education must be familiar with 
reference information listed in the TB standing delegation orders. 
 
 
     
 
 
 
 
 
 
 
 
 
 
TRANSMISSION/PATHOGENESIS: 
ρ Signs/symptoms of TB   ρ Airborne disease    
ρ Infectiousness of case   ρ Shared airspace   ρ PPD(+)  2-
10 weeks after initial infection   ρ 10% of infected will 
develop disease   ρ TB infection vs. disease  
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
INFECTION CONTROL MEASURES:    
ρ Proper use of masks   ρ Isolation/return to work   ρ 3   
negative smears, clinically improved, DOT X2 weeks    
ρ Use of tissues for coughing/sneezing   ρ Sputum           
collection      
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
 
 
 
 
 
 
 
 
 
 
 
 
EVALUATION: 
ρ PPD testing/significance   ρ CXR results   ρ No further 
PPD testing if + (always +) 
 
Υ 
 
 
 
 
 
 
 
 
 
 
 
Υ 
 
 
 
 
 
 
 
HIGH RISK GROUPS/FACTORS: 
ρ Diabetics   ρ Alcohol/drug abuse (IVDU)    
ρ Silicosis   ρ Corticosteroids   ρ Gastric resection 
ρ HIV+   ρ Foreign born   ρ Resident of correctional or 
long term care facility  
 
Υ 
 
Υ 
 
Υ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEDICATION: 
ρ Possible side effects, actions to take if side effects occur   
ρ Increased risk of side effects if post-partum, alcohol 
abuse, kidney or liver disease   ρ Benefits = cure of 
disease or prevention of infection/disease    
ρ Administration = dosage/frequency, length of treatment, 
DOT/DOPT 
 
Υ 
 
Υ 
 
Υ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DRUG INTERACTIONS: 
ρ INH: Dilantin   ρ Rifampin: prednisone, digoxin, 
quinidine, Coumadin, methadone, estrogen, oral 
contraceptives, protease inhibitors, Remicade 
 
Υ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADHERENCE: 
ρ Case = control order, quarantine, MDR-TB, death    
ρ LTBI = disease later, DOPT 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
RATIONALE FOR DOT/DOPT: 
ρ Assure compliance and adherence   ρ DOT = prevents 
drug resistance and is Standard of Care    
ρ DOPT = children <5, HIV+, contacts to MDR-TB, other 
high risk 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
TB-203 Education/Counseling Record – 08/04 (Continued on Reverse) 
 
Tuberculosis Education/Counseling Record 
 
 
Initial 
Visit 
 
1 Mo 
Date 
 
2 Mo 
Date 
 
3 Mo 
Date 
 
4 Mo 
Date 
 
5 Mo 
Date 
 
6 Mo 
Date 
 
7 Mo 
Date 
 
8 Mo 
Date 
 
9 Mo 
Date 
 
 
 
 
 
                                                                                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RATIONALE FOR MONTHLY 
MONITORING: 
ρ Assess improvement/worsening of symptoms    
ρ Toxicity/symptom review   ρ Medication refill 
ρ LFTs/other lab per protocol 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
LAB RESULTS: 
ρ LFTs/other lab per protocol   ρ Sputum per protocol   
ρ Evaluation of sputum conversion    
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
HIV 
ρ HIV pre/post test counseling  
 
Υ 
         
 
SPUTUM/SPECIMEN COLLECTION:    
ρ Early morning specimen   ρ One supervised monthly   
ρ Weekly, till 3 consecutive negative smears    
ρ Monthly, till 2 consecutive months negative cultures   
ρ Collect outdoors or in room with negative air pressure 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
 
 
 
 
 
 
 
 
 
 
CONTACT INVESTIGATION:    
ρ Rationale = find new disease, early detection and 
treatment of new LTBI   ρ 2nd testing of negative 
contacts, 10-12 weeks after break date    
ρ Concentric circle approach  
 
Υ 
 
 
 
Υ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONSENTS/AUTHORIZATIONS: 
ρ Consents explained   ρ Copies given to patient  
 
Υ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROVIDER INFORMATION: 
ρ Clinic address/phone number   ρ Nurse case 
manager=s name/phone number 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
 
Υ 
     
          
     
          
                                                         Provider   
Initials:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                              Next 
Appointment:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ρ  Provided at Indicated Month 
    Cases/Suspects Only 
 
PROVIDER NAME (Please Print) PROVIDER SIGNATURE  INITIALS DATE 
 
               
 
               
 
               
 
               
 
TB-203 Education/Counseling Record – 08/04 
 
Texas Department of State Health Services 
Clinical Assessment for Tuberculosis Medication Toxicity 
 
 
NAME: ___________________________________________________   D.O.B.: _____ /_____ /_____   SS#: _____ /____ /______  
 
   
 
 
 
 
Toxicity Assessment:   
Ask questions (1-18) when patient is on first-line drugs and ask questions (1-28) if any second-line drugs are added to patient’s regimen.  Document [+] results in the 
progress notes and notify the physician. 
Results: [ + ] = If Present [ - ] = If Denies [ NA ] = If Not Applicable
Toxicity Symptoms Date 
 
Date 
 
Date 
 
Date 
 
Date 
 
Date 
 
Date 
 
Date 
 
Date 
 
Weight          
Temperature          
Blood Pressure          
Are you experiencing any of the following 
now or since you have been on treatment? 
 
  1.  Loss of Appetite          
  2.  Nausea/Vomiting          
  3.  Urine Color Change (Dark)           
  4.  Skin Rashes/Dry          
  5.  Numbness/Tingling (Hands/Feet, Face/Mouth)          
  6.  Change in Vision           
  7.  Eye Pain/Irritation          
  8.  Jaundice (Yellow Skin/Eyes)          
  9.  Flu-like Symptoms           
10.  Fatigue           
11.  Headaches           
12.  Fever           
13.  Joint Pains/Swelling          
14.  Urine Output ↕          
15.  Bleeding  (Nose Bleeds, Hemoptysis)          
16.  Vertigo/Dizziness/Fainting           
       Teeter/Fall to Left or Right When Standing  
       (With Eyes Closed)  
         
       Weave/Stagger When Walking  (Normal Gait)           
17.  Hearing Loss/Ears Ringing/Fullness          
18.  Nervousness/Giddiness/Restlessness          
19.  Increased Gas/Stomach Cramps          
20.  Abdominal Pain/Diarrhea          
21.  Sleep Problems           
22.  Mood Changes/Depression           
23.  Change in Heart Rate           
24.  Convulsions           
25.  Memory Loss          
26.  Abnormal Behavior          
27.  Skin Discoloration           
28.  Allergic Reaction          
Drug Issued Mfg/Lot#/Exp  Route/ 
Frequency 
Amt. 
Given
Amt. 
Given
Amt. 
Given
Amt. 
Given
Amt. 
Given
Amt. 
Given 
Amt. 
Given
Amt. 
Given
Amt. 
Given
            
            
            
            
Initials*/Title           
Next Appt.           
*  See Provider Signature Sheet 
 
TB205-Toxicity Assessment (Continued on Reverse)   Revised 08/2004 
Texas Department of State Health Services 
Vision/Hearing Screening Form 
 
NAME: _______________________________________________________  
Red/Green Color Discrimination: 
The (X) mark indicates the plate cannot be read.  Screen all 14 plates.  Client must pass 10 of the first 11 plates for the test to be regarded as normal. Refer for 
evaluation if < 7 plates are read as normal.  
Results: [ N ] = Normal [ A ] = Abnormal
Ishihara 
Plate # 
Normal 
Reading 
Red/Green 
Deficiency 
Date Date Date Date Date Date Date Date Date 
  1 12 12          
  2 8 3          
  3 5 2          
  4 29 70          
  5 74 21          
  6 7 X          
  7 45 X          
  8 2 X          
  9 X 2          
10 16 X          
11 Traceable X          
  Protan Deutan          
  Strong Mild Strong Mild          
12 35 5 (3) 5 3 3 (5)          
13 96 6 (9) 6 9 9 (6)          
14 Can trace  
2 lines 
Purple Purple 
(Red) 
Red Red 
(Purple) 
         
Results               
Initials               
 
 
 
 
 
 
  
Visual Acuity: 
If initial screen was conducted with corrective lenses (glasses or contacts), follow-up screens must be done the same.  A change of 1 or more lines from the initial 
screen in either one or both eyes must be reported to the physician immediately. 
Results:   [ P ] = Pass     [ F ] = Fail     [ U ] = Unscreenable          Chart Used:   [    ]  Letter     [    ]  “E”     [    ]  Other, Specify:_______________  
Corrective Lenses:   [    ] = Yes     [    ] = No 
 
Distance  
Acuity 
Date 
 
Date Date Date Date Date Date Date Date 
Right Eye 20/ 20/ 20/ 20/ 20/ 20/ 20/ 20/ 20/ 
Left Eye 20/ 20/ 20/ 20/ 20/ 20/ 20/ 20/ 20/ 
Both Eyes 20/ 20/ 20/ 20/ 20/ 20/ 20/ 20/ 20/ 
Results          
Initials          
 
 
 
 
 
 
 
 
 
Hearing Sweep Check: 
When patient is taking amikacin, capreomycin, kanamycin, or streptomycin, for each of the four frequencies listed, record the lowest level in decibels (dB) at which 
the person responds.  Record the findings for both the right and left ear.  Refer to an appropriately licensed professional if any two of the four frequencies are 
recorded as greater than 25 dB in either ear or the same ear or if there is a change of decreased hearing level from baseline.  Start with 40 dB, if heard decrease by 10 
dB until no response is obtained or until 20 dB is reached.  If 20 dB is heard, record as 20 dB.  Once no response is obtained, increase the dB level by 5 until a 
response is obtained and recorded.  If a response is not heard at 40 dB, record as 40+ dB. 
Results:   [ P ] = Pass     [ R ] = Refer     [ O ] = Observe          Ear:   [ R ] = Right     [ L ] = Left     
Frequency Date Date 
 
Date Date Date Date Date Date Date 
Ear R L R L R L R L R L R L R L R L R L 
500 Hz                   
1000 Hz                   
2000 Hz                   
4000 Hz                   
Initials          
TB205-Toxicity Assessment  Revised 08/04 
Texas Department of State Health Services 
Tuberculosis Directly Observed Therapy Log 
 
Name:                                                                                                                                                                  DOB:                              Sex:       
Address:                                                                                                                                                              Telephone: 
Classification:     Class II        Class III        Class V          DOT Ordered By:                                        DOT Initiated:        /       /                 
Date Ordered: Medication/Dosage (Amount Given/Frequency)/Manufacturer/Lot Number/Expiration Date: Date Discontinued: 
   
   
   
   
   
   
   
   
   
 
     Toxicity Screen:    +  =  Yes     -  =  No       (To be completed for each client DOT encounter before patient takes medication) 
MONTH/YEAR: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Headaches (chronic)                 
Joint Pain (chronic) - PZA                  
Ears Ringing/Fullness - AK, CAP, KM, SM                 
Numbness/Tingling                  
**Skin Rashes/Itching                 
**Visual Problems - Ethambutol                  
**Dark Urine (coffee-colored)                 
**Jaundice (yellow skin/eyes)                 
**Abdominal Pain                  
**Nausea/Vomiting                 
**Malaise/Fatigue                 
**Fever (more than 3 days duration)                 
**Convulsions                 
**Unusual Bleeding (nose, gums, stool, 
urine, etc. or easy bruising) - RIF 
                
Other:                 
Other:                 
Provider Initials                 
Interpreter Initials                 
   **  =  Do not give DOT Dose.  Contact Nurse/Physician for further instructions.  
 
Date DOT 
Adm 
Self 
Adm 
Dose 
Missed 
DOT Provider’s 
Initials 
Client’s 
Initials 
Comments/Notes 
          /01/       
          /02/       
          /03       
          /04/       
          /05/       
          /06/       
          /07/       
          /08/       
          /09/       
          /10/       
          /11/       
          /12/       
          /13/       
          /14/       
          /15/       
          /16/       
 
TB-206  Directly Observed Therapy Log – 11/07  (Continued on Reverse) 
Tuberculosis Directly Observed Therapy Log 
 
     Toxicity Screen:    +  =  Yes     -  =  No       (To be completed for each client DOT encounter before patient takes medication) 
MONTH/YEAR: 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31  
Headaches (chronic)                 
Joint Pain (chronic) - PZA                  
Ears Ringing/Fullness - AK, CAP, KM, SM                 
Numbness/Tingling                 
**Skin Rashes/Itching                 
**Visual Problems - Ethambutol                  
**Dark Urine (coffee-colored)                 
**Jaundice (yellow skin/eyes)                 
**Abdominal Pain                  
**Nausea/Vomiting                 
**Malaise/Fatigue                 
**Fever (more than 3 days duration)                 
**Convulsions                 
**Unusual Bleeding (nose, gums, stool, 
urine, etc. or easy bruising) - RIF 
                
Other:                 
Other:                 
Provider Initials                 
Interpreter Initials                 
   **  =  Do not give DOT Dose.  Contact Nurse/Physician for further instructions.  
 
Date DOT 
Adm 
Self 
Adm 
Dose 
Missed 
DOT Provider’s 
Initials 
Client’s 
Initials 
Comments/Notes 
          /17/       
          /18/       
          /19/       
          /20/       
          /21/       
          /22/       
          /23/       
          /24/       
          /25/       
          /26/       
          /27/       
          /28/       
          /29/       
          /30/       
          /31/       
DOT SUMMARY:  
# Targeted DOT Doses # DOT Doses Given % DOT Doses Given # Self-Administered Doses # Missed Doses 
     
Compliant:     Yes            No          Comment: 
Quarantine Advised:     Yes            No          Date of Control Order:                         Date of Court Action: 
CLIENT/DOT PROVIDER AGREEMENT: 
We agree to meet at                        (Location) on  (check all days that apply) 
   Monday            Tuesday            Wednesday            Thursday            Friday            Saturday            Sunday 
at         (Time) AM / PM for DOT medication, unless alternate arrangements are made in advance by either party. 
Change in Location:                                                                          Day(s):                                                   Time:       
Client’s Signature:                                                                                                         Client’s Initials:                         
DOT Provider’s Signature:                                                                                           DOT Provider’s Initials:                   
DOT Provider’s Signature:                                                                                           DOT Provider’s Initials:                        
 
TB-206  Directly Observed Therapy Log  - 11/07 
SAMPLE 
DEPARTAMENTO DE SALUD DEL CONDADO DE YAVAPAI  
PROGRAMA PARA EL CONTROL DE LA TUBERCULOSIS 
 
TRATAMIENTO PARA PREVENCIÓN DE LA TUBERCULOSIS 
Rifampicina 
 
Su prueba positiva de tuberculosis enseña que usted está infectado con los microbios de la tuberculosis.  Usted no 
está contagioso y no puede pasar este microbio a otra persona. 
 
Después de revisar su historia médica y su radiografía, el doctor ha recomendado que usted tome un tratamiento.  
Este tratamiento baja su riesgo a la tuberculosis en el futuro. 
 
Para matar éstos microbios, usted tiene que tomar una medicina muy fuerte cada día por bastante tiempo.  Ésta 
medicina se llama “Rifampicina,” o “RIF,” y se toma por caurto meses.  Reacciones de la RIF posiblemente pueden 
incluir problemas con el hígado.  Otros síntomas son los siguientes: 
• Cansancio excesivo 
• Dolor del estómago 
• Nausea 
• Ojos amarillos, o la piel 
amarilla 
• Orina oscura 
• Pérdida de apetito 
• Pérdida de peso sin razón 
• Salpullido con comezón 
• Vómitos 
• Fiebre por 3 días o más 
• Sangrado fácil 
• Dolor en las articulaciones 
• Mareos 
• Magulladuras o moretones 
por lesiones pequeñas 
 
Mucha gente no tienen éstos síntomas.  Si usted tiene algunos de éstos síntomas, por favor, llame a la clínica y hable 
con una enfermera. 
 
Los siguientes efectos adversos son problemas menores. Si experimenta alguno de los siguientes efectos adversos, 
puede seguir tomando su medicina.  
• La Rifampicina puede hacer que la orina o las lágrimas se tiñan de anaranjado. Es posible que el médico o 
la enfermera le aconsejen no usar lentes de contacto suaves porque pueden mancharse.  
• La Rifampicina puede hacerlo más sensible al sol. Esto significa que debe usar buenos protectores de rayos 
solares y cubrir las partes expuestas al sol para que no se queme. Si anticipa estar expuesto al sol, debe 
protegerse con lociones o cremas para bloquear el sol (sunblock).  
• La Rifampicina puede disminuir la efectividad de las pastillas anticonceptivas así como  algunos implantes 
de prevención de embarazo. Las mujeres que toman Rifampicina deben usar otras formas de contracepción.  
• Si está tomando Rifampicina al mismo tiempo que la metadona (usada para tratar la adicción a las drogas), 
es posible que experimente síntomas de remoción. Su médico o enfermera quizá considere la posibilidad de 
ajustar la dosis de metadona.  
 
Es importante vigilar la salud del hígado antes y durante el tiempo que usted tome la medicina.  Para los adultos, 
sacamos la sangre antes de empezar la medicina, y si ellos desarrollan síntomas de algún problema.  Para los niños 
bajo la edad de 15 años, solamente si ellos desarrollan síntomas de algún problema. 
 
Durante el tiempo que usted está tomando la medicina RIF, es mejor no tomar alcohol de ningún tipo, especialmente 
todos los días.  El alcohol aumenta la posibilidad que usted tenga problemas con la medicina. 
 
Si usted tiene que visitar el doctor o el dentista dígale que usted está tomando la medicina RIF – es importante que 
usted le de el nombre de la medicina y que usted está tomando la medicina para prevenir la tuberculosis. 
 
Es muy importante que cualquier mujer fértil no se quede embarazada durante el tiempo que está tomando la 
medicina RIF.  Si usted necesita un método para prevenir el embarazo, venga a la clínica o vaya a su doctor.   Usted 
siempre puede recibir condones en la clínica.  
 
Date Revised 12/4/07 
INSTRUCCIONES PARA LA MEDICINA RIF:  Tome la medicina RIF a la misma hora, cada día.  Si se le olvida 
una dosis, no tome la dosis mas tarde.  Tome solamente una dosis de la medicina cada día. 
 
Cada mes, usted necesita venir a la clínica.  La enfermera le va a pesar y hacerle preguntas sobre los síntomas para 
averiguar si usted tiene problemas con la medicina RIF.  Ella hará una cita para la próxima evaluación y para 
rellenar la medicina RIF.  Si usted no puede venir a la clínica para su cita, la enfermera puede hacer arreglos para ir 
a su casa para hacer la evaluación y rellenar la medicina. 
 
Si usted tiene preguntas o problemas, favor de llamar a la clínica y pida hablar con  
Date Revised 12/4/07 
SAMPLE 
_____________COUNTY HEALTH DEPARTMENT 
TUBERCULOSIS CONTROL PROGRAM 
 
PREVENTIVE TREATMENT FOR TUBERCULOSIS INFECTION 
Rifampin 
Your positive tuberculosis (TB) skin test shows that you are infected with TB germs.  You are not contagious, and cannot 
pass the germ to anyone else. 
 
After reviewing your health history and chest x-ray, the doctor has recommended that you take preventive treatment for the 
positive skin test.  This treatment will reduce the risk of becoming ill with TB in the future.   
 
In order to destroy TB germs, a strong medication must be used on a regular basis for a long period of time.  One of the 
medications used for preventive treatment is called rifampin, or RIF, and it is taken for four months.  Adverse reactions to 
RIF include; 
• Abdominal pain 
• Dark urine 
• Loss of appetite 
• Nausea 
• Rash/itching 
• Tiredness 
• Vomiting 
• Yellow skin and/or eyes 
• Easy bleeding 
• Aching joints 
• Dizziness 
• Easy bruising 
 
Most people do not experience these symptoms, but if you do, you should call the clinic and speak with a nurse. 
 
The side effects listed below are minor problems. If you have any of these side effects, you can continue taking 
your medicine: 
• Rifampin can turn urine, saliva, or tears orange. The doctor or nurse may advise you not to wear soft 
contact lenses because they may get stained.  
• Rifampin can make you more sensitive to the sun. This means you should use a good sunscreen and cover 
exposed areas so you don't burn. If you are going to be out in the sun, use sunblock. 
• Rifampin also makes birth control pills and implants less effective. Women who take rifampin should use 
another form of birth control.  
• If you are taking rifampin as well as methadone (used to treat drug addiction), you may have withdrawal 
symptoms. Your doctor or nurse may want to adjust your methadone dosage.  
It is important to monitor the health of the liver prior to, and during the time you are taking RIF.  For adults, blood is 
drawn before starting RIF, and if they develop symptoms of side effects to the medication.  Children under age 15 
years have blood drawn only if they develop symptoms of side effects to the medication. 
 
During the time you are taking RIF you should avoid drinking alcohol, especially on a daily basis.  The intake of 
alcohol may inhibit the absorption of RIF.  It will also increase your risk of having side effects from the medication.  
 
It is important for women of childbearing age not to become pregnant during the time they are taking RIF.  If you 
need a method of birth control, you should see you health care provider, or contact the Yavapai County Health 
Department Reproductive Health clinic for an appointment.  Condoms are available at all times from our clinic.   
 
If you see a doctor or dentist for any reason while you are taking RIF, give them the name of the medication and 
explain that you are taking it for “prevention of active tuberculosis.” 
 
INSTRUCTIONS:  Take your RIF at the same time every day.  If you forget a dose, DO NOT TAKE AN EXTRA 
DOSE. 
 
The nurse will make an appointment for your next evaluation and medication refill at the time of each visit.  You 
will be weighed and questioned about possible signs of medication side effects at each visit.  If you are unable to 
come to the clinic for your appointments the nurse will arrange to come to your home or another clinic location for 
your evaluations and refills. 
 
If you have questions or problems, call  
Date Revised: 126/4/200807 
D ft A t 21 2003
Meta-model for TB Elimination
Goal:  Eliminate TB in the United States. 
 
  
 
Capacity and 
infrastructure 
• Adequate funding 
• Strong and well-
staffed programs 
• Functional data 
systems, including 
case management 
data system 
• Adequate physical, 
diagnostic, and 
treatment 
resources 
• Policies, 
procedures, and 
guidelines 
• Patient on 
appropriate 
treatment 
• Patient 
adheres to 
treatment 
• Timely com- 
pletion of 
appropriate 
treatment 
Monitoring and evaluation
• Data driven interventions 
defined & disseminated 
Inputs Activities
Enhanced 
accountability 
Reduced TB 
transmission 
= Data and programs undergo continuous improvement 
with ongoing monitoring and evaluation feedback 
Coordinate and 
communicate 
effectively with 
providers outside 
HD 
Outcomes
Reduced LTBI 
prevalence 
Reduced TB 
incidence 
Improved 
quality of 
patient life 
Provide TB education and 
training to community 
providers 
Find and treat active 
TB 
• Identify early 
• Use effective drugs 
• Reduce treatment 
barriers 
Investigate 
Contacts  
• Identify contacts quickly 
• Locate and evaluate in 
a timely manner  
Provide 
Patient 
Education 
and 
Treatment
Prevent TB in high-
risk populations 
• Engage community 
partners 
• Detect LTBI & TB 
Reduced TB 
morbidity and 
mortality 
Elimination 
of TB 
Capacity and Infrastructure to Eliminate TB
 
Goal:  Develop capacity and infrastructure, which are essential inputs/resources in the other models. 
 
 
 
 
 
 
 
Inputs/ 
Resources 
TB in the 
community 
 
Existing partnership 
• National/state 
• State/local 
• HD/PMD 
• Community 
• Local 
 
 
Existing oversight 
and state, local, 
and federal 
resources 
 
 
Existing national 
TB surveillance 
system 
 
 
Existing guidelines, 
laws, policies 
Activities 
Describe TB 
in region 
Identify 
target 
populations 
Establish 
goals and 
objectives 
 
Develop 
strategic 
plan 
Develop external 
communication systems 
and materials 
Advocate for resources 
internally and externally 
Determine related data 
elements, develop data 
definitions, and develop/ 
improve information 
reporting system 
 
Establish policies, 
procedures, and 
guidelines 
 
Develop internal 
communication systems 
and materials 
Develop staff 
organizational plan and 
job descriptions 
 
Recruit staff 
 
Provide staff 
development 
Provide strong 
supervisory and 
performance 
management system 
Network of 
knowledgeable and 
engaged partners is 
created 
Adequate physical, 
diagnostic, treatment, 
and case management 
resources  
Strong patient tracking, 
management, and 
reporting systems are in 
place 
Pool of qualified, 
trained, and motivated 
staff exists 
Consistent expectations 
and accountability 
culture among staff and 
supervisors 
Capacity to 
eliminate TB 
Efforts are 
continually 
improved based 
on evaluation and 
other findings 
Establish 
and maintain 
partnerships 
with 
community 
and 
congregate 
settings 
 
Establish 
linkages 
between 
Short-term 
Outcomes 
Intermediate 
Outcomes 
Long-term 
Outcomes 
Policies, procedures, 
and guidelines are 
implemented and 
adhered to 
 
 
 
Strong and well-
staffed programs are 
implemented that 
are consistent with 
strategic plan and 
demonstrate cultural 
competence 
 
 
 
Systems provide 
ongoing and special 
data to allow for real 
time corrections and 
ongoing monitoring 
and reporting 
Linkages ensure 
continuity of care 
 
Evaluation Capacity 
Goal:  Programs at every level conduct ongoing monitoring and timely evaluation to improve patient and public health outcomes. 
Develop and maintain appropriate comprehensive data systems and IT infrastructure (with linked data systems).  
Make better use of data. 
Evaluation capacity: 
• Common ethos  
• Formal plan  
• Funds available 
• Roles defined   
• Multidisciplinary  teams 
defined  
• Teams trained in evaluation 
theories, practice, methods 
• Ongoing training system  
• Evaluation planning and 
implementation processes  
• Common terminology (all on 
same page) 
• Standards for evaluation 
quality  
• Adequate data collection 
tools 
• Sufficient resources 
Design good evaluations 
that adhere to good 
evaluation practices  
Data gaps and quality 
issues are identified 
Disseminate evaluation 
findings and data 
systems findings 
Data-driven best 
interventions are 
disseminated 
Inputs/Resources Activities Short-term
Outcomes 
Intermediate 
Outcomes 
Long-term 
Outcomes 
Issues and service gaps 
identified 
Data and data systems 
are improved 
Explicit, public, executive 
support for evaluation: 
• Top managers publicly 
promote evaluation  
• Resource decisions reflect 
support  
• Evaluation team and/or data 
users involved  in key 
decisions 
 
Identifiable structures in place 
to promote evaluation use:  
• Resources to support 
changes indicated by 
evaluation results 
• Plans and mechanisms for  
dissemination of evaluation 
information 
Collect routine 
surveillance and case 
management data 
(RVCT, ARPE, cases, 
contacts, LTBI, etc.) 
 
 
Analyze data 
• Assess progress 
toward goals 
• Identify patterns 
 
Interpret data 
 
Monitor indicators and 
conduct performance 
measurement 
 
Routine reports that are 
useful and valid 
Advocates are created 
who have skill and 
desire and power to use 
data to improve 
program 
 
Learning culture 
 
Existing data systems: 
• Standard data definitions 
• Standard data elements 
• Patient tracking system 
• Patient management 
systems 
• Criteria for data quality 
Enhanced 
accountability: 
• Efficient resource use
• Demonstrated links 
between operations 
and outcomes 
Program efforts are 
improved 
Train TB controllers and 
program managers 
 
Align incentives with 
expectations 
 
Identify and address 
barriers to evaluation 
Collect additional data as 
needed for evaluation 
Best interventions to 
close gaps are 
identified 
Data-driven best 
interventions 
and 
improvements 
are implemented
Better TB health 
outcomes 
Elimination of TB 
 
Timely Completion of Appropriate Treatment 
Goal:  Timely identification and treatment of people with active TB. 
 
 
 
 
 
 
 
Inputs/ 
Resources 
Activities 
Adequate infrastructure 
 
• Qualified, trained, and 
motivated staff 
• Community and 
congregate setting 
partnerships 
• Policies, procedures, 
and guidelines 
• Ongoing data 
collection, monitoring, 
and reporting systems 
• Adequate physical, 
diagnostic, treatment, 
field investigation, and 
case management 
resources 
• Linkages between 
jurisdictions 
• Adequate data 
collection tools 
• Legal authority to 
ensure adherence to 
treatment 
Educate community health care 
providers and administrators of 
congregate settings 
 
Engage in active case finding 
 
Conduct early patient medical 
assessment and diagnostic tests 
 
Conduct timely cultures and 
identify drug sensitivities 
Assess patient knowledge and 
social support  
 
Provide patient education and 
augmentation of social support 
system 
 
Collaborate on medical and case 
management  
 
Choose method and schedule of 
medication administration (DOT 
and/or SAT) 
 
Provide incentives and enablers
Monitor patient for response to 
therapy and adverse drug effects 
 
Monitor patient for adherence to 
therapy 
Patient responds to 
treatment 
Early end to infectious 
period
 
 
 
 
Patient on appropriate 
treatment 
 
 
 
 
 
Patient adheres to 
treatment 
Consult with TB expert physicians 
if necessary 
Isolate if necessary 
Cases identified and 
reported early 
 
Timely treatment start 
 
Drug resistance identified 
early  
 
Effective drugs identified 
early 
Treatment plan addresses 
both medical and social 
support needs 
 
Engaged patients 
 
Reduced barriers 
Coordinated care in 
congregate settings 
 
Public and private MDs 
provide good care 
 
Good two-way 
communication between 
private MDs and local 
health department 
Short-term 
Outcomes 
Intermediate 
Outcomes 
Long-term 
Outcomes 
TB eliminated 
Timely completion  
Improved patient 
quality of life 
Reduced transmission 
of TB
Culture conversion 
Cure  
Prevention of 
development of drug 
resistance 
 
 
Prevent TB in High Risk  
Goal:  Prevent TB among high-risk populations through targeted testing and treatment. 
To identify: 
• Evaluate epi data to 
identify high-risk 
populations 
• Poll staff 
• Evaluate TLTBI data 
• Engage stakeholders (e.g., 
correctional facilities, drug 
treatment centers, CHCs, 
refugee service providers, 
homeless programs, 
immigration services, HIV 
testing, and care providers)
 
Develop tool/protocol to 
prioritize high-risk groups 
based on evidence: epi data, 
recent outbreak investigations
 
Identify appropriate staff 
 
Educate staff 
 
Educate patients 
Partner with providers 
 
Provide evaluation/TLTBI: 
• CXR 
• Medical evaluation 
• Case management 
• Monitoring 
• Incentives/enablers/ DOPT 
Monitor program yield
Appropriate treatment 
 
 
Adherence (DOPT if 
needed) 
 
 
Timely completion of 
TLTBI 
Evidence-based 
assessment of 
prevention effectiveness
Reduced TB incidence 
in high risk persons 
Inputs/Resources Activities Short-term
Outcomes 
Intermediate 
Outcomes 
Long-term 
Outcomes 
Detection of LTBI 
 
 
People offered TLTBI 
 
 
People initiate TLTBI 
Improved programs 
 
Services tailored to 
meet community needs 
 
More effective 
prevention 
Educate stakeholders 
 
Develop MOUs with 
community partners for 
diagnosis, treatment/referral, 
and coordination 
Good communication 
with community 
partners 
 
Community needs 
identified and 
understood 
 
Community partners 
adhere to guidelines 
Strategies:   Identify and prioritize high risk persons; targeted testing and treatment for LTBI; develop partnerships with providers treating high risk groups 
         Note:   Infection control is another strategy for preventing TB that will be addressed in another model 
       Notes:  LTBI = latent TB infection; TLTBI = treatment for LTBI; DOPT = directly observed preventive therapy; CXR = chest X-ray; MOU = memorandum of understanding;   
CHC = community health center 
Adequate infrastructure 
 
• Qualified, trained, 
and motivated staff 
• Community and 
congregate setting 
partnerships 
• Policies, procedures, 
and guidelines 
• Ongoing data 
collection, 
monitoring, and 
reporting systems 
• Adequate physical, 
diagnostic, and 
treatment resources 
• Linkages between 
jurisdictions 
• Adequate data 
collection tools 
TB eliminated 
 
Contact Investigation 
Goal:  Prevent TB by finding and screening contacts and active TB cases to identify and treat cases of TB and LTBI. 
 
 
 
 
 
Adequate infrastructure 
 
• Qualified, trained, 
and motivated staff 
• Community and 
congregate setting 
partnerships 
• Policies, procedures, 
and guidelines 
• Ongoing data 
collection, 
monitoring, and 
reporting systems 
• Adequate physical, 
diagnostic, and 
treatment resources 
• Linkages between 
jurisdictions 
• Adequate data 
collection tools 
Interview/reinterview 
cases 
• Build rapport 
• Provide education 
• Obtain information 
about source case 
and contacts  
 
Locate and evaluate 
contact: 
• Follow-up 
• Education 
• Examination & 
testing* 
 
Offer treatment 
 
Treat contact – case 
management 
(DOT/DOPT/incentives)
Conduct periodic review 
of cases/contacts and 
progress toward contact 
treatment goals
Cases identify contacts 
Evidence-based 
decisions about 
continuation or 
termination of contact 
investigation 
Contacts complete 
appropriate treatment 
for active TB or LTBI 
Improved approaches 
for contact investigation 
TB in contacts with 
active TB cured 
 
TB in contacts with LTBI 
prevented 
Inputs 
(May not exist in all 
programs) 
Activities Short-term
Outcomes 
Intermediate 
Outcomes 
Long-term 
Outcomes 
Monitor: 
• Data collection 
• Data management 
• Data analysis 
• Data dissemination
Reduced transmission 
of TB
TB eliminated 
Contacts treated 
 
Contacts followed up 
Contacts evaluated  
Contacts educated 
Comprehensive 
interview tool 
 
Staff trained in interview 
techniques 
Legal mandate to 
collect contact 
information from 
congregate settings 
D ft A t 21 2003
Meta-model for TB Elimination
Goal:  Eliminate TB in the United States. 
 
  
 
Capacity and 
infrastructure 
• Adequate funding 
• Strong and well-
staffed programs 
• Functional data 
systems, including 
case management 
data system 
• Adequate physical, 
diagnostic, and 
treatment 
resources 
• Policies, 
procedures, and 
guidelines 
• Patient on 
appropriate 
treatment 
• Patient 
adheres to 
treatment 
• Timely com- 
pletion of 
appropriate 
treatment 
Monitoring and evaluation
• Data driven interventions 
defined & disseminated 
Inputs Activities
Enhanced 
accountability 
Reduced TB 
transmission 
= Data and programs undergo continuous improvement 
with ongoing monitoring and evaluation feedback 
Coordinate and 
communicate 
effectively with 
providers outside 
HD 
Outcomes
Reduced LTBI 
prevalence 
Reduced TB 
incidence 
Improved 
quality of 
patient life 
Provide TB education and 
training to community 
providers 
Find and treat active 
TB 
• Identify early 
• Use effective drugs 
• Reduce treatment 
barriers 
Investigate 
Contacts  
• Identify contacts quickly 
• Locate and evaluate in 
a timely manner  
Provide 
Patient 
Education 
and 
Treatment
Prevent TB in high-
risk populations 
• Engage community 
partners 
• Detect LTBI & TB 
Reduced TB 
morbidity and 
mortality 
Elimination 
of TB 
Capacity and Infrastructure to Eliminate TB
 
Goal:  Develop capacity and infrastructure, which are essential inputs/resources in the other models. 
 
 
 
 
 
 
 
Inputs/ 
Resources 
TB in the 
community 
 
Existing partnership 
• National/state 
• State/local 
• HD/PMD 
• Community 
• Local 
 
 
Existing oversight 
and state, local, 
and federal 
resources 
 
 
Existing national 
TB surveillance 
system 
 
 
Existing guidelines, 
laws, policies 
Activities 
Describe TB 
in region 
Identify 
target 
populations 
Establish 
goals and 
objectives 
 
Develop 
strategic 
plan 
Develop external 
communication systems 
and materials 
Advocate for resources 
internally and externally 
Determine related data 
elements, develop data 
definitions, and develop/ 
improve information 
reporting system 
 
Establish policies, 
procedures, and 
guidelines 
 
Develop internal 
communication systems 
and materials 
Develop staff 
organizational plan and 
job descriptions 
 
Recruit staff 
 
Provide staff 
development 
Provide strong 
supervisory and 
performance 
management system 
Network of 
knowledgeable and 
engaged partners is 
created 
Adequate physical, 
diagnostic, treatment, 
and case management 
resources  
Strong patient tracking, 
management, and 
reporting systems are in 
place 
Pool of qualified, 
trained, and motivated 
staff exists 
Consistent expectations 
and accountability 
culture among staff and 
supervisors 
Capacity to 
eliminate TB 
Efforts are 
continually 
improved based 
on evaluation and 
other findings 
Establish 
and maintain 
partnerships 
with 
community 
and 
congregate 
settings 
 
Establish 
linkages 
between 
Short-term 
Outcomes 
Intermediate 
Outcomes 
Long-term 
Outcomes 
Policies, procedures, 
and guidelines are 
implemented and 
adhered to 
 
 
 
Strong and well-
staffed programs are 
implemented that 
are consistent with 
strategic plan and 
demonstrate cultural 
competence 
 
 
 
Systems provide 
ongoing and special 
data to allow for real 
time corrections and 
ongoing monitoring 
and reporting 
Linkages ensure 
continuity of care 
 
Evaluation Capacity 
Goal:  Programs at every level conduct ongoing monitoring and timely evaluation to improve patient and public health outcomes. 
Develop and maintain appropriate comprehensive data systems and IT infrastructure (with linked data systems).  
Make better use of data. 
Evaluation capacity: 
• Common ethos  
• Formal plan  
• Funds available 
• Roles defined   
• Multidisciplinary  teams 
defined  
• Teams trained in evaluation 
theories, practice, methods 
• Ongoing training system  
• Evaluation planning and 
implementation processes  
• Common terminology (all on 
same page) 
• Standards for evaluation 
quality  
• Adequate data collection 
tools 
• Sufficient resources 
Design good evaluations 
that adhere to good 
evaluation practices  
Data gaps and quality 
issues are identified 
Disseminate evaluation 
findings and data 
systems findings 
Data-driven best 
interventions are 
disseminated 
Inputs/Resources Activities Short-term
Outcomes 
Intermediate 
Outcomes 
Long-term 
Outcomes 
Issues and service gaps 
identified 
Data and data systems 
are improved 
Explicit, public, executive 
support for evaluation: 
• Top managers publicly 
promote evaluation  
• Resource decisions reflect 
support  
• Evaluation team and/or data 
users involved  in key 
decisions 
 
Identifiable structures in place 
to promote evaluation use:  
• Resources to support 
changes indicated by 
evaluation results 
• Plans and mechanisms for  
dissemination of evaluation 
information 
Collect routine 
surveillance and case 
management data 
(RVCT, ARPE, cases, 
contacts, LTBI, etc.) 
 
 
Analyze data 
• Assess progress 
toward goals 
• Identify patterns 
 
Interpret data 
 
Monitor indicators and 
conduct performance 
measurement 
 
Routine reports that are 
useful and valid 
Advocates are created 
who have skill and 
desire and power to use 
data to improve 
program 
 
Learning culture 
 
Existing data systems: 
• Standard data definitions 
• Standard data elements 
• Patient tracking system 
• Patient management 
systems 
• Criteria for data quality 
Enhanced 
accountability: 
• Efficient resource use
• Demonstrated links 
between operations 
and outcomes 
Program efforts are 
improved 
Train TB controllers and 
program managers 
 
Align incentives with 
expectations 
 
Identify and address 
barriers to evaluation 
Collect additional data as 
needed for evaluation 
Best interventions to 
close gaps are 
identified 
Data-driven best 
interventions 
and 
improvements 
are implemented
Better TB health 
outcomes 
Elimination of TB 
 
Timely Completion of Appropriate Treatment 
Goal:  Timely identification and treatment of people with active TB. 
 
 
 
 
 
 
 
Inputs/ 
Resources 
Activities 
Adequate infrastructure 
 
• Qualified, trained, and 
motivated staff 
• Community and 
congregate setting 
partnerships 
• Policies, procedures, 
and guidelines 
• Ongoing data 
collection, monitoring, 
and reporting systems 
• Adequate physical, 
diagnostic, treatment, 
field investigation, and 
case management 
resources 
• Linkages between 
jurisdictions 
• Adequate data 
collection tools 
• Legal authority to 
ensure adherence to 
treatment 
Educate community health care 
providers and administrators of 
congregate settings 
 
Engage in active case finding 
 
Conduct early patient medical 
assessment and diagnostic tests 
 
Conduct timely cultures and 
identify drug sensitivities 
Assess patient knowledge and 
social support  
 
Provide patient education and 
augmentation of social support 
system 
 
Collaborate on medical and case 
management  
 
Choose method and schedule of 
medication administration (DOT 
and/or SAT) 
 
Provide incentives and enablers
Monitor patient for response to 
therapy and adverse drug effects 
 
Monitor patient for adherence to 
therapy 
Patient responds to 
treatment 
Early end to infectious 
period
 
 
 
 
Patient on appropriate 
treatment 
 
 
 
 
 
Patient adheres to 
treatment 
Consult with TB expert physicians 
if necessary 
Isolate if necessary 
Cases identified and 
reported early 
 
Timely treatment start 
 
Drug resistance identified 
early  
 
Effective drugs identified 
early 
Treatment plan addresses 
both medical and social 
support needs 
 
Engaged patients 
 
Reduced barriers 
Coordinated care in 
congregate settings 
 
Public and private MDs 
provide good care 
 
Good two-way 
communication between 
private MDs and local 
health department 
Short-term 
Outcomes 
Intermediate 
Outcomes 
Long-term 
Outcomes 
TB eliminated 
Timely completion  
Improved patient 
quality of life 
Reduced transmission 
of TB
Culture conversion 
Cure  
Prevention of 
development of drug 
resistance 
 
 
Prevent TB in High Risk  
Goal:  Prevent TB among high-risk populations through targeted testing and treatment. 
To identify: 
• Evaluate epi data to 
identify high-risk 
populations 
• Poll staff 
• Evaluate TLTBI data 
• Engage stakeholders (e.g., 
correctional facilities, drug 
treatment centers, CHCs, 
refugee service providers, 
homeless programs, 
immigration services, HIV 
testing, and care providers)
 
Develop tool/protocol to 
prioritize high-risk groups 
based on evidence: epi data, 
recent outbreak investigations
 
Identify appropriate staff 
 
Educate staff 
 
Educate patients 
Partner with providers 
 
Provide evaluation/TLTBI: 
• CXR 
• Medical evaluation 
• Case management 
• Monitoring 
• Incentives/enablers/ DOPT 
Monitor program yield
Appropriate treatment 
 
 
Adherence (DOPT if 
needed) 
 
 
Timely completion of 
TLTBI 
Evidence-based 
assessment of 
prevention effectiveness
Reduced TB incidence 
in high risk persons 
Inputs/Resources Activities Short-term
Outcomes 
Intermediate 
Outcomes 
Long-term 
Outcomes 
Detection of LTBI 
 
 
People offered TLTBI 
 
 
People initiate TLTBI 
Improved programs 
 
Services tailored to 
meet community needs 
 
More effective 
prevention 
Educate stakeholders 
 
Develop MOUs with 
community partners for 
diagnosis, treatment/referral, 
and coordination 
Good communication 
with community 
partners 
 
Community needs 
identified and 
understood 
 
Community partners 
adhere to guidelines 
Strategies:   Identify and prioritize high risk persons; targeted testing and treatment for LTBI; develop partnerships with providers treating high risk groups 
         Note:   Infection control is another strategy for preventing TB that will be addressed in another model 
       Notes:  LTBI = latent TB infection; TLTBI = treatment for LTBI; DOPT = directly observed preventive therapy; CXR = chest X-ray; MOU = memorandum of understanding;   
CHC = community health center 
Adequate infrastructure 
 
• Qualified, trained, 
and motivated staff 
• Community and 
congregate setting 
partnerships 
• Policies, procedures, 
and guidelines 
• Ongoing data 
collection, 
monitoring, and 
reporting systems 
• Adequate physical, 
diagnostic, and 
treatment resources 
• Linkages between 
jurisdictions 
• Adequate data 
collection tools 
TB eliminated 
 
Contact Investigation 
Goal:  Prevent TB by finding and screening contacts and active TB cases to identify and treat cases of TB and LTBI. 
 
 
 
 
 
Adequate infrastructure 
 
• Qualified, trained, 
and motivated staff 
• Community and 
congregate setting 
partnerships 
• Policies, procedures, 
and guidelines 
• Ongoing data 
collection, 
monitoring, and 
reporting systems 
• Adequate physical, 
diagnostic, and 
treatment resources 
• Linkages between 
jurisdictions 
• Adequate data 
collection tools 
Interview/reinterview 
cases 
• Build rapport 
• Provide education 
• Obtain information 
about source case 
and contacts  
 
Locate and evaluate 
contact: 
• Follow-up 
• Education 
• Examination & 
testing* 
 
Offer treatment 
 
Treat contact – case 
management 
(DOT/DOPT/incentives)
Conduct periodic review 
of cases/contacts and 
progress toward contact 
treatment goals
Cases identify contacts 
Evidence-based 
decisions about 
continuation or 
termination of contact 
investigation 
Contacts complete 
appropriate treatment 
for active TB or LTBI 
Improved approaches 
for contact investigation 
TB in contacts with 
active TB cured 
 
TB in contacts with LTBI 
prevented 
Inputs 
(May not exist in all 
programs) 
Activities Short-term
Outcomes 
Intermediate 
Outcomes 
Long-term 
Outcomes 
Monitor: 
• Data collection 
• Data management 
• Data analysis 
• Data dissemination
Reduced transmission 
of TB
TB eliminated 
Contacts treated 
 
Contacts followed up 
Contacts evaluated  
Contacts educated 
Comprehensive 
interview tool 
 
Staff trained in interview 
techniques 
Legal mandate to 
collect contact 
information from 
congregate settings 
Arizona Administrative 
Code
Public health staff
Correctional facility staff
Inmates
Funding
Medical resources
Reporting systems
Community & 
congregate-setting 
partnerships
Implement state Tb 
rules
Medical staff education
Occupational TB screening
Inmate screening
Medical evaluations
Case management
Patient education
DOT/DOPT
Contact Investigations
Surveillance
Case data entry
Interjurisdictional transfers
Establish communication between 
correctional facility staff & local 
health departments
Counseling & support 
provided
Treatment plans developed
Referrals to local 
health departments & 
providers
ACTIVITIES
Completion of therapy
Detection of LBTI
Detection of active cases
Increased HIV screening
Improved screening programs
Increased percentage of inmates for which 
appropriate  screening is done
Improved follow-up medical care
Reduced transmission of TB
TB prevalence reduction in correctional
facilities
INPUTS OUTPUTS
Increased screening
OUTCOMES
TB Program Logic Model for Public Health 
and Correctional Facilities
Agency partnerships
Inmate Education
Inmate screening
Tb education conducted
Information provided to ADC 
regarding compliance with TB 
rules
Tuberculosis Logic Model 
I. Capacity and Infrastructure to Eliminate TB  
 
Inputs/Resources     Activities                                 
 Outcomes 
Burden of TB in the community Establish and maintain 
partnerships with community 
resources 
Short-term Outcomes 
 Establish linkages with existing 
partners 
Network of knowledgeable and engaged partners 
is created 
Existing partnerships: 
County Health Departments 
Border Health 
Navajo Nation 
Phoenix Indian Health Services 
Correctional Facilities 
Describe Burden of TB in 
community 
Adequate physical, diagnostic, treatment and case 
management resources 
 Identify target populations Strong patient tracking, management, and 
reporting systems are in place 
Existing oversight and state, 
local, and federal resources 
Establish goals and objectives Pool of qualified, trained and motivated staff exists 
 Develop strategic plan Consistent expectations and accountability culture 
among staff and supervisors 
Existing TB surveillance 
system 
Develop external communication 
systems and materials 
 
 Advocate for resources internally 
and externally 
Mid-term Outcomes 
Existing guidelines, laws and 
policies 
Determine related data elements, 
develop data definitions, and 
develop/improve information 
reporting system 
Linkages ensure continuity of care 
 Establish policies, procedures, and 
guidelines 
Policies, and guidelines are implemented and 
adhered to 
 Develop internal communication 
systems and materials 
Strong and well-staffed programs are implemented 
that are consistent with strategic plan and 
demonstrate cultural competence 
 Develop staff organizational  plan 
and job descriptions 
Systems provide ongoing and special data to allow 
for real time connections and ongoing monitoring 
and reporting 
 Recruit staff  
 Provide staff development Long-term Outcomes 
 Provide strong supervisory and 
performance management system 
Capacity to eliminate TB 
  Efforts are continually improved based on 
evaluation and other findings 
 
 
 
Glossary 
acid-fast bacilli (AFB): Microorganisms that are distinguished by their retention of 
specific stains even after being rinsed with an acid solution. An AFB examination 
involves microscopic examination of a stained smear of a patient specimen 
(usually sputum) to determine if mycobacteria are present. The relative 
concentration of AFB per unit area on a slide (the smear grade) is associated 
with infectiousness. A presumptive diagnosis of pulmonary TB can be made with 
a positive AFB sputum smear result. However, approximately 50% of patients 
with TB disease of the lungs have negative AFB sputum smear results. The 
majority of AFB in patient specimens are mycobacteria, including species other 
than Mycobacterium tuberculosis complex. A positive nucleic acid amplification 
or culture result is needed for confirmation of M. tuberculosis complex.  
administrative controls: Managerial measures that reduce the risk for exposure to 
persons who might have TB disease. Examples include coordinating efforts with 
the local or state health department; conducting a TB risk assessment for the 
setting; developing and instituting a written TB infection control plan to ensure 
prompt detection, airborne infection isolation, and treatment of persons with 
suspected or confirmed TB disease; and screening and evaluating healthcare 
workers who are at risk for TB disease or who might be exposed to M. 
tuberculosis. 
air change rate: Ratio of the airflow in volume units per hour to the volume of the space 
under consideration in identical volume units, usually expressed in air changes 
per hour (ACH). 
air changes per hour (ACH): Air change rate expressed as the number of air exchange 
units per hour. 
airborne infection isolation (AII) precautions: The isolation of patients infected with 
organisms spread through airborne droplet nuclei 1–5 μm in diameter. This 
isolation area receives substantial air changes per hour (ACH) (≥12 ACH for new 
construction since 2001 and ≥6 ACH for construction before 2001) and is under 
negative pressure (i.e., the direction of the air flow is from the outside adjacent 
space [e.g., the corridor] into the room). The air in an AII room is preferably 
exhausted to the outside but can be recirculated if the return air is filtered through 
a high efficiency particulate respirator. 
airborne infection isolation room (AII room): A room designed to maintain AII. 
Formerly called negative pressure isolation room, an AII room is a single-
occupancy patient-care room used to isolate persons with suspected or 
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confirmed infectious TB disease. Environmental factors are controlled in AII 
rooms to minimize the transmission of infectious agents that are usually spread 
from person-to-person by droplet nuclei associated with coughing or 
aerosolization of contaminated fluids. AII rooms should provide negative 
pressure in the room (so that air flows under the door gap into the room), an air 
flow rate of 6–12 air changes per hour, and direct exhaust of air from the room to 
the outside of the building or recirculation of air through a high efficiency 
particulate respirator filter. 
anergy: A condition in which a person has a diminished ability to exhibit delayed T-cell 
hypersensitivity to antigens because of a condition or situation resulting in altered 
immune function. Skin tests for anergy (i.e., control antigens) have poor 
predictive value and are not recommended. 
asymptomatic: Neither causing nor exhibiting signs or symptoms of disease. 
Bacille Calmette-Guérin (BCG): Vaccines for tuberculosis named after the French 
scientists Calmette and Guérin. The vaccines are effective in preventing 
disseminated and meningeal TB disease in infants and young children. They 
might have approximately 50% efficacy for preventing smear diagnosed 
pulmonary TB in adults. They are used in multiple countries where TB disease is 
endemic.  
baseline tuberculosis screening: Screening healthcare workers (HCWs) for latent TB 
infection and TB disease at the beginning of employment. TB screening includes 
a symptom screen for all HCWs, and tuberculin skin tests (TSTs) or blood assays 
for M. tuberculosis (BAMTs) for those with previous negative test results for M. 
tuberculosis infection. The TST or BAMT is administered at the beginning of 
employment to newly hired HCWs. If the TST method is used for HCWs who 
have not had a documented negative test result for M. tuberculosis during the 
preceding 12 months, the baseline TST result should be obtained by using the 
two-step method. BAMT baseline testing does not need the two-step method. 
blood assay for Mycobacterium tuberculosis (BAMT): A general term to refer to 
recently developed in vitro diagnostic tests that assess for the presence of 
infection with M. tuberculosis. This term includes, but is not limited to, IFN-γ 
release assays (IGRA). In the United States, the currently available test is 
QuantiFERON®-TB Gold test (QFT-G). 
boosting: When nonspecific or remote sensitivity to tuberculin (purified protein 
derivative [PPD] in the skin test) wanes or disappears with time, subsequent 
tuberculin skin tests can restore the sensitivity. This is called boosting or the 
booster phenomenon. An initially limited reaction size is followed by a larger 
reaction size on a later test, which can be confused with a conversion or a recent 
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M. tuberculosis infection. Two-step testing is used to distinguish new infections 
from boosted reactions in infection-control surveillance programs, but this 
method is not recommended for testing contacts.  
bronchoscopy: A procedure for examining the lower respiratory tract in which the end 
of the endoscopic instrument is inserted through the mouth or nose (or 
tracheostomy) and into the respiratory tree. Bronchoscopy can be used to obtain 
diagnostic specimens. Bronchoscopy also creates a high risk for M. tuberculosis 
transmission to healthcare workers (HCWs) if it is performed on an untreated 
patient who has TB disease (even if the patient has negative acid-fast bacilli 
smear results) because it is a cough-inducing procedure.  
case:  A particular instance of a disease (e.g., TB), referring only to the disease, not to 
the person with the disease. A case is detected, documented, and reported.  
cavity (pulmonary): A hole in the lung parenchyma, usually not involving the pleural 
space. Although a lung cavity can develop from multiple causes, and its 
appearance is similar regardless of its cause, in pulmonary TB disease, 
cavitation results from the destruction of pulmonary tissue by direct bacterial 
invasion and an immune interaction triggered by M. tuberculosis. A TB cavity 
substantial enough to see with a normal chest radiograph predicts 
infectiousness. 
chest x-ray: See radiography. 
clinical examination: A physical evaluation of the clinical status of a patient by a 
physician or equivalent practitioner.  
cluster (TB): A group of patients with latent TB infection or TB disease that are linked by 
epidemiologic, location, or genotyping data. Two or more tuberculin skin test 
conversions within a short period can be a cluster of TB and might suggest 
transmission within the setting. A genotyping cluster is two or more cases with 
isolates that have an identical genotyping pattern. 
confirmed TB: A diagnosis of TB disease based on positive cultures for M. tuberculosis. 
However, TB may also be diagnosed on the basis of clinical signs and symptoms 
in the absence of a positive culture. Positive cultures for M. tuberculosis confirm 
the diagnosis of TB; however, TB may also be diagnosed on the basis of clinical 
signs and symptoms in the absence of a positive culture. Culture examinations 
should be done on all specimens, regardless of acid-fast bacilli smear results.  
contact: A person who has been exposed to M. tuberculosis infection by sharing air 
space with a person with infectious TB.  
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contact investigation: Procedures that occur when a case of infectious TB is identified, 
including finding persons (contacts) exposed to the case, testing and evaluation 
of contacts to identify latent TB infection or TB disease, and treatment of these 
persons, as indicated. 
contagious: See infectious.  
conversion: A change in the result of a test for M. tuberculosis infection that is 
interpreted to indicate a change from being uninfected to infected. With the 
tuberculin skin test, an increase of more than 10 mm in induration size during a 
maximum of two years is defined as a conversion. If blood assay for M. 
tuberculosis (BAMT) is used for testing, a conversion is a change from a negative 
to a positive BAMT result over a two-year period. A conversion is presumptive 
evidence of new M. tuberculosis infection and poses an increased risk for 
progression to TB disease. The term is applied to contacts only when previous 
test results are available. A change in tuberculin status during the window period 
is not necessarily consistent with this definition.  
conversion rate: The percentage of a population with a converted test result (tuberculin 
skin test or blood assay for M. tuberculosis) for M. tuberculosis within a specified 
period. This is calculated by dividing the number of conversions among eligible 
healthcare workers (HCWs) in the setting in a specified period (numerator) by the 
number of HCWs who received tests in the setting over the same period 
(denominator) multiplied by 100. 
culture: Growth of microorganisms in the laboratory performed for detection and 
identification in sputum or other body fluids and tissues. This test usually takes 
two to four weeks for mycobacteria to grow (two to four days for most other 
bacteria). 
delayed-type hypersensitivity (DTH): Cell-mediated inflammatory reaction to an 
antigen, which is recognized by the immune system usually because of previous 
exposure to the same antigen or similar ones. Cell-mediated reactions are 
contrasted with an antibody (or humoral) response. DTH typically peaks at 48–72 
hours after exposure to the antigen. 
deoxyribonucleic acid (DNA) genotyping: A clinical laboratory technique used to 
distinguish between different strains of M. tuberculosis and to help assess the 
likelihood of TB transmission. 
directly observed therapy (DOT): An adherence-enhancing strategy in which a 
healthcare worker or other trained person watches a patient swallow each dose 
of medication and is accountable to the public health system. DOT is the 
standard of care for all patients with TB disease and is a preferred option for 
patients treated for latent TB infection. 
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disseminated TB: See miliary TB. 
droplet nuclei: Microscopic particles produced when a person coughs, sneezes, 
shouts, or sings. These particles can remain suspended in the air for prolonged 
periods and can be carried on normal air currents in a room and beyond to 
adjacent spaces or areas receiving exhaust air. 
drug susceptibility test: A laboratory determination to assess whether an M. 
tuberculosis complex isolate is susceptible or resistant to anti-TB drugs that are 
added to mycobacterial growth medium or are detected genetically. The results 
predict whether a specific drug is likely to be effective in treating TB disease 
caused by that isolate. 
enabler: A practical item given to a patient for making adherence (e.g., to treatment or 
to clinic appointments) easier.  
environmental controls: Physical or mechanical measures (as opposed to 
administrative control measures) used to reduce the risk for transmission of M. 
tuberculosis by preventing the spread and reducing the concentration of 
infectious droplet nuclei in ambient air. Examples include ventilation, filtration, 
ultraviolet lamps, airborne infection isolation rooms, and local exhaust ventilation 
devices.  
epidemiologic cluster: A closely grouped series of cases in time or place. 
erythema: Abnormal redness of the skin. Erythema may develop around a tuberculin 
skin test (TST) site, but should not be read as part of the TST result. 
exposure: The condition of being subjected to something (e.g., an infectious agent) that 
could have a harmful effect. A person exposed to M. tuberculosis does not 
necessarily become infected. Much of the work in a TB contact investigation is 
dedicated to learning who was exposed and, of these, who became infected.  
exposure incident: A situation in which persons (e.g., healthcare workers, visitors, and 
inmates) have been exposed to a person with suspected or confirmed infectious 
TB disease (or to air containing M. tuberculosis), without the benefit of effective 
infection control measures. 
exposure period: The coincident period when a contact shared the same air space as a 
person with TB during the infectious period.  
exposure site: A location that the index patient visited during the infectious period (e.g., 
school, bar, bus, or residence). 
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extrapulmonary TB: TB disease in any part of the body other than the lungs (e.g., the 
kidney, spine, or lymph nodes). The presence of extrapulmonary disease does 
not exclude pulmonary TB disease. 
false negative tuberculin skin test (TST) or blood assay for M. tuberculosis 
(BAMT) result: A TST or BAMT result that is interpreted as negative in a person 
who is actually infected with M. tuberculosis. 
false positive tuberculin skin test (TST) or blood assay for M. tuberculosis (BAMT) 
result: A TST or BAMT result that is interpreted as positive in a person who is 
not actually infected with M. tuberculosis. A false-positive TST result is more 
likely to occur in persons who have been vaccinated with Bacille Calmette-Guérin 
or who are infected with nontuberculous mycobacteria. 
fit check: A procedure performed after every respirator is donned to check for proper 
seal of the respirator. Also called “user-seal check.” 
fit test: The use of a protocol to qualitatively or quantitatively evaluate the fit of a 
respirator on a person.  
genotype: The deoxyribonucleic acid (DNA) pattern of M. tuberculosis used to 
discriminate among different strains. 
healthcare workers (HCWs): All paid and unpaid persons working in healthcare 
settings. 
hemoptysis: The expectoration or coughing up of blood or blood-tinged sputum—one of 
the symptoms of pulmonary TB disease. Hemoptysis can also be observed in 
other pulmonary conditions (e.g., lung cancer). 
high efficiency particulate air (HEPA) filter: A portable or stationary filter that is 
certified to remove more than 99.97% of  particles 0.3 μm in size, including M. 
tuberculosis-containing droplet nuclei. Use of HEPA filters in building ventilation 
systems requires expertise in installation and maintenance. 
human immunodeficiency virus (HIV) infection: Infection with the virus that causes 
acquired immunodeficiency syndrome (AIDS). A person with both latent TB 
infection and HIV infection is at high risk for developing TB disease. 
hypersensitivity: A state in which the body reacts with an exaggerated immune 
response to a foreign substance. Hypersensitivity reactions are classified as 
immediate or delayed, types I and IV, respectively. See delayed-type 
hypersensitivity. 
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immunocompromised and immunosuppressed: Conditions in which at least part of 
the immune system is functioning at less than normal capacity. According to 
some style experts, “immunocompromised” is the broader term, and 
“immunosuppressed” is restricted to conditions with iatrogenic causes, including 
treatments for another condition. Some immunocompromised conditions increase 
the likelihood that M. tuberculosis infection will progress to TB disease. Certain 
conditions also make TB disease or infection from M. tuberculosis more difficult 
to diagnose because manifestations of TB disease differ and tests for infection 
rely on an intact immune system.  
incentive: A gift given to patients to encourage or acknowledge their adherence to 
treatment.  
incidence: The number of new events or cases of disease that develop during a 
specified period. 
index (TB): The first case or patient with TB disease that comes to attention as an 
indicator of a potential public health problem.  
induration: The firmness in the skin test reaction produced by immune-cell infiltration in 
response to the tuberculin antigen that was introduced into the skin during a 
tuberculin skin test. Induration is measured transversely by palpation, and the 
result is recorded in millimeters. The measurement is compared with guidelines 
to determine whether the test result is classified as positive or negative. 
 infection control program (TB): A program designed to control transmission of M. 
tuberculosis through early detection, isolation, and treatment of persons with 
infectious TB. A hierarchy of control measures are used, including 1) 
administrative controls to reduce the risk for exposure to persons with infectious 
TB disease and screening for healthcare workers (HCWs) for latent TB infection 
and TB disease, 2) environmental controls to prevent the spread and reduce the 
concentration of infectious droplet nuclei in the air, and 3) respiratory protection 
in areas where the risk for exposure to M. tuberculosis is high (e.g., airborne 
infection isolation rooms). A TB infection control plan should include surveillance 
of HCWs who have unprotected high-risk exposure to TB patients or their 
environment of care. 
infection: A condition in which microorganisms have entered the body and typically 
have elicited immune responses. M. tuberculosis infection might progress to TB 
disease. The expression M. tuberculosis infection includes both latent infection 
and TB disease. Latent M. tuberculosis infection or latent tuberculosis infection 
(LTBI) is an asymptomatic condition that follows the initial infection; the infection 
is still present but is dormant (and believed not to be currently progressive or 
invasive). TB disease is determined by finding anatomic changes caused by 
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advancing infection (e.g., shadows from infiltrates on a chest radiograph) or by 
noting symptoms (e.g., malaise, feverishness, or cough), and typically by both. 
Positive culture results for M. tuberculosis complex typically are interpreted as 
both an indication of TB disease and its confirmation, but infecting organisms can 
be obtained from patients who have no other evidence of disease. 
infectious: Refers either to TB disease of the lungs or throat which has the potential to 
cause transmission to other persons, or to the patient who has TB disease. 
infectious droplet nuclei: Droplet nuclei produced by an infectious TB patient that can 
carry tubercle bacteria and be inhaled by others. Although usually produced from 
patients with pulmonary TB through coughing, infectious droplet nuclei can also 
be produced by aerosol-generating procedures. 
infectious period: The period during which a person with TB disease might have 
transmitted M. tuberculosis organisms to others. For patients with positive acid-
fact bacilli (AFB) sputum smear results, the infectious period begins three months 
before the collection date of the first positive smear result or the symptom onset 
date (whichever is earlier) and ends when the patient is placed into airborne 
infection isolation (AII) or the date of collection for the first of consistently 
negative smear results. For patients with negative AFB sputum smear results, 
the infectious period extends from one month before the symptom onset date 
and ends when the patient is placed into AII (whichever was earlier). 
interferon-γ  release assay (IGRA): A type of an ex vivo test that detects cell-mediated 
immune response to this cytokine. In the U.S., QuantiFERON®-TB Gold test 
(QFT-G) is a currently available IGRA. 
laryngeal TB: A form of TB disease that involves the larynx and can be highly 
infectious.  
latent TB infection (LTBI): See infection. 
Mantoux method: A skin test performed by intradermally injecting 0.1 mL of purified 
protein derivative tuberculin solution into the volar or dorsal surface of the 
forearm. This method is the recommended method for tuberculin skin testing. 
mask: A device worn over the nose and mouth of a person with suspected or confirmed 
infectious TB disease to prevent infectious particles from being released into 
room air. 
medical evaluation: An examination to diagnose TB disease or latent TB infection, to 
select treatment, and to assess response to therapy. A medical evaluation can 
include medical history and TB symptom screen, clinical or physical examination, 
screening and diagnostic tests (e.g., tuberculin skin tests, chest radiographs, 
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bacteriologic examination, and human immunodeficiency virus testing), 
counseling, and treatment referrals. 
meningeal TB: A highly dangerous and difficult-to-diagnose form of TB disease with 
infectious invasion of the tissues covering the brain. Often indolent but uniformly 
fatal if untreated, at times it is diagnosed too late to save the patient’s life or 
prevent permanent disability.  
miliary TB: A dangerous, and difficult to diagnose, form of rapidly progressing TB 
disease that extends throughout the body. Uniformly fatal if untreated, sometimes 
it is diagnosed too late to save the patient’s life. Derives its names from a 
pathognomonic chest radiograph, but certain patients with this condition have 
normal findings or ordinary infiltrates on the chest radiograph. Sometimes 
referred to as disseminated TB.  
multidrug-resistant TB (MDR-TB): TB disease caused by an M. tuberculosis strain that 
is resistant to at least isoniazid and rifampin. Treatment regimens for curing 
MDR-TB are long, expensive, and difficult to tolerate. The cure rate depends on 
the susceptibility of M. tuberculosis to alternative chemotherapy.  
mycobacteria other than tuberculosis (MOTT): See nontuberculous mycobacteria. 
Mycobacterium tuberculosis: The namesake member organism of M. tuberculosis 
complex and the most common causative infectious agent of TB disease in 
humans. In certain instances, the species name refers to the entire M. 
tuberculosis complex, which includes M. bovis and M. african, M. microti, M. 
canetii, M. caprae, and M. pinnipedii. 
N95 disposable respirator: An air-purifying, filtering-facepiece respirator that is more 
than 95% efficient at removing 0.3 μm particles and is not resistant to oil. See 
also respirator. 
negative pressure: The difference in air-pressure between two areas. A room that is 
under negative pressure has a lower pressure than adjacent areas, which keeps 
air from flowing out of the room and into adjacent rooms or areas. Also used to 
describe a nonpowered respirator. See also airborne infection isolation and 
airborne infection isolation room. 
nontuberculous mycobacteria (NTM): Refers to mycobacterium species other than 
those included as part of M. tuberculosis complex. Although valid from a 
laboratory perspective, the term can be misleading because certain types of NTM 
cause disease with pathologic and clinical manifestations similar to TB disease. 
Another term for NTM is mycobacterium other than tuberculosis. NTM are 
environmental mycobacteria. 
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nucleic acid amplification (NAA): A laboratory method used to target and amplify a 
single deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequence for 
detecting and identifying (typically) a microorganism. NAA tests for M. 
tuberculosis complex are sensitive and specific; they can accelerate confirmation 
of pulmonary TB disease.  
outbreak (TB): Relative to the local context. Outbreak cases can be distinguished from 
other cases only when certain associations in time, location, patient 
characteristics, or M. tuberculosis attributes (e.g., drug resistance or genotype) 
become apparent. In low-incidence jurisdictions, any temporal cluster is 
suspicious for an outbreak. A working definition of a potential "TB outbreak" is 
helpful for planning and response and may include any of the following six 
criteria:  
Criteria based on surveillance and epidemiology:  
 An increase has occurred above the expected number of TB cases. 
 During and because of a contact investigation, two or more contacts are 
identified as having TB disease, regardless of their assigned priority, (i.e., 
high-, medium-, or low-priority). 
 Any two or more cases occurring within one year of each other are 
discovered to be linked, and the linkage is established outside of a contact 
investigation (e.g., two patients who received a diagnosis of TB disease 
outside of a contact investigation are found to work in the same office and 
only one or neither of the persons was listed as a contact to the other). 
 A genotype cluster leads to discovery of one or more verified transmission 
links which were missed during a contact investigation within the prior two 
years. 
Criteria based on program resources:  
 Transmission is continuing despite adequate control efforts by the TB control 
program.  
 Contact investigation associated with increased cases requires additional 
outside help.  
periodic fit testing: Repetition of fit testing performed in accordance with federal, state, 
and local regulations. Additional fit testing should be used when 1) a new model 
of respirator is used, 2) a physical characteristic of the user changes, or 3) when 
the user or respiratory program administrator is uncertain that the healthcare 
worker is obtaining an adequate fit. 
potential ongoing transmission: A risk classification for TB screening, including 
testing for M. tuberculosis infection when evidence of ongoing transmission of M. 
tuberculosis is apparent in the setting. Testing might need to be performed every 
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8–10 weeks until lapses in infection controls have been corrected, and no further 
evidence of ongoing transmission is apparent. Use potential ongoing 
transmission as a temporary risk classification only. After corrective steps are 
taken, reclassify the setting as medium risk. Maintaining the classification of 
medium risk for at least one year is recommended. 
powered air-purifying respirator (PAPR): A respirator equipped with a tight-fitting 
facepiece (rubber facepiece) or loose-fitting facepiece (hood or helmet), 
breathing tube, air-purifying filter, cartridge or canister, and a fan. Air is drawn 
through the air-purifying element and pushed through the breathing tube and into 
the facepiece, hood, or helmet by the fan. Loose-fitting PAPRs (e.g., hoods or 
helmets) might be useful for persons with facial hair because they do not require 
a tight seal with the face. 
prevalence: The proportion of persons in a population who have a disease at a specific 
time. 
pulmonary TB: TB disease that occurs in the lung parenchyma, usually producing a 
cough that lasts two to three weeks.  
purified protein derivative (PPD) tuberculin: A material used in diagnostic tests for M. 
tuberculosis infection. In the U.S., PPD solution (5 tuberculin units per 0.1 mL) is 
approved for administration as an intradermal injection as a diagnostic aid for M. 
tuberculosis infection (latent infection or TB disease).  
QuantiFERON®-TB test (QFT) and QuantiFERON®-TB Gold test (QFT-G): Types of 
blood assays for M. tuberculosis that are in vitro cytokine assays that detects 
cell-mediated immune response to M. tuberculosis in heparinized whole blood 
from venipuncture. This test requires only a single patient encounter, and the 
result can be ready within one day. In 2005, QFT was replaced by QFT-G, which 
has greater specificity because of antigen selection. QFT-G appears to be 
capable of distinguishing between the sensitization caused by M. tuberculosis 
infection and that caused by bacille Calmette-Guérin vaccination. 
radiography: The diagnostic imaging techniques (including plain-film chest radiographs 
and computerized tomography) that rely on degrees of X-radiation transmission 
related to differences in tissue densities.  
reinfection: A second infection that follows from a previous infection by the same 
causative agent. Frequently used when referring to an episode of TB disease 
resulting from a subsequent infection with M. tuberculosis and a different 
genotype. 
resistance: The ability of certain strains of mycobacteria, including M. tuberculosis, to 
grow and multiply in the presence of certain drugs that ordinarily kill or suppress 
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them. Such strains are referred to as drug-resistant strains and cause drug-
resistant TB disease. See also multidrug-resistant TB. 
respirator: A Centers for Disease Control and Prevention (CDC)/National Institute for 
Occupational Safety and Health (NIOSH)-approved device worn to prevent 
inhalation of airborne contaminants. 
respiratory hygiene and cough etiquette: Procedures by which patients with 
suspected or confirmed infectious TB disease can minimize the spread of 
infectious droplet nuclei by decreasing the number of infectious particles that are 
released into the environment. Patients with a cough should be instructed to turn 
their heads away from persons and to cover their mouth and nose with their 
hands or preferably a cloth or tissue when coughing or sneezing. 
respiratory protection: The third level in the hierarchy of TB infection control measures 
(after administrative and environmental controls) is the use of respiratory 
protective equipment in situations in which the administrative and environmental 
controls do not eliminate the risk that exposures can still occur (e.g., airborne 
infection isolation rooms and rooms where cough-inducing or aerosol-generating 
procedures are performed).  
risk assessment (TB): An initial and ongoing evaluation of the risk for transmission of 
M. tuberculosis in a particular healthcare setting. To perform a risk assessment, 
the following factors should be considered: the community rate of TB, number of 
TB patients encountered in the setting, and the speed with which patients with 
TB disease are suspected, isolated, and evaluated. The TB risk assessment 
determines the types of administrative and environmental controls and 
respiratory protection needed for a setting. 
screening (TB): An administrative control measure in which evaluation for latent TB 
infection and TB disease are performed through initial and serial screening of 
healthcare workers, as indicated. Evaluation might comprise tuberculin skin test, 
blood assay for M. tuberculosis, chest radiograph, and symptom screening. See 
also symptom screen.  
secondary (TB) case: A new case of TB disease that is attributed to recent 
transmission as part of the scenario under investigation. The period for “recent” is 
not defined but usually will be briefer than two years. Technically, all cases are 
secondary, in that they originate from other contagious cases. 
smear: A laboratory technique for preparing a specimen so bacteria can be visualized 
microscopically. Material from the specimen is spread onto a glass slide (and 
typically dried and stained). Smear, stain, and microscopy methods for 
mycobacteria are specific to this genus. The slide can be scanned by light or 
fluorescent high-power microscopy. These methods require ongoing quality 
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assurance for prompt and reliable results. The results for sputum acid-fast bacilli 
(AFB) smears typically are reported as numbers of AFB per high-powered 
microscopy field, or else as a graded result, from no AFB to 4+ AFB. The quantity 
of stained organisms is associated with degree of infectiousness.  See acid-fast 
bacilli. 
source: The person or case that was the original source of infection for secondary 
cases or contacts. The source case can be, but is not necessarily, the index 
case. 
source case investigation: An investigation to determine the source case could be 
conducted in at least two circumstances: 1) when a healthcare setting detects an 
unexplained cluster of tuberculin skin test conversions among healthcare workers 
or 2) when TB infection or disease is diagnosed in a young child. The purposes 
of a source case investigation are to ascertain that the source case has been 
diagnosed and treated, to prevent further M. tuberculosis transmission, and to 
ensure that other contacts of that source case are also evaluated, and if 
indicated, provided treatment. 
specimen: Any bodily fluid, secretion, or tissue sent to a laboratory for testing.    
sputum: Mucus-containing secretions coughed up from inside the lungs. Tests of 
sputum (e.g., smear and culture) can confirm pulmonary TB disease. Sputum is 
different from saliva or nasal secretions, which are unsatisfactory specimens for 
detecting TB disease. However, specimens suspected to be inadequate should 
still be processed because positive culture results can still be obtained and might 
be the only bacteriologic indication of disease.    
sputum induction: A method used to obtain sputum from a patient who is unable to 
cough up a specimen spontaneously. The patient inhales a saline mist, which 
stimulates coughing from deep inside the lungs. 
susceptibility: See drug susceptibility test. 
suspected TB: A tentative diagnosis of TB that will be confirmed or excluded by 
subsequent testing. Cases should not remain in this category for longer than 
three months. 
symptom screen: A clinical evaluation procedure in which patients are asked if they 
have experienced any departure from normal in function, appearance, or 
sensation related to TB disease (e.g., cough). 
symptomatic: A term applied to a patient with health-related complaints (i.e., 
symptoms) that might indicate the presence of disease. In certain instances, the 
term is applied to a medical condition (e.g., symptomatic pulmonary TB). 
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targeted testing: A strategy to focus testing for infection with M. tuberculosis in persons 
at high risk for latent TB infection and for those at high risk for progression to TB 
disease if infected. 
transmission: Any mode or mechanism by which an infectious agent is spread from a 
source through the environment or to a person (or other living organism). In the 
context of healthcare-associated TB infection control, transmission is the 
airborne conveyance of aerosolized M. tuberculosis contained in droplet nuclei 
from a person with TB disease, usually from the respiratory tract, to another 
person, resulting in infection. 
tubercle bacilli:  M. tuberculosis organisms. 
tuberculin: A precipitate made from a sterile filtrate of M. tuberculosis culture medium. 
tuberculin skin test (TST): A diagnostic aid for finding M. tuberculosis infection. A small 
dose of tuberculin is injected just beneath the surface of the skin (in the United 
States by the Mantoux method), and the area is examined for induration by 
palpation 48–72 hours after the injection. The indurated margins should be read 
transverse (perpendicular) to the long axis of the forearm. See also Mantoux 
method and purified protein derivative (PPD) tuberculin. 
tuberculosis (TB) disease: Condition caused by infection with a member of the M. 
tuberculosis complex that has progressed to causing clinical illness (manifesting 
symptoms or signs) or subclinical illness (early stage of disease in which signs or 
symptoms are not present, but other indications of disease activity are present). 
The bacteria can attack any part of the body, but disease is most commonly 
found in the lungs (pulmonary TB). Pulmonary TB disease can be infectious, 
whereas extrapulmonary disease (occurring at a body site outside the lungs) is 
not infectious, except in rare circumstances. When the only clinical finding is 
specific chest radiographic abnormalities, the condition is termed “inactive TB” 
and can be differentiated from active TB disease, which is accompanied by 
symptoms or other indications of disease activity (e.g., the ability to culture 
reproducing TB organisms from respiratory secretions or specific chest 
radiographic finding). See also infection.   
tuberculosis (TB) infection: See infection. 
two-step (tuberculin) skin test: A procedure used for baseline skin testing of persons 
who will periodically receive tuberculin skin tests (TSTs) (e.g., healthcare workers 
or residents of long-term–care facilities). Two-step TSTs are used  to reduce the 
likelihood of mistaking a boosted reaction for a new infection. If an initial TST 
result is classified as negative, a second test is repeated one to three  weeks 
later. If the reaction to the second TST is positive, it should be interpreted as 
evidence of infection with M. tuberculosis and indicates that the infection was 
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most likely in the past and not recent. If the second TST is also negative, the 
person is classified as not being infected. Two-step skin testing has no place in 
contact investigations or in other circumstances in which ongoing transmission of 
M. tuberculosis is suspected.    
ultraviolet germicidal radiation (UVGI): An air-cleaning technology that can be used in 
a room or corridor to irradiate the air in the upper portion of the room (upper-air 
irradiation) and is installed in a duct to irradiate air passing through the duct (duct 
irradiation) or incorporated into room air-recirculation units. UVGI uses ultraviolet 
germicidal irradiation to kill or inactivate microorganisms.  
wheal: A small bump that is produced when a tuberculin skin test (TST)  is 
administered. The wheal disappears in approximately 10 minutes after TST 
placement. 
window period: The interval between infection and detectable skin test reactivity is 
referred to as the window period and is estimated to be 2–12 weeks.   
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